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“One very important aspect of motivation is the willingness to stop
and to look at things that no one else has bothered to look at.”
Edward de Bono
(Born in Malta, 1933)
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Abstract
This aim of the research was to explore pharmacist prescribing (PP) with a
focus on antimicrobials, in hospitals in Scotland.
A mixed-methods approach was used to collect, generate and synthesise
data. A systematic review of peer-reviewed published literature on
evidence-based roles for the pharmacist as part of an antimicrobial
multidisciplinary team, identified roles for pharmacists within the teams but
limited evidence relating to outcomes associated with these roles.
Six qualitative focus groups, with 37 hospital pharmacists in 5 Scottish
Health Boards, contextualised perceptions of barriers to, and facilitators of,
implementation of PP in hospitals. Key themes were: perceived lack of
pharmacy management support to take on a prescribing role and little
strategic attention paid to PP implementation and sustainability. These
issues were discussed in relation to PP in general and not only for
antimicrobials. Participants perceived successful implementation of PP to be
associated with factors including ward type and patient’s clinical condition.
None of the pharmacists were prescribing antimicrobials and consequently
further studies focused on PP in general.
A scoping exercise, utilising various sources of information, reinforced
findings from Phase 1; it highlighted the absence of any national or Health
Board frameworks to support implementation of PP in secondary care in
Scotland.
Consensus-based research was undertaken, therefore, to provide guidance
to facilitate service redesign involving PP in secondary care in Scotland. A
Delphi approach undertaken with 40 experts, mainly in strategic posts,
resulted in a high level of agreement in areas relating to succession
planning, rather than role development; more variability was obtained in
areas relating to future orientation of service, competencies required by
prescribers and potential development of non-medical prescribing teams.
The guidance was developed into a self-assessment toolkit providing an
iv
analytical strategy for implementation and role development of PP in
secondary care.
While the results and conclusions generated through this research need to
be interpreted with caution, the data generated is an original contribution to
the evidence base relating to PP.
Key words: Hospital pharmacy, pharmacists, pharmacist prescribing,
antimicrobials, guidelines, guidance, Scotland
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xForeword from the Author
The thesis describes my research work over the past 5 years, or so,
where I have tried to explore pharmacist prescribing in Scottish
hospitals, with a focus on antimicrobials. This experience has both
developed my research abilities, particularly in applying qualitative and
consensus data collection and analysis techniques, and contributed to
the body of evidence in this emerging research area. It has also
strengthened my academic writing skills.
In a way, I have come to this PhD in a round-about way. I first trained
as a pharmacist at the University of Malta, followed by a career as a
hospital pharmacist. During this period I pursued an MSc in clinical
pharmacy at Robert Gordon University, though I was still based in Malta.
Once I had completed the MSc, my husband commented that it would
soon be time to start my PhD though I did not think so at the time! My
husband’s career brought us to the UK where after working in a number
of cities, we finally settled in Aberdeen. Once here for a number of
years, it seemed opportune to start some studies once more with a PhD.
I also had a short maternity break during these studies, after which I
changed to a part-time student.
Throughout my hospital pharmacy experience, I often noted the misuse
and overuse of antimicrobials, particularly in areas such as surgery
where patients who were intended for short courses of prophylactic
antimicrobials had days of unneeded treatment. Similarly, I could note a
lack of knowledge surrounding therapeutic drug monitoring amongst
many of the more junior medical staff. I was often very frustrated by all
this and the amount of time “wasted” chasing up junior doctors to
amend prescriptions and often wondered how much easier it would have
been if a prescribing pharmacist could change a patient’s dose. This led
me to my initial research idea. I was lucky enough to have a supervisory
team who accepted my idea and let me explore and shape up my own
research, yet guide me without imposing their own ideas. This also
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allowed me to take up practice research rather than laboratory based
research, which I was less interested in.
Meanwhile, I was also given plenty of opportunities to demonstrate to
undergraduate pharmacy students in areas relating mainly to clinical
pharmacy, and e-tutor distance learning postgraduate students. These
opportunities allowed me to utilise my hospital pharmacy background
and provided me with the right set of skills to eventually take up a
position as a Lecturer in Clinical Pharmacy, a post which I hold to date.
Throughout the research, I have provided details of background to the
research, and have tried to provide a readable text describing my
research, its evolution and the context in which I carried it out. The first
chapter describes the global problem of antimicrobial resistance, the
response to this problem and the potential role of the prescribing
pharmacist in optimising antimicrobial use. In the second chapter, I
provide a systematic review which explores in more detail and depth the
evidence-based role for the hospital pharmacist as part of the
antimicrobial multidisciplinary team. Chapters 3 – 5 provide a description
of the actual research project which was carried out in three distinct
phases using different methods; Phase 1 involved focus group
discussions with hospital pharmacists; Phase 2 was a background
scoping exercise utilising different sources of information; Phase 3 used
a consensus method to develop guidance. Chapter 6 provides a
discussion, including the implications of the research for future policy
and practice in this area of pharmacist practice together with ideas for
future research. In addition, appendices have been provided to illustrate
with concrete examples some of the documents referred to in the thesis
and to further provide evidence as required.
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Chapter 1 – PP and potential role in optimising antimicrobial use 1
Chapter 1
An overview of the published literature on pharmacist
prescribing and potential role in optimising antimicrobial use
1.1 Introduction
The focus of this research project was to explore pharmacist prescribing
(PP) with a focus on antimicrobialsi in Scottish hospitals. The practice
setting was selected as the author has considerable experience as a hospital
pharmacy practitioner and has observed numerous cases of antimicrobial
misuse and overuse. This has led to a particular interest in this therapeutic
area. The practice of non-medical and especially PP has potential to improve
this situation.
Section 1.2 provides a review of the literature relating to the emerging role
of the pharmacist in optimising antimicrobial use with particular focus on
European and United Kingdom (UK) strategic reports. Section 1.3 describes
PP, reviewing models of PP in the UK and other countries. Section 1.4
highlights the current role of the hospital pharmacist in optimising
antimicrobial use in secondary care.
The wide and extensive use of antimicrobials, both in primary and
secondary care, has led to various organisations developing initiatives to
optimise antimicrobial use. The World Health Organisation (WHO) Global
Strategy for containment of antimicrobial resistance has defined prudent
prescribing of antimicrobials as: “… the cost-effective use of antimicrobials
which maximise clinical therapeutic effect while minimising both drug-
related toxicity and the development of antimicrobial resistance,” (1) and
appropriate use of antimicrobials as: “… [the] optimal choice, dosage and
duration of antimicrobial therapy and chemoprophylaxis based on defined
hospital antibiotic policy, monitoring of antibiotic resistance and up-to-date
guidelines.” (2) Achieving these may be a challenge where it is necessary to
i The term “antimicrobial” and “antibiotic” are often used interchangeably in the literature;
this review uses the term antimicrobial unless quoting the term as used by the authors’
specific publication.
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consider both prudent (reducing unnecessary use) and appropriate
(ensuring the right antimicrobial, dose, route and length of time while
minimising adverse effects and development of resistance) use of
antimicrobials. This mammoth task requires multidisciplinary teams with
regular and close liaison between all healthcare professionals involved.
There is a complex relationship between the use and consumption of
antimicrobials and the development of resistance, with a general view that
increased antimicrobial use will lead to an increase in resistance while more
prudent and controlled antimicrobial use will slow down the rise in the
proportion of resistant strains.(3) However, the evidence for a conclusive
relationship between antimicrobial use and development of resistance is
surprisingly sparse.(4) More recently, some pioneering studies have been
reported in the literature supporting the link between antibiotic use and
antibiotic resistance in specific geographical locations. (5-8) Resistance
results in increased overall treatment costs due to prolonged illness and
resistance to cheaper first-line antimicrobials making it necessary to use
more expensive drugs.(1) This problem becomes more urgent due to the
lack of development of antimicrobials with novel modes of action. As del
Mar describes it, “Antibiotics should be thought of like oil, a non-renewable
resource to be carefully husbanded. What we use now cannot be used some
time in the future.”(9)
Antimicrobial resistance and the threat this brings with it have long been
recognised. Inherent antimicrobial resistance existed even before
antimicrobials were introduced into medicine; in 1940, Abraham and Chain
recognised acquired antimicrobial resistance when, during the development
of penicillin, they isolated the enzyme (now termed penicillinase) that
destroys penicillin.(10) Due to the international and fast spread of
microorganisms in this era of mass travel and global trade, the problem of
antimicrobial resistance no longer remains a national one but is a European
and global problem requiring international cooperation and a global strategy
to avoid going back to the “pre-antibiotic” era. The low quality of poorly
formulated or manufactured antimicrobials in the less developed world
where often, medications are used after their expiry date, adds to the
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complexity of the problem.(11) This has been compounded by factors in
secondary care including hospital overcrowding leading to crossinfection,
immunosuppression (disease or therapeutic) and the use of more invasive
techniques which provide access for easy entry of bacteria into the patient’s
body.(1)
To support and promote appropriate antimicrobial use as a means of
containing antimicrobial resistance, the WHO issued a global strategy which
encourages international cooperation.(1) Numerous cases of current
practice and barriers to inappropriate antimicrobial prescribing are
identified. These include lack of the professional’s knowledge and training,
lack of diagnostic support, peer pressure and perceptions of patient
demands and preferences and lack of enforcement of legislation. Areas for
development within hospitals are recommended and include infection
control strategies, collation of hospital specific formularies and therapeutic
guidelines, and interventions through a coordinated multidisciplinary team
with pharmacy representation.
1.2 Strategies aimed at optimising antimicrobial use
1.2.1 The European Union and prudent use of antimicrobials
Concern due to increasing antimicrobial resistance and the need for a more
coordinated effort to tackle this led to the organisation of a series of
invitational conferences aimed at developing a common strategy to tackle
this problem. ‘The Microbial Threat’, an invitational conference involving
numerous stakeholders and aimed to discuss the increasing resistance to
antimicrobial agents, was held in Copenhagen in 1998. Final
recommendations included increased surveillance to collate data on
resistance to micro-organisms on a pan-European basis; collection of data
on the supply and consumption of antimicrobial agents; development of a
coordinated research programme around antimicrobial resistance;
promotion of actions to encourage good practice and prudent use of
antimicrobials.(12) The concept of an antimicrobial team, consisting of
microbiologists, infectious disease specialists and clinical pharmacists, to
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promote rational use of antimicrobials first emerges here. Such teams
should cover both primary and secondary care including nursing and
residential homes.(13) Teams “… should have the authority to modify
antimicrobial prescriptions of individual clinicians in accordance with locally
accepted guidelines…” (12)
Assessing the implementation of the Copenhagen recommendations was the
aim of a 2001 invitational conference held in Visby, Sweden.(14) Emphasis
was made on the need for coordinated multidisciplinary actions, with the
major problem of lack of clinical microbiologists highlighted.
Recommendations for future actions included a community strategy to
ensure data on the use of and resistance to antimicrobials is available
community wide. The implementation of prudent use of antimicrobials was
again discussed with various recommendations put forward including
educational initiatives for health professionals and the general public,
setting up and implementing guidelines for appropriate antimicrobial usage
covering all aspects of medical care, and the introduction of antimicrobial
teams. One recommendation in particular described the input of a specialist
antimicrobial pharmacist. “Ideally, the team should consist of an infectious
disease physician and/or a clinical microbiologist, a pharmacist with special
expertise in antimicrobial agents and a senior nurse.” (14)
Antimicrobial use in Europe was the theme for a further 2001 conference
held in Brussels where European Surveillance of Antibiotic Consumption
(ESAC) project was launched.(15) Recommendations for future research
included the validation of indicators of prescribing quality, the development
of evidence-based guidelines which could then be translated into indicators
of prescribing quality, and the use of Anatomical Therapeutic Classification
(ATC)/Defined Daily Doses (DDD) as supported by the WHO. One of the
workshops organised focused on interventions in hospitals related to
antibiotic use. It was recognised that there was a lack of adequately
designed trials measuring the impact of interventions on antibiotic
prescribing quality in hospitals. Consequently, better designed studies
measuring interventions and identifying barriers to intervention
implementation and problems of inappropriate antimicrobial use in
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hospitals, were suggested. Recommendations were put forward for both
national health authorities and at European level. National health authorities
were encouraged to ensure that an antibiotic formulary and guidelines were
developed and in place, together with an antimicrobial management team.
To aid in implementation, the need for adequate resources in microbiology
and infectious disease departments and close liaison with pharmacy were
highlighted. On a European level, multi-country cooperation was needed to
establish standards of antimicrobial prescribing, to optimise microbiology
and infectious diseases services as well as optimising clinical pharmacy
services. The establishment of antibiotic prescribing quality indicators was
explored during a further workshop in Belgium in 2005.(16) A European
Union–United States (EU-US) Transatlantic Task Force was also set up to
investigate ways of providing incentives to promote the development of new
antibiotics.(17)
The recommendations resulting from these conferences have been
supported by European Council recommendations and resolutions. Emphasis
was placed on taking a more global view, with the fight against
antimicrobial resistance defined as a ‘public health priority’ for all member
states.(12,18-20) In 2001, member states were advised to put in place a
national strategy for tackling antimicrobial resistance in human medicine
which should include a minimum of: surveillance of antimicrobial resistance
and use; control and prevention of resistance; education and training; and
research.(18,19) This was followed up in 2005 with members of the EU
asked to report on the progress of implementing such strategies. Gaps have
since emerged and been highlighted in areas around research initiatives,
lack of public campaigns and lack of nationally accepted guidelines. In
particular, despite the collection of data on antimicrobial use as part of
ESAC (See Table 1), it was found to be difficult to link antimicrobial
consumption data with clinical indicators.(21)
To further consolidate initiatives in this field at the European level, the
European Agency for the Evaluation of Medicinal Products (EMEA) has
issued a discussion paper on antimicrobial resistance defining actions to be
taken.(22) Main points were: providing standard recommendations to
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healthcare professionals and patients on the Specific Product Characteristics
(SPC), introducing dose recommendations for different infections to
overcome inadequate dosing, and cross-referencing between information on
the SPC and official guidelines.
1.2.1.1 The emerging role of the hospital pharmacist identified in strategic
documents
The Antibiotic Resistance, Prevention and Control [ARPAC], a project that
ran from January 2002 to June 2005, aimed at evaluating and harmonising
strategies for the prevention and control of antibiotic resistant pathogens in
European hospitals.(23) This final report places great emphasis on the
impact of hospital pharmacists in rationalising antibiotic prescribing. It
concluded that “… there is huge potential in Europe for an increased role for
pharmacists...” in measuring and benchmarking antibiotic use, as a key
member of Drugs and Therapeutics Committees and as a member of
antibiotic teams that visit hospital wards to guide and audit antibiotic
therapy. A number of recommendations related to pharmacy and antibiotic
use in hospitals are put forward as follows:
 There should be provision of clinical pharmacy services to support
antibiotic prescribing
 Pharmacists should form part of Drug and Therapeutics Committees
 Pharmacy departments should be involved in measuring and
analysing antibiotic consumption as part of a multidisciplinary team
 Antibiotic pharmacists should be appointed with a hospital wide brief
to: review antibiotic orders, design and promote guidelines,
implement and run ‘switch’ programmes and document effectiveness
of interventions.(23)
It was recommended that each nation create an educational programme
and accreditation for pharmacists to increase the number of specialists
available with an expertise in antibiotic prescribing. The report highlights
the lack of data and good quality research measuring the effects of
interventions on clinical outcome. Further research is required both in
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individual countries and on a European level to measure the effect of
antibiotic pharmacists on improving and reducing antibiotic prescribing and
to investigate the most efficient pharmacy-based intervention.
More recently, the EU has been focusing specifically on antimicrobial
stewardship (ABS) in hospitals, with the launch of its “ABS International”
project in 2006. Further workshops have been organised to achieve
consensus and develop standards for the implementation of ABS in hospitals
in the 27 member states.(24) Reports describing the projects in different
countries have started to emerge.(25) The pharmacist is put forward as an
essential member of the successful ABS team, with recommendations for
further exploration of a potential role for a specialised infectious diseases
pharmacist, similar to that seen in the US literature.
Table 1 summarises European Union initiatives aimed at optimising
antimicrobial use.
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Table 1: A summary of European Union projects aimed at optimising antimicrobial use
Acronym Full Name Website Focus
ARPAC Antibiotic
Resistance,
Prevention and
Control
www.abdn.ac.uk/arpac A European commission funded project running from
January 2002 to July 2005 and aimed at developing
a better understanding of the epidemiology of
antibiotic resistance and evaluating and harmonising
strategies for the prevention and control of antibiotic
resistant pathogens in European hospitals. The final
recommendations have been published and there is
a strong and important role for the hospital
pharmacist.
Originally
EARSS
Now
EARS-
NET
European
Antimicrobial
Resistance
Surveillance
Network
www.ecdc.europa.eu A European wide network, launched in January
1999, involving 800 laboratories in 31 countries of
national surveillance systems, providing reference
data on antimicrobial resistance for public health
purposes. It includes collecting data on antimicrobial
susceptibility of 7 bacterial isolates, analyses trends
in resistance over time and provides guidelines and
protocols.
ESAC European
Surveillance of
Antimicrobial
Consumption
www.esac.ua.ac.be A network of national surveillance systems aiming to
collect reliable and comparable antibiotic
consumption data for public health purposes in all
European countries.
ESCMID European Society
of Clinical
Microbiology and
Infectious Diseases
www.escmid.org/ Aims to improve the diagnosis, treatment and
prevention of infectious diseases by promoting and
supporting research, education and training in the
infection disciplines. Runs various study groups such
as the ESGNI (European study group on noscomial
infection).
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EUCAST European
Committee on
Antimicrobial
Susceptibility
Testing
www.escmid.org/research_pro
jects/eu_cast
Standing ESCMID committee aimed at standardising
susceptibility testing in Europe so that comparable
results and interpretations are produced.
GRACE Genomics to
combat resistance
against antibiotics
in community-
acquired lower
respiratory
infection in Europe
www.escmid.org/research_pro
jects/grace
This project was launched on 17th March 2006 to
develop better diagnostic tools such that antibiotic
use may be improved. The aim is to move towards
having “bedside testing” where one is able to
delineate infection from non-infection and viral from
bacterial infection.
TROCAR Translational
Research on
Combating
Antimicrobial
Resistance
www.escmid.org/research_pro
jects/trocar
To investigate the epidemiology of new highly
variant strains.
ECDC European Centre
for Disease
Prevention and
Control
www.ecdc.europa.eu An agency of the EU aimed at protecting human
health through the prevention and control of
infectious diseases.
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1.2.2 The emerging role of the pharmacist to optimise antimicrobial use in
the United Kingdom
Concern about the increased resistance to antimicrobials in the UK has been
discussed and debated at Government level and has resulted in a number of
reports and recommendations, with the first published in 1998.
The 7th Science and Technology Report topic concluded that “… resistance to
antibiotics and other anti-infective agents constitutes a major threat to
public health and ought to be recognised as such more widely than it is at
present.” (26) Some examples of good practice referring to hospital
pharmacy activities included: monitoring to ensure adherence to a
restrictive formulary; checking prescriptions; and providing advice to junior
doctors at ward level. The first reference is also made to a specialist
antibiotic clinical pharmacist appointed in Hammersmith Hospital leading to
a reduced infection rate and annual cost savings of £77,000. No published
evidence is however provided to support this statement. In addition, the
report highlights that clinical audits indicate that most routine prescribing of
antimicrobials is by junior doctors, especially out-of-hours, a factor which
might lead to variations in the quality of prescribing.(26) The Government
response to this report highlights the importance of prudent antimicrobial
use as a main strategy to reduce unnecessary pressure for the emergence
of resistance. To encourage prudent antimicrobial use, pharmacists, as part
of a multidisciplinary team, should be involved in developing and monitoring
adherence to local antimicrobial drug policies.(27) The Path of Least
Resistance supports this role of the pharmacist in “… controlling prescribing
and identifying inappropriate prescribing”. This report gives the role of the
hospital pharmacist an added dimension beyond a ‘policing’ role.
Pharmacists are seen as having sufficient knowledge and background to
advice prescribers and educate junior doctors.(28) Recommendations set
out in these reports were summarised in a Health Service Circular which
aimed to highlight actions for the National Health Service (NHS).(29)
The UK Antimicrobial Resistance Strategy and Action Plan endorsed by all
UK countries, aimed to provide a focussed approach in line with EU and
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WHO strategies. It highlights four main areas of emphasis: surveillance,
prudent antimicrobial use in humans and other spheres, the importance of
diagnostic and susceptibility testing and public education.(30)
Recommendations for the implementation of this UKwide strategy were
published in an interdepartmental report in 2001.(31) This report defines
prudent antimicrobial use more comprehensively when compared to the
WHO definition as “… the most appropriate way for the treatment or
prevention of human infectious diseases, having regard to the diagnosis,
evidence of clinical effectiveness, likely benefits, safety, cost and propensity
for the emergence of resistance. The most appropriate way implies that the
choice, route, dose, frequency and duration of administration have been
rigorously determined.” Responsibilities to support quality antimicrobial
prescribing are assigned to both community and hospital pharmacists who
play a key role in monitoring and advising on the appropriate use of
antimicrobial therapy. There is support for the development and wide
spread implementation of the specialist clinical antimicrobial pharmacist. In
these latter documents there is a further shift in the role of the pharmacist,
from a ‘gate-keeping’ role when monitoring and auditing adherence to
policies to a more specialist and advisory role.
Strengthening strategies to combat antimicrobial resistance are identified as
a priority in the 2002 report Getting Ahead of the Curve.(32) This need for
high quality prescribing of antimicrobials and surveillance of antimicrobial
use resulted in the injection of £12 million (starting in 2003/2004 and
continuing for three years) into the NHS in England and Wales.(33) This
was aimed at supporting the hospital pharmacy initiative for promoting
prudent use of antibiotics and proved to be a turning point, resulting in the
recognition and expansion of the specialist antimicrobial pharmacist post.
This was further reinforced in the 2003 document Winning Ways where
clinical pharmacists were assigned a key role in supporting prudent use of
antimicrobials.(34) More recently, the role of the specialist antimicrobial
pharmacist as part of the multidisciplinary team, was again highlighted in
the 2008 document, Clean, safe care.(35) Table 2 summarises the
development of the role of the antimicrobial pharmacist through UK key
documents related to optimising antimicrobial use.
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Table 2: A summary of the development of the role of the pharmacist through United Kingdom strategic documents
related to optimising antimicrobial use
Document Endorsing Body Date Focus
The Path of Least Resistance
(28)
Standing Medical
Advisory
Committee,
Department of
Health
1998 Hospital pharmacists control prescribing and identify
inappropriate prescribing through checking of
adherence to antimicrobial guidelines.
Science and Technology 7th
Report: Resistance to antibiotics
and other antimicrobial agents
(26)
House of Lords 1998 Hospital pharmacists check prescriptions and advice
junior doctors. There is a first reference to a specialist
antibiotic clinical pharmacist.
Government Response to science
and Technology 7th Report:
Resistance to antibiotics and
other antimicrobial agents (27)
UK Parliament 1998 Pharmacists as part of a multidisciplinary team are
involved in developing local antimicrobial drug policies
depending on resistance patterns and monitoring
adherence to them.
HSC 1999/049 Resistance to
antibiotics and antimicrobial
agents – action for the NHS (29)
NHS Executive 1999 Pharmacists help optimise concordance with
antimicrobial agents
UK antimicrobial resistance
strategy and action plan (30)
Department of
Health
2000 Emphasis on surveillance, prudent antimicrobial use in
humans, diagnostic and susceptibility testing and public
education but no reference to a specific role for
pharmacists
Optimising the clinical use of
antimicrobials (31)
Clinical Prescribing
Subgroup,
Department of
Health
2001 Key document with a shift towards a monitoring and
advising role for pharmacists who should be members
of antimicrobial prescribing groups. Recommendation to
introduce specialist clinical pharmacists working
exclusively on antimicrobials.
PLCOM 3. Hospital pharmacy
initiative for promoting prudent
use of antibiotics in hospital (33)
Department of
Health
2003 £12 million funding over three years to extend activities
related to clinical pharmacy specifically around
antimicrobial use. Lead to development of numerous
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posts for specialist antimicrobial pharmacists.
Winning ways. Working together
to reduce healthcare associated
infection in England (34)
Department of
Health
2003 Clinical pharmacists, in collaboration with medical
microbiologists and infectious disease physicians, are to
provide support for prudent antibiotic prescribing in
hospitals.
Healthcare associated infection:
What else can the NHS do? (36)
Healthcare
Commission
2007 Pharmacists, as part of the antimicrobial team, play a
role in development of protocols for appropriate
antibiotic use.
Clean, safe care: Reducing
infections and saving lives (35)
Department of
Health
2008 Role of the specialist antimicrobial pharmacist as part of
the multidisciplinary team, are to promote good
prescribing practice. This is important to reduce
resistance and potential antibiotic-associated
complications such as C. difficile.
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Numerous agencies, bodies and committees in the UK focus on antimicrobial
resistance and the promotion of prudent use of antimicrobials (see Table 3).
Among these is the Specialist Advisory Committee on Antimicrobial
Resistance (SACAR), set up in 2001 to advise the government on
antimicrobial resistance.(37) A prescribing subgroup of SACAR focused
specifically on prudent antimicrobial prescribing and oversaw the hospital
pharmacy initiative £12 million funding.(38) Preliminary results indicate that
due to this funding more than 90% of acute trusts have a specialist member
of staff employed, with 90% of these being pharmacists. There remains
uncertainty as to how such posts will be funded at the end of this three year
initiative.(39) Reports of a snapshot survey aimed at looking into activities
that were facilitated as a result of this £12 million fund, indicated that the
extra staff appointed were mainly reviewing antimicrobial prescribing
guidelines, conducting audit projects, and working more closely with
microbiology and infectious diseases departments. These efforts were
reducing antibiotic acquisition costs, but no data on clinical and
microbiological outcomes was available.(40) SACAR was later replaced in
2007 by the Advisory Committee on Antimicrobial Resistance and Health
Acquired Infection (ARHAI).
Antimicrobial resistance has also been on the agenda of the Scottish
Executive (now the Scottish Government) Health Department. Following a
commitment to the 2000 UKwide strategy, a specific plan for Scotland was
published in 2002.(41) The aims were to reduce overall use of
antimicrobials, minimise the morbidity and mortality associated with
antimicrobial resistance and maintain the effectiveness of antimicrobial
agents through surveillance, prudent use of antimicrobials and infection
control. Within this strategy, pharmacists are committed to review and
monitor local guidelines on antibiotic prescribing. A series of workshops
discussed strategies to prevent infections acquired while receiving
healthcare.(42) One of the workshops focused on antimicrobial resistance
and prescribing and makes recommendations to all NHS Trusts to form
multidisciplinary antibiotic prescribing teams with the involvement of
pharmacists to take on an educational role. The Right Medicine, which
outlines a strategy for pharmaceutical care in Scotland, also highlights the
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importance of regular reviews of antibiotic prescribing by pharmacy teams
within each ward or unit.(43)
The Scottish Executive promoted the role of the antimicrobial pharmacist in
a document published in August 2005 aimed at making recommendations
for good antimicrobial practice in acute hospitals.(44) This highlighted
various problems including wide variations in antimicrobial prescribing and
policy, insufficient liaison between microbiology, clinicians and pharmacists
and inadequate supervision of prescribing by junior doctors. A
multidisciplinary antimicrobial team is recommended with participation of a
lead doctor and pharmacist along with microbiology, infectious diseases and
senior management representation. This was re-inforced in 2008 in The
Scottish Management of Antimicrobial Resistance Action Plan [ScotMARAP]
where the establishment of an antimicrobial team in each health board with
a lead antimicrobial pharmacist was once more endorsed.(45) Funding to
support the appointment of an antimicrobial pharmacist was highlighted in a
Chief Executive letter in the same year.(46)
The practice of PP within the UK has been viewed by some as a natural
extension to the role of the hospital pharmacist, including the antimicrobial
pharmacist, potentially providing several opportunities for the pharmacist to
optimise antimicrobial prescribing.(47,48) The following section aims to
describe different models of PP, both within and outwith the UK. This is
followed by a focus on the reported role within the UK of the hospital
pharmacist in optimising antimicrobial use, with an exploration on whether
any of these roles involve PP.
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Table 3: United Kingdom associations that focus on promoting the prudent use of antimicrobials and tackling antimicrobial
resistance
Acronym Full Name Website Focus
APUA Alliance for the
prudent use of
antibiotics
www.tufts.edu/med/apua Founded in 1981 and set up in 50 countries to
strengthen society’s defences against infectious
diseases by promoting appropriate antimicrobial
access and use and controlling resistance on a
worldwide basis. UK founded in 2003 in conjunction
with BSAC.
BSAC British Society for
Antimicrobial
Chemotherapy
www.bsac.org.uk Set up in 1971. Aims to set standards for
antimicrobial susceptibility testing and use, support
microbiologists in practice and offer continuing
professional development for its members. There is
also a separate website related to management of
hospital infection.
HCAI &
AMR
Department of
healthcare acquired
infection and
antimicrobial
resistance
www.hpa.org.uk/infections/about/dir
/dir_hcai.htm
(weblink no longer active)
Set up in 2001 and falls within the remit of HPA. It is
responsible for collecting surveillance data related to
healthcare acquired infection and antimicrobial
resistance. Replaced by ARHAI as below.
HPA Health Protection
Agency
www.hpa.org.uk/default.htm Set up in April 2003 in response to Getting ahead of
the curve. Offers integrated approach to UK public
health and incorporates infectious diseases, chemical
radiation and environmental hazards and emergency
preparedness.
HIS Hospital Infection
Society
www.his.org.uk Aims to bring together resources related to hospital
associated infection.
SACAR Standing Advisory
Committee on
Antimicrobial
Resistance
www.dh.gov.uk/ab/Archive/SACAR/
index.htm
www.dh.gov.uk/ab/ARHAI/index/ht
m
Set up in 2001 in response to the UK antimicrobial
resistance strategy and action plan. Prescribing
subgroup oversees the hospital pharmacy initiative.
This was later replaced by ARHAI.
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1.3 Pharmacist prescribing
1.3.1 Models of pharmacist prescribing outwith the United Kingdom
This section provides an international viewpoint on the models of PP. This
allows the reader to compare the different models of PP and its
implementation in different countries in relation to the UK. Since PP was
pioneered in the US, most of the literature available comes from here. An
overview of international PP models is available in the literature.(49)
1.3.1.1 Pharmacist Prescribing in the United States
PP has been driven by a necessity to improve healthcare delivery, with the
inability of pharmacists to prescribe resulting in time and cost impediments
to the delivery of patient care. There are two models of PP in the United
States (US) – dependent or independent authority.(50) Dependent
prescribing authority implies that the PP authority is delegated by an
independent prescriber, usually a physician, on the basis that the
pharmacist is capable of performing the delegated duties. The two have
shared responsibility for the patient’s overall outcome usually defined
through a collaborative drug therapy management (CDTM) agreement
where the physician diagnoses and makes treatment decisions and the
pharmacist selects, monitors, modifies or discontinues drug therapy as
indicated in the agreement. The CDTM may take various forms such as
general written protocols, policies or procedures or protocols for each
specific patient.(51) Independent prescribing (IP) authority implies that the
prescriber is authorised to prescribe all drugs without the supervision of
another healthcare professional.(50) The American College of Clinical
Pharmacists (ACCP) argues that prescribing within current healthcare
systems can no longer be independent due to the complexity of drug
regimens. It defines prescribing as encompassing a broader set of activities
including selecting, initiating, monitoring, continuing, modifying and
administering medications. The role of a pharmacist within a CDTM is
consequently advocated since this makes use of the expertise of both the
physician and the pharmacist.(52)
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The extent of the PP authority depends on whether the setting they are
practising is within the remit of state or federal law. The state law, which
changes from one state to another, usually favours a model where the
pharmacist is a dependent prescriber and therefore prescribing is based on
protocols or physician-defined care plans. Many states that have introduced
pharmacy prescribing have opted for this model and include California,
Kansas, Mississippi, Nevada, New Mexico, North Dakota, Oregon, South
Dakota, Texas and Washington.(50) By the end of 2003, 38 states allowed
PP for various CDTM (compared to 14 states at the end of 1996).(51) This
expansion in PP has been due to further evolvement of the healthcare
system including greater awareness of patient safety, further data showing
improved healthcare outcomes with pharmacist participation, increasing age
of the population and increased need for management of chronic diseases
and increased patient self-participation and shared responsibility for their
healthcare.(51) To ensure greater cohesiveness, it has been recommended
that prescribing authority should be obtained on a national level, embracing
all areas of pharmacy practice.(53) Examples of dependent prescribing
authority may be found in both primary and secondary care. In ambulatory
care settings, pharmacists assume responsibility for the management of
chronic conditions such as hypertension, asthma, diabetes, hyperlipidaemia
and psychiatric disorders.(54) Within a hospital environment, pharmacists
may adjust infusions of heparin therapy against a written protocol agreed
by a physician or assume responsibility for in and outpatient pain
management, including prescribing of adjunct therapy such as antiemetics,
antihistamines, laxatives and benzodiazepines.(55) Hospital pharmacists
may also be involved in automatic therapeutic substitution to ensure that
only drugs on the formulary are prescribed.(55) The American Society of
Health Care System Pharmacists (ASHP) has included PP under CDTMs as
one of its goals in the 2015 initiative. For hospital inpatients to achieve best
use of medicines it aims to have 90% of hospitals having pharmacists
manage medication therapy in collaboration with other members of the
healthcare team. This also holds for non-hospital patients such as clinic and
home-care settings.(56) Independent prescriptive authority at state level is
in place in Florida, though pharmacists may only prescribe from a limited
formulary and against strict protocols including antiemetic preparations,
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antidiarrhoeals and smoking cessation products. (50,52,57) There has,
however, been little updating of the formulary and consequently many of
the items on the formulary have become over-the-counter medicines.(55)
Interestingly, the ACCP does not support pharmacist IP based on (a) the
fact that pharmacists are not trained diagnosticians and (b) current and
future healthcare systems are moving towards collaboration and a
multidisciplinary approach.(52)
The federal government is keener to expand the prescribing authority of the
pharmacist and move towards pharmacist IP. This may be implemented
within a federal institution irrespective of the state laws and
regulations.(50) A directive of the Veteran Affairs (VA) Department lays this
down clearly “... Because states cannot regulate the activities of the federal
government, or its employees when acting within the scope of their federal
employment, except by congressional consent, state laws and regulations
relating to medication orders and prescriptions do not affect scope of
practice statements under this directive.”(58) Within the VA department,
clinical pharmacy specialists have worked as independent providers
prescribing medicines, reviewing and ordering laboratory tests, performing
venepuncture, analysing lab and diagnostic test data, performing physical
examinations and assisting in management of medical emergencies,
adverse drug reactions, acute and chronic conditions and administering
medicines.(59) Total IP authority was pioneered by Florida VA pharmacists
in outpatient clinics.(60) This expanded role of the pharmacy specialist has
been used as a model for other federal agencies such as the US Army and
the Indian Health Service.(50,61) One of the main barriers to PP in the US
has been the pharmaceutical industry since pharmacists were perceived as
more likely to prescribe generics than doctors.(55) The American College of
Physicians and American Society of Internal Medicine have issued a position
statement on the expanding role of the pharmacist in which reference is
made to PP.(62) This supports physician-directed pharmacist-physician
collaborative practice agreements but limits these to the involvement of the
pharmacist in patient education and hospital rounds. It categorically states,
“... we need to ensure that physicians control prescriptive rights and have
the final approval over all patient care decisions.” It also comments about
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pharmacist IP and does not support this, claiming that there is no evidence
that this will benefit the patient and that pharmacists are not trained to
initiate therapy. It again emphasises that “This is clearly an area that
should remain under physician authority.”
Prior to the expansion of this role of the pharmacist, in the early 1980s,
studies were undertaken to prove the advantages of pharmacists to a
clinical service. This extended role of the pharmacist within a clinical service
is now generally accepted as an integral part of healthcare and looking into
the cost effectiveness or cost benefit comparisons with physician prescribing
is no longer seen as a priority in many institutions.(55) Training for
pharmacists to prescribe is not centralised and pharmacist prescribers need
to be credentialed within their employing institution.(63)
1.3.1.2 Pharmacist Prescribing in South Africa
Pharmacists working in rural communities in South Africa were previously
issued with a permit 22A [12] allowing them to provide prescription only
medicines based on their own discretion. This was issued following
completion of the Primary Care Drug Therapy Course (PCDT). The aim was
to provide a service to patients in rural communities where most patients go
to the pharmacy before seeing a doctor and usually have no prescription. At
this point, the main barrier towards expanding the number of medicines
that may be dispensed by the pharmacist was the medical profession who
seemed to show “... fierce and organised resistance.” (64)
1.3.1.3 Pharmacist Prescribing in Canada
PP in Canada is limited and varies across provinces. Where PP occurs, this is
mainly dependent or delegated prescribing based on a collaborative
prescribing model involving an agreement between a pharmacist and a
physician.(65) There is a lack of consistency in terms of legislation across
Canadian states: some states such as British Columbia, Saskatchewan and
Quebec, support independent PP of emergency contraception; some other
states allow adapting existing prescriptions, while the broader prescribing
privileges for pharmacists are within Alberta.(65 -67) The Canadian Society
of Hospital Pharmacists advocates collaborative prescribing within
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healthcare facilities arguing that this makes use of the diagnostic expertise
of the physician and the pharmacotherapy expertise of the pharmacist.(68)
It also claims that this will provide improved patient outcomes and
increases the successful and efficient delivery of pharmaceutical care.(69)
1.3.1.4 Pharmacist Prescribing in Australia
PP has been a topic of discussion and debate in Australia with comments
that Australia has been slow to catch on to this approach to prescribing.(70)
The Society of Hospital Pharmacists of Australia supports extending
prescribing rights to pharmacists provided that these are competency
based.(71) Extension of the roles of and services provided by pharmacists
are being proposed to make better use of the pharmacists’ knowledge and
improve consumer access to medicines without compromising patient
safety.(72) Describing a PP model suitable in an Australian context has been
the topic of a published report.(72) Four models of prescribing are proposed
which differ depending on the practice setting:
(a) Medication maintenance – would be based on a collaborative
approach to manage patients in residential care facilities where
pharmacists review, renew and monitor medication based on a patient-
specific plan drawn up by a doctor who is also responsible for initiating
therapy.
(b) Advanced practitioners – this is a hospital based model where
pharmacists would be able to prescribe in a supplementary role in
designated areas within the hospital. Examples include pre-admission
clinics, outpatient clinics, specialist inpatient clinics.
(c) Protocol management – this would allow pharmacists to prescribe
medication according to a defined population based protocol such as
anticoagulation clinics
(d) Pharmacists’ formulary – this would allow pharmacists to prescribe
medications from a ‘pharmacist formulary’ and would require current
pharmacist only medicines to be incorporated into such a formulary.
Views of hospital pharmacists on PP have been explored through a
combination of a questionnaire and a focus group discussion, though the
study was limited and involved only 15 hospital pharmacists from one
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institution.(73) The pharmacists identified potential areas for
implementation of prescribing including repeat prescribing for patients with
chronic conditions, adjusting doses according to protocols and prescribing
discharge medications. Legal and ethical responsibilities, workload,
opposition from physicians and legislation emerged as potential barriers. A
wider scale questionnaire based study conducted in New South Wales
indicated that the majority of pharmacists who responded supported an
expanding PP role, acknowledging that further training was required to take
on the role.(74)
1.3.2 Development of pharmacist prescribing in the United Kingdom
The main drive towards the development of non-medical prescribing in the
UK, including PP, has been the need to make greater use of the skills and
specialisation of different healthcare professionals by creating a more
flexible system to prescribe, supply and administer medicines. This has
been the focus of the two ‘Crown Reports’ – the first published in 1998
specifically discussed patient group protocols while the second review in
1999 made recommendations on potential expansion of prescribing roles of
healthcare professionals.(75,76) The Department of Health has followed up
these recommendations with the non-medical prescribing programme. The
ultimate aim is to provide patients with better services, ensuring that safety
is not compromised.(77)
The second Crown Report describes two models of prescribing: independent
prescribing (IP) and dependent prescribing (later known as supplementary
prescribing [SP]). IP occurs when the prescribing practitioner is responsible
for patient assessment, diagnosis and clinical management, a definition that
was later revised with the implementation of non-medical IP. Dependent
prescribing usually involves delegation of authority to a non-medical
prescriber from an independent prescriber who is responsible for the initial
assessment and diagnosis.(78)
Patient Group Directions
These were initially known as ‘patient group protocols’ and allowed non-
prescribers to supply or administer medicines against a protocol without the
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need to identify the patient individually. The then legal uncertainty and lack
of consistency in the application of such protocols, both in primary and
secondary care needed to be clarified and this was the aim of the first
Crown Report.(75) This set out a description of a group protocol and made
recommendations about safe practice including criteria for content,
development and implementation. It emphasized the importance of
ensuring patient safety at any time, concluding that patient group protocols
should not replace prescribing on a named patient basis, which is preferred.
It may however have a use, in reducing patient waiting times, speeding up
patient discharge, avoiding hospitalisation and making better use of
professional skills. This report was implemented through Health Services
Circular 1998/051.(79) Proposals in the Crown Report were followed up in
the consultation document MLX 260 which proposed changes to the legal
framework to ensure that any legislative ‘loopholes’ were dealt with. There
is also a change in terminology from ‘patient group protocol’ to ‘patient
group direction (PGD)’. The legal definition of a PGD emerges as “...a
written instruction for the sale, supply and/or administration of named
medicines in an identified clinical situation. It applies to groups of patient
who may not be individually identified before presenting for treatment.”
(80) It clearly defines criteria for a PGD and proposes a list of healthcare
professionals (including pharmacists) who may supply under a PGD.(81)
Further consultations led to the expansion of healthcare professionals who
may prescribe under PGDs.(82,83)
Interestingly, specific guidance on PGDs for antimicrobials has been given.
The Department of Health (DOH) states that since resistance to
antimicrobials is a public health matter, PGDs for the use of antibiotics
should be drawn up very carefully and only with the specialist advice of a
microbiologist or public health specialist. PGDs for the use of antibiotics for
the management of minor ailments such as viral sore throats should be
avoided, and any PGDs using antibiotics should be regularly reviewed and
audited.(80,83)
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Supplementary Prescribing
The whole framework describing the potential development of SP forms the
basis of the final Crown Report Review of Prescribing, Supply and
Administration of Medicines.(76) The report argues that change was needed
in response to numerous factors including increased professional
specialisation, increased knowledge of both patient and carers and their
desire to seek advice from a wider range of healthcare professionals and a
desire on the part of the patient for seamless care. It goes on further to
note that most patients were under the care of multidisciplinary teams and
despite the fact that it was not necessarily the doctor who prescribed
medication, it was often the doctor who was asked to sign the prescription.
In view of these changes, the report, “… recommend(s) that the legal
authority to prescribe in the UK, or to authorise supply at NHS expense,
should be extended beyond currently authorised prescribers.” (76) The
concepts and definitions of both ‘independent’ and ‘dependent’ prescribing
were introduced at this stage. To ensure patient safety, prescribers should
keep within their remit of competence and should be familiar with co-
morbidities and multiple pathogens.
Following on from the Crown Report, a joint Medicines Control Agency and
DOH consultation document was issued in 2002.(84) This proposed changes
to the legislation that would permit Prescription-Only-Medicines (POM) to be
prescribed by a supplementary prescriber as part of a clinical management
plan. It suggests that following diagnosis and overall clinical assessment of
a patient, the responsibility including prescribing may be passed on to
another professional. There is also a change in terminology from ‘dependent
prescribing’ to ‘SP’ defined as follows: “A voluntary partnership between the
responsible independent prescribing and a supplementary prescriber, to
implement an agreed patient specific clinical management plan with the
patient’s agreement, particularly but not only in relation to prescribing for a
specific non-acute medical condition or health need affecting the patient.”
It was proposed to initially apply this to nurses and pharmacists, with the
possibility of later expanding to other healthcare professionals. Many of the
responses to this consultation document were positive, however a number
of concerns were raised around issues of accountability and indemnity cover
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as well as the time involved in drawing up clinical management plans.
Unnecessary prescribing of antimicrobials was of particular concern to the
Royal College of Pathologists, SACAR and the Public Health Service Board,
though this was unlikely to be a problem since most antimicrobials are
prescribed in the short term.(85)
Legislation was amended in 2003 to allow SP to come into force through
amendment of Section 63 of the Health and Social Care Act 2001.(86)
Guidance for implementation in England and Scotland was later issued.(87-
89) Emphasis was placed on appropriate training and practitioner
accreditation and the Royal Pharmaceutical Society of Great Britain (RPSGB)
has produced an outline curriculum for the training of pharmacist SP.(90)
This includes a period of learning under the supervision of an independent
prescriber. Central to SP is the Clinical Management Plan (CMP), which
needs to be drawn up for each individual patient and forms the basis for
patient management within the agreed framework between the two
healthcare professionals. Detailed guidance and templates have been
provided in various sources.(91)
Further amendments to the legislation have enabled expansion of
prescribing rights to other healthcare professionals including
physiotherapists, radiographers, podiatrists, chiropodists and optometrists.
Amendments in April 2005 have also enabled supplementary prescribers to
prescribe controlled drugs and unlicensed medications.(86)
Independent Prescribing
The Medicines and Healthcare products Regulatory Authority (MHRA) and
DOH jointly produced consultation in 2005 on introducing IP by
pharmacists, which broadened the remit of prescribing privileges by the
profession. The consultation was again based on the final Crown Report and
similar reasons were put forward as those for SP, to support expansion of
prescribing responsibilities beyond the medical profession.(92) In this
document, the definition of an independent prescriber has been broadened
when compared to the initial definition in the Crown Report, to include both
diagnosed and undiagnosed conditions as “… a practitioner responsible for
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the assessment of patients with undiagnosed or diagnosed conditions and
for decisions about the clinical management required, including
prescribing.” The proposal envisages a number of advantages if prescribing
rights were extended to pharmacists including: better use of their skills in
pharmacology and therapeutics, greater patient access to medications, a
reduction in doctors’ workloads and enabling the NHS to reach its targets. A
number of options for models of IP were proposed. Respondents were asked
to comment on each of these proposals.
1) No change
2) Prescribing for certain conditions from a limited formulary
3) Prescribing for any condition from a limited formulary
4) Prescribing for specific conditions from a full formulary
5) Prescribing for any condition from a full formulary
6) Different approaches for different clinical settings
7) A hybrid approach
It is interesting to note that the medical associations responding tended to
favour option 1 or 2. Arguments in favour of these included that diagnosis is
a very complex process beyond the skills of a pharmacist, commercial
interests of community pharmacists may be a concern, a lack of access to
the patient record especially in the community, the possibility of over-
prescribing antibiotics and a need to separate dispensing and prescribing
roles. As one association commented “… extending the role of the
pharmacists might undermine the medical degree and remove the central
role of the GP [General Practitioner].” (93) Overall, option 5 was the
majority choice preferred option with emphasis on a need to have “scope of
practice statements” where the prescriber diagnoses and prescribes
depending on his/her own skills. None of the medical associations favoured
this option with issues around complex diagnosis of multiple conditions and
antibiotic prescribing again raised. This is in line with previous policy
documents put together by the General Practitioners Committee discussing
the future of prescribing.(94,95) In the GPs views, the primary aim of PP is
a reduction in GP workload: “Can we give away GP prescribing that we do
not want as long as the GP workload goes with it?” (94) There is support
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for PP of Over-the-Counter (OTC) and Pharmacy-only (P) medications,
including prescribing for patients who are exempt on the NHS, an emphasis
on the need to shift more medicines from POM to P, and a need for greater
pharmacy involvement in repeat prescribing. Interestingly, there is no
reference to the Crown reports and the proposals to expand prescribing
privileges of non-medical professions.
Following this consultation, the DOH announced in a press release, that
nurse and pharmacist powers will be extended allowing for IP of any
condition from a full formulary for nurses and pharmacists. The Secretary of
State added that “ …extending prescribing responsibilities is an important
part of our commitment to modernise the NHS. By expanding traditional
prescribing roles, patients can more easily access the medicines they need
from an increased number of highly trained health professionals.” (96) As
from May 2006 amendment of the Medicines for Human Use (Prescribing)
Order allowed independent nurse and PP.(97) Legislation retains a similar
definition to IP as that in the MHRA consultation document, and emphasizes
that prescribing should be as part of a multidisciplinary team and with a
single accessible patient record. Pharmacists may prescribe drugs for any
condition from a full formulary with the exception of controlled drugs and
unlicensed medications. Emphasis is made on the importance of adequate
supervision, audit of practice and continuing professional development.
Guidance on the implementation of IP also recommends that apart from
exceptional circumstances, the dispensing and prescribing activities should
be kept separate.(98) The RPSGB issued an outline curriculum for training
programmes to prepare pharmacist prescribers. There was now a need to
develop assessment and diagnostic skills needed by a prescriber likely to be
prescribing autonomously. There was also emphasis on a need for the
pharmacist to be aware of personal limitations and a scope of professional
competence.(99) The RPSGB also issued guidance to outline the training
needs of supplementary prescribers who will be training to become
independent prescribers.(100)
A consultation process was carried out in 2007 to seek views of
stakeholders on the IP of controlled drugs by pharmacist and nurse
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independent prescribers.(101) Though this consultation recommended a
change in legislation, pharmacists and nurses cannot currently
independently prescribe controlled drugs since a change to the Misuse of
Drugs Regulations, 2001, is still awaited. Further change in legislation in
2009 enable pharmacist and nurse independent prescribers to mix
medicines prior to administration in all clinical areas and to prescribe
unlicensed medicines.(102-104) Table 4 summarises key developments
relating to PP.
Table 4: A summary of UK legislation relating to PP
Year Development
1999 Crown Report recommended potential expansion of
prescribing roles to other healthcare professionals (76)
2003 Section 63 of the Health and Social Act 2001 amended to
allow pharmacist SP as part of a CMP (86)
2005 Amendments allowing pharmacists SP of controlled drugs
and unlicensed medications as part of a CMP (86)
2006 Amendment of The Medicines for Human Use
(Prescribing) Order allowing pharmacist IP of all licensed
drugs except controlled drugs (97)
2009 Amendments allowing pharmacists IP of unlicensed
medicines and mixing of medicines prior to administration
in clinical practice (103,104)
The expansion of prescribing rights to pharmacists has not been met
favourably by medical associations, the BMA GP Committee commenting
that “ This announcement raises patient safety issues and we are extremely
concerned that the training provided is not remotely equivalent to the five
or six years’ training every doctor has undertaken.” (105) The BMA’s
consultants’ committee goes even further saying “This is an irresponsible
and dangerous move. Patients will suffer.” (105) An editorial in a leading
medical journal published shortly after the decision was announced argues
that it is likely for nurses and pharmacists to prescribe responsibly within
their remit of expertise and competence. It does however conclude that the
decision to expand pharmacist and nurse prescribing rights might have been
taken at a later stage, when more evidence is available to support
this.(106) This opinion has been supported by the World Medical
Association’s General Assembly in 2010. In a statement representing the
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opinion of 50 national medical associations, they comment that in the
interest of patient safety, “… the physician was the best qualified individual
to prescribe independently.” (107)
1.3.3 Implementation and Outcomes of pharmacist prescribing in the United
Kingdom
This section aims to provide a descriptive account of the application of PP,
followed by a critical appraisal of PP primary research in the UK.
1.3.3.1 Descriptive accounts of the application of pharmacist prescribing in
the United Kingdom
The following provides an overview of practice settings and areas of care of
PP in the UK; most of the information is based on narrative reports and
reviews.
February 2004 saw the first pharmacist prescribers to be registered by the
Society with the first prescription written by a supplementary prescriber
reported in March 2004.(108,109) Following this, there have been reports
on the delivery of PP and plans for service development in different
healthcare settings which may be divided roughly into four models:
community pharmacy, hospital, general practice settings and at the
primary/secondary care interface.(110) In some cases, pharmacists had
already been making recommendations to doctors, and consequently SP
became an extension of previous practices, particularly in a hospital setting.
As one pharmacist puts it “We used to write the prescription out and the
doctor would sign it…Supplementary prescribing, in a sense, is a way of
legalising what the pharmacists did before.” (111) All reports in the
literature are descriptive narratives of the implementation of pharmacist SP
in the different areas of care with no studies measuring the outcomes of PP.
The broad practice of hospital pharmacists lends itself well to PP, with
hospital pharmacists having access to patient records and already practicing
as part of a multidisciplinary team.(112) Again, most of the reports in the
literature are descriptive, commenting on pharmacist implementation of SP
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in secondary care, with no robust research design or measure of outcome.
For example, one NHS Trust is reported to use the skills of pharmacist
prescribers in different care settings, such as the clinical nutrition team,
Human Immunodeficiency Virus (HIV) outpatient clinic setting and in critical
care where dose adjustment of drugs requiring therapeutic drug monitoring
(such as aminoglycosides and vancomycin) is carried out.(111) In another
case scenario, PP has been used to improve discharge planning on a cardiac
unit.(113) SP outpatient clinics have also been reported in
rheumatology.(114)
Supplementary PP within primary care medical practices may be logistically
easier than within a community pharmacy setting due to the relatively
easier access to both the independent prescriber and patient records.(112)
Reports of pharmacist-led clinics in primary care settings include
hypertension and clinical risk reduction clinics as well as a menopause and
osteoporosis clinic.(115-7) Different reports of improved patient outcomes
involving pharmacist SP include a mean reduction in glycosylated
haemoglobin, cholesterol and systolic blood pressure following a pharmacist
run primary care clinic for patients with uncontrolled type 2 diabetes, and a
reduction in waiting time for oncology patients needing amendments to
their antiemetic and cytotoxic drug regimens.(118) However, there are no
studies measuring the outcomes of PP in these scenarios.
1.3.3.2 Pharmacist prescribing research in the United Kingdom
Studies exploring intra-professional perspectives of pharmacist prescribing
A) Supplementary prescribing
Early experiences of pharmacist SP were explored through a cross-sectional
survey, with a piloted and validated postal questionnaire sent to all
pharmacist prescribers, (n=488 after removing the pilot sample of 30)
registered in June 2005 in Great Britain.(119) This was the first such large
scale study and therefore crucial in providing baseline information on early
implementation of SP. The authors obtained a response rate of 401 (82.3%)
with respondents representing hospital, community and primary care
settings. 48.6% of respondents self-reported practicing SP, with
practitioners in primary care settings most likely to be implementing SP
Chapter 1 – PP and potential role in optimising antimicrobial use 31
compared to those in community or hospital pharmacies. Prescriptions had
been mainly written for cardiovascular medications. Participants identified
job satisfaction, increased self confidence, greater recognition and time
savings as benefits of implementing SP. Financial and organisational
problems, a general lack of awareness of the pharmacist’s role and
restrictions due to the clinical management plan emerged as the main
barriers to PP. Results from an open question in this same survey were
reported separately.(120) Interestingly, SP emerged as a natural extension
of the pharmacist roles particularly in hospital and primary care settings.
“Supplementary prescribing has little changed my practice – it has legalised
what I did anyway.” (120) The legally required CMPs were considered to be
restrictive and time consuming, with pharmacists commenting that it may
be easier to write up a prescription and get the independent prescriber to
sign it, rather than complete a CMP. Consequently, independent PP was
perceived as a potential solution to this problem.
Hobson et al’s report was a questionnaire based national survey, designed
to explore the implementation of pharmacist SP in England.(121) Previously
validated and piloted questionnaires were sent out to pharmacists (n=151
secondary care trusts; n=273 primary care trusts) in both primary and
secondary care who would oversee implementation of pharmacist SP.
Results (response rate=68% for both surveys) indicated that the number of
supplementary prescribers tended to be higher the bigger the NHS Trust or
size of hospital. Total parenteral nutrition (TPN) or clinical nutrition was
identified as the speciality with most supplementary prescribers. Other
clinical areas where pharmacists were being trained to be supplementary
prescribers included HIV, cystic fibrosis and surgery/orthopaedics.
Interestingly, there were more secondary care pharmacist prescribers than
primary care pharmacist prescribers possibly since in primary care,
prescribing is often being used to set up a new service whereas in
secondary care it is being used to “… legitimize services already being
provided.” (121) This differs from conclusions drawn by George et al, where
pharmacists in primary care settings were most likely to be implementing
prescribing. This is possibly due to the fact that the latter questionnaires
have been sent out to the practising pharmacists rather than the
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pharmacists implementing the prescribing.(119) Different geographies may
also have contributed to these differences with George et al having included
Great Britain while Hobson et al included only England.
In a small-scale study, Warchal et al used a piloted questionnaire (n=63;
response rate=60.4%) and telephone interviews (n=10) to explore
supplementary prescribers’ attitudes and experiences related to their
extended roles, with 30% of pharmacists then on the register invited to
participate.(122) Pharmacists were asked reasons for introducing SP, with
the majority indicating a wish to make better use of existing skills and to
benefit patients. Barriers to prescribing were mainly related to the
infrastructure, and included availability of computer generated
prescriptions, lack of remuneration for the new role and a lack of continued
support. Hospital pharmacists encountered fewer barriers than primary care
or community pharmacists, mainly due to the availability of patient notes
and pre-existing supportive infrastructure. Most of the respondents
(n=81.6%) intended to become independent prescribers within the next five
years and hence develop their role as opportunities and training became
available.
Tully et al explored pharmacists’ views and experiences towards the change
in responsibility and accountability as part of SP. (123) This was achieved
by conducting a pair of interviews with 8 participants who practised mainly
in secondary care; the first was pre-training, and the second 6-8 months
after completing training to qualify as a SP. At the first interview, most
pharmacists were enthusiastic and optimistic to supplementary prescribe
seeing this as an opportunity to regularise their work and provide a
smoother service. Post-training, a number of barriers most of which were
highlighted in other research, emerge. The CMP as a requirement of SP and
the lack of staff to sustain the service, were the main concerns. Again, as in
other research, the participants were keen to move on to independently
prescribe.
Results of another UKwide study exploring the views of pharmacist
supplementary prescribers on their current and potential future roles as
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prescribers, have been reported by Weiss et al.(124) Semi-structured
interviews were conducted with a UKwide purposive sample of 23
pharmacists, practising in both primary and secondary care settings. While
some pharmacists felt that SP was no change to their previous practice,
other pharmacists felt it increased their professional status. Concerns were
raised about ways of ensuring that prescribing was within the individual’s
competency. Pharmacists also highlighted the importance of ensuring
effective communication within a team if the prescribing process was being
broken down. As in other research, participants were not comfortable in
their own clinical examination and diagnostic skills.
Tables 5, 6a and 6b present a critical appraisal of these publications.
B) Independent Prescribing
As may be expected, being such a novel topic, there is little evidence
exploring pharmacists’ awareness, views and attitudes on being
independent prescribers. George et al aimed to explore this in a sample
(n=500) of Scottish community pharmacists, who were sent a validated and
piloted questionnaire.(125) A 43.4% response rate was reported. The
respondents appeared to be well informed and 91.2% knew about proposals
for pharmacists to become independent prescribers. Interestingly, though
80.5% reported being happy to be independent prescribers, only 53.5%
believed that it was their professional duty to do so. Participants perceived
better patient access to medications as the main advantage of pharmacist
IP. As expected, pharmacists who were already supplementary prescribers
and “leading edge practitioners” were more likely to embrace the idea of
pharmacist IP (the original Crown Report definition was used in this study
rather than the broader definition later incorporated in the final legislation –
see Section 1.3.2). Though this study provides some valuable insight, it is
limited to community pharmacists in Scotland; it would be interesting to
explore the willingness of pharmacists to take on IP in other areas of
practice throughout the UK.
C) Impact of pharmacist prescribing on patient care
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Few UK studies in the literature measure the impact of the pharmacist
supplementary prescriber on patient care. A small-scale, single-site trial has
been reported and seeks to measure the outcome of PP in an intensive care
unit (ICU). A retrospective trial of before and after SP was carried out to
determine the level of adherence to guidelines of pharmacist supplementary
prescribers with doctor prescribers of anti-infective agents in haemofiltered
patients.(126) Results showed that 53.7% of prescriptions issued by
doctors adhered to guidelines while 100% of the prescriptions issued by
supplementary prescribers were appropriate. Though a single-centre small-
scale non-randomised trial, it shows that PP may impact positively on acute
care. In a separate commentary, the author highlights problems
encountered on ICU, which are common to other areas of secondary care,
with emphasis on the fact that proposed changes to patient’s medications
agreed and discussed during the ward round were not implemented by
doctors. Reasons may include doctors forgetting, considering other matters
as a priority or a lack of understanding. The author argues that due to the
mainly drug-focused activities of the pharmacists, PP is a natural extension
of the pharmacist role and consequently PP was introduced in this practice
setting to optimise patient care.(127)
Studies exploring inter-professional perspectives of pharmacist prescribing
One study (128) aimed to determine the factors that would enable or inhibit
implementation of non-medical prescribing, focusing on the attitudes of key
stakeholders to non-medical prescribing. Data were generated through a
number of semi-structured interviews with stakeholders (medical staff,
pharmacists and nurses) working in a secondary care environment. Though
medical staff accepted PP, they were only prepared to do this within set
boundaries and protocols within which pharmacists could prescribe. They
expressed concern around pharmacist IP, even if this involved “more
simple” cases including prescribing of analgesics and switching
antimicrobials from the intravenous to the oral route. When compared to
nurses, pharmacists were seen as being disadvantaged in that they did not
have enough patient contact to know the patients well enough to be able to
prescribe safely. A concern about the pharmacist’s lack of diagnostic skills
was also raised. This study raises issues on potential barriers which may
Chapter 1 – PP and potential role in optimising antimicrobial use 35
arise due to the encroachment of traditional roles with the advent of non-
medical IP.
These barriers were also highlighted in other research (129) that involved
focus group discussions and interviews with pharmacists who were enrolled
on a SP course, and medical staff who had agreed to act as their mentors
during their SP training. This research aimed to explore pharmacists’ and
mentors’ views on the introduction of pharmacist supplementary prescribers
and thus recruited participants in different practice settings, prior to them
embarking on their training programme. Again, the mentors felt that SP
was the more appropriate process for PP since it set the barriers within
which they would be able to prescribe. Issues were raised also about the
lack of pharmacist diagnostic skills that are required as part of IP. Despite
these difficulties, both pharmacists and mentors believed that pharmacist
SP is likely to improve overall patient care. The same participants were
followed up 12 months after the pharmacists qualified.(130) Most
pharmacists who were actively prescribing worked in a hospital setting.
Participants believed that optimal settings for PP were outpatient clinics or
chronic diseases that are protocol-driven. Both pharmacists and their
mentors felt that pharmacist SP enabled pharmacists to progress
professionally and to gain confidence in their skills, with a strong mentor-
pharmacist relationship making it more likely for the pharmacist SP to be
successful. Pharmacists perceived a degree of professional encroachment by
both nurses and doctors, with these other healthcare professionals feeling
threatened by the pharmacists’ new role. Other barriers included the
paperwork involved in implementing CMPs and a lack of pharmacy resource
to maintain the service. Pharmacists believed that progression to IP was the
way forward, though both pharmacists and mentors believed that
pharmacists would be likely to independently prescribe if a diagnosis had
already been made, and where the condition is protocol-driven.
Pharmacist prescribers participating in research conducted by Stewart et al.
were also eager to take on IP in the future, though doctors, particularly in a
primary care setting, were concerned about the lack of pharmacist
diagnostic skills. This study adopted a case-analysis approach and
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interviews were conducted with pharmacist supplementary prescribers,
doctors who were their linked independent prescribers and patients.(131)
Pharmacists viewed SP as “… a natural extension to their advisory role,
almost legalising their current practice.” Patients were initially apprehensive
about having a pharmacist consultation but provided positive feedback
following their experiences. All stakeholders felt that patient outcomes were
positive following the introduction of pharmacist SP. Healthcare
professionals perceived enhanced teamwork to be the main benefit while a
lack of support together with patient demands were reported to be the main
challenges of pharmacist SP.
A study, focusing in a primary care setting, aimed to explore pharmacists’
and GPs’ perceptions on the potential effect of pharmacist SP on
professional boundaries.(132) Pharmacists included in this research were
early adopters and commented that it was through their own initiative that
they had identified an area within which they could prescribe. As in other
research, they felt that a pre-existing strong working relationship with the
GP practice was likely to ensure more successful implementation of
pharmacist SP. A good level of patient acceptance was reported by both GPs
and pharmacists; however there were mixed reactions and views as to
whether a pharmacist SP was threatening the medical prescriber’s
professional identity.
Further details and a critical appraisal are at Tables 5, 6a and 6b.
Studies exploring patient perspectives of pharmacist prescribing
One small-scale study has aimed to evaluate patients’ perceptions of a
pharmacist-led SP hypertension clinic.(133) A self-administered piloted
questionnaire was sent to all patients (n=127) who had been invited to
attend the clinic, including those who had refused the appointment. 57% of
respondents felt the standard of care was better than previous care and
86% indicated that they could make an appointment more easily. Patients
who refused the appointment indicated that they would like to continue with
their present GP or nurse rather than a pharmacist. Others said that they
were given an inconvenient appointment date or time. This study may be
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viewed as an audit of the service provided; no statistical analysis was
performed and the author states that the questionnaire was aimed at
finding ways to improve the current service being offered. As with all
questionnaire based studies, non respondent bias may be a disadvantage
since the non respondents may be patients who felt they had a negative
experience of the clinic. However, it does indicate that there was a general
acceptance of patients for non-medical prescribing.
Another small-scale study (134) as part of a larger case-based study,(131)
aimed at exploring patients’ perspectives of pharmacist SP in Scotland. This
involved distributing pre-piloted questionnaires based on previous research,
to patients (n=180) as they attended their appointments with a pharmacist
SP mainly in community settings (further detail of the settings has been
provided in Table 6a below). A response rate of 57.2% (n=103) was
achieved and the main conditions managed by the pharmacists were
hypertension and asthma. Though around 89% of patients were totally
satisfied with their consultation, 65% still preferred to consult a doctor.
A broader study aimed to determine views on attitudes of the Scottish
general public on non-medical prescribing, with a focus on PP through a
postal pre-piloted questionnaire.(135) A 34.6% (n=1728) response rate is
reported. 56.6% of respondents were aware that a healthcare professional
other than a doctor could prescribe their medication, with greatest
awareness of the pharmacist’s role. Television and newspapers were the
main source of this information. Patients were comfortable mainly with a PP
a medicine previously prescribed only by a doctor, with just over half
supporting a prescribing role for a pharmacist. Concerns were raised about
the lack of diagnostic skills of the pharmacist and a lack of privacy in a
pharmacy. Overall, patients appeared to accept a prescribing role for a
pharmacist though, prescribing a smaller range of medicines than doctors
and if a diagnosis had been made by a doctor.
A recently published study aimed to explore patients’ perceptions of the
capability of a pharmacist to be a non-medical prescriber; it also explores
any preferences patients may have between consulting a pharmacist or a
nurse.(136) This was achieved by conducting semi-structured interviews in
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primary and secondary care settings, with both patients who had
experience of a PP and those who did not. Patients perceived pharmacists to
have an inferior knowledge to doctors and nurses with a lack of patient
awareness of pharmacist length of training. They suggest that they would
trust a pharmacist more once a relationship has been established.
Discussions focused mainly around community pharmacies, with numerous
concerns relating to clinical governance and confidentiality in community
pharmacies expressed. The findings of this study somewhat contradict those
by Stewart et al (135) described above; these differences in findings may
be attributed to different geographical areas and different methods
employed in the studies.
A critical appraisal of the studies may be found at Tables 5, 6a and 6b
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Table 5: A critical appraisal of questionnaire based surveys exploring pharmacist prescribing (137,138)
(note this table is 5 pages long)
Criteria George et al 2006
(125)
George et al 2006
(119)
George et al
2006 (120)
Hobson et al 2006
(121)
Stewart et al
2009 (135)
Study population
and survey sample
Study population
clearly defined and
appropriate
A random sample
from all
community
pharmacies in
Scotland n=500
All pharmacist
supplementary
prescribers
registered in June
2005 n=518
All pharmacist
supplementary
prescribers
registered in
June 2005
n=518
All chief
pharmacists in
primary (PCT)
(n=271) and
secondary care
trusts (SCT)
(n=143) in
England
A random sample
of members of
the general
public (n=5000)
aged 18 or over
obtained from
the UK electoral
roll
Sampling strategy Ex
stratified, randomized,
sequential, inclusion
and exclusion criteria
Randomized using
random numbers
Not applicable since
all prescribers were
included
Not applicable
since all
prescribers were
included
Not applicable
since all chief
pharmacists were
included
Random sample
but method for
randomization
not described
Sample size
determined
beforehand with a
suitable description of
how this was achieved
n=500 but no
information
provided on how
sample size was
determined or
what proportion of
community
pharmacies this
included
Not applicable; no
sampling required
Not applicable;
no sampling
required
Not applicable; no
sampling required
n=5000 but no
information
provided on how
sample size was
determined
How the survey was
conducted Ex face-to-
face interviews;
telephone interviews;
Mailed
questionnaire
addressed to the
managing
Mailed
questionnaire
Mailed
questionnaire
Mailed
questionnaire;
SCT
questionnaires
Mailed
questionnaire
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mailed questionnaire pharmacist were addressed to
the chief
pharmacists; PCT
questionnaires
were addressed to
the PCT
pharmacist or
pharmaceutical
advisor
How the response rate
was maximised
Two questionnaire
reminders sent to
non-respondents
at 4-weekly
intervals
Three reminders
sent to non-
respondents at 2-
weekly intervals
Three reminders
sent to non-
respondents at
2-weekly
intervals
Second mailing of
questionnaire
after 3 weeks;
follow up
telephone call
after 4 weeks to
SCT, mailing to
PCT; last mailing
after 3 weeks
Two
questionnaire
reminders sent to
non-respondents
at 4-weekly
intervals
Response rate
including a description
of participants who
were unsuitable for
research or refused to
take part
n = 217 (43.4%) n =401 (82.2%) n=401 (82.2%)
but only about
1/3 completed
the open
question
n=68% for both
surveys
n=1728
(34.6%); n=343
(6.9%) returned
undelivered due
to addressee
moving
Description and
discussion of any
potential response
bias
Considered;
authors discuss
the possibility that
most respondents
who had an
interest in IP were
more likely to
respond
Not discussed; but
unlikely to be any
response bias due
to the high
response rate
Considered Not discussed Considered;
authors discuss
the possibility
that non-
respondents had
little interest in
the topic
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Questionnaire
A description of the
questionnaire
development Ex what
process was used to
create the
questionnaire, was a
literature search done
to identify key areas,
were previous
questionnaires
adapted or combined
Provided; this was
based on policy
documents
Not provided Not provided Provided;
informed by a
literature review,
interviews with
policy makers and
academic
pharmacists and a
focus group.
Provided; this
was informed by
the current
literature
Reliability testing;
assessing
reproducibility and
consistency
Not described Described Not described Not described Described;
limitations of the
study relating to
test-retest
reliability are
highlighted
Content or face
validity testing
Done by an expert
panel of
practitioners and
researchers
Done by four
experts
Done by four
experts in non-
medical
prescribing
Done Done by an
expert panel of
academic
pharmacy
practitioners and
researchers
Piloting Done by sending
to 30 random
pharmacists;
some minimal
changes followed
Done by sending to
30 pharmacists
selected randomly;
some minor
revisions followed
Done by sending
to 30
pharmacists
selected
randomly; some
minor revisions
followed
Done by sending
to 17 SCT
pharmacists and
30 PCT
pharmacists;
some minor
revisions followed
Done by sending
to 500 members
of the public;
some minimal
changes followed.
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A description of the
questionnaire content
Ex the number of
questions/items, open
or close ended
questions
Clearly described Clearly described Clearly described Clearly described Clearly described
Analysis
What sort of analysis
was carried out and
was this appropriate?
Ex correct statistical
tests for quantitative
answers; qualitative
analysis for open
ended questions
Statistical tests
were presented
for quantitative
answers; content
analysis
performed for
qualitative
analysis but not
presented in this
paper
Statistical tests
were presented for
quantitative
answers; no details
are provided on
analysis of open
questions
Descriptive
statistics
provided;
statistical tests
were not
presented for
quantitative
answers; content
analysis of open
question
provided here
with adequate
thematic
description and
illustrative
quotes
Descriptive
statistics
provided;
statistical tests
were presented
for quantitative
answers
Statistical tests
were presented
for quantitative
answers; key
themes identified
through open
question
presented but no
discussion of
derivation of
these themes.
Results
Reporting of all
relevant data to
include
Provided Provided Provided Provided Provided
Reporting of both
significant and non-
significant results
Provided Provided Not applicable Provided Provided
Adequate reporting of
qualitative results
Not available Not available Provided Not available Partially provided
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Discussion
The results in relation
to the objectives of
the study
Discussed Discussed Discussed Discussed Discussed
Possible
interpretations
Discussed Discussed Discussed Discussed Discussed
Comparisons with
other studies
Discussed but few
studies to
compare with
Discussed but few
studies to compare
with
Discussed but
few studies to
compare with
Not discussed, but
few studies to
compare with
Discussed but
authors
acknowledge that
few studies to
compare with
Strengths and
limitations
Discussed Discussed Discussed Discussed Discussed
Future research Not included Discussed Discussed Not discussed Discussed
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Table 6a: A critical appraisal of qualitative based research on pharmacist prescribing (139)
(note this table is 6 pages long)
Criteria Warchal et al
(122)
Buckley et al (128) Lloyd et al (129) Tann et al (132) Stewart et al (131)
Research design
Justification by
authors of research
design to address
the aims of the
research
No No No No No
Is a qualitative
method appropriate
Yes – a mixed
method used here
where participants
were sent a
questionnaire
containing both
open and closed
questions;
answers were then
validated through
a telephone
interview. It aims
to explore the
attitudes of
pharmacist
supplementary
prescribers to their
training and
extended roles
Yes – aims to
explore the
attitudes of
stakeholders to
non-medical
prescribing
Yes – aims to
explore the
context and views
of pharmacist
supplementary
prescribers and
their mentors
Yes – aims to
explore the
perceptions of GPs
and pharmacists of
SP
Yes – a mixed
method involving
interviews, video
recording and a
questionnaire used
as part of a
qualitative case-
study approach.
Only the interviews
are reported in this
paper.
Questionnaires
distributed to the
patients are
reported
elsewhere. (134)
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Sampling of
participants
Sampling strategy
Ex purposive,
theoretical,
exclusion and
inclusion criteria
Purposive
sampling; only
pharmacists
known to have
completed the
course were
recruited. However
no details provided
as to why the
specific
participants were
invited to
participate.
Demographics of
participants
provided.
Purposive
sampling; no
details provided of
the characteristics
of participants
included
Purposive
sampling;
demographics of
participants
provided
Purposive
sampling; no
details provided of
characteristics of
participants.
However, a
comprehensive
background
provided on the
GP practices where
participants
practised.
Purposive
sampling; a
comprehensive
account is provided
on how the 10
case study sites
were generated.
Was the sampling
in line with the
research aims
Yes Yes Yes Yes Yes
Any justification of
sample size Ex
limited sample,
data saturation
Not provided Not provided Yes Not provided Not provided
Any discussions
provided around
participant
recruitment Ex
have any refused
Provided Not provided Provided Provided Provided
Were participants
selected the most
Yes, though there
is no discussion
Details of
participants not
Yes Yes Yes
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appropriate to
provide the type of
knowledge sought
by the study
around how these
participants were
sampled from all
the supplementary
prescribers
provided so cannot
0be determined
Data generation
Method for data
generation clear Ex
focus group,
interviews
Clear.
Questionnaire and
telephone
interviews
Clear.
Semi-structured
interviews
Clear.
A combination of
focus groups and
semi-structured
interviews
Clear. A
combination of
focus groups and
interviews
Clear.
Telephone
interview
Method for data
generation explicit
including
development and
piloting Ex has
topic guide been
used
Provided Not provided Provided Not provided
though the topics
discussed were
highlighted
Provided
Setting for data
collection clear
Yes – participants
provided a mix of
hospital, primary
care and
community
pharmacy settings.
Yes – a secondary
care trust
Yes – pharmacists
and their mentors
prior to starting
training as
supplementary
prescribers.
Involved hospital,
community and
primary care
pharmacy settings.
Yes – three
practices within
two primary care
trusts with a high
proportion of
pharmacist SPs.
Yes – participants
provided a
spectrum of both
geographical
location within
Scotland and
pharmacy settings,
though only one
case was hospital
based.
Justification of
methods chosen
Not provided Not provided Not provided Not provided Not provided
Consideration of
who collects the
Not provided Not provided Provided Not provided Provided
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data
Any modification of
methods during the
study and why
None None None None None
Clear format of the
data collected Ex
transcripts, audio-
recordings, video-
recordings
Clear.
Questionnaire;
transcripts from
telephone
interviews were
recorded manually
Clear.
Audiorecordings of
interviews which
were then fully
transcribed
Clear.
Audiorecordings of
discussions and
interviews which
were then fully
transcribed
Clear.
Audiorecorded
with detailed field
notes taken
Clear.
Audiorecorded and
transcribed
verbatim
Discussion around
data saturation
Not provided Not provided Provided Not provided Provided
Reflexivityii
Researcher bias
and potential
influence
considered at the
planning stage of
the research Ex
formulation of
research questions
Not discussed Not discussed Discussed Not discussed Not discussed
Researcher bias
and potential
influence
considered during
the data collection
Not discussed Not discussed Discussed Not discussed Not discussed
Ethical issues
Consideration of
ethical issues that
the study may have
Not discussed Ethical approval
sought; all
participants and
Ethical approval
sought; all
participants and
Ethical approval
sought: all
participants and
Ethical approval
sought: all
participants and
ii This involves answering the question “Has the relationship between researcher and participants been adequately observed?”
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arisen and steps
taken to deal with
these
quotes provided
are anonymised
quotes provided
are anonymised
quotes provided
are anonymised
quotes provided
are anonymised
Data analysis
Clear description of
analysis process
used or framework
applied
No Yes Yes Yes Yes
Clear description of
derivation of
themes and
categories from
data
No Yes Yes Yes Yes
Provision of
sufficient data to
support findings
Yes Yes Yes Yes Yes
Consideration of
any contradictory
data that may have
arisen
Yes Yes Yes Yes Yes
Researcher bias
and potential
influence
considered during
the data analysis
Not discussed Not discussed Yes Yes, though not
discussed
Yes, though not
discussed
Results
Results are clear
and explicit
Yes Yes Yes Yes Yes
Evidence provided
both for and
against the
researcher’s
Yes Yes Yes Yes Yes
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arguments
Consideration of
issues around
credibility Ex
triangulation, more
than one analyst
Discussed Not discussed Discussed Discussed Discussed
Discussion
The results in
relation to the
original research
question
Considered Considered Considered Considered Considered
The results in
relation to the
current literature
Provided though
limited by lack of
literature available
Provided Provided Considered Considered
Issues around
transferability and
application of
research
Provided Provided Provided Provided Provided
Future research Provided Provided Provided Not provided Provided
Conclusion
appropriate to
research aim
Yes Yes Yes Yes Yes
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Table 6b: A critical appraisal of qualitative based research on pharmacist prescribing (cont.) (139)
(note this table is 4 pages long)
Criteria Hobson et al (136) Tully et al (123) Weiss MC et al (124)
Research design
Justification by authors of
research design to address the
aims of the research
No Yes No
Is a qualitative method
appropriate
Yes – aims to explore
patients’ perceptions of
capability of pharmacist
to prescribe and whether
patients had any
preferences between
consulting a pharmacist
or a nurse and why
Yes – aims to explore
pharmacists’ views and
experiences towards the
change in responsibility
and accountability as
part of SP
Yes – aims to explore
pharmacists’ views on their
current and potential future
role as a prescriber
Sampling of participants
Sampling strategy Ex
purposive, theoretical,
exclusion and inclusion criteria
Purposive sampling – this
included 4 sites in
primary and secondary
care where a pharmacist
was actively prescribing.
Randomization used to
select patients. Both
patients who had
experience of a PP and
those who did not were
recruited to allow
comparisons to be made.
Demographics of patients
provided
Purposive sampling but
no details provided of the
participants with
exception of setting and
geographical location
Purposive sampling – a
sample of pharmacists from
all the UK who were on the
SP register at the time of
the study
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Was the sampling in line with
the research aims
Yes Yes Yes
Any justification of sample size
Ex limited sample, data
saturation
Yes – patients were
recruited until data
saturation was achieved
Not provided Not provided
Any discussions provided
around participant recruitment
Ex have any refused
Not provided Not provided Provided
Were participants selected the
most appropriate to provide
the type of knowledge sought
by the study
Yes Yes Yes
Data generation
Method for data generation
clear Ex focus group,
interviews
Clear. Semi-structured
interviews
Clear. Semi-structured
interviews
Clear. Semi-structured
interviews and case studies;
only the interviews are
reported here
Method for data generation
explicit including development
and piloting Ex has topic guide
been used
Provided Partially provided – some
detail given on focus of
interviews but nothing on
development or use of a
topic guide
Not Provided
Setting for data collection clear Yes – both primary and
secondary care
Yes – mainly secondary
care
Yes – both primary and
secondary care
Justification of methods chosen Not provided Not provided Not provided
Consideration of who collects
the data
Not provided Not provided Not provided
Any modification of methods
during the study and why
None None None
Clear format of the data
collected Ex transcripts, audio-
recordings, video-recordings
Yes – interviews were
audio-tape recorded and
transcribed
Yes – interviews were
audio-tape recorded and
transcribed
Yes – interviews were audio-
tape recorded and
transcribed
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Discussion around data
saturation
Provided Provided Not provided
Reflexivity
Researcher bias and potential
influence considered at the
planning stage of the research
Ex formulation of research
questions
Not discussed Not discussed Not discussed
Researcher bias and potential
influence considered during the
data collection
Not discussed Not discussed Not discussed
Ethical issues
Consideration of ethical issues
that the study may have arisen
and steps taken to deal with
these
Ethical approval sought;
all participants and
quotes provided are
anonymised
Ethical approval sought;
all participants and
quotes provided are
anonymised
Ethical approval sought; all
participants and quotes
provided are anonymised
Data analysis
Clear description of analysis
process used or framework
applied
Yes Yes Yes
Clear description of derivation
of themes and categories from
data
Yes Yes Yes
Provision of sufficient data to
support findings
Yes Yes Yes
Consideration of any
contradictory data that may
have arisen
Yes Yes Yes
Researcher bias and potential
influence considered during the
data analysis
Not discussed Not discussed Not discussed
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Results
Results are clear and explicit Yes Yes Yes
Evidence provided both for and
against the researcher’s
arguments
Yes Yes Yes
Consideration of issues around
credibility Ex triangulation,
more than one analyst
Not discussed Not discussed Not discussed
Discussion
The results in relation to the
original research question
Considered Considered Considered
The results in relation to the
current literature
Provided Provided Provided
Issues around transferability
and application of research
Provided Provided Provided
Future research Provided Provided Provided
Conclusion appropriate to
research aim
Yes Yes Yes
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1.4 The role of the hospital pharmacist in improving antimicrobial
prescribing in the United Kingdom
The potential value of the hospital pharmacist in improving antimicrobial
prescribing has been described in the literature. Overall, many publications
describe the pharmacist’s intervention with few controlled trials evaluating
the outcomes of such interventions. Trials often tended to focus on
economic evaluations with little or no evaluation of clinical or patient
outcomes. Further details are in Chapter 2. This section will describe the
role within the UK of the hospital pharmacist, including the antimicrobial
pharmacist, in improving antimicrobial prescribing and will explore whether
there is a potential for PP to enhance this role.
In his commentary on the role of the hospital pharmacist in antimicrobial
management, Cooke encourages the collaboration of the pharmacist with
the microbiologists and other clinicians.(38) The potential role of hospital
pharmacists has been described in various papers and includes:
(38,48,140,141)
 Promoting guidelines, formularies and policies using guidance from
SACAR to ensure consistency in content and quality
 Encouraging prescribers to use systemic medication rather than
topical medication due to increased resistance with the latter
 Taking the lead in intravenous to oral switching where appropriate
 Ensuring appropriate duration of treatment using various strategies
such as automatic stops
 Using pharmacokinetic knowledge to ensure optimal antimicrobial
dosing in individual patients
 Ensuring appropriate administration of antimicrobials required for
surgical prophylaxis
 Resistance monitoring and sensitivity possibly with selective reporting
in collaboration with microbiology departments
 Preparation of intravenous antimicrobials
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 Encouraging the development of information technology (IT)
prescribing support systems with links to local antimicrobial
sensitivity profiles
 Leading on educational initiatives to train prescribers including
running formal training initiatives, education during ward rounds and
providing feedback following audits
 Ensuring patient safety by monitoring for allergies
 Providing information on the safe use of antimicrobials in specific
clinical situations such as in organ dysfunction, pregnancy and breast
feeding.
The need to have increased pharmacy involvement and the increased
complexity and specialization in this field have led to the development of
specialist posts with a dedicated full time antimicrobial pharmacist [also
referred to as an infectious diseases, antibiotic or infection management
pharmacist]. This role has been promoted by the £12 million funding
provided over three years by the DOH, as part of a pharmacy initiative to
promote the prudent use of antibiotics in England. (33) Hand comments
that these pharmacists are likely to have a consulting role with daily duties
including providing advice on management of patients with infections,
monitoring antibiotic therapy and ensuring compliance with Trusts’ antibiotic
prescribing policies.(142) In larger hospitals, an expanding role for the
pharmacist may imply a more managerial role where the antimicrobial
pharmacist advises through a team of ward-based clinical pharmacists.(47)
It was reported that the proportion of hospitals with an antimicrobial
pharmacist increased from 6% in 2000 to 88% in 2005 following this
funding.(143) The broader spectrum of activities will vary depending upon
the needs of the hospital but may also include education of different
healthcare professionals, participating in forums and committees,
monitoring and auditing antibiotic use and maintaining prescribing control
systems. Hand comments that education “ …is likely to be the most
effective, although time consuming use of a microbiology pharmacist’s
time.” (142) A cross-sectional survey demonstrated that these are the most
common responsibilities of antimicrobial pharmacists. To promote best
practice, share experiences and provide educational support, the United
Kingdom Clinical Pharmacists Association (UKCPA) has a special interest
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group networking antimicrobial pharmacists. Other pharmacists working in
specialities where antimicrobial prescribing is crucial to patient care such as
surgery and critical care, also have access to this group.(144-5) To date,
there is little evidence reporting the effects of interventions of antimicrobial
specialist pharmacists or other models on prescribing control.(39)
It is likely that with the introduction of supplementary and independent
prescribing, the role of the antimicrobial pharmacist in the UK may
expand.(47-8) This will need the pharmacist to move away from the
traditional gate keeping role to a more supportive role. When discussing
this, Weller et al comment that doctors “… need to see the benefits of
advice and support from the pharmacist, rather than viewing them as a
policy enforcer.” (47) Pharmacists are likely to be at least as knowledgeable
as junior doctors and are likely to be more familiar with local guidelines and
policies, given that junior doctors spend little time within a given
speciality.(47) Implementation of SP has provided the pharmacist with a
wide range of opportunities such as automatic stop orders or oral switches
without the need to consult a clinician. Interestingly, these are roles which
pharmacists, on their own or as members of a multidisciplinary team, have
taken on before the introduction of SP and are the focus of a systematic
review described in Chapter 2.
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Chapter 2
Antimicrobial optimisation in secondary care – the pharmacist
as part of a multidisciplinary antimicrobial programme: a
systematic literature review
2.1 Introduction
2.1.1 The role of the pharmacist within multidisciplinary antimicrobial teams
Traditionally, the pharmacist has often been placed as an enforcer of
guidelines, with a “policing” role. This has been reinforced by the findings of
a systematic review describing interventions to improve antibiotic
prescribing practices for hospital inpatients.(146) Studies included in the
review depended on a pharmacist as a deliverer of the intervention (22/66
studies). While the systematic review revealed that physicians tend to lead
even more restrictive stewardship practices than pharmacists, the
interventions made by pharmacists were predominantly persuasive and
included education, guideline development, reminders to physicians and
clinical audit and feedback. The literature indicates a desire by pharmacists
to move away from this “antibiotic policing” role to one where the
pharmacist is a “co-therapist.” (147) Setting up antimicrobial
multidisciplinary teams (AMDT) with pharmacist involvement, has been one
approach to breaking down the barriers between traditional healthcare
professional roles. Programmes involving AMDT appear to be the way
forward when attempting to implement strategies aimed at optimising
antimicrobial use in secondary care.(144,148-152) When discussing such a
multidisciplinary approach to antimicrobial stewardship, Paskovaty et al
have summarised requirements to ensure its success: obtaining baseline
information such as antimicrobial expenditure and resistance patterns to
understand the background of the institution; selecting strategies to
implement the antimicrobial stewardship that are tailored according to the
needs of the institution; determining team members and their roles and
responsibilities; establishing support of hospital administration both in
terms of funding and in terms of team empowerment; building good
relationships with other clinicians to facilitate acceptance of
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recommendations; providing feedback to prescribers as well as conducting
clinical audits with feedback to monitor effectiveness of programme.(148)
A report by Schentag et al described a pioneering programme with
pharmacist involvement, driven to follow up expensive empiric regimens
following the availability of cultures and sensitivity reports by streamlining
and shortening of the antimicrobial treatment.(153) Two specialist clinical
pharmacists led the intervention with the support of infectious diseases (ID)
physicians and microbiology. The usual patient management with empiric
treatment of antimicrobials was initiated; cultures were then reviewed by
the pharmacists following approximately 48 hours and any changes were
proposed by discussion with the prescribers. Types of interventions included
dosage adjustments, conversion from intravenous (IV) to oral medication
and earlier discontinuation of antimicrobial therapy. The authors reported a
high physician acceptance rate and cost savings that covered the costs of
the personnel required. Better patient outcomes were also reported though
no evidence was given to support this. The report did not give details of
pre-intervention data and there was no comparison between pre- and post-
intervention variables. Interestingly, the pharmacists made
recommendations to the prescribers, but did not automatically make any
changes to treatment and consequently it was at the discretion of the
prescriber whether or not to change treatment.
2.1.2 Evolvement of the antimicrobial multidisciplinary team
The concept of a multidisciplinary team to improve antimicrobial prescribing
and ultimately reduce antimicrobial resistance and improve patient safety,
was introduced by the Infectious Diseases Society of America (IDSA) which
recommended the establishment of “Antimicrobial Agents Teams” within
hospitals.(154) This team is responsible for ensuring optimal use of
antimicrobialsiii within the institution and would be led by an (ID) physician.
Other team members recommended by IDSA are an infection control
practitioner, clinical microbiologist and clinical pharmacist, with the latter
having a relatively limited role and being responsible for providing
information related to addition or deletion of antimicrobials from the
iii The term “antimicrobial” and “antibiotic” are often used interchangeably in the literature;
this review quotes the term as used by the authors in the specific publication being referred
to.
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hospital formulary. This concept of an antimicrobial multidisciplinary team
was reinforced in subsequent IDSA position statements of 1997 and 2007,
the latter referring to “Antimicrobial stewardship teams”. The 2007
guidance places the clinical pharmacist as key personnel within the team
together with the ID physician, also making recommendations that the
pharmacist should have training in infectious diseases.(152,155) This has
been viewed by many as a change in position compared to previous
guidelines.(156)
The recommendation to introduce antimicrobial multidisciplinary teams as a
way to optimise antimicrobial use has also been echoed by the EU and
introduced in Copenhagen in 1998. Antimicrobial teams aimed at promoting
the rational use of antimicrobials and, consisting of microbiologists, ID
specialists and clinical pharmacists should be in place in both primary and
secondary care settings and “… should have the authority to modify
antimicrobial prescriptions of individual clinicians in accordance with locally
accepted guidelines.” (12) Recommendations have also been made within
the UK and have been described in Section 1.2.2.
The aim of the review being described here is to achieve the following
objectives through a systematic literature review:
a) To explore the evidence based clinical role of the pharmacist in
optimising antimicrobial use when working within a multidisciplinary
antimicrobial team in secondary care
b) To determine the published outcomes of interventions to optimise
antimicrobial prescribing through a multidisciplinary team with
pharmacy involvement
2.2 Method
The method for this systematic literature review reflects updated guidance
published by the Centre for Reviews and Dissemination, University of
York.(157)
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2.2.1 Review team
The review team was made up of AT and DS. Where agreement was not
reached, it was planned to involve a 3rd person DM, in the discussions;
however this was not necessary. A consultant microbiologist with expertise
in antimicrobial stewardship and antimicrobial policies was an advisor to the
team.
2.2.2 Inclusion and exclusion criteria
The inclusion criteria were as follows:
 Full text papers published in peer reviewed journals. Where only
abstracts or letters were retrievable, the authors were contacted to
determine whether full texts had been published. Papers that were
not available as full text were discarded since it is difficult to appraise
studies where no full text is available
 English language
 Papers reporting both descriptive accounts and primary research
involving a multidisciplinary antimicrobial team with pharmacy
involvement. Descriptive accounts were included since it was not
expected to find many trials.
 Papers involving interventions targeting hospital inpatients.
Papers where there was either no multidisciplinary team or where the
pharmacist had no role within the intervention were excluded. Papers
involving interventions targeted at residents in community or ambulatory
care settings were also discarded.
2.2.3 Search strategy
The databases Medline (through Pubmed), International Pharmaceutical
Abstracts (IPA) and Embase were searched between the years 1995-2006.
Medline and Embase are the databases most commonly used and
recommended for healthcare interventions.(157) However, not all pharmacy
literature is captured in these databases; consequently, though there is
significant overlap between the databases, IPA was also included to broaden
the pharmacy literature covered. The search was conducted in early 2007
and was started at 1995 to enable identification of literature some years
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before the Crown Report was published in 1999 and would therefore identify
any changes in practice due to introduction of pharmacist SP.
The following search words were used: antibiotics, antimicrobials, anti-
bacterials, antiinfectives, pharmacists, outcomes, interventions,
multidisciplinary, hospital, microbiology, infection management, antibiotic
stewardship, antibiotic support team, antibiotic optimisation and antibiotic
control programmes. The search words were used in different combinations.
A detail of the number of hits obtained for each combination is at Appendix
2.1.
The bibliography lists of published reviews (4,146,148) were searched for
any other relevant papers and the reference lists of included papers were
also searched for any other relevant material. However, no papers were
identified in this manner.
2.2.4 Screening
A total of 761 hits were obtained through the Medline search, 697 through
the IPA search and 530 through Embase. Sixty one papers were identified
as potentially relevant on the basis of their title and abstract. Initial
screening resulted in 27 abstracts discarded because full papers were not
available despite contacting authors as necessary. Thirty four full papers
were retrieved for full paper screening. Ten were discarded because they
were either descriptions of programmes in ambulatory care, or were
programmes with no pharmacy involvement. Twenty four full publications
were included in this review. A schematic representation of the screening
process is at Figure 1.
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Figure 1: Schematic representation of screening process
IPA = 697 Medline = 761 Embase = 530
Papers for initial
screening
n = 1988
Titles and abstracts identified as
potentially relevant after initial screening
n =61
Excluded Full papers not
available
n = 27
Full copies retrieved and assessed for
eligibility
n = 34
Excluded
In
ambulatory
care or
nursing
home
n = 4
Intervention
not involving
pharmacist
as part of
MDT
n = 6
Total publications included in this review
n = 24
Descriptions
n = 8
Primary research
critically appraised
n = 9
Electronic Search
Thematic reviews
and opinion papers
n = 7
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2.2.5 Quality assessment
Papers were reviewed for quality by AT and DS using standard criteria for
critical appraisal published in the literature. Where available, criteria
published as part of the Critical Skills Appraisal Programme (CASP) were
used. In the case of Randomised Control Trials, some additional criteria
were obtained from the CONSORT statement. No CASP criteria were
available for Interrupted Time Series studies and therefore criteria available
through the Cochrane Effective Practice and Organisation of Care Group
were used. Details of all criteria used are found in the results section
below.(158-160)
2.3 Results
2.3.1 Descriptions of multidisciplinary teams
This section summarises descriptions of different programmes aimed at
optimising antimicrobial use within various institutions and run by
multidisciplinary teams. The publications (eight descriptions) offered insight
and experiences into the team structure, the running, and the different
strategies adopted, thus offering some valuable information. However,
many of the findings reported are descriptive and do not employ any
standard research methods to measure the impact of the interventions
made. Table 7 is a summary of these descriptive reports and accompanies
the text below.
Many of the team approaches reported originate from the UK. A West
London model described such a team with a strong pharmacy input, the
team being chaired by a chief pharmacist and the specialist ID pharmacist
acting as secretary to this group.(161) The group identified a set of seven
key elements that were considered vital to ensure successful antibiotic
stewardship. These included strong leadership, dedicated individuals with
responsibility for leading on antibiotic use, adequate resources and
education and training. This has led to the appointment of an ID pharmacist
with a high clinical profile and defined responsibilities, with regular
attendance of microbiology led ward rounds and weekly educational
meetings. The ID pharmacist has a major role in education and training in
areas beyond the traditional boundaries such as training of phlebotomy staff
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to ensure adequate sampling for therapeutic drug monitoring. Ward clinical
pharmacists have been included in the agenda and liaise closely with the ID
pharmacist to discuss the management of individual patients. Though no
evidence was given to support the statement, the authors reported that the
ID pharmacist post has led to reduced costs and better quality of antibiotic
prescribing. A successful multidisciplinary approach to promote the prudent
use of antimicrobials has also been reported in Manchester.(162) This
pharmacist and microbiologist led strategy was multifaceted and consisted
of three main elements: education and training mainly directed at junior
doctors; restriction of certain IV antibiotics with selective microbiological
reporting and switching of IV-to-oral antibiotics by pharmacists through a
patient group direction; and monitoring, including drug expenditure, drug
usage data and point prevalence data. This approach was described as
reducing the number of patients on IV therapy inappropriately and keeping
antimicrobial consumptions and costs down despite predictions for these to
rise. Interestingly, this is one of the few reports where the pharmacist is
actually making changes to patient’s medication (IV-to-oral switching)
rather than just making recommendations. The success of these strategies
led the Trust to plan future developments which included a joint antibiotic
pharmacist and microbiologist ward round on all general wards.
Collaboration between clinical pharmacistsiv and the microbiology
department was the mainstay of a programme piloted over 7 months in
Ipswich.(163) The clinical pharmacists here, on a daily basis, referred
patients requiring a review of their antimicrobial treatment to the AMDT and
used specific criteria. The specialist clinical pharmacist and a microbiologist
daily reviewed these patients, documenting any recommendations where
changes in treatment were required and giving feedback to the referring
clinical pharmacist. The programme was well received with 92 reviews
carried out requiring 52 interventions. No descriptions of outcomes of the
programme are provided. Similar collaboration between clinical pharmacists
and microbiology has also been set up in Southampton and a three month
observational study has been reported.(164) A high rate of acceptance was
observed (100% on care for the elderly wards and 95% on medical wards)
iv The clinical pharmacist is responsible for the rational and optimal use of drugs in all
healthcare settings. In secondary care, the clinical pharmacist is usually mainly ward-based
and may also be referred to in some literature as a ward pharmacist.
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and the authors estimated a cost savings after deducting the costs
associated with the team’s intervention. More recently, reports indicated
that pharmacy technicians were also involved in multidisciplinary teams and
have been given key roles in monitoring antimicrobial use and the set up of
audits.(165)
Team approaches as part of antimicrobial management programmes have
also been reported and described outside the UK, and particularly in the
US.(147,166-168) Different methods of patient identification were reported
ranging from daily screening of patients on IV antimicrobials through the
pharmacy system to referral of the patients by other clinical ward
pharmacists. Many of the teams were established in response to increased
costs, and financial outcomes were mainly reported. The interventions made
by the antimicrobial teams were claimed to have improved quality of
prescribing and patient care with no negative patient outcomes; however,
there was often little evidence to back these statements. Further detail is
found in the table below. Other descriptions have involved a
multidisciplinary approach to optimising antimicrobial use in a specific area
of care, for example optimising antibiotic prophylaxis of surgical-site
infections.(169) Unfortunately, insufficient information is provided both
about the team composition and outcomes of such interventions, making
them difficult to evaluate.
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Table 7: Descriptions of programmes run by multidisciplinary teams with pharmacist involvement
Author
Year
Country
Site Professionals
involved in
teamv
Description of programme Findings reportedvi
Lee et al, 1995,
US (147)
Hospital
but further
details not
provided
Pharmacists
ID physicians
Clinical pharmacists identified and reviewed all
patients on antimicrobials, using the institution’s
guidance as a reference point. Patients requiring
intervention were referred to the team who made
the necessary recommendations to the prescribing
physician.
A 16% decrease in
antimicrobial costs
No adverse effects on
hospital length of stay or
readmission rates
Burke et al,
1995,
US (167)
310-bed
university
teaching
hospital
ID physicians
Clinical
pharmacists
Microbiologist
Nurses
Not clearly described. A description of the set up
and running of the team is provided rather than a
description of the way the programme was run.
A decrease in antimicrobial
costs
A decrease in length of
stay for patients with
pneumonia
A reduction in mortality for
patients with pneumonia
Lacy et al,
1997, US (166)
760-bed
tertiary
community
teaching
hospital
Pharmacists
ID specialists
Pharmacists identified and assessed appropriateness
of all patients receiving IV antimicrobial therapy
with the help of a computer programme algorithm.
This occurred both at the dispensary and on wards.
Patients requiring interventions were discussed with
ID specialists and recommendations made to the
prescribing physician who also made changes in
treatment.
Acceptance rate for
recommendations is 95%
A decrease in antimicrobial
purchases
A decrease length of stay
for patients with
pneumonia
Cooke et al,
2004, UK (161)
1000-bed
tertiary
Chief pharmacist
ID pharmacist
Multi-faceted programme involving numerous
activities. ID pharmacist had a high profile with a
Authors reported a
significant impact on cost
v Descriptive term used here is as used at source
vi These are the findings reported by the authors; there is often little evidence to support these and hence have been classified in this review as
descriptive reports
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teaching
hospital on
two sites
Microbiologists
Infection control
Clinical
pharmacists
consultant role and regularly attended ID ward
rounds and educational meetings and activities for
different members of the multidisciplinary team.
Clinical pharmacists were involved and worked
together with the ID pharmacists referring any
patients who needed further intervention, and
participated in the implementation of antibiotic
policies and collected data for audits and point
prevalence studies.
and quality of antimicrobial
prescribing
Pasquale et al,
2004,
US (168)
996–bed
network
consisting
of 3 sites
ID physicians
Clinical
pharmacist
Multi-faceted programme initially involving the
drawing up and dissemination of guidelines. Patients
on IV antibiotics were identified daily through the
hospitals’ computer system and reviewed by a
pharmacist for inappropriate antibiotic use. Patients
on antibiotics that were already restricted and
therefore required the approval of an ID physician
were excluded. Patients on inappropriate antibiotic
use were referred back to the ID physician and
recommendations made to the prescriber.
77% of interventions made
were accepted.
Interventions mainly
involved IV-to-oral switch
for levofloxacin [a case-
control evaluation on this
reported elsewhere in this
review], modification of IV
therapy dose, duration and
frequency, and changing
an antibiotic to improve
cover
Estimated reduction in
costs reported
Williams et al,
2005,
UK (162)
900-bed
university
teaching
hospital
Clinical
pharmacists
Microbiologist
Multi-faceted programme initially involving the
drawing up and dissemination of antibiotic
guidelines with some IV antibiotics being restricted
and requiring microbiology approval. Selective
microbiological reporting together with daily reviews
of all patients on IV antibiotics by the clinical
pharmacists and medical teams was launched
concurrently. A policy was introduced where
pharmacists were allowed to switch patients with
respiratory infection from IV-to-oral medication
using a patient group directive. An education and
Reduction in the number of
patients on IV antibiotics
for more than 48 hours
Reduction in number of
patients on inappropriate
IV antibiotics when
compared to the NHS trust
policy
Reduction in rise of the
annual antibiotic
expenditure
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training campaign was run by microbiology and
pharmacy with various methods used for
dissemination of the guidelines. Regular audits and
point prevalence studies were planned to monitor
achievements.
Cheeseman M,
2006,
UK (163)
800-bed
district
general
hospital
Clinical
pharmacists
Microbiologist
Clinical pharmacists referred patients requiring
review of their antimicrobial treatment to a
pharmacy-microbiology team, on a daily basis. The
latter reviewed these patients making any
recommendations required and documenting these
in the patient notes; feedback was also provided to
the referring pharmacist.
Project piloted over 7
months – 92 reviews
requiring 52 interventions;
the most common
intervention was
inappropriate choice of
antimicrobials
No further outcomes were
reported
Weeks C,
2006,
UK (164)
University
teaching
hospital.
Service
provided
on 208
beds in
medicine
and a 90
bed Care
of the
Elderly
unit
Clinical
pharmacist
Microbiologist
Clinical pharmacists referred patients requiring
review of their antimicrobial treatment to a
pharmacy-microbiology team – patients prescribed
intravenous and second line antibiotics were
referred. The microbiologist reviewed treatment
making use of any relevant pathology data and
made any changes required in the medication. The
pharmacist ensured that the recommendations
adhered to the hospital formulary and had taken the
individual patient parameters into consideration.
The authors provide an
observational study over a
3 month period. 69
patients seen in care for
the elderly and 263 in
medicine. Stopping
antimicrobials and
narrowing the focus of
therapy were the most
common interventions.
Changing IV-to-oral
medication was more
common in medicine
compared to Care of the
Elderly. A high acceptance
rate was reported.
No differences in mortality
or length of stay were
noted.
An estimated reduction in
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costs was made after
having deducted the costs
for the team.
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2.3.2 Published research involving multidisciplinary teams
A number of trials have been published aimed at reporting the outcomes of
multidisciplinary teams with pharmacy involvement as an intervention with
the goal of improving antimicrobial prescribing in hospital inpatients. Nine
studies were identified; five from the US, one from Canada, one from
Switzerland, one from France and one from Argentina.
The primary aim of most interventions was to optimise antimicrobial
prescribing. The initial perception in most cases was that antimicrobial
overuse was a common practice in the institution. Reducing associated
costs through rationalisation of antimicrobials was a major driving force in
most studies; many set out to prove the cost effectiveness of the AMDT to
hospital management. Further details of the studies together with a critical
appraisal approach have been summarised in Tables 8, 9 and 10 below.
2.3.2.1 Team members
The core members of the team were the ID physician and clinical
pharmacist with the team having dedicated and protected time for antibiotic
management. Often a partnership between the team members was reported
with shared responsibilities when assessing individual cases and in ensuring
appropriateness of antimicrobial prescribing. The pharmacist on the team
was involved in:
 Prescriber education on a one-to-one basis by making written or
verbal recommendations following identification of inappropriate
antimicrobial prescribing (170-174)
 Making recommendations to switch IV therapy to oral therapy as
appropriate (168,175)
 Running therapeutic interchange programmes (175)
 Enforcing restriction policies when these were in place (173,175,176)
The role of the pharmacist could not be determined in one study.(177)
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2.3.2.2 Nature of interventions
Different programmes were reported in the trials, many of which were
tailored to the specific institution and may be grouped according to the
nature of the intervention as described below. The classification used here is
adapted from Paskovaty et al.(148) Other classifications of interventions
have also been described elsewhere in the literature.(146)
Clinical Pathways: These involved the development of peer reviewed
guidelines followed by dissemination and educational programmes. Lutters
et al report such an intervention specifically targeted at management of
urinary tract and respiratory tract infections in a geriatric hospital.(170)
Post-prescribing evaluation combined with clinical pathways where the
appropriateness of the initial antimicrobial prescribed was assessed against
hospital guidelines and any other laboratory data available. This allowed
streamlining where broad empiric therapy was narrowed according to the
individual patient’s needs with recommendations for changes made by the
antimicrobial team. Various studies describe such an intervention. Carling et
al report post-prescribing evaluation with prescriptions for specific
parenteral antibiotics evaluated by the team for adherence to the
institution’s guidelines.(171) Recommendations were then made to the
prescribers as required. Similar interventions were reported by Gums et al,
Fraser et al and Bantar et al, with patients screened to ensure appropriate
antimicrobial therapy and written and verbal recommendations made to
prescribers where changes were appropriate.(172,174,177) Other studies
report screening of parenteral antimicrobial treatment against guidelines
making recommendations where conversion to oral treatment was
appropriate.(168,175) Salama et al also report automatic interchanges by
pharmacy staff to facilitate adherence to the institution’s guidelines.(175)
Clinical pathways combined with restriction policies: Here, second line
agents were restricted and required prior approval by members of the team.
The choice of antibiotics restricted was based most commonly on
costs.(173,175,176) Likely impact of the antibiotics on bacterial ecology
(176), and the adverse effect profile (173) were other factors taken into
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consideration. Pharmacists within the AMDT and the dispensary were the
principal providers of this programme, often validating the prescription,
issuing approvals where appropriate and making recommendations as
necessary.(173,175)
2.3.2.3 Study designs
All trials were single site and the hospital bed capacity varied between 250-
772 beds. The sites were tertiary teaching hospitals, community hospitals or
geriatric care hospitals. Most of the studies were interrupted time series
(n=4) with audit points pre and post intervention (170-1,175 -6); two
(172,174) were randomised controlled trials; one was a comparative study
with no randomization (173); one was mainly a descriptive study but
included a small-scale case control trial (168); one an uncontrolled before
after study.(177) A critical appraisal of the trial design is summarised in
Tables 8, 9 and 10.
2.3.2.4 Outcomes reported
Most of the trials were economically driven and initiated to achieve a cost
saving for the institution. When reporting outcomes, few trials have taken
the cost of the intervention into account and most trials have not
considered the impact on patient outcomes.
Drug related outcomes
These outcomes were related to appropriate antimicrobial prescribing; for
example, the prescribing of a recommended antimicrobial at the appropriate
dosage or duration for a specific condition usually as indicated by the
institution’s formulary. Most trials measured the adherence of prescriptions
to guidelines and preset criteria such as adjustment of dose if the patient
had organ dysfunction. Saizy-Calleart et al report that following the
intervention, there was an initial reduction in the number of inappropriate
prescriptions, followed by a rise until a constant level was reached.(176)
Other studies indicate that adherence with guidelines increased following
the intervention with a reduction in the number of recommendations
necessary (171); it was not possible to determine the impact of the
intervention in one study since no pre-intervention data were
available.(170) In a comparative study, Gross et al aimed to compare the
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recommendations made by the AMDT (8am to 5pm) to the ID fellows who
provided the service out-of-hours (5pm to 11pm) and at weekends.(173)
The AMDT was more likely to adhere to guidelines compared to 75% of
recommendations made by the ID fellows. Fraser et al measured the need
for re-administration of antimicrobials after 7 days, arguing that this was a
measure of the efficacy of the antimicrobial prescribed, and consequently,
of appropriateness of choice and reported a reduced need for re-
administration in the intervention group as compared to the control
group.(174)
Microbiological outcomes
These outcomes were related to the prevalence of antibiotic resistant
bacteria and reported only in few trials. A maintenance or improvement in
bacterial susceptibility was reported and further details are available at
Tables 8, 9 and 10.(171,176,177)
Indicators of clinical outcomes
These included the length of hospital stay, inpatient mortality and 28 day
mortality. A reduction in hospital length of stay was reported following
introduction of the intervention though this was not always statistically
significant.(172,174,177) Recommendations made by the AMDT were more
likely to result in a clinical cure both when compared to the advice given by
ID fellows, and when compared to a historical control group. (173,168)
Again these reported differences were not always statistically significant. A
reduction in the need for parenteral antibiotics emerged though again this
was not always statistically significant.(168,174) Gums et al also identify a
reduction in the number of both non-intensive care unit (statistically
significant) and intensive care unit beds (not statistically significant)
together with a non statistically significant reduction in mortality in the
intervention group.(172)
Financial outcomes
These included the healthcare resource costs, including the costs involved in
implementation of the intervention. Economic benefits were reported in all
trials, and related to a reduction in use of antibiotics, use of cheaper
therapeutic equivalents or earlier IV-to-oral conversions. Not all differences
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were statistically significant. The cost of the intervention made was not
always considered as outlined in Tables 8, 9 and 10.
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Table 8: A critical appraisal of trials using an Interrupted Time Seriesvii design to measure outcomes of interventions to
optimise antimicrobial prescribing through a multidisciplinary team with pharmacy involvement (1996 – 2006) (158)
(note this table is 8 pages long)
Criteria Salama et al Canada
1996 (175)
Saizy-Callaert et al
France
2003 (176)
Carling et al USA 2003
(171)
Lutters et al
Switzerland
2004 (170)
Objectives of the
programme (as stated by
authors)
“To increase the
quality of
antimicrobial
prescribing and to
control runaway
costs of
antimicrobial
therapy”
“To rationalise antibiotic
usage, based on a
participatory approach
and aimed at obtaining a
durable change in
prescribing practices”
“To minimise the
inappropriate use of
third-generation
cephalosporins”
“A comprehensive
educational antibiotic
management
programme designed to
improve antibiotic use
and reduce treatment
costs in elderly patients
with suspected urinary
or respiratory tract
infections”
Site description
Number of sites Single site Single site Single site Single site
Setting 465-bed university
tertiary care
teaching hospital
600-bed teaching
hospital
Medium size community
teaching hospital (exact
bed capacity not
specified)
304-bed teaching
geriatric hospital
Nature of intervention
Intervention as described
by the authors
Initially during the
12 month pre-
intervention period:
Streamlining of the
Programme combined:
Developing local
prescribing guidelines
based on consensus and
A prospective antibiotic
monitoring procedure
where adherence to
hospital
Phase I; a baseline
phase lasting 12
months during which
antibiotic utilization
vii Interrupted time series designs are multiple observations over time which are interrupted usually by an intervention or treatment. Long time
series require at least 20 observations; short time series need to have at least three pre and three post-intervention observations and involve
multiple t-tests, analysis of variance or repeated measures analysis to protect against threats of internal validity.
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antimicrobial
hospital formulary
Automatic 3 day
stop order for all
antimicrobials
Clinical antimicrobial
guidelines that were
disseminated using
various methods
Then the
intervention
consisted of the
development of a
multidisciplinary
antimicrobial use
programme with:
Automatic
therapeutic
interchanges with
nine possible
interchanges
identified
Antimicrobial
restriction policy
restricting eight
antimicrobials;
these were only
permitted for use in
approved indications
Intravenous to oral
switch encouraged
for specific
antimicrobials
disseminated through a
pocket size guide
An antimicrobial
restriction policy for the
most expensive
antibiotics and those
most likely to affect
resistance patterns;
these could be prescribed
on a named patient
prescription by a senior
hospital doctor, were
validated by pharmacy
and supplied for 48-72
hours to encourage
review
Regular assessment of
antibiotic prescriptions to
ensure adherence to
guidelines
Training and information
provided to prescribers
recommendations for
specific parenteral
antibiotics is assessed
using a standard data
collection tool.
Prescribers are given
individual written and
verbal feedback and
recommendations
Evaluations and feedback
are made by an ID
specialist and a clinical
pharmacist specialising in
infectious diseases
reviews were
performed
Phase II – lasted 9
months and involved
development of
evidence-based
guidelines in
collaboration with
physicians
Phase III – intervention
over 9 months
consisted of an
intensive educational
programme during
which guidelines were
disseminated through
cards and lectures.
Weekly ward rounds
were held by the MDT
to assess compliance
with guidelines and
provide physician
feedback
Phase IV – a 6 month
post intervention phase
during which physicians
received only guidelines
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Professionals involved in
team
Physicians,
pharmacists,
nurses, hospital
administration
Pharmacist,
bacteriologist, ID
physician
Clinical pharmacist, ID
physician
ID physician,
pharmacist and
pharmacologist
Study design
Number of observations
pre-intervention
13 observations
performed monthly
over 12 months
Only available for
economic outcome:
annual antiinfectives
expenditure data
provided for 3 years pre-
intervention
Antibiotic use: annual
values for DDD/1,000
patient beds measured
for 3 years pre-
intervention; each
individual value is not
provided
Antibiotic costs: annual
values of cost of
parenteral antibiotics per
1,000 patient days
measured and provided
as above
Annual incidence of all
resistant pathogens
provided for 3 years pre-
intervention
One point prevalence
study was carried out
per trimester; 7
observations carried
out pre-intervention; 3
observations during the
intervention
Number of observations
post-intervention
29 observations
performed monthly
over 30 months
Adherence of prescription
to guidelines: 6
observations where data
was collected over a one
month period; these are
not at regular intervals
Economic outcome:
annual expenditure data
for 4 years post-
intervention
Trends in bacterial
Antibiotic use: annual
values for DDD/1,000
patient beds measured
for 7 years post-
intervention but again
individual values are not
provided
Antibiotic costs: annual
values of cost of
parenteral antibiotics per
1,000 patient days
2 point prevalence
studies carried out
post-intervention, one
per trimester
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resistance: annual trends
for 4 years post-
intervention
provided
Annual incidence of
resistant pathogens
provided for 7 years
post-intervention
Adherence of
prescriptions to
guidelines; annual
number of interventions
made measured for 7
years post-intervention
but individual values not
provided
Clearly defined point when
intervention occurred
Clearly described:
intervention
launched and month
specified following
collection of
baseline data over a
13 month period
Clearly described:
intervention launched
between baseline year
and first year when post-
intervention data
collected
Clearly described Clearly described:
intervention launched
at Phase III of trial
Patient recruitment
Selection of patients Not clear All patients receiving an
antibiotic in all
departments; no details
provided on type of
patients
All patients on parenteral
third generation
cephalosporins,
aztreonam, parenteral
fluoroquinolones and
imipenem
All patients receiving at
least one antimicrobial
on day of study; details
of patient
characteristics are
provided
Inclusion and exclusion
criteria
Not clear Patients with HIV were
excluded
As above Not clear
Control group if any Not included Not included Not included Not included
Number of patients Not specified Total over 4 years: 1221 Not specified Total number of
records screened
3,383. 680 included
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since receiving at least
one antibiotic agent
Method of determination Not clear Way in which patients
were identified not clear
Way in which patients
were identified not clear
Way in which patients
were identified not
clear
Outcomes measured Monthly usage
patterns of
restricted
antimicrobials
Antimicrobial costs
as a % of total drug
costs and the total
antibiotic cost
Adherence of
prescriptions to
guidelines; where no
guidelines available,
appropriateness was
assessed by experts
Antimicrobial cost as a %
of total drug expenditure
and per hospital patient
Trends in bacterial
resistance for MRSA,
EPESB, CRPviii
Antibiotic use expressed
as DDD/1,000 patient
beds
Antibiotic expenditure
expressed as parenteral
antibiotic use per 1000
patient beds
Incidence of Clostridum
difficile, ceftazidime
resistant
enterobacteriaceae,
MRSA and vancomycin
resistant enterococci
Assessment of adherence
of prescriptions to
guidelines for antibiotics
specified above
Total antimicrobial use
Assessment of
prescriptions against
guidelines during ward
rounds; these were
classified as total,
partial, none or
ascertainment
impossible
Antibiotic costs –
measured by
cumulative antibiotic
costs for all patients
receiving an
antimicrobial on point
prevalence day
Results
Description Monthly use of
restricted antibiotics
reduced or
remained the same;
sharpest drop in use
of ceftazidime,
imipenem and
vancomycin
Number of inappropriate
prescriptions first fell,
then rose and remained
constant
Both the antimicrobial
cost as a % of total
expenditure and the cost
per hospital patient fell
Use of third generation
cephalosporins and
aztreonam decreased;
use of other antibiotics
remained stable
Reduction in costs
Reduction in incidence of
Clostridium difficile and
Results are not
provided for each of the
12 point prevalence
studies conducted but
have been grouped and
totals are provided for
each Phase and
comparisons provided
viii MRSA: Methicillin-resistant Staphylococcus aureus; EPESB: Enterobacteriaceae producing extended spectrum -lactamases; CRP: ceftazidime-
resistant pseudomonas
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Both the
antimicrobial
expenditure as a %
of total drug costs
and the total
antibiotic costs fell
Incidence of EPESB fell;
MRSA and CRP remained
constant
ceftazidime resistant
enterobacteriaecae, but
no changes in incidence
of other pathogens
Compliance with
guidelines increased and
number of interventions
required decreased
between Phase I and IV
Total number of
antibiotics prescribed
fell
Cumulative daily
antibiotic costs for all
surveyed patients fell
75% of prescriptions
assessed for adherence
to guidelines complied
totally. This was only
performed during Phase
III of the study
Statistics used No multiple t-tests,
analysis of variance
or repeated
measures analysis
included
Fisher’s exact test and
Chi-squared; no multiple
t-tests, analysis of
variance or repeated
measures analysis
included
Multiple test analysis
used
Proportions compared
using Fisher’s exact
test and Chi-squared;
means compared using
analysis of variance
and Kruskal-Wallis test;
trends analysed using
regression
Statistical significance Not done Incidence of EPESB fell
significantly over the four
years but no pre-
intervention data to
compare this with (p<
0.001)
Expenditure costs per
patient fell significantly
between 1994 and 2000
(p<0.001)
Reduction in antibiotic
use was statistically
significant (p <0.001)
Reduction in incidence of
Clostridium difficile
(p=0.002) and
ceftazidime resistant
enterobacteriaecae was
statistically significant
(p=0.02)
Both the total number
of prescriptions and
cumulative daily costs
fell significantly when
comparing Phase I with
Phase IV (P<0.001)
It is not possible to
compare pre- and post-
adherence to guidelines
since this performed
only in Phase III
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Quality criteria
Intervention is independent
of other changes
Not clear Done: number of HIV
patients fell significantly
over the study period
and were therefore not
included; other
parameters such as bed
stay remained the same
Not clear Not clear
Intervention is unlikely to
affect data collection
Not clear Not clear Not clear Not clear
Blinded assessment of
primary outcome (authors
state specifically that the
primary outcome variables
were assessed blindly or
outcome variables are
objective)
Done Done for all outcomes
except when assessing
adherence of prescription
to guidelines
Done for all outcomes
except when assessing
adherence of prescription
to guidelines
Done with antibiotic
use and costs
Not done when
assessing adherence to
guidelines
Completeness of data set
(dataset should cover 80-
100% of the total number
of participants or episodes
of care in the study)
Not applicable since
the number of
patients included
has not been
specified
Done Not applicable since the
number of patients
included has not been
specified
Done
Reliability of outcome
measures (if two or more
raters have at least 90%
agreement or kappa 0.8 or
if outcome obtained from
an automated system)
Done – antimicrobial
usage and costs are
being measured
Done when antimicrobial
usage, costs and trends
in bacterial resistance
are being measured
Not done when assessing
adherence of prescription
to guidelines
Done when antimicrobial
usage, costs and trends
in resistant pathogens
measured.
Not done when assessing
adherence of prescription
to guidelines
Done when antibiotic
use and costs are being
measured
Not done when
assessing adherence of
prescription to
guidelines
Comments Does not involve a
specialised MDT but
a hospital wide
multidisciplinary
Information about pre-
intervention not given for
all outcome measures
Costs of programme have
been considered by
authors but no details
around this costing are
The study objectives
indicate that the aim is
to assess the impact of
guidelines targeting
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programme with
pharmacy
participation.
Though reference is
made to quality of
antimicrobial
prescribing as one
of the objectives,
there are no details
of how these were
measured and if the
programme had any
impact.
Cost analysis does
not include cost of
the interventions.
Though authors comment
that the intervention
required a large initial
investment, this is not
costed when taking into
account cost savings.
One of the few studies
that considers resistance
patterns.
provided.
One of the few studies
where follow up is over a
prolonged period of time,
indicating the possible
sustainability of a long
programme.
One of the few studies
that puts emphasis on
resistance patterns.
urinary tract infections
and respiratory tract
infections; yet all
patients on
antimicrobials are
included in each of the
point prevalence
surveys conducted.
Cost analysis does not
include cost of
educational
programme.
Despite no intensive
educational ward
rounds during Phase 4,
the reduction in
antibiotic use was
sustained.
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Table 9: A critical appraisal of trials using a Case-Control design to measure
outcomes of interventions to optimise antimicrobial prescribing through a
multidisciplinary team with pharmacy involvement (1996 – 2006) (160)
Criteria Pasquale et al US 2004 (168)
Objectives of the programme (as
stated by authors)
“To assess the interventions of an Antibiotic
Support Team related to the IV-to-oral
switch of levofloxacin“
Site description
Number of sites 3
Setting 963-bed network spread over 3 sites;
intervention made on one site; bed capacity
here not specified
Nature of intervention
Intervention as described by the
authors
Patients started on an IV antibiotic within
the last 24 hours were identified and
assessed by a pharmacist for
appropriateness of antibiotic use against set
guidelines. The pharmacist evaluated
patients who were on an IV antibiotic to
determine whether they were suitable for
an IV-to-oral switch. Where the antibiotic
prescribed was not according to the
guidelines, the pharmacist referred to the
ID physician. When necessary,
recommendations for changes in treatment
were made to the prescribing physician
Professionals involved in team A clinical pharmacist and an ID physician
Patient recruitment
Selection of cases and method of
recruitment
Patients (n=22) started on IV levofloxacin
for the treatment of community acquired
pneumonia (CAP) between March-
November 2000 were identified through the
hospital computer system for review by the
team
Selection of controls and method of
recruitment
Patients (n=26) started on IV levofloxacin
for the treatment of CAP between March-
November 1999 were recruited
retrospectively. Further details on
recruitment are not provided
Inclusion and exclusion criteria Patients in obstetrics and gynaecology
units, special care nursery, in the
haemodialysis unit, on a one-dose
prophylactic antibiotic or who had a
consultation with an ID specialist were
excluded from review by the Antibiotic
Support Team. However, it is not clear
whether these patients were also excluded
from this case-control study. Patients on
initial IV levofloxacin and a diagnosis on
CAP were included
Number of patients included in case
and control groups
Method of determination Cases were selected through the hospital
computer system during the study. It is not
clear how controls were selected
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Were there sufficient numbers included
in the two groups Ex use of a power
calculation
Not specified
Matching of case and controls These were matched based on
demographics and the severity of illness of
the CAP using a published score system.
The authors report that there was no
statistically significant difference between
the two groups, but details of the statistical
methods used here is not provided
Validity and reliability of recorded data
for historical controls
Not considered
Outcomes measured Clinical outcomes were classified into
positive, negative or neutral. A description
of each is provided.
Duration of antibiotic therapy
Length of hospital stay
Results
Description More positive clinical outcomes were
recorded for the cases compared to controls
(91% compared to 88%)
Fewer days of IV therapy in case compared
to controls (1.6 days compared to 2.9 days)
Length of stay was 0.4 days less for case
compared to controls
Statistics used (including consideration
of any confounding variables)
Clinical outcomes not statistically
comparable; P<0.005 when comparing IV
therapy and P=0.375 when comparing
length of stay. However details of statistics
used not provided; confounding variables
not considered
Quality criteria
Blinded assessment of primary outcome
(authors state specifically that the
primary outcome variables were
assessed blindly or outcome variables
are objective)
Duration of therapy and length of stay
objective outcomes.
No information provided about
determination of clinical outcomes.
Completeness of data set (dataset
should cover 80-100% of the total
number of participants or episodes of
care in the study)
All included
Reliability of outcome measures (if two
or more raters have at least 90%
agreement or kappa 0.8 or if outcome
obtained from an automated system)
Not specified
Comments This small-scale case-control study is part
of a wider study aimed at determining the
nature of interventions of an Antibiotic
Support Team. Most of the paper reports a
descriptive study about the nature of the
interventions made by this team. Numerous
criteria required to ensure the robustness of
the study are not provided in the report. It
is therefore not possible to conclude
whether they were considered by the
authors when designing the trial
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Table 10: A critical appraisal of trials using a Randomized Control Trial
design to measure outcomes of interventions to optimise antimicrobial
prescribing through a multidisciplinary team with pharmacy involvement
(1996 – 2006) (159,178,179) (note this table is 4 pages long)
Criteria Fraser et al US
1997 (174)
Gums et al US
1999 (172)
Objectives of the
programme (as stated by
authors)
“To evaluate (the)
clinical, microbiological
and economic
effectiveness” of “a
case-oriented education
approach”
“To test the hypothesis
that a timely consult
from a multidisciplinary
antimicrobial therapy
team would improve the
quality of care, reduce
patient charges, and
result in net savings to
the hospital”
Site description
Number of sites One One
Setting 600-bed tertiary care
teaching hospital
275-bed community
hospital
Nature of intervention
Intervention as described by
the authors; where the
intervention was
administered
The MDT prospectively
reviewed all the patient
medical records using a
systematic approach at
baseline, on alternate
days and until 3 days
after treatment with
antibiotics was
discontinued. Where
recommendations were
made, these were left in
the patient notes.
After two hours of
randomization, the
prescriber received
relevant
recommendations from
the team; these were
placed in the patient’s
chart and telephoned or
faxed if urgent.
Professionals involved in
team
ID fellow
Clinical pharmacist
ID physician
Clinical pharmacy fellow
Microbiology laboratory
personnel
Patient recruitment
Method for identification of
patients
Through pharmacy
records; adult inpatients
on 1 of 10 specified
parenteral antibiotics for
3 or more consecutive
days were included
Through various
methods including
screening of charts,
reviewing of
aminoglycoside and
vancomycin levels and
daily screening of
culture and sensitivity
reports
Method for generation of the
randomization schedule (Ex
table of numbers, computer
generated)
Computer generated
random number table
Not specified
Method for implementation
of the randomization
sequence (Ex numbered
envelopes)
Not specified Not specified
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Who has implemented the
randomization
Not specified Not specified
Matching of patients in
intervention and control
group; supply of baseline
information for both groups
Baseline information for
both groups supplied;
no details supplied on
methods used to match
patients in both groups
Achieved though
stratification of
randomization according
to infectious diseases
category such that 2
patients in each
category were in each
arm of the trial;
relevant baseline
information for both
groups supplied
Any differences reported
between the two groups
None None
Inclusion and exclusion
criteria
Clearly defined Clearly defined
Method of determination of
number of patients in each
group
Not specified Not specified
Were there sufficient
numbers included in the two
groups ex use of a power
calculation
Not specified Not specified
Blinding
Was blinding conducted;
were participants, staff or
study personnel blinded
Not specified Only staff in the control
group were blinded
Outcomes measured Antibiotic costs and
length of parenteral
treatment; need for
readministration of
antibiotics after 7 days;
length of patient stay
Primary outcome:
length of stay (LOS)
after randomization
Secondary outcomes:
economic evaluation
and survival
Results
Description A decrease in antibiotic
costs and length of
parenteral treatment; a
decrease in the need for
readministration of
antibiotics within 7
days; a decrease in LOS
in the intervention
group
A decrease in LOS after
randomization; a
reduced number of both
ICU and non-ICU days;
overall reduction in
patient charges;
reduced mortality in
intervention group
Statistics used (including
consideration of any
confounding variables)
Chi-squared and t-tests
were performed for
normal distributions;
nonparametric variables
for others; Multivariable
linear regression was
performed to account
for any variables
t-test and Chi-squared
were used to determine
any differences in
baseline variables;
Weibull regression was
used to compare all
intervention and control
group end point
medians; Fisher’s exact
test was used to
compare mortality
Statistical significance Decreased costs Decreased LOS (p =
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(p<0.04) and decreased
need for
readministration of
antibiotics (p=0.02)
were SS; decreased
duration of parenteral
treatment (p=0.08) and
decreased LOS
(p=0.11) not SS
0.0001) and number of
ICU days (p=0.0001)
were statistically
significant (SS); SS
reduction in patient
charges (p=0.008); no
SS in non-ICU bed days
(p=0.081) and in
survival (p=0.175)
Were all participants who
entered the trial accounted
for; if there were
withdrawals, is a description
provided giving reasons why
Yes 252 patients were
recruited with 260
reviews performed; one
patient was excluded
since he was readmitted
after less than 31 days;
31 were excluded
because ID were
involved in a
consultation; 3 were
excluded because
contact was made with
the prescribers to
ensure patient safety
Yes 272 patients were
recruited; withdrawals
clearly defined (20); a
further 14 patients were
excluded from the
analysis because the
prescribers did not
accept the team
intervention
Quality criteria
Blinded assessment of
primary outcome (authors
state specifically that the
primary outcome variables
were assessed blindly or
outcome variables are
objective)
Yes – all outcomes
reported were objective
Yes – all primary
outcomes reported were
objective
Completeness of data set
(dataset should cover 80-
100% of the total number of
participants or episodes of
care in the study)
Yes Yes
Reliability of outcome
measures (if two or more
raters have at least 90%
agreement or kappa 0.8 or
if outcome obtained from an
automated system)
Yes – all outcomes
measured came through
automated systems
Yes – all outcomes
measured came through
automated systems
Methods used to enhance
the quality of measurements
(Ex multiple observations;
training of assessors)
Not available Not available
Discussion
External validity of the trial
findings
Not provided Not provided
Interpretation of results
including consideration of
potential bias and
imprecision
Provided with a clear
discussion about the
limitations of this study
Provided – but bias and
imprecision not
considered
Comments A pioneering study
involving an RCT.
Economic outcomes do
One of the few RCTs
within this area; an
attempt to link both
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not take costs of the
intervention into
consideration. Mainly an
economic driven trial
with little consideration
for patient outcomes
despite evaluation of
clinical and
microbiological
outcomes being initial
aims. The authors
consider the need for
readministration of
antibiotics after 7 days
and LOS as indirect
measures of response to
antibiotic treatment.
patient outcomes
through optimisation of
antimicrobial use, with
economic outcomes,
with the latter taken
into consideration to
obtain evidence to
present to
management. Economic
evaluation takes cost of
intervention into
consideration
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2.4 Discussion
2.4.1 Strengths and limitations
This review adds to the current body of literature since it is the first review
specifically considering the role of the hospital pharmacist within the AMDT.
The method used follows updated guidance published by the Centre of
Review and Dissemination updated guidance (157) and methods for
establishing the review team, the inclusion and exclusion criteria, the search
strategy and screening process and the quality assessment have been
carefully considered to ensure a robust process has been employed. An
expert in the topic was external advisor to the team. It is exhaustive in that
it has considered both descriptive reports and primary research about the
topic, though it has not considered grey literature and papers that were not
in English.
2.4.2 Key findings in relation to review research questions
The paucity of data available, the small-scale, single-site nature of the trials
and the study quality made it difficult to draw any finite conclusions about
outcomes following interventions by an AMDT. Only two of the studies were
randomised controlled trials and most were conducted over short time-
scales making it difficult to draw any conclusions about sustainability of the
projects. The study design often did not consider the cost of the
intervention, and there is a focus on cost containment with little
consideration for microbiological or patient outcomes. Only positive
outcomes were reported with no publications making any reference to
possible negative outcomes.
Bearing in mind the above comments on the quantity and quality of the
published reports (both descriptive and evaluative) a crucial role was
identified for the pharmacist as part of a multidisciplinary programme that
may be considered as follows:
(a) A role for the dispensary pharmacist who often screened initial
antimicrobial requests. This was particularly important where restriction
policies were being applied.
Chapter 2 – Systematic Review 90
(b) A role for the general clinical pharmacist who was often on the ward and
in an ideal position to identify those patients with specific pharmaceutical
needs and give feedback to the specialist pharmacist. Other roles included
guideline development, formulary management, IV-to-oral conversions and
evaluations of programme outcomes through monitoring of drug usage.
(c) The pharmacist who had undergone specialist training in infectious
diseases and antimicrobials and was an integral part of the antimicrobial
team. In collaboration with other professionals within the team, the
pharmacist was involved in streamlining empiric treatment following
availability of microbiology reports, reviewing more complex patients
referred to by the ward clinical pharmacist, participating in educational
meetings and attending ward rounds.
Interestingly, the pharmacist was only making changes to the patient’s
medication in two papers: an IV-to-oral switch led by a patient group
direction (see section 1.2.2), and an automatic therapeutic interchange
where the physician was notified that the change had been made.(162,
175)
Of the nine evaluative trials identified, most were economically driven due
to the institution’s spiralling costs relating mainly to antimicrobial
expenditure and the cost savings following implementation of the AMDT are
the only outcome reported; most set out to prove to hospital management
the cost-effectiveness of an AMDT with little or no consideration of the costs
required to set up the AMDT and the intervention made as part of the
programme. The effect of the AMDT on antibiotic usage is difficult to
compare due to lack of standardisation of the units of measurement. The
few trials that considered patient outcomes mainly used the length of
hospital stay as a marker of effectiveness (172,177); this may however be
imprecise as an outcome measure making it difficult to interpret the
data.(4) It is not possible to draw any conclusions as to how the teams had
any effect on bacterial resistance due to the lack of data available.
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2.4.3 Discussion of findings and potential future research
Clinical pathways followed by post-prescribing evaluations by the AMDT,
was the programme most commonly established in the trials identified. This
involved establishing clinical guidelines and providing feedback to
prescribers on adherence to the guidelines. This allowed for the streamlining
of patients’ treatment through recommendations rather than restrictions
and may reflect the institutions’ desire to move away from control and
policing in an effort to rationalise antimicrobial treatment. All trials reported
are single site and it is therefore difficult to extrapolate findings from one
institution to another. The lack of benchmarking in relation to the hospital
demographics (Ex teaching, number of surgeries, number of acute
admissions) do not allow generalisability of the findings. It is not possible to
determine which of the interventions is likely to be most effective since
institutions tailored a programme most likely to be effective in the given
institution. None of the trials were directly comparing the interventions
made by the AMDT, so it is not possible to conclude which may be a more
effective intervention. Besides, many of the programmes reported come
from the US and the different healthcare systems make it impossible to
generalise findings and extrapolate to other healthcare systems due to the
different practices and resistance patterns within different institutions and
countries. This has also been highlighted by other reviews.(146,148)
To build more robust evidence supporting the most suitable intervention to
optimise antimicrobial use and the role of the pharmacist within such
teams, there is a need for further research as also concluded in other
reviews.(4,146,148,180) Some examples of potential areas of research
include:
 Trials over a longer period of time to determine which intervention is
the most sustainable
 Trials which address the current deficiencies in methods to enhance
external validity such as standardising the units of measurement of
antimicrobials (Ex using the defined daily doses) and defining hospital
demographics
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 Trials which address the impact of teams on patient and
microbiological outcomes, mainly resistance patterns.
Pharmacists may potentially be involved in optimising antimicrobial use
through PP, a role which has not been reported in the published literature.
The growing responsibilities of the pharmacist to enable PP allow
pharmacists to potentially expand on their current roles within hospitals
including that as part of AMDT. The advent of pharmacist IP enables them
to proactively start or change a patient’s treatment without the need to first
contact a physician and this may include optimisation of antimicrobial
treatment. This is likely to reduce the time required for writing up
prescriptions providing quicker access of the appropriate medication to
patients. Antimicrobial treatment may lend itself to such expanding roles,
for example, IV-to-oral switch in accordance with clinical guidance and the
patient’s clinical status, streamlining antimicrobial treatment following
availability of culture and sensitivity reporting or prescribing antimicrobials
in accordance with evidence-based guidelines as part of surgical
prophylaxis. The growing problem of antimicrobial resistance makes it likely
that new ways of practice need to be explored in the future to help optimise
antimicrobial use in hospitals. This may include PP. There is little primary
research on PP in hospitals, and no research was identified that focuses on
a specific drug including antimicrobials. The following research project aims
to explore PP in Scottish hospitals, with a focus on antimicrobials. Results of
the research may help policy makers who are looking for novel ways of
integrating the pharmacist prescriber as part of the AMDT.
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Chapter 3
Focus group discussions
3.1 Introduction
There has been considerable evolution of the research aims and
methodology when comparing the original research proposal to the aims
and objectives in this Phase 1 of the research. The main sources of
information and influence in this were the literature review and discussion
with the supervisory team. Figure 2 shows the approach taken and the way
in which both the research question and methodology evolved.
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Figure 2: Schematic representation of evolution of research aim and
methodology
Initial Research Aim –
To explore the structures,
processes and outcomes involved
in PP of antimicrobials in
secondary care
Questionnaire –
cross sectional
survey to measure
pharmacist’s views
and attitudes to PP
of antimicrobials in
secondary care
Case study to
explore a
context where
PP is being
implemented
Identify a tool
to measure
quality of
antimicrobial
prescribing and
use this to rate
the quality of
PP
a) too complex and
time consuming to
develop a sampling
frame since no
readily accessible
database of
required
information
b) little
information
around the topic in
literature to inform
the questionnaire
Discarded
No site has
been identified
where
pharmacists
are prescribing
antimicrobials.
Therefore this
case study is
not currently
feasible.
Discarded Discarded
No site has
been identified
where
pharmacists
are prescribing
antimicrobials.
Therefore this
outcome
measure is not
currently
feasible.
To explore pharmacists’ views
and perceptions of pharmacists’
prescribing in secondary care
with a focus on antimicrobials
Focus on a more exploratory
approach to the research
Through
a series
of focus
groups
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3.2 Methodology
3.2.1 An overview of methodological approaches in research
Traditionally, there have been two key approaches in research: the
quantitative approach dealing with numbers and statistics and the
qualitative approach focusing on words and text.(181) This section briefly
compares the distinctive theoretical frameworks on which each is based.
Rather than being a comprehensive discussion of each method, emphasis is
placed on aspects that are of relevance to this research.
Authors have argued that qualitative research, unlike quantitative research,
is interested in idealism rather than realism.(182) This implies that it tries
to determine what people’s perception of reality is. Conversely, quantitative
research is based on realism, with scientists claiming that it is possible to
state objective truths about the material world. Critics of quantitative
research claim that this is not possible; science actually produces the best
conclusions in the current historical context and with the tools presently
available. The natural versus artificial debate has also emerged with
qualitative research linked to the natural, and quantitative to the artificial,
implying that the latter deals only with experimental work. The different
methods of reasoning involved in qualitative and quantitative methods have
been broadly classified as inductive and deductive respectively. The
deductive approach in quantitative methodology starts with a broad theory
that is proven or disproved through observation in an experimental
environment. Conversely, qualitative methods take the opposite approach,
and start with observation to generate theories and are thus more
exploratory in nature. The latter tends to develop concepts while the former
tends to develop indicators.(181,182) This may be shown graphically as
follows: (183)
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Deductive approach:
Theory Hypothesis Experimentation Confirmation
Inductive approach:
Observation Pattern Tentative hypothesis Theory
It is easy to visualise that a circular process may be drawn up and that any
form of research is actually a combination of deductive and inductive
processes as shown in Figure 3.(183)
Theory Hypothesis Experimentation
Figure 3: Schematic representation showing both inductive and deductive
approaches in quantitative research
Induction
Confirmation
of
hypothesis
Rejection
of
hypothesis
New
Hypothesis
Deduction
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3.2.2 Choice of method for Phase 1
The aim of Phase 1 of the project was:
To explore pharmacists’ views and perceptions of pharmacists’ prescribing
in secondary care with a focus on antimicrobials.
The research objectives for Phase 1 of the project were to explore:
 To what extent pharmacists were using their prescribing privileges
 Pharmacists’ perceptions of the usefulness of PP in practice with a
focus on antimicrobials
 Pharmacists’ perceptions of the potential barriers towards PP in
secondary care with a focus on antimicrobials.
A schematic representation of development of methods for Phase 1 is at
Figure 2. This phase of the research aimed to explore participants’ views
and perceptions, and is consequently more interested in answering the
“why” rather than “what” is happening around PP in secondary care. The
research aim cannot be answered using numbers or statistics, but the in-
depth and rich descriptions characteristic of qualitative research are
required to illustrate views and perceptions. It would be difficult to capture
these using a survey questionnaire with “yes” and “no” or “tick-box”
answers. An alternative would be an open-ended questionnaire; however
this would assume the agreement of participants to fill this appropriately
and would likely be very time-consuming on their part. Besides, such a
questionnaire was unlikely to give the sufficient depth required and
consequently, a qualitative method was likely to access data and
information inaccessible to quantitative methods. Due to the originality of
the subject being researched, there is little information available in the
literature to guide the development of quantitative research tools, and
consequently this research may be viewed as being exploratory; again
qualitative research is the more appropriate in such a case scenario, since
this will generate information for subsequent explanatory or predictive
research.(182) The choice of research method was therefore made on the
basis of which is the more appropriate to achieve the project aim and which
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is more likely to produce the most answers to the questions being asked,
rather than on the basis that one form of research is superior to another. As
Hammersley is quoted in Murphy “… which of these approaches is most
appropriate should depend on our purposes, and the stage that our
research has reached, not on paradigmatic commitments.” (182)
Considering the above, a qualitative methodology may offer a number of
advantages as a research method here over quantitative research namely
(181,182):
 Since it is an iterative process, there is a constant interplay between
data collection and data analysis and consequently the design of the
study emerges as the research progresses in response to earlier
observations. This is of particular relevance to this research since
findings in Phase 1 of the project will inform later phases.
 Viewing events and actions from the perspective of those being
studied; this allows use of methods such as focus groups and in-
depth interviews, which allow the researcher to be as close as
possible to the participants rather than putting forward the
researcher’s ideas as in a survey questionnaire. This is especially
important in this research due to the lack of literature and
information about the topic to inform the development of a
questionnaire. The research also aims to capture views and attitudes,
which may be more effectively achieved by the use of a qualitative
methodology. Bryman as described in Murphy, uses the following
description “The quantitative researcher adopts the posture of an
outsider looking in on the social world...Among qualitative
researchers there is an urge to ‘get close’…to be an insider…by
getting close to their subjects and becoming an insider they can view
the world as a participant in that setting.” (182) This may however
also pose certain problems mainly for the researcher to leave behind
all ideas and prejudices and analyse and investigate the participants’
views as a point of departure. It is therefore imperative that the
researcher clearly illustrates how he or she has arrived at the
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interpretation of the actions of others. The process used is examined
in more detail in Section 3.2.4 below.
3.2.3 Methods used in qualitative research
Methods in qualitative research may be divided into those where data are
naturally occurring and those where data are generated. The naturally
occurring include observation (which may be covert or overt), document
analysis (which may be both formal or informal such as diaries or letters)
and conversation analysis. This is of particular use where behaviour and
interactions need to be explored in the natural environment of the group
being studied. Analysis relies heavily on the researcher’s interpretation of
what is being observed or read.(184) Generated data include in-depth
interviews and focus groups. Such methods involve the participant’s
reconstruction of attitudes, beliefs, behaviour or other aspects that are
being investigated; they are a unique source of information in
understanding participants’ own perspectives of the phenomenon being
investigated relying heavily on their own interpretation, though this may be
further interpreted by the researcher.(184)
3.2.4 Study Design
3.2.4.1 The use of focus groups
Generated data methods of collection were considered to be more
appropriate than naturally occurring since they would provide insight into
the pharmacists’ perceptions together with their own interpretation into why
they held these views and perceptions. The research aim and questions
were explored through focus group discussions with hospital pharmacists.
Kitzinger comments that focus groups have been shown to be an effective
way of exploring the attitudes of staff within a health service and were
therefore a suitable choice for this research.(185)
The focus group method is a form of group interview first introduced by
Merton et al, where a moderator guides the interview by asking a number of
focused questions, and participants within the small group discussing those
topics raised by the moderator, asking each other questions and
commenting on each others’ experiences and points of view.(181,185) The
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discussion within the group is therefore the generated data in focus groups.
Participants are usually selected because they come from a similar
background or have shared a similar life experience. Morgan recommends
having six to ten participants in each group; it may be more practical to
have smaller groups if the participants are likely to have a lot to contribute.
A typical focus group lasts about 90 minutes.(186,187) The number of
groups conducted varies immensely in the literature with one project
reporting up to 52 conducted groups.(181) Usually, the higher the level of
diversity within each group, the more ideas generated and consequently the
more focus groups are needed. It is normally recommended to conduct
groups until theoretical saturation is reached, where no new ideas are
generated and where the moderator feels confident that he/she may predict
what the next group will discuss.(181) Focus groups are usually audio-
recorded and transcribed with transcription-based analysis, though there
have been reports of note-based and memory-based analysis. A transcript-
based analysis is recommended since it allows capturing of the group
dynamics with knowledge of “who is saying what.” (181,187)
Focus groups were preferred over in-depth interviews for Phase 1 of the
research for the following reasons: (181,184,187,188)
 A focus group design would allow participants to probe each other’s
reasons for holding certain views and ideas rather than just a
question-answer as would occur in a normal interview; consequently
participants may influence each other’s response. In this context, it
would enable discussion between participants who are supplementary
prescribers or training to become prescribers, and those who are not
supplementary prescribers. It would also stimulate discussion
between pharmacists working in different specialities.
 Arguing and discussion between the members of the group may
result in a more realistic result than just an interview. Again, having
mixed groups would enable probing and a better understanding of
any differences that may exist between different areas where
pharmacists were practising. However, this may lead to a problem
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with dynamics within the group which need to be effectively managed
by the moderator.
 May be regarded as more “naturalistic” when compared to interviews;
in real life people rarely build up ideas, work or function in isolation
but rather in groups. This may be of particular relevance here since
all the group participants are already part of an existing work group.
 Individual’s responses are usually more spontaneous; being away
from the interview question-answer design, participants in a focus
group will only answer the question if they feel strongly and have a
definite feeling about the subject not because they have to.
 Since the focus is on the group rather than the individual,
participants may feel more secure since what is being said will not
necessarily be attributed to the individual but rather to the group.
Focus groups therefore enable inclusion and contribution from people
who would otherwise not participate if a one-to-one interview were
held.
The following approaches were adopted to enhance a systematic approach
in this research.
 The moderator who was also the author and analysed the data was
trained prior to embarking on the project and attended courses
relating both to qualitative methods and the data management
software NVIVO.
 A topic guide was used to provide a systematic approach, yet
allowing the participants to discuss issues.
 All discussions were recorded and transcribed “ad verbatim” by the
moderator/author. This allowed for capture of data that would not be
possible to write down and helped with a rigorous analysis.
 Where possible, an assistant moderator was present to take further
notes where relevant.
 A clear account was provided of the process used to collect and
analyse the data.
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 Inter-rater reliability checks were incorporated in the analysis process
to ensure that another researcher came to the same conclusions
when using raw data.
Each is discussed in further detail below.
3.2.4.2 Governance issues
The project was approved by the ethical review panel of the School of
Pharmacy. Since NHS personnel were involved as participants, ethics
approval was sought through the Multi-centre research ethics committee for
Scotland (MREC). The full submission is in Appendix 3.1. MREC advised that
the project did not need to be reviewed by an NHS ethics committee since it
involved only staff and not patients and did not involve an intervention. This
reply may be found at Appendix 3.2. However, Research and Development
(RandD) approval was obtained for each acute organisation where a focus
group was to be conducted. This was at times a very lengthy process with
applications taking up to three months to be processed. Overall, it took 7
months to obtain all the necessary approvals. An example of an obtained
approval is at Appendix 3.3.
Acute chief pharmacists in the selected NHS health boards were initially
approached and given a brief overview of the project and asked whether
they would be willing to participate, with all agreeing to participate. They
were then asked to provide a list of all senior pharmacists who were Grade
D and above, their speciality and whether or not they were supplementary
prescribers or in the process of completing the course. Pharmacists were
then stratified by the main variables of prescribing status, and clinical area;
where possible, one pharmacist was selected per group to ensure as far as
possible representation of the main variables identified above. In the rare
circumstance were two pharmacists worked within one speciality, one
pharmacist was approached, this being organised blindly. Participants were
sent a recruitment pack which included: an invitation letter, some
background information about the study and a consent form (see Appendix
3.4). Participants could withdraw from the study at any point. The author
stored all the signed consent forms in a locked drawer.
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Media cards with focus group recordings were stored in a locked drawer
separate from the consent forms. These will be destroyed once the research
is completed. To ensure participant anonymity, all transcriptions were
carried out by the author who was also the moderator at all focus group
discussions. Only anonymised transcripts were available as paper copies
and distributed to other members of the supervisory group for review.
When inputting data into NVIVO (data management programme), only the
anonymised data were entered. Storage of all information is on a password
protected laptop. Any electronic or paper data will be destroyed once the
research has been written up.
3.2.4.3 Sampling and recruitment for focus groups
Choice of locations
Sampling of locations was purposive, with the aim of including
representation from health boards where specialised ID units were present,
and representation from health boards where such services were not
available. It was also aimed to have health boards with a mix of rural and
urban catchment areas. To achieve this variation, the following health
boards were recruited. Four health boards with specialised ID units were
included in the study. These had ID units within large teaching hospitals
with tertiary referral services, offering a mix of urban and rural location.
Two health boards were selected since there were no specialised ID units
present and no ID consultants within these health boards. Due to their
geographic location they also provided representation of the more rural
areas both having one main district general hospital.
The health boards were recruited largely in order of when RandD approval
was granted. Unfortunately, a focus group discussion was not conducted in
one of the district general hospitals due to a delay in research governance.
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Recruitment of participants
Sampling was purposive, with the intention of including representation from
ward based clinical senior pharmacists (usually Grade D or over, though this
was changing with the NHS ‘Agenda for change’ programme) who were
supplementary prescribers (or in stages of their SP course) or not, hospital
pharmacists working in different specialities (eg critical care, surgery,
respiratory, orthopaedics, diabetes and endocrine) where antimicrobial
prescribing is essential to patient care. Specialities with no ward based
activities, such as medicines information and quality assurance, were
excluded from the sample. Senior pharmacists were included in the study
rather than more junior grades since it was more likely for this grade of
pharmacists to have sufficient work experience within an area to be
specialist pharmacists and to have a better understanding of the role, if
any, of PP within that area. Having a mix of practitioners working in
different specialities would allow identification of any relevant distinctions
between different, but typical, settings/areas and individuals’ perceptions of
PP. The sampling frame therefore included all pharmacists falling within
these categories. Mixing the groups, particularly with respect to different
prescribing status, would potentially be able to generate more discussion.
To allow for a discussion involving ‘hands on’ current practitioners,
pharmacists who were higher up in management and chief pharmacists
were purposely omitted at this stage of the research. Together with the
recruitment pack, participants were sent a background survey which they
were asked to complete if they agreed to participate in the study. The latter
was aimed to obtain more details about the pharmacist’s experience with
the speciality PP of antimicrobials within the department. The survey was
reviewed for face and content validity by the same experts reviewing the
topic guide as described below. It was aimed to have 6-8 participants in
each group rather than run larger groups with 10 or more participants. This
would allow for a well balanced discussion where all participants have time
to air their views; it would be unlikely for the participants to have enough
time to express their views if a larger group was convened.(186) Krueger
goes on to comment that groups of more than 10 participants greatly limit
the amount of input from each individual, restrict the flow of ideas and on a
more practical level, are difficult to assemble and moderate.(189) It would
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also have been unlikely to be able to recruit more than 10 participants from
each site. Signed consent forms were returned in a provided stamped and
addressed envelope prior to participation in the focus groups.
3.2.4.4 Planning and conducting the focus groups
Choice of moderator
The author was the moderator and led all the group discussions. To ensure
efficacy of group moderation, the author attended various focus groups
organised by the school to observe the proceedings. Subsequently, the
author attended a week long specialised training programme focusing on
qualitative methodologies, with focus group moderation being one of the
topics covered.ix She also familiarised herself with specialised literature to
gain further insight into group dynamics and conducting focus groups.
The moderator had no association with any organisations where the focus
groups were carried out. Having the author as moderator was a major
advantage since this ensured that the moderator was familiar with the
project aims. Efforts were made to minimise moderator bias as
recommended by Stewart et al: a standard introduction was used (Appendix
3.5), which was the same for all focus groups; personal bias was minimised
by not only welcoming and reinforcing points of view with which the author
was in agreement but also other emerging ideas; questions asked aimed to
explore both the potential and the barriers of the topic under investigation;
and welcoming and reinforcing points of view that were not consistent with
themes that emerged from previous focus groups.(188) Since the
moderator was neutral and the research was not being carried out on behalf
of any sponsor, reinforcing points of view likely to be pleasing to the client
were not applicable in this case. Having the author present at all focus
groups allowed the “gist” and “feel” of the group to be captured; qualities
that would have been missed if only the transcript was used for analysis.
Krueger recommends having an assistant moderator present at every focus
group as part of a systematic approach, acting as an extra pair of eyes and
observing and noting the participants’ body language throughout the
ixSocial Research Association Course held in Edinburgh in March 2006
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discussion. He also goes on to acknowledge that very often it is not possible
to have an assistant moderator in the private setting mainly due to financial
constraints.(190) Where available, an assistant moderator accompanied the
author with a standard field note reporting form based on the literature
used for note taking. (Appendix 3.6) The assistant moderators were also
provided with a checklist to enable rating of the moderator and ensure
continual development and improvement of the moderating skills.(190)
Presence of the assistant moderator therefore provided intermittent validity
to check the process being used and to offer insight into the groups. This
exercise was particularly valuable during the initial groups. Due to logistical
problems, it was not always possible to have an assistant moderator
available at all focus groups. Where no assistant moderator was available,
two recorders were used to ensure efficient recording of the group
discussion. When assistant moderators participated, neutrality was also
ensured. All assistant moderators were from the school of pharmacy and
were not involved in teaching any courses that the participants were likely
to be undertaking.
Development of the topic guide
To ensure that a consistent and systematic approach was taken when
asking the participants questions and to ensure that all the study objectives
were covered, a topic guide was developed. When drawing up the topic
guide, a questioning approach was taken rather than a list of topics to be
explored during the focus group. The questioning route produces more
efficient analysis because it minimises subtle differences in questions.(191)
However, it may produce a lack of spontaneity when the questions are
being asked. Rather than having a “rolling interview guide” where the
questions were changed depending on answers to previous focus groups,
consistency in the questions was kept across groups and enabling a more
systematic approach to the analysis.(188,189) A more “moderately”
structured approach was taken when developing the questions for the topic
guide; the questions aimed to answer the specific research objectives but at
the same time explore participants’ views about the topic.(186) The aim
was to have a balance between the author’s focus and the group’s interests.
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The first questions were aimed to be biographical and related to the
participants’ own prescribing status; this was viewed as a way of creating a
relaxed group dynamic and get the discussion started, particularly since the
groups were being audio-recorded. The questions were developed to flow
from the more general to the more specific questions. An initial set of
questions was developed by the author as at Table 11. This was then
reviewed for face and content validity, by the three members of the
supervisory team, two academics, one with a special interest in non-medical
prescribing and another with an expertise in qualitative research methods
and two academics external to the university. The reviewers were asked to
comment about the readability of the questions and the extent to which the
questions answered the research objectives. The questions were also
circulated to a national infection management interest group coordinated by
the UKCPA; however only one response was obtained, with other members
commenting that they found it difficult to critique mainly due to a lack of
familiarity with qualitative research methods. The final version of the topic
guide used is at Table 12.
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Table 11: Initial version of topic guide
TOPIC GUIDE FOR FOCUS GROUPS DISCUSSION
1. I wonder whether we may start by having a brief introduction from each participant
including speciality and whether or not supplementary prescriber or on the course.
Is supplementary prescribing (SP) used in the day-to-day job? Are there any plans
for those who are not supplementary prescribers to become SPs as part of future
objectives?
2. Does your department support and encourage PP?
[Prompts: finance course; provide study leave to attend residentials; allow for study
time; provide a framework to apply PP in practice; provide current job cover to take SP
forward]
3. Is there a role for pharmacist supplementary prescribing of antimicrobials in
secondary care?
[Prompts: pharmacist adequate knowledge and background to prescribe antimicrobials
especially compared to HOs and SHOs and registrars in some specialities; better quality
use of medicine; better medicines management; ever discussed the potential of
pharmacist antimicrobial prescribing with colleagues or clinicians]
4. Are you prescribing antimicrobials as part of your day-to-day job? Is there any
other PP antimicrobials within the department and if yes what speciality? Do you
have any specific clinical management plans drawn up specifically for antimicrobials
or any patient group directions eg IV-to-oral switches?
5. If you are prescribing antimicrobials what has been the feedback from:
a) doctors b) nurses c) patients [any differences between if on acute ward or chronic
conditions as an outpatient eg HIV or cystic fibrosis] d) other colleagues
[Prompts: more holistic care of patients; ensure patient concordance; ensure patient
have a better understanding of their condition and why antimicrobials are needed;
improve patient discharge process; patients having a longer appointment time at an out-
patient clinic]
6. Do you feel more comfortable writing prescriptions for antimicrobials for a)
diagnosed conditions b) undiagnosed conditions
7. Are there any benefits which you have already seen or any potential benefits of PP
of antimicrobials?
[Prompts: closing gap in current patient care; ability to save time chasing doctors; filling
in a gap that a medical practitioner may have left; improved continuity of care; increase
pharmacist profile and job satisfaction within the working environment]
8. Are there any barriers, problems or potential problems that may arise if PP
antimicrobials?
[Prompts: stepping over the traditional inter-professional boundaries eg doctors and
nurse practitioners; shortage of hospital pharmacist and increased workload; separation
of prescribing/dispensing tasks which may be especially a problem in rural areas;
problem with not having the pharmacist for 7 days and possible disruption of service;
problems with indemnity/increased liability; setting up of clinical management plans for
individual patients on acute wards where there is a constantly changing clinical
background]
9. Is there anything that has been missed or that anyone would like to add?
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Table 12: Final version of topic guide
TOPIC GUIDE FOR FOCUS GROUPS DISCUSSION
1. I wonder whether we may start by having a brief introduction from each participant
including speciality, and whether or not a supplementary prescriber or on the course.
THEN, for those who are not supplementary prescribers, are there any short-term plans to
become SPs as part of future objectives?
2. For those who are supplementary prescribers, to what extent is this being used in the
day-to-day job?
THEN if SP is not being implemented what are the reasons for this?
3. For everyone, moving onto antimicrobials, what are your thoughts on pharmacist SP
of antimicrobials in secondary care?
Consider different patient groups:
a. intensive care
b. respiratory
c. elective surgery
d. orthopaedics, trauma
e. dosing of antimicrobials in renal patients
f. outpatients/inpatients as chronic/acute conditions
4. Have you ever discussed the possibility of pharmacist antimicrobial prescribing with
colleagues or clinicians?
THEN for anyone already prescribing antimicrobials what has been the feedback from other
healthcare professionals, colleagues or patients.
Now moving onto PP (both supplementary and independent). With independent prescribing,
there is no need for a CMP and a pharmacist may prescribe both if the doctor has diagnosed
a condition or can diagnose and prescribe.
5. In a hospital environment, what is the feasibility of a PP when
a. a diagnosis has been made
THEN, b. when a pharmacist has to diagnose and then prescribe
6. What is the value of both pharmacist antimicrobial supplementary prescribing and
independent prescribing in secondary care?
If we start with a) the positive thoughts
b) the negative thoughts
7. What attitude does pharmacy management have towards pharmacist SP of antimicrobials?
8. Are there any barriers, problems or potential problems that may arise if pharmacist is
a) supplementary prescribing antimicrobials
b) independent prescribing antimicrobials
9. Is there anything anyone would like to add?
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After conducting the first focus group, it was felt that giving examples as in
question 3 may be leading; a minor change was therefore made and these
examples were omitted in the subsequent focus groups. Participants during
the first focus group were also asked to summarise the results of the
discussion in one written sentence. This was however dropped since the
participants felt that this was very difficult to complete and express;
besides, on analysis, this did not help to gain a better understanding of the
discussion.
Prior to asking any questions on the topic guide, there was a brief
introduction where the participants were given reasons why they had been
chosen to participate, were reminded that the discussions were being
recorded, and were asked not to speak over each other. It was also
emphasized that the aim of the groups was to stimulate discussion rather
than reach consensus. The focus groups were held within the hospital
premises, since this location was suitable for the participants. Many of the
groups were held over lunch breaks with lunch provided by the university;
the lunch offered an opportunity for the moderator to interact and get to
know the participants. The seating arrangement was similar for most groups
with a circular seating arrangement adopted for most groups; where
possible the moderator avoided sitting at the head of the table to create a
more informal environment. On average, the focus groups lasted around 60
minutes (40-70 minutes) and were conducted between July 2006 and
January 2007.
Audio-recording and transcriptions
Transcript-based analysis is usually the most rigorous form of analysis and
therefore, though time consuming, was opted for in this project. To ensure
a complete, thorough and systematic capturing of data, all focus groups
were digitally audio-recorded, with the participants’ consent, and
transcribed “ad verbatim.” This systematic approach allowed reconstruction
of critical parts of the focus groups during the analysis phase.(189) All
transcriptions were prepared by the author to ensure “immersion” in the
data. All audio-recordings were securely kept until the writing up stage and
were then destroyed. Audio-recordings were heard only by the author, who
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was also present at the focus groups. They were anonymised following
transcribing and only the anonymised versions were used for data analysis.
3.2.4.5 Analysing the focus group results
Approach to analysis
There are no clearly agreed rules or procedures as to the correct approach
to analysis of qualitative data with variations occurring depending on the
traditions of the discipline, the main focus and the aims of analysis.(184)
This is emphasized by Patton who makes the following comment: “Do your
very best with your full intellect to fairly represent the data and
communicate what the data reveal given the purpose of the study.” (192)
The objective of the analysis in this research was to have a better
understanding of the participants’ views and perceptions towards PP in
secondary care in terms of: the current use of prescribing skills and the
perceived opportunities, feasibility, challenges and barriers of PP in
secondary care with a focus on antimicrobials. The themes were initially
identified through a narrative analysis and were very loose terms based on
the participants’ own views. The author tried to understand the way the
account was constructed and the meaning of the “story” that the
participants were relating and trying to put forward. Content analysis was
then carried out to understand the way the theme was presented and
frequency of occurrence. The use of a combination of approaches has been
reported in the literature and often there is not one clear cut approach but a
crossing of boundaries.(184) A thematic summary was then drawn up to
produce a descriptive account of each focus group. A ‘cross-sectional’
approach was adopted in that the same themes were applied to the whole
dataset, initially manually and then computer-assisted, such that chunks of
data representing a theme were placed together. Use of a cross-sectional
approach has been criticised since it may produce a separation of the theme
from the context; other authors have however commented that this is the
advantage of using such an approach and is the only way of understanding
and interpreting data.(184) There has also been much debate around the
use of computer-assisted software; those in favour of their use have
included consistency of approach, ease of linking and easier
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conceptualisation of data and theory building as advantages. Reported
disadvantages have been a removal from context, a way of trying to put
“scientific method” into qualitative research, an over-emphasis on counting
rather than other forms of analysis, and a temptation to take a “shortcut.”
(184,189) The latter has been overcome in this project by initially building a
manual thematic index followed by a descriptive account of each group.
Following this, data were entered into NVIVO7 such that chunks of text
where a specific theme emerged were grouped together. This therefore
gave the facility to help organise data across the whole group using
“software for data administration and archiving.” (184) The complete
transcripts were entered into the software package and though anonymised,
the author could identify who was speaking through the coding system
used, helping to keep the analysis in context.(189) The author attended a
training course on the use of NVIVO organised by the University in
December 2006.
The analytical process and tools used
Ritchie et al have summarised the required features of an analytical tool as
follows, recommending that the process chosen should have all of the
features:(184)
 Remains grounded in the data with constant and frequent re-visiting
of data and quick and easy access to the original data
 Permits captured synthesis allowing data reduction without loss of
meaning of the original text
 Facilitates and displays ordering such that the data may be inspected
in blocks that are related to the specific subject
 Permits within and between case searches
 Allows systematic and comprehensive coverage of the dataset
implying that the same method is applied across the whole of the
dataset
 Permits flexibility allowing additions or amendments at any point in
the analysis
 Allows transparency to others.
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The actual process may be viewed as taking the form of an “analytic
hierarchy” made up of 3 stages: data management, descriptive accounts
and explanatory accounts.(184) The whole process is an iterative process
implying that this is not a linear approach or a sequential process as in
quantitative data analysis, but rather each of the steps is revisited at
different stages of the analysis. Murphy similarly described the analysis
process as involving both the data management, which allow data reduction
and consequently allow data to be handled more efficiently, and the
procedures where the relationships and features are identified.(182) These
processes usually occur simultaneously as the data progresses. Murphy
goes on to describe theoretical sensitivity, which involves the element of
individuality in qualitative research, both in terms of the setting studied and
in terms of the researchers. Therefore, though one may include thorough
descriptions of methods used, one cannot completely standardise methods
for qualitative analysis.
Data management involves sorting and reducing the data making them
more manageable through generation of themes followed by labelling and
sorting of all the text, manually or computer-aided. Descriptive accounts
make use of the synthesized data to prepare a description. At this point, it
is important to keep referring to the words used by the participants and to
the content of people’s accounts. The researcher may then move on to
develop typologies as a way of classification and segmentation of different
characteristics emerging. Explanatory accounts usually occur at a later
stage and involve building explanations and trying to answer any pattern
and outcomes in data that are observed. It is important that the whole
process used is clear such that other readers and other researchers may
view the logic of construction of conclusions.
To aid in the analytical process in this research, the analysis tool
‘framework’ was used, a method developed in the UK in the 1980s at the
National Centre for Social Research by Ritchie and Lewis. It is a matrix-
based analytical method and was selected since it facilitates rigorous and
transparent data management ensuring that all steps involved can be
systematically conducted and can be viewed and assessed by researchers
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other than the primary analyst.(184,193) The framework method was also
considered to be the most suitable since the research was led by pre-
defined objectives and a “semi-structured” topic guide was used to facilitate
the focus groups, thus giving the research more structure at the start than
would be typical of qualitative research. The author also attended a
specialised course (as previously specified) that used the ‘framework’ tool
and therefore felt more confident with this method. There are five main
stages to this approach:(193)
 Familiarisation: involves immersion in the raw data. In this case, the
author collecting the data was also the analyst and was therefore
already relatively familiar with the data. Furthermore, to aid in the
process, the author transcribed the audio recordings herself and read
these transcripts over and over again.
 Identifying a thematic framework. The end product was a detailed list
of themes – effectively an ‘index’ which could then be applied to the
whole text.
 Indexing – Applying the thematic framework to the whole text
systematically. The term ‘indexing’ rather than ‘coding’ is being used
since it is fitting the index into the text without any interpretation as
coding would imply.
 Charting – Rearranging the data according to the appropriate part of
the framework to which they relate. This is done by synthesising the
material into charts sorted out by the themes. This ensures that there
is no ‘context stripping.’
 Mapping and interpretation – using the charts to find associations and
provide descriptions and explanations.
Due to the recent development of this method of analysis, there is little
critique of this in the literature.
A more detailed step-by-step breakdown of the method used for analysis is
found below.
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1 The transcript for the first focus group was read and recurring themes
and ideas were identified. Examples include clinical management plan
as a limitation of pharmacist SP.
2 The themes were sorted and grouped under a smaller number of
categories building the thematic index or framework. This was
reviewed as more themes emerged. Throughout this process, the
language was kept as close as possible to that used by the
participants with little reference to the literature i.e. the process was
“grounded in the data.”
Barriers to PP
Category Limitations of pharmacist SP
Themes Clinical Management Plan
3 The transcript was then labelled and this involved an indexing
process where the themes and concepts were applied to different
parts of the data i.e. which theme is being mentioned in which part of
the data.
4 This was initially done manually with notes written in the margins on
the transcript, and then electronically using NVIVO7. Where sections
of the data fitted into more than one theme, these were ‘multi-
indexed.’
5 The above was repeated for each focus group transcription. New
themes were added on as they emerged from each focus group. As
the data was understood better, themes were also collapsed to create
broader categories. Data saturation was eventually reached when no
more new themes emerged. Different versions of the thematic index
and the final version generated through NVIVO7 are at Appendix 3.7
and 3.8.
6 The data were sorted by category and theme electronically such that
all the material falling under a specific theme was organised together.
To keep the data within context, though the data were anonymised,
the author was able to identify which participant said what. Also the
texts were labelled to know the context i.e. which focus group the
data originated from.
Chapter 3 – Focus Group Discussions 116
During all the above processes involved in data management, there were
regular discussions with the supervisory team as an “auditing” process.
7 All the data on a specific theme within each focus group were brought
together. This would allow for a comparison of that theme across
groups.
8 This step was repeated by another author and compared to obtain
feedback and check for concordance. This inter-rater reliability
constituted the “audit” element used throughout the project and
aimed to improve the consistency of the analysis.(193) The initial
focus group analysed was reviewed by 2 other researchers and
served as a validity check.
9 The transcripts were re-read while listening to the recording and the
frequency, extensiveness and intensity of comments were noted.
10 The indexed transcripts, together with the information as organised
within NVIVO were used to perform across group content analysis
and write up the results.
Data selection and presentation
This is a comprehensive output where a detailed and extensive portrayal
of the findings is presented. The report is a descriptive account telling
the ‘story’ and taking into account all views, even atypical ones. The
structure of the report is that of the emerging themes. There is use of
verbatim passages to contextualise what is in the narrative text. Using
verbatim quotations helps to clarify links between data, interpretation
and conclusion, and strengthens the validity and credibility of
findings.(194) Bowling also comments that when using a narrative
format “Data need to be presented so that their richness is not lost.”
Quotations have been selected to illustrate the divergence of opinion and
more than one quote is provided if there were different perspectives.
Each quote has an “identity tag” which highlights the key characteristics
of the speaker.
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Figure 4: Schematic representation of methodology adopted for Phase 1 of
the project involving focus groups
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3.3 Results
3.3.1 Introduction
3.3.1.1 Demographics of participants
A total of 56 pharmacists were approached with 39 pharmacists consenting
to participate and 37 of whom actually participated in one of the six focus
groups. The main reasons for non-participation were lack of availability due
to being off work or due to other work commitments. Two pharmacists
could not participate in the final discussion despite having consented, due to
other urgent work commitments that had to be dealt with at the time. Table
13 provides some information about the overall mix of each group, also
providing details about the demographics and services offered at each focus
group location. Though it would have been ideal to provide information
about the population covered by each health board where a focus group
was held, this was not provided to help ensure participant anonymity.
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Table 13: General demographics, location and participant mix in each
focus group
Services
Offered
No of
pharmacists
invited
No of
pharmacists
consented
No of
pharmacists
participating
No of
supplementary
prescribers
1 District
general
hospital with
no ID unit;
577 beds
11 6 6 4 and 1 in
training
2 Tertiary
centre with
an ID unit &
2
antimicrobial
pharmacists;
1000 beds
10 6 6 1 in training
3 Tertiary
centre with
no ID unit;
>900 beds
10 7 6 3
4 Tertiary
centre with
an ID unit
and an ID
pharmacist;
800 beds
10 7 7 2 in training
5 Tertiary
centre with
an ID unit
and an ID
pharmacist;
900 beds
8 7 7 4 and 1 in
training
6 Tertiary
centre with
an ID unit; a
number of
specialised
pharmacists;
932 beds
6 6 5 2 and 1 in
training
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Of the 37 participants, 32 were female and 19 were supplementary
prescribers or undertaking training; they had been in practice for an
average of 14 years and had been in their current speciality for an average
of 6.3 years. Table 14 provides details about the characteristics of the
participants. To protect the participants and ensure anonymity, participants
for all the six focus groups have been grouped into one table and numbered
consecutively in order of recruitment.
3.3.1.2 An overview of the dynamics and interactions within each group
As discussed in greater detail in the methodology section (Section 3.2), a
number of processes were used to capture the dynamics and interactions
within each group. The author was the moderator, thus allowing for the
“feel” and the “gist” of each group to be captured, rather than just basing
analysis on a written transcript. The moderator was neutral to the
organisation, had not worked in any of the secondary care environments
where the groups were run, and did not personally know any of the
participants helping to develop a more objective perspective. Where
available, an assistant moderator participated, acting as an extra pair of
eyes to observe the participants’ body language throughout the discussion,
making notes using a standard field note reporting form. The assistant
moderator then acted as a validity check by reading the descriptions
generated for each group. This section aims to describe the dynamics and
interactions captured within the group. There is no attempt at content
analysis here.
Location 1
All questions within the topic guide were covered during a focus group that
lasted approximately 67 minutes. Overall, the group tended to have more
lengthy discussions around the feasibility and value of PP rather than the
barriers and challenges. The group was in agreement throughout with no
areas of conflict or disagreement identified.
Participant 1 was a “middle management” pharmacist and consequently
gave valuable insight into higher pharmacy management issues and
associated bureaucracy areas of which the other group participants may
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have been less aware. Being a clinical team leader, he brought this
experience to the group and informing the discussion about how the PP had
developed. It proved very difficult to stimulate participant 2 into the
discussion despite encouragement from the moderator. Participants 3 and 4
did not participate extensively, but did on occasion raise issues they
considered relevant. Participant 5 was a clear opinion leader voicing issues
about changes within the department. The issues of potential changes
within the department were discussed by this participant but she does not
appear to be professionally threatened by any of the changes.
Location 2
All questions within the topic guide were covered during a focus group that
lasted approximately 70 minutes. The discussion tended to focus more on
barriers and challenges of PP rather than the feasibility and value. Overall
all members of the group gave their views and opinions about the topic
throughout the discussion, and being audio-recorded did not seem to hinder
them from voicing their opinion about issues that were possibly sensitive.
They were in agreement with no conflicting issues arising.
The group was very cooperative, and the participants were keenly willing to
identify and move to another venue when the room originally booked turned
out to be double booked. Participants 7 and 9 had very strong opinions and
views about the subject. However, they did not try and dominate or
influence other members of the group.
Location 3
All questions within the topic guide were covered during a focus group that
lasted approximately 70 minutes. Overall all members of the group voiced
their views and opinions about the topics under discussion. There were no
clearly dominant personalities and no key areas of disagreement. It was a
very lively discussion with members of the group asking each other
questions and probing for further information. The group did not appear to
bias in favour of, or against PP of antimicrobials; both the feasibility and
value and the barriers were equally discussed, though there seemed to be
greater discussion around the challenges and logistical issues of
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implementing PP. Overall, the group seemed to have considerable amount
of experience. The participants were in agreement most of the time, and
discussed areas where they disagreed. The latter focused mainly around
roles, responsibilities and experiences involving other members of the
multidisciplinary team. There was little need for intervention from the
moderator. Recording the discussion did not appear to hinder participants
from voicing their opinion and sometimes using colloquial language. The
discussion was sometimes difficult to transcribe since the group members
tended to speak over each other.
Participants 15 and 18 were very strong opinion leaders, though they did
not dominate or overpower other members of the group. Participant 13 was
regularly called out of the room having to respond to bleeps, though she did
participate in the discussion.
Location 4
The focus group lasted approximately 40 minutes, a shorter discussion
group compared to the other groups, and in that respect was not typical of
other focus groups conducted. All questions in the topic guide were covered
in about 20 minutes; the moderator then asked some more questions, using
a “rolling interview guide,” which were related to themes emerging from the
previous groups. Prompts were sometimes used to try and encourage
participation. Interestingly, not all participants were consistent in their
points of view throughout the discussion; for example, participant 19
initially indicated that she felt there was no role for PP of antimicrobials in
her speciality but then later goes on to identify potential areas for
pharmacist optimisation of antimicrobial treatment. This inconsistency may
be related to participants being influenced by one another during the
discussion, and help to produce the rich and complex data linked to focus
groups.
There were no dominating personalities and none of the group members
were strong opinion leaders. Participant 23 did not participate much in the
discussion, possibly because she felt that the potential of PP of
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antimicrobials was not very relevant to her area of practice i.e. palliative
care.
Location 5
All questions within the topic guide were covered during a focus group that
lasted approximately 60 minutes. The discussion was lively with some
members of the group agreeing strongly to PP, and others feeling that PP
was not part of the role of the ward based clinical pharmacist. There were
areas of disagreement during the discussion, most of which were not
resolved, but resulted in participants speaking over each other or trying to
convert one another to their point of view.
There were some complex dynamics in this group that were observed and
documented by the assistant moderator. These are described as follows:
Participants 26 and 27 were very confident and engaged in conversation
and discussion throughout. Both were assertive without being aggressive.
Participant 28 had a very strong and dominant personality, often trying to
convert others to his point of view. This was expressed through his body
language which was at times observed to be aggressive and he interrupted
and tried to shut down other speakers (particularly participants 26 and 27)
who did not always agree with his point of view. Participants 31 and 32 did
not contribute much to the discussion and did not appear to be confident
and at ease within this particular group. Both participants were specifically
offered an opportunity to contribute to the group, and participant 32 did
participate more in the discussion following this, though she still remained
ill-at-ease.
Location 6
All questions within the topic guide were covered during a focus group that
lasted approximately 50 minutes. The focus group initially took the format
of a group interview, with the participants taking it in turns to respond to
questions asked by the moderator; but this soon developed into a
discussion with the participants asking one another questions. Generally the
pharmacists recounted their own experiences and thoughts adding on to
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what the other participants were describing. The group did not appear to
bias in favour of or against PP, with both the feasibility and value and the
barriers to prescribing discussed.
Overall the discussion was a balanced discussion with all members of the
group giving their views and opinions about the topic, with no dominant
personalities and with no real areas of disagreement. There was no attempt
by any member of the group to influence other members. Most of the
members of the group were antimicrobial or infectious diseases
pharmacists, and in this respect they were different from other focus groups
held previously that were more heterogeneous. This led to the discussion
being focused around antimicrobials and antimicrobial utilisation with little
or no reference to other specialities.
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Table 14: Characteristics of focus group participants
Participant Sex Speciality Years as
pharmacist
Years in
speciality
SP status Use of prescribing skills in
day-to-day job
1 M Medicine/Managerial 18 16 Yes Through a diabetes clinic where
patients are referred for control of
hypertension; antihypertensive
medication is prescribed according
to the British Hypertension
Society Guidelines 2004 and the
local joint formulary
2 F Medicine 18 5 Yes As above
3 F Sterile Production 22 6 On a SP course Eventually planning to prescribe
TPN for patients. Participant feels
that “there is a definite need for
the service in the hospital”
4 F Woman and child
health
17 10 No
5 F Surgery and
Anaesthesia
12 5 Yes Running of an abdominal aortic
aneurysm clinic in collaboration
with a nurse, aimed at optimising
cardiovascular risk factor control.
This may involve prescribing of
statins, aspirin and beta blockers.
Prescribing is against local
protocols developed by the
cardiologists and vascular
surgeons
6 F Renal 5 2 Yes Not currently; but planning to
prescribe once protocols have
been established in areas related
to anaemia associated with renal
disease and renal bone disease
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Participant Sex Speciality Years as
pharmacist
Years in
speciality
SP status Use of prescribing skills in
day-to-day job
7 M Cardiothoracic Unit 18 1 No
8 F Critical Care 22 5 No
9 M Renal 16 5 No
10 F Respiratory Medicine 7 4 Applied for
course
Plans to use this to prescribe
antimicrobials for cystic fibrosis
outpatients
11 F Endocrinology 11 4 No
12 F Antimicrobials 7 1 No
13 F Liver
transplant/General
Surgery
6 1 No
14 F Musculoskeletal 24 12 Yes Yes, but not on a regular basis;
sometimes writes up CMPs for
individual patients
15 F Neonatology,
Obstetrics and
Gynaecology
26 16 On a SP course Adjusting doses of gentamicin and
vancomycin and IV-to-oral
switches as part of a prescription
amendment policy on the neonatal
unit
16 F Renal vascular 32 7 Yes Not used; held back due to
approval of a divisional policy
17 F Renal transplant 11 6 Yes Not used; held back due to
approval of a divisional policy
18 F Acute Medicine 15 7 No
19 F Neurosciences 9 1.5 No
20 F Colorectal surgery 28 8 No
21 F Infectious
diseases/HIV
20 12 No
22 F Medicine for the
Elderly/Acute Medicine
6 3 No
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Participant Sex Speciality Years as
pharmacist
Years in
speciality
SP status Use of prescribing skills in
day-to-day job
23 F Palliative care 7 2.5 No
24 F Haematology 9 2.5 Applied for
course
Plans to use this to prescribe
chemotherapy and supportive
treatment; does not plan to
prescribe antimicrobials
25 F Respiratory/Cardiac/
Cystic Fibrosis
11 4 On a SP
course
Plans to use this to prescribe
antimicrobials for cystic fibrosis
outpatients and other medicines
for other respiratory patients;
though does not plan to start off
with antimicrobials but with “more
simple things”
26 F Critical
Care/Managerial
15 7 No
27 F General
Surgery/Managerial
15 2 Yes Not currently making use of
prescribing qualification
28 M General Medicine and
Cardiovascular/
Managerial
25 15 On a SP course
29 M Gastroenterology/
Liver/Nutrition
12 4.5 Yes Not currently making use of
qualification but planning to use
this in nutrition and methotrexate
therapy for Crohn’s patients
30 F Managerial/Specialist
Services
7 2.5 Yes Planning to start a Roaccutane
clinic in February 2007
31 F Medical Admissions 2 6 months No
32 F Infectious
Diseases/Respiratory
4 8 months Yes Not currently making use of
prescribing qualification
33 F Infectious diseases/
HIV/ HCV/
Antimicrobials
20 19 On a SP course
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Participant Sex Speciality Years as
pharmacist
Years in
speciality
SP status Use of prescribing skills in
day-to-day job
34 F Academia/
Respiratory/
Infectious Diseases
20 17 No
35 F Antimicrobial
utilisation
7 3 No
36 F Antimicrobial
utilisation
21 3 No
37 F Acute Medicine/
Respiratory
14 9 Yes Not currently making use of her
prescribing skills
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3.3.1.3 Background Survey
This survey was sent out to the participants at the recruitment phase and
was aimed at providing information around PP, with two of the questions
exploring PP of antimicrobials within the specific location as follows:
a) Are you or any colleagues prescribing antimicrobials?
Yes  No  
If yes, can you provide more details on what conditions you are prescribing
for and what antimicrobials are involved?
____________________________________________________________
__________________________________________________________
b) Are there any PGDs (eg intravenous to oral route conversion) for
antimicrobials in your department?
Yes  No 
If yes, please list.
____________________________________________________________
__________________________________________________________
Results to these two questions are summarised in Table 15. None of the
pharmacists participating were SP antimicrobials at the time of discussion.
Some pharmacists highlighted the availability of PGDs involving
antimicrobials; many were aimed at nurse prescribing through the PGDs.
Answers also included reference to some other policies and are described in
the table below.
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Table 15: Results of background survey
Pharmacist supplementary
prescribing of antimicrobials
PGDs available in hospital relating to
antimicrobials
Other policies
1 No Nurse led PGDs:
 Administration of benzylpenicillin or
clindamycin for management of
streptococcal infection for women at
childbirth
 Administration of piperacillin with
tazobactam in immunocompromised
haematology and oncology adult
patients with febrile neutropaenia not
allergic to penicillin
 Impression that this is underutilised
by nurses on wards
 Trust joint formulary policy for IV-
to-oral switch
2 No No  Guidance of IV-to-oral switch set up
and running parallel with an
educational campaign
3 No No  Prescription amendment policy
allowing pharmacists to change
doses of gentamicin and vancomycin
as part of TDM and IV-to-oral
switches on a neonatal unit
4 No No No
5 No  IV-to-oral switch PGD which seemed
to be restricted to specialist
departments such as ID
 Not all pharmacists were aware of this
No
6 No  Nurse led PGDs involving the
administration of ceftriaxone and
flucloxacillin in cellulitis patients
 Adjustment of aminoglycosides and
dose adjustments of antimicrobials
in cystic fibrosis patients on ICU
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3.3.2 Pharmacists’ perceptions of the barriers and challenges towards
pharmacist supplementary and independent prescribing in secondary care
The aim of this phase of the research was to explore the pharmacists’
perceptions of PP in secondary care with a focus on antimicrobials.
Discussions focused mainly on general PP with antimicrobial examples
provided where relevant. This same approach has been taken when
describing the results. Therefore a description of findings about general PP
is initially presented with specific antimicrobial examples provided where
these were discussed.
It is worth noting that, in most focus groups, there was more extensive
coverage of challenges and barriers as opposed to feasibility and value.
Since these focus groups were conducted between July 2006 and January
2007, all participant prescribers or those in training were supplementary
prescribers. Therefore discussions around SP drew mainly on the
participants’ own experiences. However, independent prescribing had not
yet been introduced and discussions focused solely on participants’
perceptions rather than their own experiences.
The results here are presented without any comments since these are
considered and a discussion provided in Section 3.4. The categories and
themes are organised according to Table 16 below. Extracts from the focus
group discussions are provided to illustrate these themes.
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Table 16: Categories and themes relating to barriers and challenges
towards pharmacist supplementary and independent prescribing in
secondary care
Category Themes
Lack of management support Lack of support to take on prescribing role
Lack of planning to implement PP
Current working practices and
processes
Lack of provision of a 24-hour service
Lack of time spent on the ward
Logistical issues
Lack of resource and capacity Inability to sustain new services
Lack of adequately trained pharmacists
Limitations of pharmacist SP The clinical management plan
Concerns relating to
pharmacist IP
Lack of pharmacist training to make a diagnosis
Issues within the pharmacy
profession
Lack of pharmacist confidence
Lack of evidence of clinical outcome of PP
Concerns about increased responsibility and
financial remuneration
Concerns relating to other
healthcare professionals
Communication difficulties with other team
members
Deskilling of junior doctors
Lack of support and professional rivalry
Concerns about patient safety Risk if pharmacist prescribes
Concerns about training of
pharmacist prescribers
Assessment of competencies and skills to
prescribe
Competencies of newly qualified pharmacists
Experiences on SP training
3.3.2.1 Lack of management support for expanded role
The lack of management support was a major concern and was discussed at
length during all focus groups. Two main themes emerged and are:
Lack of encouragement to take on a prescribing role
Pharmacists felt that there was a lack of communication and provision of
information about prescribing courses by pharmacy management. There
were no reports of discussion between pharmacy managers and practising
pharmacists about potential prescribing roles within different specialties.
“ …x I don’t feel there is an awful lot of support for doing the course though,
because you do get an email every six months, ‘Who wants to go on the
prescribing course?’, and then about a month later you do get another
x “… “ at the start of a quotation indicates that there are words or dialogue before this excerpt in the
original focus group transcript.
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email, and it’s usually all very short notice as well…”
(Female, non-supplementary prescriber, 20 years in pharmacy, 12 years in infectious diseases/HIV)
Therefore, the individual rather than the management was largely perceived
as the main driving force, identifying a potential role for him/herself within
the specialty.
“ … I was not particularly encouraged to do this [prescribing course].xi I
informed them that I wanted to do this and it was never suggested that I
should do this or that it has ever been suggested to the rest of you…”
(Female, on SP course, 7 years in pharmacy, 4 years in respiratory medicine)
A pharmacist who was on the SP course felt that there was a lack of support
in terms of study leave and protected time to complete essential elements
of the course such as ‘reflective essays’ and ‘the period of learning in
practice.’ The pharmacist therefore felt that completion of the course
depended primarily on the individual’s motivation.
“ … but again, in our department you get no time to do any study, no time
off, study leave … everything has to be done in your spare time. So it’s not
the most encouraging.”
(Female, on SP course, 7 years in pharmacy, 4 years in respiratory medicine)
Some pharmacists commented that more resource was required to change
working practices enabling pharmacists to take additional roles;
management was perceived as not committed to provide this.
“ … because you have to have a commitment from management to allow
you to do these things [attend regular ward rounds to prescribe]; and I
think that’s where we’re in this fox [Sic]xii at the minute where we don’t
know what we want to do or we know what we want to do but we don’t
know how to go about it.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in critical care/management)
xi [] indicate words that were not actually spoken by the participant but have been added for clarity and
to aid contextualizing the quotations.
xii [Sic] this indicates that the preceding word has been written up as believed to be intended by the
participant.
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“I almost get the feeling that if you were to take on that role, that would be
an add-on, you wouldn’t get anything taken away from what you’re already
doing.”
(Female, non-supplementary prescriber, 11 years in pharmacy, 4 years in endocrinology)
“Unfortunately, I think the department is quite negative in that you don’t
want to get people to expand because you know well next week you’ll have
their wards to cover as people are on holiday. They tend to look at the
negative side of things; yes we’re going to be stretched at some point so
we’re not going to offer the chance to do something else, we’ll just keep it
as is.”
(Female, non-supplementary prescriber, 7 years in pharmacy, 1 year as antimicrobial pharmacist)
A pharmacist in a middle management role perceived higher management
to have different priorities; pharmacy higher management was perceived as
being keener and more motivated to manage risk and make efficiency
savings rather than promote the development of the role of a specialist
clinical prescribing practitioner. He goes on to comment that the fact that
the directors of pharmacy are not themselves prescribers may discourage
other pharmacists to take on a prescribing role.
“And there is no way on earth here our Director of Pharmacy or head of
department in primary or secondary care will ever think about prescribing
themselves, and to me, that is a barrier because it doesn’t develop the kind
of ethos in the environment and motivation within a group of staff to
develop service in that way.”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/managerial)
Pharmacists in two focus groups commented that the lack of financial
rewards for a perceived increase in responsibility was a potential barrier.
“I think to be fair we’d end up becoming the cheap man’s prescriber, if
we’re expected to be prescribing the same as most of the medical staff on
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the ward and take the same responsibility ...xiii but the wages might not
even increase.”
(Male, non-supplementary prescriber, 18 years in pharmacy, 1 year in cardiothoracic unit)
Pharmacists in focus group 6, who were antimicrobial specialist
pharmacists, thought that there was no specific drive or incentive to
encourage prescribing of antimicrobials unless this was part of a cost
cutting exercise. Examples of such cost cutting were given and included,
shorter bed stays due to optimisation of treatment, use of cheaper but as
effective antibiotics and a better knowledge of interactions and potential
adverse effects.
Lack of planning to implement PP
Most pharmacist non-supplementary prescribers expressed reluctance to go
on the course unless there was a clear prescribing role identified within their
specific area of practice.
“ … I’ve been asked several times ‘Do I want to do it’ and I’ve answered
‘Well, not really because I don’t know where I am going to use it.’”
(Female, non-supplementary prescriber, 21 years in pharmacy, 3 years in antimicrobial utilisation)
“I’d like to in the future but at the moment, it’s hard to see how it would fit
in with my current practice.”
(Female, non-supplementary prescriber, 28 years in pharmacy, 8 years in colorectal surgery)
Both pharmacist supplementary and non-supplementary prescribers
highlighted the fact that a significant number of pharmacists were not
making use of their prescribing qualification due to the lack of planning to
integrate the pharmacist prescribers within the multidisciplinary team. A
pharmacist shared her experience as follows:
“When I did the SP course, my consultant is actually a general medical
consultant, so it’s actually very difficult to implement it in general medicine
xiii “… “ as part of a quotation indicates that in the original focus group transcript, the two extracts
divided by the “ …” did not follow on directly but were separated by other words not in this quotation.
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… so although I’ve got the qualification in theory, I’ve not done anything
about it because I’m still waiting to see what role I can have.”
(Female, supplementary prescriber, 14 years in pharmacy, 9 years in acute medicine/respiratory)
The pharmacists commented that management needed to have a clearer
plan to enable the implementation of PP, prior to allowing pharmacists to
enrol and complete any course.
“I think management are quite keen for us to do it, and to get more and
more people, but what their final vision is, I have no idea.”
(Female, on SP course, 11 years in pharmacy, 4 years in respiratory/cardiac)
“ … there was a big pressure from the centre to produce supplementary
pharmacist prescribers, but there was less attention at the time to having a
plan as to what they actually do once they became supplementary
prescribers … I suppose that’s coming home to roost now and we’ve got an
ever growing number of prescribers and it’s not clear how they should
practice or in what way they should practice.”
(Male, on SP course, 25 years in pharmacy, 15 years in medicine/cardiovascular/management)
“I think people have been encouraged to go on the course with no direction
where they’re going to use it and maybe that’s why people are not using it
as soon as they qualify, because there’s no direction at the moment.”
(Female, supplementary prescriber, 15 years in pharmacy, 2 years in general surgery/management)
A pharmacist expressed her concern that a lack of utilising prescribing skills
may lead to the practitioner forgetting what was learnt during the course.
During the discussion, pharmacists tried to pinpoint why, in their view,
management were keen to have pharmacists with a prescribing qualification
despite no clear plan for its implementation. A middle management
pharmacist (Participant 28) thought this was “a catch-up type role”; since
the newly qualified pharmacists were perceived to now possess a
prescribing qualification, pharmacy management were encouraging the
more experienced specialist pharmacist to pursue this too. Having this
larger number of pharmacist prescribers might then facilitate its
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implementation. Another pharmacist perceived potential tensions with the
nursing profession:
“I think another fear for management is that if we don’t do it now, then
nurses are going to get in there and we are better placed to do it than
nurses, so we need to be organized.”
(Female, on SP course, 9 years in pharmacy, 2.5 years in haematology)
3.3.2.2 Current working practices and processes
Lack of provision of a 24-hour service
This was highlighted at all focus groups as a barrier to the successful
implementation of PP. Pharmacists thought that standard working hours
covering 9am to 5pm only was a major barrier, particularly since there was
currently no contingency to provide a PP service outside these hours.
Outside a pharmacist’s working hours, prescribing would therefore need to
be handed back to other healthcare professionals. As one pharmacist
highlighted, providing such a service would need all pharmacists to be
experienced prescribers thus able to provide 24-hour cover, which they
deemed to be an unlikely scenario.
“ … you could argue that the on-call service at the weekend would be able
to go and prescribe, but at the moment, that would not happen because
you would require all the pharmacists to be prescribers. I would imagine
that is highly unlikely that everybody would be at the same level.”
(Female, supplementary prescriber, 12 years in pharmacy, 5 years in surgery/anaesthesia)
Participants noted that prescribing services were being built around
individual practitioners rather than a team. This may also lead to problems
with no one available to cover any absences needing to hand back to other
healthcare professionals.
“I think one of the challenges in a small hospital would be, even if I was a
supplementary prescriber and could prescribe antimicrobials what would
happen when I wasn’t there? It wouldn’t be a team, therefore this
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responsibility for prescribing would then have to pass on to another
profession...”
(Female, non-supplementary prescriber, 21 years in pharmacy, 3 years in antimicrobial utilisation)
Lack of providing a 24 hour, seven day a week service was perceived as a
particular barrier to pharmacists prescribing antimicrobials and was raised
as an issue at all groups. Pharmacists distinguished between acute
situations, where it was unlikely for a pharmacist to be available to
prescribe antimicrobials, and less urgent scenarios, where a PP
antimicrobials may be more feasible (see Section 3.3.3.1 for more details).
Examples of the former included:
(a) Emergency admissions requiring an antimicrobial to be started
immediately
“ … when they [antibiotics] are getting prescribed, especially if they are
IV’s, if they [patients] are admitted as an emergency, often we are not
always there at the point of admission when the decision [diagnosis] is
actually made.”
(Female, non-supplementary prescriber, 11 years in pharmacy, 4 years in endocrinology)
“ … often they come in out-of-hours and its sort of emergency, start first
line antibiotics straight away … they need to be started at 3 o’clock in the
morning if that’s when they’re admitted which obviously doesn’t suit
pharmacy”
(Female, on SP course, 9 years in pharmacy, 2.5 years in haematology)
(b) Following up recommendations from microbiology
“ … being there at the right time, so if a diagnosis comes through from
Micro or from somewhere, they’re not going to wait for the pharmacist to
come to the ward; they’re going to prescribe the antibiotics right there and
then.”
(Female, non-supplementary prescriber, 20 years in pharmacy, 12 years in infectious diseases/HIV)
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(c) Providing a service to specialist areas
“I don’t think you can do it [PP] in a specialist area like that [ICU] because
they’re [medical staff] there seven days a week.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in critical care/management)
Lack of time spent on the ward
Most pharmacists believed that they needed to spend regular and a
substantial number of hours on the ward daily with attendance at ward
rounds and with a contribution to decision making about prescribing. This
would facilitate integration as prescribers within the ward-based clinical
team.
“You can’t just be popping into the wards; somebody will do the mornings
and somebody the afternoons; the sporadic way we sometimes do wards as
a pharmacist, you couldn’t continue that practice if you are taking on
more.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in critical care/management)
“ … [for successful PP] I think being an accepted part of the clinical team
and not being perceived as somebody based in pharmacy or outside of the
department in which they occasionally appear and more often than not
disappear.”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/managerial)
Logistical issues
Discussion in most focus groups questioned whether having a PP on a ward
was actually necessary. This was suggested as there are often more medical
staff than pharmacists on a ward and consequently medical staff were most
likely to be on the ward at any one time. Therefore participants argued that,
while in theory, a doctor diagnosing and a PP may seem like ideal, this is
very difficult to implement logistically.
“It just is the practicalities of it really; if you and the doctor walk round the
ward all day together, then that would work, but it doesn’t work like that;
Chapter 3 – Focus Group Discussions 140
until there is one pharmacist per one ward and you’re on the ward at every
ward round and you’re involved in everything.”
(Female, on SP course, 7 years in pharmacy, 4 years in respiratory medicine)
A participant also viewed the fact that pharmacists are usually linked to a
ward rather than a clinical team as another barrier, since this working
practice did not provide an opportunity to follow up a patient on
antimicrobials throughout their hospital stay. Another pharmacist mentioned
that not all consultants may approve of a PP. Consequently if SP, it may be
difficult to filter out which patients to prescribe for. This may be a particular
issue for example, if the pharmacist has taken over the prescribing of a
specific drug such as vancomycin since they would be able to prescribe for
patients under the care of one consultant but not those under the care of
another.
3.3.2.3 Lack of resource and capacity
Inability to sustain new services
This theme emerged at all focus group discussions. Most pharmacists
thought that there were a relatively small number of pharmacist prescribers
when compared to other healthcare professionals. Many were already
stretched for time to cope with their current workload so they would need
additional support to take on any new roles.
“It would always be the resources of having enough people to take on an
extra role over and above what you are already doing.”
(Female, on SP course, 11 years in pharmacy, 4 years in respiratory/cardiac)
“ … we’re so pushed for time probably we would need to have more support
… I mean you wouldn’t get your basic work done on a day-to-day basis.”
(Female, non-supplementary prescriber, 7 years in pharmacy, 1 year as antimicrobial pharmacist)
A pharmacist commented that finding and recruiting pharmacists to
maintain current services was already a struggle so it would be difficult to
recruit and retain more pharmacists. Securing funding for new posts was
also a major barrier.
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This small number of pharmacists, and indeed the lower number in any
speciality have shaped the way in which prescribing roles are developing. To
enable sustainability of a service with manageable patient numbers,
pharmacists reported prescribing in smaller areas of practice or in clinics on
a sessional basis. They also reported that this lack of resource makes it
unlikely for their role to be covered if away.
“ … possibly the biggest barrier for us at the moment is sustaining service
where we developed it around prescribing, so that’s why we haven’t gone
for admissions areas, we’ve gone for small-scale areas where we know the
patients’ cases are manageable.”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/managerial)
Participants feel that this may be even more pronounced with
antimicrobials, where it is likely that there will be large numbers of patients
prescribed antimicrobials at any one time.
“At any one time how many patients are there likely to be on
antimicrobials? That workload could be just overwhelming to the extent that
would be what was concentrated on as opposed to some other things.”
(Female, supplementary prescriber, 12 years in pharmacy, 5 years in surgery/anaesthesia)
To enable sustainability of a service involving PP of antimicrobials within the
current resources, it would be necessary to target patients rather than
review all patients.
“ … with the throughput of patients and the number of pharmacists versus
the number of patients who are likely to be on antimicrobials, it could make
things very difficult unless you have a way of targeting patients who need
your more specific help or advice…”
(Female, supplementary prescriber, 12 years in pharmacy, 5 years in surgery/anaesthesia)
For pharmacists to take on prescribing on wards, they highlighted that they
would need to closely monitor spending more time on wards. However, this
may not be an option with current staffing levels.
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“ … we would need to have enough staff so that the pharmacist would be at
the ward round and be very closely involved with what’s happening to the
patient and it would just not be possible with the current resources.”
(Female, non-supplementary prescriber, 20 years in pharmacy, 12 years in infectious diseases/HIV)
It was thought that the larger numbers of nurses facilitated more
sustainability of services and consequently they have been able to take on
areas of care with larger numbers of patients.
“ … one pharmacist, as well as their own jobs, small roles, bite size little
pieces; we’re not going to capture volumes of patients; we don’t have the
resource like nursing have where they just see volumes of patients.”
(Female, supplementary prescriber, 7 years in pharmacy, 2.5 years in specialist services/management)
Lack of adequately trained pharmacists
This potential barrier was brought up during one discussion, where one
pharmacist was concerned that there may not be sufficiently trained
pharmacists to deal with the more complex patients requiring
antimicrobials.
“Are we able to provide the workforce to fit into those roles, to treat those
more complex patients, as rapidly as the legislation is changing to enable to
prescribe? So the workforce itself could be perceived to be a barrier, the
number of available pharmacists with those skills to treat those complex
patients.”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/managerial)
3.3.2.4 Limitations of pharmacist supplementary prescribing
The Clinical Management Plan
The CMP as a requirement of SP was viewed as a major barrier to the
implementation of SP in secondary care and was a theme discussed at
every focus group. Pharmacists thought that it would be very time
consuming to draw up a CMP for every patient for whom the supplementary
prescriber was planning to prescribe. The large patient turnover would imply
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having many CMPs which could take up a substantial part of a prescriber’s
day. Pharmacists believed that this may not be a good use of resource
particularly since patients are likely to be in hospital only for a short period
of time.
“ … trying to get an individual CMP for every single patient, then if they
were almost in for two or three days; that’s the biggest hurdle.”
(Male, on SP course, 25 years in pharmacy, 15 years in medicine/cardiovascular/management)
“ … but I think that you would spend all day doing paperwork just to
prescribe something; whereas you might just discuss it and get somebody
else to prescribe it.”
(Female, on SP course, 7 years in pharmacy, 4 years in respiratory medicine)
“ … we can’t generate CMPs every time patients are admitted because we
are not there or simply because the throughput of patients is too high.”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/managerial)
Agreeing the CMP with the prescriber is another step in the process which
extends the time required to complete a CMP. One pharmacist was
concerned that this would cause a delay in patients accessing their
medicines, when compared to the current prescribing processes.
“Giving patients access to skills and medication as well is another aspect of
it; if you’re waiting for a CMP, in any area to be agreed with the consultant”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/managerial)
“The time involved to sit down and draw up a CMP and agree with the
consultant about the patient.”
(Female, non-supplementary prescriber, 6 years in pharmacy, 3 years in medicine/geriatrics)
Some pharmacists thought that obtaining patient consent may be a problem
in some areas of secondary care which also made using a CMP in an acute
setting a challenge.
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“If the patient is very ill you don’t want to be putting a form in front of them
saying “Sign this”, they don’t know what their treatment is, so it’s difficult in
an acute setting…”
(Female, supplementary prescriber, 15 years in pharmacy, 2 years in general surgery/management)
Pharmacists believed that when developing a CMP for an individual patient,
it would be difficult to envisage all eventual potential requirements
particularly in an acute setting where there may be a rapid change in a
patient’s condition. This would require regular review of the CMP.
“It is not hugely practical; it’s not practical in secondary care, I would say,
because you can’t envisage every possibility.”
(Female, supplementary prescriber, 14 years in pharmacy, 9 years in acute medicine/respiratory)
This was also deemed to be the case with antimicrobials where patients
may be admitted for an acute infective episode. Overall, the CMP was
viewed by participants as being more suited for chronic conditions as
indicated by the period of review required as part of the plan.
Some pharmacists recommended developing generic CMPs for the
management of specific conditions to overcome some of these barriers
highlighted above. This may lend itself particularly well to an area such as
antimicrobials, where the plans may be based on the hospital’s antibiotic
policy. However, they believed that whereas this may be an option for
standard treatments such as surgical prophylaxis, it may be difficult to
implement for more complex conditions and patients.
“The problem is as well, there’s going to be so many individual patients,
you’ve got to think about allergies, what they’ve had before they’ve come in
with cellulitis; you can’t have a standard cellulitis management plan.”
(Female, supplementary prescriber, 4 years in pharmacy, 8 months in respiratory/infectious diseases)
3.3.2.5 Concerns relating to pharmacist independent prescribing
Lack of pharmacist training to make a diagnosis
Pharmacists, whether supplementary prescribers or not and in all locations
felt that they were not adequately trained to make a diagnosis, when
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compared to the medical profession. This was despite the additional training
as part of the independent prescriber’s curriculum.
“It took five years of medical school, there must be some point to that; so
how are we suddenly going to be able to diagnose?”
(Female, non-supplementary prescriber, 21 years in pharmacy, 3 years in antimicrobial utilisation)
“They [bodies involved in setting up the IP curriculum] must assume you’re
a doctor then! You can’t just train someone to diagnose and say that’s the
same as seven years of medical school. Ridiculous.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in acute medicine)
“I think we would have to take extra training, apart from the straight
forward things.”
(Female, on SP course, 26 years in pharmacy, 16 years in neonatology/obstetrics)
“If you are going to be an independent prescriber, should you just go and
train as a doctor to start with which I personally never wanted to do; I did
not want to be a diagnostic person; I don’t know how others feel about
that; so I don’t know how much training; but years and years.”
(Female, non-supplementary prescriber, 22 years in pharmacy, 5 years in critical care)
Some pharmacists commented that although making a diagnosis in a
community pharmacy may be feasible, this would not necessarily translate
to the hospital setting.
“Especially [prescribing without a diagnosis] in hospital because they are
sicker, not like OTC for community pharmacy, when you can do straight
forward simple diagnosis.”
(Female, on SP course, 9 years in pharmacy, 2.5 years in haematology)
Some pharmacists thought that further specialist training in making a
diagnosis would be required, particularly if prescribing antimicrobials.
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“Because infection is a bit more complicated than that; sometimes they
wouldn’t have been diagnosed with infection in terms of what they’ve had
before … we’re not trained to [prescribe without a diagnosis].”
(Female, non-supplementary prescriber, 7 years in pharmacy, 3 years in antimicrobial utilisation)
“Are we able to provide the workforce to fit into these [prescribing] roles, to
treat those more complex [HIV] patients, as rapidly as the legislation is
changing to enable to prescribe?”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/managerial)
A lack of skills to assess the severity of the patient’s illness particularly with
limited information was perceived by some pharmacists as a further
limitation to the pharmacist independently prescribing antimicrobials in
hospital.
“I think it would be difficult for us from a point of view of how ill a patient is
and what [antimicrobials] they require to be treated with, because that is
really the medical staff’s assessment of how unwell a patient is and whether
they require intravenous, whether they require a larger dose, whether its
just oral, whether its topical.”
(Female, supplementary prescriber, 7 years in pharmacy, 4 years in respiratory medicine)
“ … but it’s the actual knowing of whether it warrants it or not, say you have
no bloods, no sensitivities, nothing and someone just presents at a routine
clinic appointment feeling a bit chesty.”
(Female, supplementary prescriber, 7 years in pharmacy, 4 years in respiratory medicine)
3.3.2.6 Issues within the pharmacy profession
Lack of pharmacist confidence
The lack of individual pharmacist’s confidence was viewed as a barrier by
both some prescribing and non-prescribing pharmacists.
“I think pharmacists in general are a very cautious breed. I think it might be
that we’re not confident [to prescribe]; we’re used to being behind the desk
or behind a book or something.”
(Male, non-supplementary prescriber, 18 years in pharmacy, 1 year in cardiothoracic unit)
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Specialist antimicrobial pharmacists believed that this lack of confidence
may be more pronounced with antimicrobials.
“ … some pharmacists find antimicrobials quite scary to prescribe and much
more difficult than anything else that they would normally do.”
(Female, non-supplementary prescriber, 20 years in pharmacy, 17 years in respiratory/infectious
diseases)
“I think general pharmacists wouldn’t be keen to prescribe antimicrobials
because they wouldn’t feel confident doing that”
(Female, non-supplementary prescriber, 21 years in pharmacy, 3 years in antimicrobial utilisation)
This view was reiterated by others who perceived this lack of confidence as
a reflection of the novelty of this expanded role and a fear of the perceived
increase in responsibility the role may bring with it.
“I don’t know, maybe in 10 years’ time it might be a quite different
conversation. We all seem very nervous, I suppose it’s new, maybe that
would change with a bit of experience.”
(Female, non-supplementary prescriber, 20 years in pharmacy, 12 years in infectious diseases/HIV)
“ … that’s [prescribing] quite a step to take because we’ve always got a
barrier there; there’s a doctor there who signs it although we might take
50% of the responsibility if we give bad advice or we write something wrong
or that sort of thing, there’s always a nice little buffer zone there.”
(Male, non-supplementary prescriber, 18 years in pharmacy, 1 year in cardiothoracic unit)
Another pharmacist thought this lack of confidence is a reflection of a
pharmacist’s undergraduate training and lack of experience in prescribing.
“I don’t think pharmacists are trained to be confident to deal with that
[prescribing]; I think we’d build up confidence when we’re working.”
(Male, non-supplementary prescriber, 18 years in pharmacy, 1 year in cardiothoracic unit)
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Pharmacists thought this may change due to the changes in pharmacist
training which incorporate more prescribing in the undergraduate
curriculum.
“I do think that pharmacists who are newly qualified may not think in the
same way we feel; they may be more confident because they’ve done their
training stuff at an earlier stage than we would have.”
(Female, non-supplementary prescriber, 11 years in pharmacy, 4 years in endocrinology)
“The new generation, prescribing is a big deal to us, but it’s not going to be
a big deal to them.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in acute medicine)
Some other pharmacists were concerned that some of the newly graduated
pharmacists may however be too overconfident and this may result in them
not appreciating the extent of training and experience required to prescribe
safely.
“ … there will always be some who are just a bit too cocky and that’s a
scary thought. So they’re the ones who might go ‘Oh yes, that’s fine. I’ll
prescribe everything’ without the practical or the clinical experience.”
(Female, non-supplementary prescriber, 6 years in pharmacy, 3 years in acute medicine/geriatrics)
“ … you could have inappropriate people who are full of confidence thinking
that they are great supplementary prescribers and inexperienced as well.”
(Female, non-supplementary prescriber, 22 years in pharmacy, 5 years in critical care)
Lack of evidence of clinical outcomes of pharmacist prescribing
This theme emerged at several of the focus group discussions. One
pharmacist argued that to be an integral part of the clinical team and take
on a prescribing role, the prescribing pharmacist needed to be seen as a
resource who would add benefit to patient care. To gather support for the
implementation of PP in secondary care, she stated that there was a need to
prove that it would add value to patient care.
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“ … at the end of the day, people are not going to lay out any money
whatsoever if they don’t see it [PP] as beneficial to patient care.”
(Female, on SP course, 26 years in pharmacy, 16 years in neonatology/obstetrics)
Participants in a focus group felt that the pharmacy profession did not
always take the right approach to proving its worth. This highlighted that
rather than measuring outcome in terms of improvement in patient care,
pharmacists measure outcome in terms of cost reduction or try to
demonstrate superiority to other professional rivals. This was perceived to
be a barrier to the expansion of PP in secondary care since it had resulted in
a lack of evidence of clinical outcomes for PP.
“ … there’s always a focus on demonstrating that we’re improving things in
pharmacy, demonstrating that we’re worth investing in … I don’t think we
should always necessarily need to demonstrate that we’re better than other
professional groups … I don’t think you’ve got to demonstrate that you’re
better as a pharmacist than a nurse or better as a nurse than a medic.”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/managerial)
Concerns about increased responsibility and financial remuneration
This theme was discussed mainly in focus group two. Pharmacists here
perceived prescribing as implying an increase in responsibility and appeared
reluctant to take this on without any financial remuneration.
“We were actually discussing this, and whether it would come down to
financial incentives, and also legal, medico-legal insurances to cover if you
were an independent prescriber.”
(Female, non-supplementary prescriber, 22 years in pharmacy, 5 years in critical care)
3.3.2.7 Concerns relating to other healthcare professionals
Communication difficulties with other team members
Although this issue was not discussed at all focus groups, there were
lengthy discussions when the issue was raised, with pharmacists drawing on
their current experiences as ward based pharmacists. A lack of
documentation by physicians in medical notes was thought to make it
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difficult for a pharmacist to monitor the patient’s progress, such that
prescribing may become an option only if the pharmacist prescriber is an
integrated part of the multidisciplinary team.
“That’s where all these problems come together, in communication. Doctors
are insisting on having communication on their ward round so that way they
communicate with each other, whereas the way they communicate with the
rest of the hospital is in silence! Half a dozen words in the notes and you’re
meant to try and interpret, to try and read … Among all these problems that
we’re talking about, the common big thing in the middle is poor
communication.”
(Male, supplementary prescriber, 12 years in pharmacy, 4.5 years in gastroenterology/liver/nutrition)
A pharmacist suggested potentially managing only certain infections which
are protocol regulated, such as urinary tract infections. Other pharmacists
thought this practice may lead to confusion on the ward since it would be
difficult for the pharmacist prescriber to have a defined role and ensure the
wider team is aware of this. One pharmacist shared a different experience
where lack of communication was due to other members of the team not
reading the patient’s medical notes on a weekend resulting in the patient
receiving inappropriate therapy.
“ … So with the best will in the world, you sit down, go through it, you
document it all, and yet still.”
(Female, supplementary prescriber, 24 years in pharmacy, 12 years in musculoskeletal)
Some discussions raised the issue of communication difficulties with the
microbiology department in relation to decision-making and a potential lack
of defined roles and responsibilities within the team. Participant experiences
resulted in a mixture of positive and negative descriptions of team-working
with the latter being more common. Most felt that microbiologists did not
take a holistic approach when giving advice being only concerned with the
choice of drug. There was also an inconsistent approach from one individual
microbiologist to another. Consequently, it was considered more
appropriate for a pharmacist to take recommendations from microbiology. A
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prescribing pharmacist was thought to be better placed to prescribe than
more junior doctors who were unlikely to challenge any recommendations
made.
“The advantage of a pharmacist taking advice from Micro is that I think,
sometimes if you’ve got junior doctors they tend to take ‘Oh, microbiology
said prescribe vancomycin 1g twice a day.’ ‘Yes but the patient’s 40kg and a
renal function of … just change the dose!’ If they just choose the drug
without being so specific and then as pharmacists ‘Yes OK, I’d take the drug
on board and I’ll think about the dose myself.’ ”
(Female, non-supplementary prescriber, 6 years in pharmacy, 3 years in medicine/geriatrics)
“They don’t ask basic questions; that’s what concerns me; because I had a
call from one of the SHOs nervous about dosage, fluconazole 12mg/kg and
the microbiologist hadn’t asked the liver function.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in acute medicine)
Deskilling of junior doctors
Pharmacists in some of the focus group discussions expressed their concern
that should they take on prescribing roles, medical staff might miss the
opportunity to learn safe and effective prescribing. This knowledge would be
required at least out of hours and on weekends where it was thought
unlikely for a prescribing pharmacist to be available.
“There’s a risk of them being deskilled as well, they just think, ‘Oh I don’t
need to know about antibiotics, the pharmacist will think about it.’ So they
are then in a situation where they do have to think about it and they don’t
know what they should be prescribing.”
(Female, non-supplementary prescriber, 21 years in pharmacy, 3 years in antimicrobial utilisation)
“Changing doses could be certainly [a role for the pharmacist prescriber]
but as we keep saying, the whole education thing would be an issue, but
that would be possible, and it is the sort of thing we would do just now
though we go to the doctor and say “This dose is wrong, can you sign this
please?”
(Female, on SP course, 9 years in pharmacy, 2.5 years in haematology)
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“It needs to be us on a daily basis actually making them [educating
doctors]; perhaps that will be worst if we become independent prescribers
because if you’re an independent prescriber, and they’ve made a balls of
the Kardex; … you would change it so you wouldn’t actually get them to
correct their own mistake.”
(Female, supplementary prescriber, 32 years in pharmacy, 7 years in renal vascular)
Lack of support and professional rivalry
Some pharmacists felt there was a lack of support and acceptance of their
expanded role from doctors and professional rivalry, mainly from nurses.
“So I think some areas there will be the confidence issue, with the medics
thinking, ‘Does the pharmacist know about the individual patient to be able
to take on this role?’”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in critical care/management)
The pharmacist further highlighted that doctors may perceive nursing staff
better placed to take on a prescribing role due to there being traditionally
more contact between a patient and a nurse. This was notwithstanding the
fact that pharmacists may be more knowledgeable from a pharmacology
perspective compared to nurses. One pharmacist thought that any
pharmacist prescriber would be more closely monitored.
“ … there would be a lot of scrutiny as to your prescribing habits and if
mistakes were made, I think you would come under more criticism than if a
doctor.”
(Female, non-supplementary prescriber, 9 years in pharmacy, 1.5 years in neurosciences)
A pharmacist in another discussion was in disagreement and perceived
doctors as likely to support pharmacists rather than nurses to take on a
prescribing role.
“I’ve spoken to some medics and I’ve read things in some papers and
journals … I do get a gist where if you’ve got to toss up between a nurse
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and a pharmacist doing some prescribing, the medical establishment are far
happier or are not too bothered for a pharmacist but are a bit concerned if
nurses have to do it.”
(Male, non-supplementary prescriber, 18 years in pharmacy, 1 year in cardiothoracic unit)
A specialist antimicrobial pharmacist also believed that this would apply if
pharmacists were to prescribe antimicrobials.
“ … the Scottish Microbiology Forum, they actually put in a complaint in that
they didn’t want nurses doing SP because they didn’t want another group
[prescribing antimicrobials], they said they were OK with pharmacists SP,
but they didn’t want nurses to be SP antibiotics, because they reckon there
would be a massive over-prescribing of antibiotics.”
(Female, on SP course, 20 years in pharmacy, 19 years in infectious diseases)
A perception that professional rivalry may be an issue was brought up by
some pharmacists who viewed nurses as direct competitors who could take
on PP jobs. Nurses and their management were perceived as more pro-
active than their pharmacy counterparts and had already identified areas of
care with a potential for a non-medical prescribing role.
“So the nursing profession I think are jumping ahead to do this [prescribe].
But again, I think they have a head start because they are more in your
face, they are more high profile and they would do these things because
there are many of them.”
(Male, non-supplementary prescriber, 18 years in pharmacy, 1 year in cardiothoracic unit)
Some pharmacists thought that doctors may be a barrier, since having a
pharmacist prescribe may be perceived as an encroachment on a doctor’s
traditional role, particularly if independently prescribing.
“I wonder if it would be a challenge with doctors accepting PP if they’ve
always done it.”
(Female, non-supplementary prescriber, 20 years in pharmacy, 12 years in infectious diseases/HIV)
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“I think it would be more acceptable to the medical staff, they would accept
us more, maybe they would have more confidence if they had diagnosed,
and we would just take it on from there, than have the pharmacist out there
to diagnose.”
(Female, supplementary prescriber, 14 years in pharmacy, 9 years in acute medicine/respiratory)
3.3.2.8 Concerns about patient safety
Risk if pharmacist prescribes
Pharmacists viewed themselves as currently having a major role in ensuring
patient safety through clinically checking medication prescribed for
inpatients at ward level. If a pharmacist prescribed for an inpatient, though
the chart would be reviewed by many other members of the team, no-one
would carry out a clinical check in the same manner as the pharmacist
would. This, in the view of the participants, might be an additional risk and
compromise patient safety.
“One of my concerns, both supplementary or independent, at the moment
when a junior doctor prescribes, or any other doctor prescribes, we are
clinically checking, so we’re checking that the dose is appropriate. Nobody is
checking us. You’ve not got a double check. OK, you might be competent,
but everybody can make a mistake but nobody is checking that. There’s
nothing in place for that.”
(Female, supplementary prescriber, 15 years in pharmacy, 2 years in general surgery/management)
“I mean one of our major roles in this hospital is to reduce clinical risk and
that is checking prescribing, and if we’re expected to do a lot of the
prescribing, its not controlled … who is going to check that person, and
that’s my concern.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in acute medicine)
Where a pharmacist was prescribing, organizational systems seem to be in
place to ensure that discharge prescriptions were checked by a second
pharmacist and consequently, pharmacists were not so concerned about
patient safety. One pharmacist, however, raised the issue that safety may
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be compromised if the checking pharmacist does not specialise in the same
area of practice as the prescribing pharmacist.
“Because we have that scenario down in oncology at the moment, I mean I
don’t feel competent in oncology at all, and I’m doing the professional check
that the prescription is appropriate … but you’re checking a pharmacist who
works in that area … so that has taken us back one step safety wise I think,
by having the PP, if we don’t then think how we are able to then have a
double check on their work.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in critical care/management)
3.3.2.9 Concerns about training of pharmacist prescribers
Assessment of competencies and skills to prescribe
Discussions in some groups focused around the areas of competence that a
pharmacist prescriber would need to have to ensure safe prescribing.
“So you can’t let loose anybody in that kind of environment without the
appropriate training or peer review before they are enabled to do that. So
demonstrating competency, I think is really essential in our hospital
environment with acute, severely ill patients if we are going to be
independent prescribers.”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/administration)
However, pharmacists perceived that it may be a challenge to demonstrate
such competencies, since these are based on self-assessment and on
recognition of gaps in knowledge by the prescribing pharmacist.
“It’s one of those things, a gap in your knowledge, how do you know that
you’ve got a gap?”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in critical care/management)
“How are you going to prove competencies; it’s not part of knowledge
service framework, it’s not part of agenda for change so if you’re doing
performance appraisals in line with knowledge service framework, then
prescribing is not in there. Then how do you prove competencies?”
(Female, supplementary prescriber, 11 years in pharmacy, 6 years in renal transplant)
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This led on to discussions about professional obligation where the
pharmacist must recognise their own competencies and their own
limitations.
“You would be able to demonstrate that you have a professional
competence in the area in which you worked; so ... if a pharmacy manager
says ‘I want you now to go in dermatology and be a supplementary
prescriber,’ then you have a professional obligation to say to them, ’Well, I
can’t do that because I don’t have the necessary skills or knowledge or the
competency to do that.’ ”
(Male, on SP course, 25 years in pharmacy, 15 years in medicine/cardiovascular/management)
Being based on self-assessment, pharmacists expressed their concerns
about the risks of over-confidence, which may lead to a few pharmacists
prescribing outwith their skills and competencies.
“My understanding of it is you yourself judge whether you are competent
and you know, some people are very critical, some people think they’re
wonderful.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in acute medicine)
“I think there will be a few of us who will be taking care; a few of us would
want to go into a territory where we don’t feel comfortable.”
(Female, supplementary prescriber, 26 years in pharmacy, 16 years in neonatology/obstetrics and
gynaecology)
Competencies of newly qualified pharmacists
Some pharmacists expressed their concern about newly qualified
pharmacists taking on prescribing roles. Despite the fact that they were
perceived as having a prescribing qualification, this would not necessarily
indicate that they were sufficiently specialised to take over these roles. This
might be more of an issue with the introduction of IP.
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“I think they [newly qualified] have to acknowledge that they have to get
plenty of practice based experience behind them and that they really only
have got the qualification on paper at the moment.”
(Female, applied for SP training, 9 years in pharmacy, 2.5 years in haematology)
Numerous issues were raised which might need to be considered and
resolved; for example, the grade and years of experience when a
pharmacist may take on prescribing roles.
“But with the newly qualified pharmacists coming out with a prescribing
qualification ... What training and what has to be in place before they can
actually take these roles on?”
(Female, supplementary prescriber, 7 years in pharmacy, 2.5 years in specialist services)
Experiences on supplementary prescribing training
Issues around experiences related to SP training were raised at one focus
group although there was very little discussion. One pharmacist commented
that the “theoretical” assessments as part of the course were not in any
way related to her area of practise and expertise:
“The problem when I did the course was I picked medical because there
really wasn’t an area where I would be prescribing on the course, so it
wasn’t relevant to the area.”
(Female, supplementary prescriber, 15 years in pharmacy, 2 years in surgery/managerial)
3.3.3 Pharmacists’ perceptions of the feasibility of pharmacist
supplementary and independent prescribing in secondary care
This section describes pharmacists’ perceptions of the feasibility of
pharmacist supplementary and independent prescribing in secondary care.
As in section 3.3.2, discussions around SP drew mainly on the participants’
own experiences. However, at the time of this study, IP had not yet been
introduced and discussions focused solely on participants’ perceptions
rather than their own experiences. Again as in section 3.3.2, a description
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of findings about general PP is initially presented with specific antimicrobial
examples provided where these were discussed.
The results here are presented without any comments since these are
considered and a discussion provided in section 3.4. The categories and
themes are organised according to Table 17 below. Extracts from the focus
group discussions are provided to illustrate these themes.
Table 17: Categories and themes relating to feasibility of pharmacist
supplementary and independent prescribing in secondary care
Category Themes
Feasibility dependent on
environment of practice in
secondary care
Feasibility dependent on patient’s clinical
condition
Feasibility dependent on areas of clinical care
Pharmacists’ perceptions of the
advantages of PP
Perceived advantages of PP of antimicrobials
Perceived advantages of pharmacist SP
Perceived advantages of pharmacist
independent prescribing
Issues within pharmacy
profession
Pharmacy management support to take on
prescribing role
Issues around other healthcare
professionals
Acceptance of the pharmacist prescriber by
the medical profession
A need to work within a multidisciplinary team
3.3.3.1 Feasibility dependent on environment of practice within secondary
care
The feasibility and potential for PP was largely attributed by the participants
to the clinical environment of practice with discussions around this arising
during all focus groups.
Feasibility dependent on patient’s clinical condition
Pharmacists, irrespective of whether supplementary or non-prescribers, felt
that there was a greater challenge when implementing non-medical
prescribing in acute care, where the patient’s condition is rapidly changing.
Pharmacists therefore perceived that prescribing for patients with chronic
conditions in secondary care may be more feasible.
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“I don’t think it’s [PP] really been designed for inpatients; I think
[prescribing is feasible] in the outpatient setting, where they are not acutely
unwell, [or] chronic conditions where they will be reviewed”
(Female, non-supplementary prescriber, 11 years in pharmacy, 4 years in endocrine)
Since in-patients requiring antimicrobials were usually very sick and
required immediate intervention, participants thought that this may be
more pronounced due to the nature of antimicrobial treatment
“A lot of [antimicrobial] prescribing there [secondary care] is probably
acute, initially when they have their diagnosis, so I don’t know you would
necessarily see much of a role there.”
(Female, non-supplementary prescriber, 11 years in pharmacy, 4 years in endocrinology)
Chronic conditions were linked to more stable patients, mainly in outpatient
settings and it was here that participants believed pharmacist prescribers
could play a role in managing antimicrobial treatment.
“ ... in-patients, it’s usually an emergency, during the night you’re going to
get prescribed antibiotics, and we’re not here, whereas out-patients is
planned work.”
(Female, non-supplementary prescriber, 7 years in pharmacy, 3 years in antimicrobial utilisation)
Numerous clinical examples of specific chronic conditions where pharmacist
antimicrobial prescribing may be feasible were given throughout the
discussions. Often, no distinction was made between pharmacist
supplementary or independent prescribing. These are summarised in Table
18.
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Table 18: Clinical examples of chronic conditions where pharmacist
antimicrobial prescribing may be feasible
Condition Illustrative quote
HIV patients
Bronchiectasis
patients
Cystic fibrosis
patients
Out-patient
antibiotic clinics
Antibiotic
prophylaxis
“So I do think more stable [HIV] patients could be managed by a
pharmacist, and again in an out-patient setting ... that’s an area
where I think a pharmacist supplementary prescriber could make a
contribution.”
(Female, non-supplementary prescriber, 21 years in pharmacy, 3 years in
antimicrobial utilisation)
“XXX doing her bronchiectasis clinic, that’s a completely different
situation altogether [compared to in-patients] … she’ll need to run
the prescribing of the appropriate antibiotics and other treatment.”
(Female, supplementary prescriber, 11 years in pharmacy, 6 years in renal
transplant)
“It would probably work for the kind of [cystic fibrosis] out-patients
we have, they come and they know what’s wrong with them, we
know what’s wrong with them, so they get antibiotics every 3-4
months, so it would probably work for that situation if I was
around.”
(Female, on SP course, 11 years in pharmacy, 4 years in respiratory/cardiac)
“I think we have a role in chronic patients … because we deal with
patients that have repeat courses of IV antibiotics on a regular
basis … it’s just that the patients do need their antibiotics
particularly cystic fibrosis [patients] and I don’t see any reason why
we can’t [prescribe] in these cases.”
(Female, supplementary prescriber, 7 years in pharmacy, 4 years in respiratory
medicine)
“I work in an antibiotic clinic ... these [patients] are prescribed
antibiotics and we’re changing them from what they are in hospital
to what they would be on as an outpatient, and there’s a potential
role there.”
(Female, non-supplementary prescriber, 7 years in pharmacy, 3 years in
antimicrobial utilisation)
“You could certainly have a role in prescribing prophylactic
antibiotics if you have a set policy with different surgical
procedures and just making sure that they are only prescribed for a
number of doses rather than continued for 48 hours or 96 hours or
whatever.”
(Female, non-supplementary prescriber, 7 years in pharmacy, 1 year in
antimicrobials)
“I think possibly in my area [haematology], the prophylaxis could
be omitted, or extra antimicrobials are prescribed when they’re not
actually required, so you could possibly do it [prescribe] there, but
for treatment I think, it would be a lot more difficult.”
(Female, on SP course, 9 years in pharmacy, 2.5 years in haematology)
“Probably there’s quite a role in prophylactic surgery, ensuring that
it was actually prophylactic and stopped.”
(Female, non-supplementary prescriber, 20 years in pharmacy, 17 years in
respiratory/infectious diseases)
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Feasibility dependent on areas of clinical care
(a) Ward type
Pharmacists thought that the practice setting where PP was to be
implemented could influence whether this was feasible. A distinction
emerged between general medical wards and high dependency units such
as the intensive care unit (ICU) and the coronary care unit (CCU).
Pharmacists perceived that there may be less scope for PP in the latter
practice setting due to the constant presence of more senior and more
specialised medical staff. With prescribing on general wards being the remit
of the more junior doctors, the potential need for input from pharmacist
prescribers might be greater.
“I wouldn’t see myself doing much prescribing in the CCU because a senior
doctor’s there all the time; it’s a different setting but up on the general
wards it’s a bit free for all; there’s much less senior input; in fact there’s a
serious lack of it so there’s a much bigger potential in that sort of area as
opposed to a high dependency, heavily staffed [units].”
(Male, on SP course, 25 years in pharmacy, 15 years in medicine/cardiovascular/management)
Another pharmacist, drawing on her experiences, perceived implementation
of PP within outpatient clinics or in specialities as the more feasible practice
settings when compared to general ward areas.
“When I did the supplementary prescribing course, my consultant is actually
a general medical consultant, so it’s actually very difficult to implement it in
general medicine; it’s more appropriate within a speciality or within a clinic
session.”
(Female, supplementary prescriber, 14 years in pharmacy, 9 years in acute medicine/respiratory)
Examples of potential pharmacist-led outpatient clinics were given by the
other participants and included reviewing of hypertension medication or
primary prophylaxis of myocardial infarction and stroke within a diabetes
clinic.
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“Within the diabetes clinic, then there is scope for reviewing their
hypertension medication, or their renal and cholesterol monitoring or
effective at prevention of MI/stroke; that sort of area in a clinic setting.”
(Female, non-supplementary prescriber, 11 years in pharmacy, 4 years in endocrine)
(b) Areas where providing considerable advice
Pharmacists perceived a good starting point for their prescribing as
including areas of care where they were already providing considerable
advice and input. Here they would often be recommending changes to the
prescribed medication which had to be endorsed by very junior staff.
“I think where the supplementary prescribing fits at the moment is in a
situation where without supplementary prescribing, we go and chase a
house officer to change something for us whereas supplementary
prescribing allows us to change that for ourselves; it allows us to take
responsibility for making that decision, not going to find that poor little 21
year old house officer who knows nothing to change it for you.”
(Male, supplementary prescriber, 12 years in pharmacy, 4.5 years in gastroenterology)
Such current practices cited included warfarin dosing, total parenteral
nutrition, adjustment of doses in organ dysfunction and therapeutic drug
monitoring (TDM).
“ … TDM vancomycin, warfarin dosing, nutrition, you know, that’s where we
really are advising at the moment and those are probably easier things for
us to take on.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in critical care/management)
“I think that’s even a role for a supplementary prescriber, that’s one of the
things you get involved with a lot on the wards, adjusting doses,
augmentin, aciclovir…because of renal impairment.”
(Female, on SP course, 20 years in pharmacy, 19 years in infectious diseases)
“There is specific things like vancomycin and gentamicin where the doctors
don’t know what they are doing. So you’re the one who works out what the
dose is based on the pharmacokinetics, so the doctors can’t really do that
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and don’t have access to the information and just now, they are relying on
us to tell them exactly what to do, whereas you know, if there’s pharmacist
supplementary prescribers doing that, then it’s easier, but then you have to
make sure that you communicate to the doctors more.”
(Female, on SP course, 20 years in pharmacy, 19 years in infectious diseases)
(c) Clinical areas where protocols and guidelines are available
The availability of protocols and guidelines was perceived as facilitating
implementation of PP and consequently as another potential area for
introducing PP. The guidelines and protocols could be utilised to build a CMP
if SP, and similarly applied to IP but without the need for a patient specific
CMP.
“For most patients that we see, or for the common things that we see within
our own specialties, there are agreed protocols and pathways that are
normally followed. And that’s what you would do anyway in a CMP if you
were going to be a supplementary prescriber … and independent prescribing
removes that hurdle [CMP], but it doesn’t change the medicines not the
circumstances if you would prescribe them, I would think.”
(Male, on SP course, 25 years in pharmacy, 15 years in medicine/cardiovascular/management)
Examples were provided of current practices where guidelines were being
applied to facilitate pharmacist SP.
“At the moment, we are just prescribing any anti-hypertensive according to
the British Hypertension guidelines 2004.”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/managerial)
Another pharmacist described the development of protocols to facilitate the
implementation of SP.
“I’ve done my course but in the renal unit, we’re still trying to develop
protocols; first of all we think of doing it in renal bone disease … and we are
in the process of coming up with the anaemia protocols that would enable
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to supplementary prescribe for the community patients and possibly the
haemodialysis patients.”
(Female, supplementary prescriber, 5 years in pharmacy, 2 years in renal)
Following guidelines was viewed by the participants as an inherent part to
antimicrobial prescribing.
“That is what we currently do when we recommend things [antimicrobials],
follow guidelines.”
(Female, supplementary prescriber, 14 years in pharmacy, 9 years in acute medicine/respiratory)
Where protocols could be followed was perceived as a potential opportunity
for introducing PP of antimicrobials. This was especially because this was
unlikely to require any specialist training to implement. Examples given
included IV-to-oral switch and management of TPN line-infections.
“Certain groups of patients are targeted at the point of admission to apply
the formulary processes [through PP] perhaps around IV-to-oral switch.”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/managerial)
“Certainly IVSWOT which is IV-to-oral switch therapy … there are specific
criteria for using oral therapy as opposed to IV therapy, so that’s another
potential role [for SP] as well.”
(Female, supplementary prescriber, 14 years in pharmacy, 9 years in acute medicine/respiratory)
“I think that something all pharmacists could probably do would be IV-to-
oral switching of antibiotics … changing someone from IV-to-oral therapy, I
think that can be done at many levels in pharmacy.”
(Male, supplementary prescriber, 12 years in pharmacy, 4.5 years in gastroenterology/liver/nutrition)
“I was thinking about TPN patients who end up with line infections;
treatments for them are standard until you get something identified which
can take up to 48-72 hours.”
(Male, supplementary prescriber, 12 years in pharmacy, 4.5 years in gastroenterology/liver/nutrition)
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Pharmacists were more comfortable with adjusting existing treatment rather
than initiating treatment. This would also fit in with their current work
practices.
“Pharmacists aren’t often around at the time of prescribing of
antimicrobials. So it’s about changing of regimens.”
(Female, non-supplementary prescriber, 20 years in pharmacy, 17 years in respiratory/infectious
diseases)
“If I was prescribing, I would probably be parenteral first, then analgesia,
and then probably antimicrobials but generally changing IVs to orals and
stopping as opposed to initiation.”
(Female, non-supplementary prescriber, 28 years in pharmacy, 8 years in colorectal surgery)
“I think it’s just looking at the dose they want and making sure it is
appropriate for that individual, so I suppose I look at it more for somebody
to make the decision to initiate the treatment and I want to make sure it’s
the appropriate thing for the patient, based on what else they are on.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in critical care/management)
“You would also do it [prescribe] if positive results come back with cultures
and sensitivities and you can be narrowing down and utilise your skills.”
(Female, supplementary prescriber, 12 years in pharmacy, 5 years in surgery/anaesthesia)
(d) Areas of care where shortage of doctors
Reference was made to clinical areas of practice where there may be a
shortage of doctors as another feasible starting point for a pharmacist
prescriber.
“I think the numbers [of HIV patients] are increasing and they are very
short of medical staff.”
(Female, non-supplementary prescriber, 21 years in pharmacy, 3 years in antimicrobial utilisation)
(e) Management of minor ailments and symptom relief
Pharmacists also perceived a potential role in the management of minor
ailments and prescribing for symptom relief in secondary care, such as
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thrush, constipation and dry skin. This was compared to the community
pharmacist’s response to patients presenting with minor ailmentsxiv.
“You can see a role in community and minor ailments and stuff like that,
and there may be a role for it in basic stuff like in A & E like ‘I’m from Spain
and I forgot my tablets’ … a pharmacist can deal with that.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in acute medicine)
“I think it’s probably more symptomatic, the treatment that you’d be talking
about, because there’s not many patients in hospital who don’t have a
diagnosis already or a working diagnosis that’s brought them into hospital
but then they acquire a lot of things like UTIs or they get dry skin, you
know, there’s loads of other minor things that you don’t maybe need
specialist knowledge to do”
(Male, on SP course, 25 years in pharmacy, 15 years in medicine/cardiovascular/management)
“Another thing we could do is minor ailments, say for example you would be
seeing an HIV patient on regular HIV medication and they come with
something that sounded like oral thrush.”
(Female, non-supplementary prescriber, 7 years in pharmacy, 3 years in antimicrobial utilisation)
3.3.3.2 Pharmacists’ perceptions of advantages of pharmacist prescribing
Perceived advantages of pharmacist prescribing of antimicrobials
This theme emerged at several of the focus group discussions. Participants
were of the opinion that a PP antimicrobials was more likely to implement
recommendations within the hospital formulary and adhere to local policies.
This application of evidence, particularly when choosing empirical therapy,
might result in a reduced risk of developing resistance, particularly in areas
of high risk as in high dependency units.
“We could have a lot of benefit in controlling not only the appropriate choice
of empiric treatment particularly in situations like ICU or other high
dependency areas where patients are severely ill and exposed to resistant
xiv Prescribing here would be different to the community pharmacy “minor ailments” scheme,
where pharmacists can “prescribe” pharmacy or general sales list medicines in response to
patients presenting with minor ailments, if they are usually exempt from NHS charges.
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organisms; the risks around developing resistance are reduced as well as
improved potential outcome because we are applying evidence from the
formulary.”
(Female, supplementary prescriber, 12 years in pharmacy, 5 years in surgery/anaesthesia)
“Well. I think also choice of antibiotic because sometimes we have certain
ones that are restricted and a lot of junior doctors might prescribe those
and they might have not checked the set criteria, so you would give advice
at the moment on ‘Why are you prescribing this. Could you not use as
alternative?’ So certainly maybe on choice once it’s been agreed that they
need to treat, we would probably be prescribing.”
(Female, supplementary prescriber, 15 years in pharmacy, 2 years in general surgery/management)
Optimisation of antimicrobial use through PP of antimicrobials was also
perceived as indirectly leading to a reduction in overall costs through
shorter bed stays, using cheaper but same spectrum antimicrobials,
ensuring appropriate duration and switching to oral use when feasible.
“If you’re choosing more appropriate antibiotics, in theory, you should have
shorter bed stays. Again that’s all coming down to costs but yeah
optimisation of treatment. And they [pharmacist prescribers] may be
initially using as effective but cheaper antibiotic rather than going in straight
with the big guns.”
(Female, supplementary prescriber, 14 years in pharmacy, 9 years in acute medicine/respiratory)
“ … so you know apart from the dosage side, we need to use it for minimal
times, for the duration as well, which is another which comes into my area,
and also from an obviously economic and possibly from a patient
compliance, ease of administration, is it IV or change over as well.”
(Female, on SP course, 26 years in pharmacy, 16 years in neonatology/obstetrics and gynaecology)
“I think another thing is that we all know that in surgery in particular, you
get prophylactic doses that go on and on and on; so that’s one area you can
come in and go ‘There’s no need for that. You really need to get it stopped.’
If we were prescribing in the first place, then you would stop it.”
(Female, supplementary prescriber, 11 years in pharmacy, 6 years in renal transplant)
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Participants in different groups were also of the opinion that pharmacists
would be more likely to take into consideration allergies and drug
interactions when prescribing antimicrobials.
“Allergies as well, when taking drug histories, quite often allergies to
antibiotics are not reported; so we’re more aware of that; making sure the
patients aren’t prescribed, or the allergies are true allergies; it’s not just
stomach upset.”
(Female, supplementary prescriber, 32 years in pharmacy, 7 years in renal vascular)
Perceived advantages of pharmacist supplementary prescribing
Despite the pharmacists identifying numerous restrictions that SP may
impose in a secondary care environment, some pharmacists also identified
some advantages of current implementation of SP. SP was perceived as a
route for a pharmacist to build up confidence and utilise and maintain their
prescribing skills, consequently acting as a “stepping stone” towards IP.
“Starting off as a supplementary prescriber, and then moving on to be an
independent prescriber, then it’s quite a good progression really to build up
your confidence and skills and working relationships you know; doctors
being confident that you’re prescribing well.”
(Female, non-supplementary prescriber, 20 years in pharmacy, 12 years in infectious diseases/HIV)
“It is very useful for us to be utilising our prescribing skills, because you
know, if you don’t use it you’re going to lose it. And we’re looking forward
to developing independent prescribing roles in the not too distant future;
hopefully within the next year to eighteen months. So our skills that we’ve
developed to date are going to be more appropriately used in an acute
hospital environment in independent prescribing roles.”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/administration)
One pharmacist believed that documenting treatment options within the
CMP may help to keep the SP prescriber “in check” especially when less
experienced pharmacists are involved in prescribing. This setting of
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boundaries within which to prescribe may be especially important in cases
of legal and professional aspects since it helps to lay down clear lines of
accountability for the prescribing pharmacist.
“You are on your own as a prescriber and it’s clear that when you are
supplementary prescribing you are actually on your own legally but at least
you can say I’ve got a CMP and this is the limit to what they agreed for me
to do.”
(Male, supplementary prescriber, 18 years in pharmacy, 16 years in medicine/administration)
Perceived advantages of pharmacist independent prescribing
Most pharmacists perceived IP to be more feasible to implement in an acute
sector because this would allow prescribing pharmacists to prescribe for a
diagnosed condition without the restrictions imposed by a CMP.
“Although we might qualify as independent prescribers, in the hospital
sector, we are not going to use it in the sense of what it’s meant; it’s going
to free us up from having clinical management plans for patients and that’s
where it will be used; but you’d still be doing it as what a supplementary
prescriber would be doing. You’re not going to actually change the types of
prescribing you’re doing, it’s just taking you a step away from
documentation.”
(Female, supplementary prescriber, 11 years in pharmacy, 6 years in renal vascular)
“If you were going to be a supplementary prescriber, if you were going to
work the letter of the law, you would have to get an independent prescriber
to sign them off for each individual patient. So it’s not that you would be
doing anything different, in terms of what you might actually be prescribing
but it takes a step out of the process which is actually quite prohibitive in an
acute setting … that’s the hurdle and independent prescribing removes that
hurdle.”
(Male, on SP course, 25 years in pharmacy, 15 years in medicine/cardiovascular/management)
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“It really is another form of supplementary but without the management
plan.”
(Female, on SP course, 26 years in pharmacy, 16 years in neonatology/obstetrics and gynaecology)
3.3.3.3 Issues with the pharmacy profession
Pharmacy management support to take on prescribing role
This theme emerged during some of the focus group discussions. Overall
there were lengthier discussions about the lack of management support for
pharmacists to take on a prescribing role (see section 3.3.2.1). Some
pharmacists thought that despite pharmacy management potentially
supporting staff to train as supplementary prescribers, there was a lack of
vision as to where this would be implemented.
“ So I think they [pharmacy management] are supportive, yeah, but I think
maybe people doing the course ought to have a clearer idea of what they
want to do, to get the most out of it.”
(Female, non-supplementary prescriber, 21 years in pharmacy, 3 years in antimicrobial utilisation)
“I think management are quite keen for us to do it, and to get more and
more people but what their final vision is, I have no idea.”
(Female, supplementary prescriber, 11 years in pharmacy, 4 years in respiratory/cardiac)
“The individuals, it’s the top of the tree, would like all pharmacists to be
trained as supplementary prescribers at least because that is a priority for
the profession; but I would say with regard to changing our roles to allow
us to do it, that’s not quite happened yet.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in critical care/management)
Participants also believed that support for prescribing might be a financially
driven incentive, for example stopping antibiotics by a pharmacist
prescriber might result in a cost saving.
“I think the aim of folk would be to save money”
(Female, on SP course, 20 years in pharmacy, 19 years in infectious diseases)
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“It may be stopping rather than starting antimicrobials…yeah, financially
driven.”
(Female, non-supplementary prescriber, 20 years in pharmacy, 17 years in respiratory/infectious
diseases)
“Personally, [management will support] only if it brings money back into the
department at the moment is my personal view.”
(Female, supplementary prescriber, 7 years in pharmacy, 4 years in respiratory medicine)
3.3.3.4 Issues with other healthcare professionals
Acceptance of the pharmacist prescriber by the medical profession
This theme emerged at some of the focus group discussions. Some
pharmacists had already discussed the role of a pharmacist prescriber with
doctors and this was viewed as feasible in areas such as HIV, oncology and
haematology, and antimicrobials as part of CF patient management.
“I discussed HIV prescribing of antiretrovirals, and the doctors involved
were very keen.”
(Female, on SP course, 20 years in pharmacy, 19 years in infectious diseases)
“The consultants within oncology and haematology are quite keen to do as
well, and are very keen to get it [PP] established as soon as possible.”
(Female, on SP course, 9 years in pharmacy, 2.5 years in haematology)
“But they’re all for it [PP of antimicrobials in CF] so I’m sure if it would fit in
other areas, other consultants would be all for it as well. There was no
discussion; they just said ‘Great, give me the form to sign.’ That’s all I can
say.”
(Female, on SP course, 7 years in pharmacy, 4 years in respiratory medicine)
Other pharmacists thought that doctors might support the role of a
pharmacist prescriber in areas such as post-transplant patients and where
pharmacists were already providing considerable advice and input.
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“I think transplant they would be quite keen because they are very aware of
the interactions between various antimicrobials and immunosuppressants.”
(Female, supplementary prescriber, 32 years in pharmacy,7 years in renal vascular)
“Vanc [vancomycin] and gent [gentamicin] you know; they are very
confident of the pharmacist’s ability so that’s probably one area where they
would be accepted.”
(Female, supplementary prescriber, 14 years in pharmacy, 9 years in acute medicine/respiratory)
“It would be relatively easy to extend that to other antimicrobials; it’s often
just letting the toe in the door and just letting medics know what we can do
and letting them become confident with what we can do.”
(Female, non-supplementary prescriber, 20 years in pharmacy, 17 years in respiratory/infectious
diseases)
“And I think if we were able to [prescribe] as we all become supplementary
and independent prescribers we would find support from the medical and
surgical consultants to switch IV-to-oral.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in acute medicine)
“I think traditionally, ITU being such a high priority, high risk area we
always gave a very good service there; the pharmacist is already accepted
as a member of the team, so I don’t think that would be a huge jump to get
them to accept your prescribing.”
(Female, supplementary prescriber, 14 years in pharmacy, 9 years in acute medicine/respiratory)
One pharmacist commented that consultants in her area of practice were
willing to support PP, provided the pharmacist would regularly attend ward
rounds.
“They [consultants] said I wouldn’t be prescribing on the ward until I was
an active part of the ward round five days a week … they didn’t see it as an
obstacle, they didn’t want to say no to it, but they definitely didn’t want the
role to develop if that person wasn’t going to commit to being around at the
time when decisions were being made about prescribing which is at the
ward round.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in critical care/managerial)
Chapter 3 – Focus Group Discussions 173
Another pharmacist perceived doctors supporting and having confidence in
a pharmacist who they had worked with for a prolonged period of time.
“And probably doctors are confident in pharmacists in that they know
they’ve been working with for years. Whether you would have the same
confidence in somebody new that they didn’t know, you know somebody
new in the post.”
(Female, non-supplementary prescriber, 28 years in pharmacy, 8 years in colorectal surgery)
A need to work within a multidisciplinary team
Pharmacists in some groups believed that if they were taking on prescribing
roles, it would be more feasible and probably safer practice to work within a
multidisciplinary team, even more so, since currently, decision making
related to prescribing tended to be more within a team rather than on an
individual basis. This might involve changes in current roles, where
pharmacists tended to work more as individuals rather than as part of a
team.
“There are very few things that are actually done, individuals making a
decision; it’s all discussed, and then the decision made of what to prescribe
so I think, we have to change our way or working which enables us to take
on these [prescribing] roles.”
(Female, non-supplementary prescriber, 15 years in pharmacy, 7 years in critical care/management)
The lack of skills of a pharmacist to make a differential diagnosis would also
make it necessary for pharmacists to work within a multidisciplinary team,
where the knowledge of different healthcare professionals would
complement each other.
“There is quite a lot of scope within the ICU to be involved as part of the
multidisciplinary team, bearing in mind that you will not be taking full
responsibility for the prescribing of antimicrobials for that patient. But
because of our knowledge of differential diagnosis, we have to be part of
the team; we do not have those [diagnostic] skills.”
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(Female, supplementary prescriber, 12 years in pharmacy, 5 years in surgery/anaesthesia)
To make full use of the skills of different members of the multidisciplinary
team and to integrate the newer roles of the prescribing pharmacist, a
participant recommended the introduction of an antimicrobial team, possibly
made up of an infectious diseases physician, a microbiologist and a
pharmacist. She goes on to comment that such teams have already been
set up in England and could be a way of integrating the pharmacist involved
in prescribing antimicrobials.
“What they have down in England is to have an antimicrobial team, and
they get referred patients by pharmacists, and this team goes round [to
review patients], and [is made up of] a microbiologist, an infectious
diseases physician and a pharmacist … a lot of what they do is stop
antibiotics but that’s a potential role for a supplementary prescriber;
because actually one of the teams involves a microbiologist who’s not a
consultant microbiologist, he’s not a doctor microbiologist, he is a scientist
microbiologist, and he actually doesn’t have the power to stop prescribing
and it’s the pharmacist who’s involved in stopping the prescribing, so that’s
a potential role.”
(Female, on SP course, 20 years in pharmacy, 19 years in infectious diseases)
Throughout, emphasis has been placed on developing collaboration with
microbiologists, who are most likely to have access to vital information
about sensitivities required for the effective and optimal prescribing of
antimicrobials.
“If you collaborate with them [microbiology]; for example with me, my first
port of call would be, if I take on supplementary prescribing [of
antimicrobials], to discuss the whole matter with them [microbiology].”
(Female, on SP course, 26 years in pharmacy, 16 years in neonatology/obstetrics and gynaecology)
One specialist orthopaedic pharmacist had already developed this working
relationship with microbiology:
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“I work with microbiology quite closely, so I do have access to sensitivities,
the data”
(Female, supplementary prescriber, 24 years in pharmacy, 12 years in musculoskeletal)
She went on to give examples from her current practice of the importance
of collaborative work between pharmacy, the microbiologist and the
orthopaedic surgeon caring for the patient, to ensure optimal and
appropriate choice of antimicrobial for the individual patient.
“ I think it does have to be a collaborative approach, so between surgical
and microbiology; my interest is treatment of prosthetic joint infection and
sometimes you don’t get growth florets from the cultures … but you know
there’s an infection there; you have to go back to the surgeon, because a
joint can appear to be clinically infected and you can have no more growth
on culture; so you couldn’t prescribe on the evidence [from microbiology];
so microbiology would have to get the surgical opinion as well.”
(Female, supplementary prescriber, 24 years in pharmacy, 12 years in musculoskeletal)
3.4 Discussion
3.4.1 Key findings
This phase of the research set out to explore:
 The extent to which pharmacists were using their prescribing
privileges
 Pharmacists’ perceptions of the usefulness of PP in secondary care
with a focus on antimicrobials
 Pharmacists’ perceptions of potential barriers towards PP in
secondary care with a focus on antimicrobials.
Out of all 19 participants who indicated they were supplementary
prescribers or in training:
 Four were using their prescribing skills, three regularly and one
occasionally writing up a CMP
 Eight were not using their prescribing privileges
 Seven were in training
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None were prescribing antimicrobials; two in training indicated that they
planned to prescribe antimicrobials for cystic fibrosis patients following
qualification. To the knowledge of the participating pharmacists, no other
pharmacists within the hospital were prescribing antimicrobials. One
pharmacist was involved in changing doses as part of TDM of vancomycin
and gentamicin and in IV-to-oral switching, in line with a hospital
prescription amendment policy. Hospital wide PGDs involving antibiotics
were mainly reported to be nurse-led.
Overall, there were more in-depth discussions on barriers to PP compared
to usefulness. When discussing SP, pharmacists drew on actual
experiences; however since independent prescribing had not yet been
introduced, perceptions of the future were discussed. Pharmacists in all
focus groups perceived that the usefulness of PP was determined by the
clinical environment, which included the patient’s clinical condition and the
areas of clinical care. Numerous examples were provided relating
specifically to antimicrobials. Pharmacists perceived the main barriers
towards PP in secondary care to be: the lack of management support for
expanded roles, the current working processes and practices (such as a lack
of provision of 24 hour service), a lack of resource and capacity (such as an
inability to sustain new services), and the CMP as a requirement of SP.
Drawing up the CMP and lack of provision of a 24-hour service were
perceived as being a major barrier towards PP of antimicrobials since it was
likely that patients prescribed antimicrobials were admitted with an acute
episode that was rapidly changing.
3.4.2 Strengths and limitations
To the author’s knowledge, this is the first research that has focused on PP
of a specific drug or drug groups in secondary care. The roles of the
pharmacist in the optimisation of antimicrobials as part of a
multidisciplinary team have been well established.(195) The author
supports the opinion of Weller et al that it is likely that the introduction of
PP will be adopted as a new way of practice in the future as part of
strategies aimed at optimising antimicrobial use.(47) The focus on
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antimicrobials may help policy makers who are looking for novel ways of
integrating the pharmacist prescriber as part of this antimicrobial
multidisciplinary team. Despite the fact that the focus is mainly on SP,
(since IP was not yet introduced at the time of the discussions) the study
may help inform the successful implementation of IP since problems and
barriers highlighted may be similar. The author believes that the choice of
focus groups as a method offered more in-depth information than if a
questionnaire was used particularly since this was exploratory research
looking into pharmacists’ perceptions.
The study has numerous strengths with respect to the sampling strategy.
The focus group participants purposely did not include pharmacists who
were in higher management. The author felt that including members of
higher management and in positions of power might lead to suppression of
other pharmacists leading to them not airing their opinions especially when
discussing topics which were directly related to management views and
support of PP within the institution. Both supplementary prescribers and
non-prescribers were included and the groups were therefore
heterogeneous with respect to prescribing experience. This is unlike most of
the published literature which focuses mainly on pharmacists who are
supplementary prescribers or in training.(123,130-132,196,197)
Heterogeneous groups were employed to help stimulate discussion among
participants. The sampling strategy also ensured that the pharmacists were
experienced and “hands on” in a mix of specialties. A maximum of six to
eight participants was aimed for per group to allow for participants to have
sufficient opportunity to express themselves which may not have occurred if
larger groups were used.(186,189)
Throughout the research, approaches were incorporated (when data
gathering and during the analysis process) to minimise the author’s and
supervisory team’s bias and to enhance validity. These included ensuring
appropriate training of the author, having a systematic approach when
conducting the focus groups, transcribing all discussions “ad verbatim” to
allow for more rigorous analysis and having more than one researcher
reviewing transcripts for emerging themes. These aspects are described in
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detail at section 3.2.4. Data saturation was achieved when no more new
themes emerged at focus group six.
The study is limited by geographical location within Scotland. There was
much debate about this issue between the author and the supervisory
team; however the devolution of healthcare in the UK has resulted in non-
uniform health policy and practice, hence basing the final study in Scotland.
The views of the participants cannot be considered representative of all
hospital pharmacists and, as in all focus group discussions, participants may
have felt under pressure to agree with dominant views.(189)
3.4.3 Discussion of findings and comparison with the literature
Published evidence indicates that the devolution of the UKxv healthcare
system may have resulted in different priorities for PP in Scotland, Northern
Ireland, England and Wales. Thus, pioneering literature based exclusively in
Northern Ireland (129,130) shows that the greater majority of pharmacists
who trained as supplementary prescribers work in a hospital setting while
literature based exclusively in Scotland (131) indicates that most were
based in a primary care setting. Another questionnaire based study of
pharmacist SP in England reports that 47% of respondents were using their
training but no information is provided on healthcare setting.(196)
Literature which explores GBxvi wide PP indicates that most trained
supplementary prescribers were based in hospital (119,120) whilst the
fewest were based in community pharmacies.(198)
Few of the published studies provide details on the extent to which the
trained prescribers were making use of their prescribing privileges. Where
available, this seems to reinforce that two groups of prescribers have been
successful at implementing SP; hospital pharmacists have been most
successful at implementing pharmacist SP in Northern Ireland (130) and
primary care pharmacists in Scotland.(131) Reports of a GB wide study
exploring early experiences of supplementary prescribers shows
pharmacists in primary care settings were most likely to prescribe despite
xv UK – United Kingdom which includes England, Scotland, Wales and Northern Ireland
xvi GB – Great Britain which includes England, Scotland and Wales
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the fact that hospital pharmacists were more likely to be trained as SP;
42% of trained hospital pharmacists were not prescribing.(119) A survey of
pharmacists overseeing the implementation of pharmacist SP in England
showed similar percentages were planning to implement SP in both
secondary and primary care settings (57% and 56% respectively). (121)
Results from our study show that few of the supplementary prescribers
were actually making use of their skills and none were prescribing
antimicrobials. Most of the pharmacists who were on a course had identified
where to start prescribing once qualified, with two pharmacists planning to
prescribe antimicrobials. This is in line with reports from the literature which
show that the focus of both training and implementation of pharmacist SP in
Scotland in the initial phases appeared to be in the primary care setting.
This potentially indicates that primary care was a priority for the
implementation of pharmacist SP for Scottish health boards resulting in a
lack of implementation in secondary care in Scotland. However, the author
believes that the implementation of pharmacist SP is a very complex issue
influenced by numerous potential factors. This is shown by the fact that
despite reports that most GB pharmacists training as supplementary
prescribers worked in hospital, yet most pharmacists implementing SP were
in primary care. It is also worth highlighting that the different
methodologies of the published studies and the varying timescales over
which they were published make it difficult to draw any definite conclusions.
Pharmacy management was perceived by most participants to be one of the
main barriers, not supporting the training required to take on a prescribing
role and lacking a plan to facilitate the implementation of pharmacist SP
following qualification. This was also true for antimicrobial prescribing where
there was no specific drive or incentive to encourage PP unless as part of a
cost-cutting exercise. This may potentially reflect the fact that
implementation of PP is not an organisational priority as evidenced by the
lack of organisational recognition as reported elsewhere in the
literature.(120,130) A lack of support of directors of pharmacy for this
expanded role of the pharmacist also comes across by the fact that most or
none are themselves prescribers. The apparent lack of a plan to implement
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PP was causing frustration among pharmacists who had qualified as
supplementary prescribers and were not making use of training, and also
causing reluctance to train among those who were still to embark on the
training. The author thinks that further research is required involving
pharmacy management to investigate potential reasons for this apparent
lack of support and implementation plan. This is crucial to facilitate service
development involving PP and to ensure there is no loss of motivation
among staff or loss of trained personnel due to changing of jobs.
This perceived lack of organisational support indicates that in our study, the
individual pharmacists emerged as the driving force initiating the process
necessary for training and completing the course, often within their own
time. Following training, they were utilising their own initiative to identify
prescribing roles within their specialties and often appeared to be taking on
a higher workload to implement an expanded role. It is likely that these
pharmacists are innovators, a social category first defined by Ryan et al and
later further characterised by Rogers, as individuals having an ability to
understand and apply complex technical knowledge, being venturesome and
coping with a degree of uncertainty about an innovation.(199) Other reports
in the earlier literature researching PP also characterise individuals who
were amongst the first to train as prescribers as innovators.(123,131) Other
social categories identified by Ryan et al are early adaptors, early majority,
late majority and laggards.(199) Interestingly, a survey of pharmacists who
were not prescribing or in training classified themselves as innovators or
early adapters, though they were still reluctant to take on prescribing, with
many feeling they did not have sufficient support to take on expanded
roles.(198) This is in conflict with evidence derived from a survey of
pharmacists who were overseeing the implementation of PP in different
healthcare settings and who believed that most pharmacists would want to
take on prescribing.(63) In view of this, the author believes that
investigating further the behaviour of social categories other than
innovators as defined by Ryan et al may help inform wide-scale service
developments, and especially help inform the successful implementation of
pharmacist IP in secondary care.
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There is considerable literature discussing the potential lack of support of
the medical profession to pharmacist supplementary and IP due to a fear of
encroachment on the doctor’s role.(124,129,130) It is difficult to determine
why there is such a perception but the initial opposition of medical
associations to the introduction of non-medical prescribing may be a reason
and has been described in detail in Chapter 1. Interestingly, though there
was some discussion about this in some focus groups, the participating
pharmacists did not perceive this potential lack of support as of major
concern. This probably reflects that more experienced ward based
pharmacists were included in this study, and were already well established
members of the multidisciplinary team such that there was no professional
rivalry between the professions. Indeed, some pharmacists who had
already discussed the potential of implementing pharmacist SP in their
specialty were met with encouragement and specific potential roles
identified. Gaining and ensuring the support of the medical profession may
be a way of ensuring the successful implementation of PP. Interestingly,
some professional rivalry with the nursing profession emerges, with
participants commenting that they are being trained as prescribers to make
sure there are enough numbers as there are nurse prescribers. This has
been reported elsewhere in the literature where nurses believe that they are
better placed to prescribe than pharmacists.(200) Some go further to
comment that PP is an encroachment of nursing territory.(130)
The pharmacists were concerned that current working practice encouraged
pharmacists to work more on an individual basis rather than as part of a
multidisciplinary team. They felt that this practice would need to change
allowing pharmacists to become more integrated within the multidisciplinary
team to ensure safe implementation of PP. This may be even more
important if the pharmacist is independently prescribing and is required to
ensure effective communication and an appropriate skill mix within the
teams especially since pharmacists perceived themselves as having a lack
of diagnostic skills. This may be especially so with antimicrobials where
pharmacists thought they would need further specialist diagnostic training
together with training on assessing the severity of the patient’s condition
due to the potential complexity of the patients. Working as part of the
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multidisciplinary team would also help overcome the likely lack of
enthusiasm by doctors for pharmacists to become independent
prescribers.(129,131) The multidisciplinary team with pharmacy
involvement has been very well developed in the area of infection and
antimicrobial teams promoting optimal use of antimicrobials are now well
established in most UK hospitals.(195) There may therefore be further
scope for the development of a prescribing role for a specialist antimicrobial
pharmacist working within such teams, although the need for clarification
and defined responsibilities of all the members of the team would be
necessary.
Despite the numerous perceived barriers and challenges to implementing PP
in secondary care, the introduction of PP in this healthcare setting has often
been reported in the literature as a natural extension of the pharmacist’s
role. The practice of ward-based hospital pharmacists lends itself well to PP,
with access to patient clinical records and pharmacists already reviewing
charts and making recommendations on a daily basis, with junior doctors
only signing off prescriptions, very often not really understanding what they
were signing.(201,202) Pharmacists who were SP in a hospital setting
commented that SP “streamlined and legalised practice.” (130)
Interestingly, doctors who were mentors to pharmacist prescribers were
also of this opinion.(129) In previous research, pharmacists report
“informal” prescribing, though there was a wide variation in this from
making verbal recommendations with no documentation, to actually writing
up prescriptions due to a shortage of medical staff.(123) Pharmacists in our
study also thought that there were areas where they were already making
considerable input, such as in TDM and in dosing for organ dysfunction, that
may be particularly suited for initiating PP. Some clinical applications of PP
of antimicrobials have been reported in the literature though no reports
were found on outcomes. These included repeat prescribing of
antiretrovirals in HIV positive out-patients and dose adjustments of
antibiotics in an intensive care unit.(203,204) A study by Hobson et al
looked at the views of pharmacists who were overseeing implementation of
PP.(121) Roles were identified in areas where the pharmacist input was
already well established and included HIV care, following protocols for
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antibiotic prophylaxis in surgical-orthopaedic preadmissions clinics and
cystic fibrosis patients. Anecdotal evidence through discussions as part of a
UKCPA special interest group have indicated pharmacists starting and
stopping antibiotics as part of surgical prophylaxis and dose adjustment of
gentamicin and pharmacists planning to implement prescribing by adjusting
antibiotic regimen and doses depending on sensitivity results, interactions
and renal and hepatic function. These reported activities were similar to
potential roles identified by pharmacists in this study, though a broader
range of activities were identified here. Pharmacists in this study felt that
they had sufficient pharmacological knowledge to take on antimicrobial
prescribing, especially when compared to the more junior doctors. Other
stakeholders have also perceived pharmacists to be competent in
pharmacology and pharmacotherapy, though lacking in counselling and
diagnostic skills.(197) This is similar to views of the pharmacists in this
study who though knowledgeable to prescribe, would rather do so for a
diagnosed rather than undiagnosed condition.
Pharmacists in our study appeared keen to progress from supplementary to
IP, the latter seen as a more feasible option in secondary care offering more
flexibility since no CMP is required. The participants perceived the CMP as a
major barrier to implementation of PP particularly in secondary care and
perceived it to be especially unsuitable for the management of patients with
infection who were likely to be complex and whose condition was rapidly
changing. They thought it would only be suited for use in patients with
chronic conditions or an option in areas of care where patients were likely to
receive standard treatment, such as surgical antibiotic prophylaxis. The CMP
has also been reported as a major barrier to implementation of PP in other
research (123,130,131,197) with IP offering “more autonomy and clinical
responsibility.” (205) One study involving pharmacists who were SP
revealed that some were actually reverting to the previous way of getting
doctors to sign their prescription or prescribing without using a CMP.(123)
As indicated by some participants in our study, SP may become a
transitional model, and may be the initial form of prescribing undertaken by
the pharmacist till enough confidence has been gained to prescribe
independently.
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Pharmacists in this study put forward a model of PP that would be both
feasible and ensure patient safety in secondary care. This would involve a
doctor making a diagnosis and starting new treatment and an independent
pharmacist prescriber adjusting and monitoring treatment without the need
for the CMP. This model would enable some barriers to PP in secondary care
discussed above to be overcome and would ensure that both doctors and
pharmacists are confident with the process involved in that all professions
were working within their own competence. Similar models have been
reported elsewhere as the way forward for PP in secondary care.(129,130)
Weiss et al report a slightly different model where the nurse conducts
clinical examinations, the doctor diagnoses and the pharmacist monitors
and adjusts drug treatment.(124) Whichever model, the author believes
that the potential fragmentation of the prescribing process makes it
imperative to have robust communication and very clearly defined roles and
responsibilities within the multidisciplinary team to ensure patient safety.
3.4.4. Conclusion
The study shows that despite pharmacists being trained as prescribers in
secondary care, there is a lack of implementation which emerges across
most health boards where the focus groups were conducted. This has led to
a lack of motivation and frustration among pharmacists, especially since
numerous potential areas where PP is feasible have been identified by the
participants. It is not possible to pin-point one reason for this lack of
implementation through this phase of the research though numerous
interplaying factors emerge such as a lack of management support, some
current working practices and difficulties with implementing SP in an acute
healthcare setting. It is also difficult to establish whether this is a Scotland-
wide issue and further background research needs to be conducted to try
and clarify this.
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Chapter 4
Background Scoping Exercise
4.1 Introduction
The analysis of the focus group discussions was followed up 12 months later
by a background scoping exercise conducted between February and May
2008. This informed how PP in secondary care, particularly the prescribing
of antimicrobials, had developed since the initial focus group research. In
turn, this would potentially allow a more reasoned discussion of the
subsequent stages of the research as the original research questions
seemed no longer appropriate. Figure 5 summarises the approach taken.
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Figure 5: Schematic representation of evolution of the research following
focus group analysis
Analysis of themes emerging from
focus group research
What are the
perceptions of other
stakeholders of PP of
antimicrobials in
secondary care? This
could involve
interviews and a
questionnaire based
on focus group
analysis.
Difficulties were:
a) To identify and define
stakeholders both from a
policy and strategy
perspective and from a
practice point of view
b) Areas to explore were
likely to be very different
when comparing healthcare
professionals to strategic
professionals so unlikely to
be possible to have one
questionnaire
c) It was unlikely that a
questionnaire to non-
pharmacy stakeholders
would contribute to further
develop the area
What are the
perceptions of all
hospital pharmacists in
Scotland on PP of
antimicrobials? This
could involve a
questionnaire based on
focus group analysis.
Since a substantial
number of hospital
pharmacists had
already participated in
research, it was
unlikely that this
would yield any more
information
Is it feasible to
recommend a
framework for
development of PP of
antimicrobials? This
could be based on a
detailed case study
involving a pharmacist
prescribing
antimicrobials.
Background information
gathered by consulting
some relevant personnel
indicated that different
trusts had different ways of
implementing and
supporting PP, with
emphasis on primary and
community as opposed to
secondary care
Focus groups indicated that
no pharmacists were
prescribing antimicrobials
so at this point it was
unlikely that this research
would contribute to practice
development
Aim: To conduct a scoping exercise to
determine the extent of implementation of
PP in secondary care in Scotland
Considered
Potential research questions
Considered Considered
Discarded
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The aim of this part of the research is highlighted in Figure 5. A number of
objectives were linked to this aim:
 To update information on the extent to which pharmacists who
participated in the focus group discussions were using their
prescribing privileges and to determine whether any were prescribing
antimicrobials and to obtain more detail on the prescribing role of any
PP antimicrobials
 To investigate the existence of a national Scottish framework or
guidance for PP
 To investigate what documents were available at a local level to guide
PP and whether any focused specifically on secondary care and to
determine what healthcare professionals were involved in the
developing and authoring of frameworks [definitions and further
details are provided at Section 4.4].
The method and results will be presented separately for each objective. This
fact-finding exercise was carried out between February and May 2008.
4.2 Objective 1
Objective
To update information on the extent to which pharmacists who participated
in the focus group discussions were using their prescribing privileges, to
determine whether any were prescribing antimicrobials and to obtain more
detail on the prescribing role of any PP antimicrobials.
4.2.1 Follow up of focus group participants
Method
An email was sent in February 2008 to all 19 pharmacists who were either
prescribers or on the prescribing course and had previously participated in
the focus group discussions. Email addresses were available through
previous research. They were asked to provide information as follows:
“I am now planning Phase 2 of my research which is likely to evolve from
results in Phase 1 and I am following up participants from Phase 1 who
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were supplementary prescribers or on the course. I was just wondering
whether there have been any changes to your circumstances and whether
you are making use of your prescribing skills. If yes in what area and does
this involve antimicrobials at all?”
A reminder email was sent out to non-respondents and a letter was sent by
post in March 2008 to remaining non-respondents.
Results
A response was obtained from 17 participants and is summarised as
follows:
(a) Four participants had moved to other health boards and no contact
details were available
(b) One participant was on maternity leave
(c) Three participants had not yet completed their course, mainly due to
other work commitments
(d) Six participants were not making use of their prescribing qualification
(e) Three participants had converted/were converting to IP and were
using their prescribing skills in their area of practice. One was
prescribing antimicrobials.
Further details are at Table 19.
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Table 19: Prescribing status of focus group participants at follow up
Participant
number
Prescribers or on
course at focus groups
Follow up prescribing status
1 SP Left post – no contact details
2 SP Converting to IP; currently prescribing
antihypertensives in a diabetes clinic
3 On SP training course Not yet completed course
5 SP Changed specialty; not prescribing
since now in a post with no direct
patient contact
6 SP Left post – no contact details
10 On SP training course Completed SP training; converted to
IP; currently prescribing
antimicrobials to cystic fibrosis
patients
15 On SP training course Completed SP training; not
prescribing; planning to convert to IP
which is perceived to be more
appropriate for the relevant patient
groups
16 SP Not prescribing
17 SP Left post – no contact details
25 On SP training course Left post – no contact details
27 SP Changed specialty; not prescribing
since currently not working on wards
28 On SP training course Not yet completed course
29 SP Converting to IP; currently prescribing
nutrition; not planning to prescribe
antimicrobials
30 SP On maternity leave
32 SP Not prescribing
33 On SP training course Not yet completed course
37 SP Not prescribing
4.2.2 Further follow up of participant 10
Participant 10 was the only pharmacist who was prescribing antimicrobials
at the follow up stage. To obtain a more complete picture of the current
status of PP among focus group participants, interviews were conducted
with the pharmacist and the medical consultant with whom she worked. The
latter was also the independent prescriber she worked with as a
supplementary prescriber. Though an interview with a patient for whom the
pharmacist had prescribed was considered, it was unlikely that the
information that a patient would provide could contribute much to the
research.
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Method
The North of Scotland Research Ethics Committee was contacted to provide
advice on the need for an NHS Ethics application. The committee advised
that an application was not required, classifying this as a minor amendment
to the previous application. NHS R and D were also informed (Appendix
4.1).
Both the pharmacist and the consultant were initially approached by e-mail
to determine whether they would be willing to participate in an individual
one-to-one interview. The e-mail address for the pharmacist was available
from the previous focus group discussions, while that for the consultant was
available through the hospital website. Following positive responses, a
recruitment pack was sent to each with a participant information sheet and
a consent form indicating that the interview would be audio-recorded (see
Appendix 4.2). A short interview schedule evolved through discussions
within the supervisory team.
Follow up interview with prescribing pharmacist
1. I wonder whether it would be possible to review the way in which you were
practising prior to the prescribing course? You had just registered on the SP
course at the focus group.
2. Can you describe the way in which you are practising following the
prescribing course? What are the drug groups and who are the patient
groups you are prescribing for?
3. How was this role identified? How did this come about and who drove it?
4. Has this been as expected? Have there been any specific challenges and
barriers to overcome? Is there potential to expand this role further?
5. Do you expect any changes once you qualify as an independent prescriber?
6. What has been the feedback from colleagues, medics, nurses and patients?
Chapter 4 – Background Scoping Exercise 191
Follow up interview with consultant
1. I wonder whether it would be possible to review the way in which patients’
antimicrobial treatment was managed prior to the pharmacist’s involvement
as a supplementary prescriber?
2. How would you describe your experience as a mentor during the
pharmacist’s supplementary prescribing course?
3. Can you describe the way in which the management of patient’s drug
treatment has changed following the pharmacist’s prescribing course? What
are the drug groups and who are the patient groups involved?
4. How was this role identified? How did this come about and who drove it?
5. Has this been as expected? Have there been any specific challenges and
barriers to overcome? Is there potential to expand this role further?
6. What are your views on pharmacist independent prescribing? Do you expect
any changes once the pharmacist qualifies as an independent prescriber?
7. What has been the feedback from other medics, nurses and patients?
Interviews were carried out in September 2009. The interviews lasted
between 20 and 30 minutes. These were held with a specialist respiratory
pharmacist who was prescribing independently and with a consultant
respiratory physician. Recordings were transferred onto a password
protected computer and will be destroyed once the research has been
completed. Since the aim of these interviews was to gain more detail of the
pharmacist’s prescribing role, a descriptive account of the interview was
generated rather than an ad verbatim transcription for analysis. Once
completed, the descriptions were sent to each participant for participant
verification with no changes made by the participants. Key points were
identified relating to the success of PP and the prescribing partnership.
Results
Interview with pharmacist
The following are key issues emerging from this interview:
 The transition from supplementary to independent prescribing
enabled the pharmacist to work outwith CMPs. However, she felt
these were still useful as a guide to the drug management of specific
disease states.
Chapter 4 – Background Scoping Exercise 192
 The pharmacist was involved in prescribing antimicrobials to cystic
fibrosis in- and out-patients. This involved both empirical prescribing,
and prescribing following the availability of culture and sensitivity
results. The pharmacist reviewed all patients prior to bronchoscopy in
a pharmacist and nurse led clinic thus ensuring that all appropriate
medication had been prescribed prior to the intervention. She also
prescribed in response to symptoms, such as laxatives, titration of
analgesia and antacids, and believed that this area of prescribing was
a potential starting point for a pharmacist working in any speciality.
 The pharmacist’s perceptions were that feedback about this expanded
role was positive, at medical, nursing and dispensary levels. This led
to pharmacy management encouraging other pharmacists to identify
potential areas for prescribing within their areas of expertise.
 The pharmacist attributed the success to the fact that she knew the
cystic fibrosis patients very well and had worked closely with the
consultant involved prior to her training to prescribe.
 The pharmacist described what she perceived as some disadvantages
that were a consequence of her prescribing independently. These
were deskilling of junior doctors and a missed second check on
prescriptions written up by the pharmacist. The department was
putting a number of safety procedures in place to tackle the latter.
Interview with consultant
The following are key issues emerging from the interview:
 The consultant highlighted prescribing of antimicrobials for cystic
fibrosis patients as the main service provided by the prescribing
pharmacist. Other areas she was involved in included assessing
appropriateness of inhaler device for the individual patients,
prescribing palliative care for lung cancer patients and ensuring that
treatment charts were written up accurately and making any
necessary changes.
 Advantages of having a pharmacist prescriber included the fact that
she knew the patients very well, unlike junior medical staff who
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tended to rotate frequently, safer prescribing with less errors and
more rational prescribing with an opportunity for a reduction in costs.
 The consultant highlighted the potential of conflict between a doctor
and pharmacist due to a difference in opinion as a potential
challenge.
 He felt that the mentoring process during the pharmacist’s
prescribing training was a positive experience which did not involve
any additional work. He thought this was mainly due to the fact that
the two were already working closely beforehand and expressed his
concern that this might be very different if it was another pharmacist
whom he did not know very well.
 He believed that PP was a very positive experience and should be
expanded to other specialities.
4.3 Objective 2
Objective
To investigate the existence of a national Scottish framework or guidance
for PP
Method
(a) To obtain information on a national level, an e-mail was sent out in
February 2008 to the Chief Pharmacist of the Scottish Government for
further information as follows:
“I am a PhD student at The Robert Gordon University currently researching
around PP in secondary care. The first part of this project has involved focus
groups in five health boards in Scotland exploring pharmacists' views and
perceptions. I am now into the planning part for Phase 2 which is being
informed by Phase 1 of the project. It appears that this second phase will
evolve mainly around policy making associated with PP.
I am trying to determine whether or not a national framework for
PP has been formulated in Scotland. I am aware that
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a non-medical prescribing frameworkxvii is available and has been published
by NHS Scotland but this seems to cover nursing prescribing only.
Consequently, I was wondering whether it would be at all possible to
provide any further information or key contact persons around this.”
(b) Similar correspondence was sent to a generic email address at NHS
Quality Improvement Scotland, to determine whether any guidelines or
standards where available or under development and relating to both PP
and NMP.
Results
(a) The response from the Scottish Government indicated that the draft
national framework document available entitled “A Safe Prescription”xviii
(206) did not specifically mention PP due to a number of concerns of the
Government policy makers:
 Administrative issues relating to the new community pharmacy
contract and how pharmacist IP would evolve in the future
 Governance issues relating to the fact that pharmacist independent
prescribers may also be dispensers
Consequently, separate broad guidance for NHS Health Boards was issued
by the Scottish Government in December 2007 to support PP focusing
mainly on PP in primary care services.(207)
(b) Information provided indicated that no national guidance or standards
had been published or were being developed in relation to PP or NMP.
xvii This refers to the NHS Scotland document entitled “Non-Medical Prescribing in Scotland”
and published in September 2006. This provides guidance for the implementation of non-
medical prescribing by nurses in Scotland but makes no reference to PP.
xviii This document was later published in September 2009 and updated in August 2010 as “A
safe prescription. Developing nurse, midwife and allied health profession prescribing in NHS
Scotland.”
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4.4 Objective 3
To investigate what documents were available at a local level to guide PP
and whether any focused specifically on secondary care, and to determine
what healthcare professionals were involved in the developing and
authoring of frameworks.xix
Method
(a) The Scotland Directors of Pharmacy Group was contacted to obtain a list
of Directors of Pharmacy for all 14 health boards in Scotland. In February
2008, a letter (at Appendix 4.3) was sent to all directors of pharmacy [n =
13; one director covered two health boards] providing them with the aim of
this scoping exercise and a background survey they were asked to complete
and return in the self-addressed envelope provided. The following
background survey was developed through discussion with the supervisory
team.
xix The term “framework” is used here. It was however evident that there was no standard
terminology or approach across the 14 health boards as presented in further detail in Table
20 below.
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Background fieldwork into frameworks, strategies and models of PP
Please tick as appropriate.
1a. Has a framework been drawn up to provide a broad outline for pharmacist
prescribing within the health board?
Yes □
No □
1b. If yes, would it be possible to provide a copy of this framework?
2a. Has a strategy been drawn up for PP within the acute sector?
Yes □
No □
2b. If yes, would it be possible to provide a copy of this?
3a. Are there any models of PP within the acute trust?
Yes □
No □
3b. Are there any written standards to aid pharmacist prescribers?
Yes □
No □
3c. Are any pharmacists prescribing or planning to develop prescribing within
the area of antimicrobials?
Yes □
No □
4. Approximately how many pharmacists are involved in PP in the acute sector –
both in developing policies and in using their prescribing skills?
______________________________________________________________
5. Please feel free to add on any comments you would like to make.
______________________________________________________________
(b) The NMP lead in Grampian, who was also the lead for PP, agreed to
provide further information about implementation of NMP in Grampian. To
obtain further information about the implementation of NMP including PP in
other Scottish health boards she sent out an email to all NMP leads as
follows:
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Dear All
We have a pharmacy PhD student in Grampian who is carrying out a study
on non-medical prescribing. She would like contacts in other health board
areas. Would you mind if I gave her your contacts?
The contacts who provided their email addresses and were willing to be
involved in the research were asked to provide information as follows:
“Thank you for accepting to help me with my research. My research is
around PP of antimicrobials in secondary care and I am at this point
planning Phase 2 of my project. At this point I am trying to build up a
database of contacts, mainly involving professionals who are involved in
NMP within their health board particularly if they have been involved in
drawing up a framework for NMP within the health board. I wondered
whether you could indicate whether a) there is a NMP framework in your
health board and whether this includes pharmacy b) your position with
respect to NMP within the health board.”
Further contacts were obtained through the leads where relevant. The work
place email addresses of these contacts were stored on a password
protected file for potential future use in further research.
Results
(a) Eleven [out of thirteen] completed background surveys on PP were
returned by the Directors of Pharmacy.
(b) NMP leads in all health boards in Scotland were willing to provide
information about NMP including PP within their health board. They provided
seven documentsxx relating to NMP. A summary of information obtained
through (a) and (b) above is in Table 20.
xx The general term “documents” is being used here since health boards used different
terminology including framework, policy, strategy and Standard Operating Procedure.
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Table 20: A snapshot of pharmacist prescribing in Scotland – May 2008
HB NMP framework in
place
Aim of
document
Pharmacy
involved in
authoring
NMP
Framework
for PP
Strategy
for PP in
acute
sector
Models
of PP
in the
acute
sector
Written
standards
for PP
PP or
planning to
prescribe
antimicrobials
Other
information
provided
1 Yes – (undated)
Termed “Non-
medical prescribing
policy”
“To provide a
governance
framework
related to NMP”
Yes - but
nurse led
development
No No No Yes Yes - planning No active
pharmacist
prescribers at
present
2 Yes – April 2008.
Termed “Non-
medical prescribing
policy”
“Code of
practice”
Yes – NMP
group
chaired by
Director of
Pharmacy
No No No No No 15 out of 35
qualified PP
actively
prescribing in
primary care
3 No – currently under
development
“Comprehensive
strategy and
operational
policy”
Yes - but
nurse led
development
No No No No No
4 No – currently under
development
Yes -
Director of
Pharmacy
involved
Very small
number (not
provided) of
prescribers in
acute sector
5 Yes – currently being
reviewed due to the
introduction of IP
6 Yes – May 2007.
Termed “Policy and
Framework for Non-
Medical Prescribing
including
Independent
Contractors”
“Sets the
guidance for
non-medical
prescribers in
NHS Grampian
to promote safe
and effective
prescribing”
Yes – policy
developed by
Non-Medical
Prescribing
Group of
which
pharmacist
members
Yes – this is
part of the
NMP policy
and
framework
No Yes – this is
part of the
NMP policy
and
framework
Yes 2 pharmacists
involved in
developing
policies and
prescribers in the
acute sector
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7 Yes – October 2006.
Termed “Standard
Operating Procedure
for Nurse/Pharmacist
Supplementary and
Nurse Independent
Prescribing”
“Sets out the
process and
steps required
from enrolment
to practice as
non-medical
supplementary
and independent
prescribers”
Yes, lead
pharmacist
for
prescribing
leads central
prescribing
team
Yes Yes Yes Yes –
RPSGB
standards
for
pharmacist
prescribers
Yes - planning 15 registered
pharmacists of
whom 1/6th are
actively
prescribing. A
NMP group dealing
with mental health
issues is being
established and
likely to cover
primary and
secondary care
8 No – currently under
development
Yes – but
nurse led
development
No No No No Yes - planning 1 PP in acute
sector
9 Yes – October 2006.
Currently under
review. Termed
“Framework for non-
medical prescribing”
“Seeks to
provide that [a
governance
framework in
relation to non-
medical
prescribing]
framework in
relation to non-
medical
prescribing”
Yes – both in
original
development
and in
updating
Yes – this is
part of the
general
framework
for non-
medical
prescribing
No Yes No Yes 12 pharmacists
involved in
developing
policies and
prescribers in the
acute sector
10 No – currently under
development
No No No No No No 4 pharmacists
involved in
developing
policies and
prescribers in
acute sector
11 Yes – October 2007.
Termed “Non-
Medical Prescribing
Policy”
“Set out the
systems and
procedures that
must be
adhered to, to
Yes Yes – as part
of general
non-medical
prescribing
policy
Yes Yes Yes Yes – planning 15 pharmacists
involved in
developing
policies and
prescribers in the
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assure safe and
effective non-
medical
prescribing.”
acute sector
12 Yes – January 2008.
Termed “Non-
Medical Prescribing
Policy.” An adjunct
document “Policy
and procedure for
Non-Medical
Prescribing” in draft
form
“To support best
practice for the
delivery of
patient care.”
Yes No – in
development
as part of
“Policy and
procedure for
Non-Medical
Prescribing”
No No No No 4 pharmacists
involved in
developing
policies and
prescribers in the
acute sector
13 No – currently under
development
Yes No pharmacist
prescribers within
this health board
14 No – currently under
development
Yes No No No No Yes – planning No pharmacist
prescribers within
this health board
HB – Health Board; NMP – Non-Medical Prescribing.
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4.5 Discussion
4.5.1 Key findings
This phase of the research was conducted between February and May 2008
and set out to inform how PP in secondary care, and particularly the
prescribing of antimicrobials, had evolved since the initial focus group
research. This was carried out utilising different sources of information
including: a longitudinal follow up of the focus group participants; investigating
the existence of a national Scottish framework by obtaining information
through the Scottish Government; and exploring any local health board level
guidance to facilitate PP.
It was evident from the 12-18 month follow up of focus group participants that
there had been little evolution regarding the implementation of PP in the
secondary care health boards studied. This lack of progress was despite the
fact that non-medical prescribing legislation had advanced now permitting
pharmacists to train and register as independent prescribers.(96) The
interview with one pharmacist independent prescriber and one medical
consultant within the same multidisciplinary team described successful
implementation of both PP of antimicrobials and PP in response to minor
ailments. Both interviewees reported a positive response from other
stakeholders but none were formally interviewed.
Response from different Scottish Government bodies indicated that no national
frameworks or standards had been published or were being developed in
relation to PP, despite a national framework guiding nurse, midwife and allied
health professional IP.(206) This was mainly due to the Scottish Government
policy maker’s concerns relating mainly to the implementation of pharmacist IP
in a community pharmacy setting [personal communication]. A broad
administrative guidance for NHS Health Boards was issued in 2007 by the
Scottish Government with a main focus on implementation of pharmacist IP in
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primary care entitled “Pharmacist Independent Prescribing – Guidance for NHS
Health Boards.” (207)
Eleven out of 13 Directors of Pharmacy and NMP in all health boards provided
information on the availability of documentation to guide PP at a local level
together with information on the development and authoring of NMP
frameworks where these were available. Eight NMP frameworks were in place,
with different nomenclature reported; most were termed “policies”, one was a
“standard operating procedure” and two included the word “framework.”
[Further details of the terminology used are found at Section 4.4]. Six were
reported to be under development. Pharmacy had been involved to a varying
extent in authoring most NMP frameworks; some reported nurse led
development, some reported pharmacists chairing working groups and one
reported a pharmacist leading the development. Most health boards did not
have a specific framework for PP; where this was available, it was a part of the
NMP framework. Few had a strategy in place for PP in the acute sector. Two
health boards reported having PP antimicrobials and four health boards
reported having pharmacists planning to prescribe antimicrobials.
4.5.2 Strengths and limitations
This phase of the study provides information on the evolution of the
implementation of PP in secondary care within the health boards studied. A
review of the literature revealed no published studies which used a longitudinal
approach to explore the evolution of PP by following up a group of pharmacist
prescribers. This would be important since PP is still in early stages of its
development, and consequently it is probable that practices would change over
time. Similarly, no information was available to provide a snapshot of
documentation available relating to PP within all Scottish health boards. This
enables any differences in implementation of PP in the different health boards
to be determined.
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To enhance reliability, when conducting the interviews, both interviewees were
provided with their own descriptive summary of the interviews.
Limitations were mainly related to difficulties encountered in obtaining the
relevant information. For example, when following up focus group participants,
it was not possible to follow them all for different reasons including changing
jobs and maternity leave. It was also a very lengthy process to obtain contact
details of all NMP leads in Scotland since no readily available database was
identified which had this information. It was therefore a very lengthy and
labour intensive process involving much correspondence to collate such a
database and meeting all data protection requirements.
Though three pharmacists were identified as independent prescribers or
converting to IP, only one was prescribing antimicrobials. Consequently only
one pharmacist and the medical consultant on the team, who was also her
mentor during her training, were interviewed to further inform this background
scoping exercise. The author believes that the conclusions that may be drawn
from these interviews are therefore limited, though helping to provide more
descriptive information on the implementation of PP.
4.5.3 Discussion
Follow up of the focus group participants indicated that there was little
evolution in implementation of PP in secondary care within the sampled health
boards, despite the legislative change which allowed IP.(96) This lack of
progression to and uptake of IP is a sharp contrast to participants’ views
expressed during the focus group discussions. At that time, they perceived IP
as the more feasible model in secondary care since there were no restrictions
imposed by the CMP and also more easily allowing for prescribing in an
environment where there were potential rapid changes in a patient’s condition.
They also thought it was especially relevant if prescribing antimicrobials. Many
had also indicated that they would rather train as independent prescribers than
supplementary prescribers. The three pharmacists who had still not completed
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training cited other work commitments as the reason for this; the author
believes that this reinforces focus group participants’ perceptions that there
were other priorities within the hospital pharmacy departments, and hospital
pharmacy managers still did not have a clear implementation plan in place to
facilitate PP.
The interview with the pharmacist independent prescriber described successful
implementation within the multidisciplinary team of both PP of antimicrobials
and prescribing in other areas mainly in response to minor ailments. The
pharmacist described a model involving running out-patient clinics in
collaboration with nursing staff. Though this model has been described in the
literature it is different to the model proposed by pharmacists during the focus
group discussions.(124) Further research may be carried out to determine
other successful models where PP has been implemented in secondary care
and to identify the key factors associated with success by conducting an in-
depth case study. The pharmacist commented that pharmacy management
were now more aware of the potential of PP and were consequently
encouraging other pharmacists to train as prescribers. However, no defined
strategy for the expansion and implementation of PP within this health board
was apparent from the interview. Deskilling of junior doctors and missing the
second check were the pharmacist’s main concerns. These were similar to
concerns that have been raised both during the focus group discussions and in
the literature.(129)
The interview with the consultant was the first involvement in this research of
other potential stakeholders. It was evident that this consultant considered the
pharmacist a trusted skilled member of the multidisciplinary team who was
well qualified to prescribe making a significant contribution to patient care. He
attributed this good working model and team integration to prior working
relationships. This is similar to reports in the literature where a previous
working relationship between a consultant and pharmacist were important for
future successful implementation of PP in secondary care.(129)
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The information obtained from Scottish Government bodies reinforced that the
focus of the Scottish Government, at least during the initial phases of PP, was
mainly primary care.(207) This supports the findings of early published
research reporting that the training and implementation of PP in Scotland was
successful mainly in primary care (Section 3.4.3).(131) However, despite the
focus of the Scottish Government not changing, information obtained through
the interview with the pharmacist independent prescriber together with
anecdotal evidence from specialist discussion forums indicates that more
pharmacists are now training and successfully implementing PP in secondary
care. The author believes that due to the complex and numerous factors that
influence the implementation of PP, it is not possible to determine at this stage
to what extent the Scottish Government policies are actually influencing where
PP is predominantly implemented successfully.
Information obtained at local health board level reinforced that there were no
standard frameworks available to aid in the planning and implementation of
PP, even as part of general NMP frameworks. Where documents were
available, they had heterogeneous nomenclature, aims and content. Different
health boards were also at very different stages of implementation of NMP
including PP. Though no conclusions may be drawn on what drives successful
implementation of PP, the information available seems to indicate that there is
an association between availability of a framework for NMP, including PP, and
the number of pharmacists actively prescribing. Health boards where the NMP
framework was being reviewed and updated reported having more pharmacist
prescribers than those where the framework was still at the development
stage. Interestingly, NMP including PP in one health board was evolving to
develop a framework within a specialty area (mental health). Similarly, health
boards having a framework for PP in the acute sector were those where
pharmacists were likely to be prescribing.
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4.5.4 Conclusion
This scoping exercise has identified a lack of evolution of PP in secondary care
within the health boards sampled, despite a change in legislation allowing for
non-medical IP. The Scottish Government focus, at least in the initial phases of
PP, appears to have been primary care, with no framework available for
implementation of PP in secondary care. Likewise, few of the Scottish health
boards reported having a framework in place to facilitate implementation of PP,
including secondary care. However, availability of a framework seemed to be
linked with a larger number of actively prescribing pharmacists and
consequently potentially more successful implementation of PP.
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Chapter 5
Development of consensus guidance to facilitate a service
redesign to involve pharmacist prescribing in secondary care
5.1 Introduction
As discussed in Chapter 4, the scoping exercise highlighted a potential “gap”
between training of pharmacists as prescribers and implementation of
pharmacist prescribing in secondary care. To aid implementation, this phase of
the research aimed to develop consensus guidance to facilitate service
redesign to involve PP in secondary care [a discussion on choice of method is
in Section 5.3.1 below]. This guidance was based on evidence gathered from
the focus group discussions and the scoping exercise.
5.2 A brief overview of consensus methods
The aim of formal consensus methods is to define the extent to which
participants agree with a given issue; “agreement” refers to both the extent of
agreement with the issue being proposed and the extent to which participants
agree with one another. There is no agreement in the literature as to what
consensus is; Jackie et al refer to this as “one of the most contentious
components of the method.” (208) There are three main methods described in
the literature that may be applied to seek formal consensus: the Nominal
Group Technique (NGT), the Delphi Technique (Delphi) and the Consensus
Development Conference. All methods attempt to systematically gather expert
opinion usually in areas where there is a lack of or incomplete evidence. These
methods are not intended to generate “right” answers, but what experts in the
field think is important in relation to the topic at the point in time.(209) There
are few studies comparing the different methods, and there appears to be no
evidence that any one method is superior to another.(210) As comprehensively
summarised by Campbell et al, these methods are useful for the following
reasons:(211)
Chapter 5 – Development of Consensus Guidance 208
“Enhance decision-making, develop policies and estimate unknown parameters
Facilitate the development of quality indicators or review criteria
Support quality assessment and thus quality improvement as well as clinical
governance
Synthesize accumulated expert opinion/professional norms
Identify, quantify and subsequently measure areas where there is uncertainty,
controversy or incomplete evidence”
Consensus methods have been criticised for a lack of credibility, validity and
reliability including questionnaire design, methods of defining and selecting
experts and a lack of definition of consensus levels.(212) However, these
issues may be overcome by ensuring a rigorous method and having a clear
“decision trail” (as described in greater detail later in the context of this
research).(211,213) Other critics have questioned whether the consensus
reached is a true or an apparent consensus where participants conform to a
central response due to peer pressure rather than their own acceptance of the
position adopted by the group. This may be more pronounced in face-to-face
discussions.(214) There may also be subject bias since it is likely that those
most interested in the subject will respond or participate.(209)
The following is a brief description and critique of each method.
5.2.1 The Nominal Group Technique
NGT is a technique developed in the United States in the 1960s and is in the
form of a highly structured facilitated meeting bringing together experts in the
field, though there appears to be no published guidance on definition of
‘expert’. The following are key elements of NGT with some modifications also
reported in the literature:(211,212,215)
 Experts are identified, assembled and asked to individually list issues
related to the topic under discussion independently and privately.
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 During the meeting, each individual, in turn [‘round-robin feedback’],
presents the most important idea to the group and the facilitator [who
is an expert on the topic or a non-expert who has credibility with the
participants] records this on a flip-chart, such that all members of the
group may view the list under development. The process is repeated
until no new ideas are generated.
 A highly structured discussion follows where all ideas are discussed and
clarifications made. Similar suggestions are grouped together. Usually
15 minutes are allocated to discuss each item.
 Participants then privately and in writing rank each idea as part of the
process at the meeting.
 The ranking is presented to the whole group for discussion. If
agreement is reached, then consensus is established. If not, the item is
deferred for later discussion.
 The overall ranking is re-ranked in light of the discussion.
 The final rankings are presented to the group.
Discussions can be audio-recorded to allow qualitative analysis particularly if
there are any divergences. Supporters of this technique claim that the
structured approach to the discussion both ensures that there is a discussion of
all ideas generated rather than just one or two ideas and gives the opportunity
for all to express their opinions.(210) Disadvantages include cost and the fact
that an expert facilitator may bias outcomes by expressing his/her opinion or
by having done so in the past [e.g. through publication]. (212)
5.2.2 The Delphi Technique
Delphi may be considered to be a mixture of quantitative and qualitative
methods. Delphi originated in the 1950s and was developed by the RAND Air
Force Corporation in America as a forecasting tool to estimate key nuclear
targets in America from a Soviet point of view.(211) It has been modified for
use in a number of applications within the healthcare area.
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Delphi proceeds in a series of rounds as follows:(211,212,215)
 The initial stage involves development of a questionnaire on a specific
topic using open-ended questions which is sent to experts in the area of
research who are invited to provide opinions and views about the topic.
The questionnaires are usually self-administered and completed by mail
or electronically.
 The responses are analysed qualitatively and the questionnaire is
reformulated by drafting statements that are suitable for ranking.
 This is resent to the panel and each individual is asked to rank the level
of agreement or disagreement with each statement provided.
 The results are re-analysed quantitatively and the panel members are
provided with the responses of other panellists and given the
opportunity to reconsider their responses and re-rank statements.
 The cycle is repeated until group convergence of consensus is obtained
and the final results are fed back to the participants.
A “Delphi approach” has been described where the initial questionnaire consists
of structured or semi-structured questions that are derived using alternative
sources such as the literature or surveys.(213)
The Delphi technique offers the following advantages:
 This process gathers the opinions of experts without needing to meet.
(209,213) and lends itself to be conducted electronically hence
performed more economically, conveniently and in the timescale
required.
 Since opinions are expressed anonymously, it helps overcome the
disadvantage of dominating individuals within group discussions. In
open group discussions, individuals may feel a pressure to conform to
the main ideas generated by the group.(215,216) In addition,
individuals are given time to consider the topic rather than being
pressurised to make a decision at the meeting.
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 Controlled feedback with the responses of the rest of the group
provided anonymously. Participants consequently have the opportunity
to re-consider issues that they may have thought unimportant or
missed.(209,214)
 Statistical aggregation of the group response ensures that the views of
all members of the group are considered and all views are given equal
weighting.(214)
Disadvantages include:
 Extensive time commitment from the participants (213)
 Anonymity may lead to lack of accountability if participants have hastily
completed the questionnaire (213)
 Lack of face-to-face interaction may diminish the potentially positive
aspects of discussion of any disagreement.(210)
5.2.3 Consensus Development Conference
This technique was developed by the US National Institute of Health. The aims
of this method are to co-ordinate consensus development and provide methods
of applying these.(212) Though it has been applied in countries outside the US,
this method requires resources that are not usually readily available to most
researchers.(215) The process takes the following format:
 An open meeting which may last a few days is convened with selected
participants.
 During this chaired meeting, evidence is presented about the topic by
experts and other groups or individuals who are not part of the decision-
making group.
 The decision-making group then privately discusses the evidence
presented and attempts to reach a consensus. This is also a chaired
meeting.
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Since it is expensive and difficult to organise, this method has only been used
by large-scale health organisations.
5.3 Study design
5.3.1 Aim and objectives
The aim of this phase of the research was to develop consensus guidance to
facilitate service redesign to involve PP in secondary care.
The objectives were:
 To use evidence generated through the focus groups to formulate
statements about service development involving PP in secondary care
 To develop a questionnaire incorporating these statements for ranking
using a Delphi technique
 To identify key stakeholders likely to be involved in a service redesign
involving PP in secondary care to form the expert panel for the Delphi
study
 To confirm or otherwise the evidence obtained through the focus groups
by seeking the opinion of an expert panel
 To formulate the consensus guidance to facilitate service redesign based
on the Delphi results
A consensus method was chosen in this context since the implementation of PP
in secondary care is an area of pharmacy practice where there is still little
evidence (see Chapter 1). This phase of the research also provided
triangulation as a quality assessment step where the evidence obtained from
the focus groups in the previous research was confirmed. Consensus methods
are useful where there is a lack of evidence-base and to support quality
assessment.(211) A Delphi method was chosen due to the advantages
described above mainly that it can be conducted electronically and within the
timescale provided without a need for the expert panel to meet.
Chapter 5 – Development of Consensus Guidance 213
5.3.2 Questionnaire development
This is summarised at Figure 6 below.
Figure 6: Development of questionnaire
Statements drawn up for each criterion
Literature and focus
group discussions
Quotes were identified to contextualise
the statements
Focus group
discussions
Drafts reviewed by members of
supervisory team
See Appendix 5.1
for examples
Liaise with school IT support officer for
electronic format and user testing
Included
academics and
pharmacist
prescribers
Draw up and define criteria which
contribute to role development and
facilitate service redesign
Literature,
discussion with
experts and focus
group discussions
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No published literature was identified on key factors and guidance facilitating a
service redesignxxi when a preliminary search was conducted in the pharmacy
database International Pharmacy Abstracts (IPA). However, relevant literature
was identified relating to nursing and midwifery professions. Discussions were
consequently held with local and national experts as follows: a consultant in
public health, the director of pharmaceutical care model schemes, the non-
medical prescribing lead in Grampian and a senior lecturer with extensive
expertise in nursing development. They highlighted key documents that were
subsequently adopted for use in this research. Through this literature, criteria
which may facilitate a service redesign were identified.(217) These fell into two
categories: service management which includes criteria aiming to encourage
the efficient provision of the health service being provided, and role specific
aiming to provide details of the educational and training support which needs
to be provided to promote role expansion, the work expected to be
undertaken, and the expected future orientation of the service. Each of the
categories was sub-divided into criteria derived mainly from the literature and
summarised in Table 21 below.(217) Other role development criteria were
identified in the literature such as those relating to involvement in research
activity and leadership qualities. However, evidence from the focus group
discussions indicated that the role of the pharmacist prescriber was still
developing and consequently these criteria were not relevant at present.
xxi This has been defined by NHS Scotland as “an approach to improve outcome and efficiency in
health” and is available at : http://www.clinicalgovernance.scot.nhs.uk/section2/redesign.asp
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Table 21: Criteria that may facilitate a service redesign involving pharmacist
prescribing in secondary care
Service Management Role Development
1. Succession Planning 1. Education
2. Inter-professional Working 2. Future orientation of service
3. Quality Evaluation
4. Practice Development
5. Outcome measures
To ensure consistency in understanding throughout this research, a definition
of each criterion derived mainly from the literature and a rationale for each
criterion derived mainly from the focus group results were drawn up. These are
as follows:
A. Service Management
1. Succession Planning
Definition: This means that there are managerial processes in place
within a health board to ensure that the role is not reliant on one person
alone and that a system of staff development, supervision and support is
in operation to enable others to take on the role.(217)
Rationale: Statements within this section aim to assist successful
planning, strategy development for pharmacist prescribing and
implementation of pharmacist prescribing making best use of the
resource available. They aim to highlight the importance of the planning
phase of the service redesign consequently making it possible to identify
areas where pharmacists may improve the quality of patient care by
utilising their prescribing skills following qualification.
2. Inter-professional Working
Definition: This means that the pharmacy role is part of a system of
integrated professional working which is inclusive in nature.(217)
Rationale: Statements within this section aim to act as a trigger to
ensure that other members of the multidisciplinary team likely to be
stakeholders in the process, are involved at each stage of the service
redesign. This is likely to assist the acceptance and uptake of pharmacist
prescribing both within the institution, and within a specific area of care.
This would also encourage the building of efficient multidisciplinary
teams.
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3. Quality Evaluation
Definition: This refers to the issues including quality assurance and
audit processes, risk management and clinical governance which are
used to evaluate the pharmacist prescribing service and ensure a safe
and effective running of the service.(217)
Rationale: Statements within this section aim to highlight the need to
analyse the implementation of a pharmacist prescribing service to
ensure that its introduction does not compromise patient safety and
quality of care. Any service redesign would need to take into account
guidance issued by the Royal Pharmaceutical Society of Great Britain
relating to this matter.(218,219)
4. Practice Development
Definition: This refers to the overall change in practice within
secondary care which may be expected to accompany a service redesign
which involves the establishment of pharmacist prescribing. (217)
Rationale: Statements within this section aim to act as a trigger to
consider how the development of the pharmacist prescribing role will fit
into current pharmacy service provision in secondary care. It may be
necessary to analyse, review and change some current practices to
ensure that these will not jeopardise the sustainability of a pharmacist
prescribing service.
5. Outcome Measures
Definition: This refers to the evidence of both positive and negative
consequences which are available to enable the professional merit of the
role to be assessed at two levels: direct patient care and effect on other
health professionals.(217)
Rationale: Statements within this section aim to act as a trigger to
consider what outcomes may be indicative of the consequences of
pharmacist prescribing. Outcomes must be valid, reliable and easily
measurable and need to relate to both the clinical effects and the actual
processes and procedures adapted. These may be of particular
importance since there is little evidence available describing the
outcomes of pharmacist prescribing.
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B. Role Development
1. Education
Definition: This refers to the individual continuing professional
development and the opportunities for continuing education provided for
prescribing trainees and following qualification as a pharmacist
prescriber.(217)
Rationale: Statements within this section aim to highlight the
importance of considering areas such as competencies and continuing
professional development for pharmacists who are prescribers. These
may be of particular importance with the advent of independent
prescribing, where a pharmacist may prescribe any licensed medication
(other than controlled drugs) for any undiagnosed condition. With
prescribing being a relatively newer task for pharmacists in secondary
care, it may be necessary to provide support both for prescribing
trainees and prescribing pharmacists, to ensure they are comfortable
within this expanded role.(220)
2. Future orientation of the service
Definition: This refers to the advisory or supportive role of the
pharmacist prescriber towards other healthcare professionals and
patients. It also includes the level of practice that might be regularly
expected from a specialist pharmacist prescriber and may include
expanding the boundaries of pharmacy practice, demonstrating
independent clinical decision making, carrying out systematic
assessment and intervention and portraying a sophisticated use of
clinical knowledge.(217)
Rationale: Statements within this section aim to project the likely
future development of the role of the pharmacist prescriber, possibly
moving from a “generalist” practitioner to a “specialist” practitioner.
Statements relevant to service redesign were constructed from thematic
analysis of the focus group discussions. The statements were then grouped
under the seven criteria above based on relevance. It was evident that some
areas were discussed during the focus groups in much greater detail than other
topics and consequently some sections are longer than others. To contextualize
statements, to provide evidence that the statements were derived from the
discussions and to offer a link between the statement and practice, an
illustrative quote was provided for each statement. More than one quote was
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initially identified for each statement and the quote in the final version of the
questionnaire was selected based on which was the most appropriate to reflect
the statement. Numerous drafts were produced and were reviewed by
members of the supervisory team. Drafts illustrating the development of the
questionnaire are available at Appendix 5.1. Members of the research team
reviewed drafts mainly in terms of:
 Clarity of definition and rationale for each criterion
 Appropriateness and clarity of statements ensuring that there were no
double-barrelled statements
 Relevance of statements to the specific criterion
 Appropriateness and choice of illustrative quotes provided
 Ease of use and comprehension for respondents.
A self-completed, electronic method of survey administration was chosen. Very
little literature was identified critically describing the strengths and weaknesses
of these methods of administration relating specifically to Delphi. The
discussion below therefore refers to administration of survey questionnaires.
Self-completed postal survey questionnaires offer a number of advantages
over face-to-face or telephone interviews:(221)
 Can cover a large geographical area – this was especially relevant here
since the expert panel was likely to cover the whole of Scotland (a
detailed description of selection of participants is provided later)
 Data may be collected from all respondents simultaneously. This allows
for same “context” and “history” since all questionnaires are received at
the same time
 Avoids interviewer bias
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There are also a number of disadvantages of self-completed postal
questionnaires:(221)
 Low response rates – these may be even more of an issue in this study
due to busy schedules of respondents. A discussion on methods adopted
to enhance response rates is found below in Section 5.3.5.
 Non-response bias where the characteristics of non-respondents may be
different to those of respondents. However, no information is available
on how non-response may bias results in a Delphi study. (211)
 May be an “inflexible” method since one cannot probe further as in an
interview. To try and overcome this, participants were provided with a
“comments” section to provide any additional statements or other
relevant issues they thought were omitted.
 No control over who completes the questionnaire.
Advantages of self-completed web based delivery compared to a postal
delivery include:
 Time and cost-savings with quicker response speeds reported (222,223)
 Allows more precise tracking (e.g. undeliverable email) (223)
 Convenient since it is completed at the participant’s leisure (222)
 Better response quality (e.g. longer answers to open-ended questions)
(223)
 Some evidence that a wider range of rating scales is used compared to
paper-and-pencil methods. (221)
Disadvantages include:
 Limited to respondents with web access which may bias towards areas
and individuals with higher income resulting in racial and ethnic groups
not represented.(222) This makes it difficult to obtain a sampling frame
that is truly representative of all the population.(223) This is unlikely to
be an issue in this study since all participants have e-mail and web
access through their place of work.
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 Security and data integrity – there may be concerns about
confidentiality that discourages participants.(222) Further details on
precautions adopted in this study are in Section 5.3.3 below.
 Technical troubles may produce different looking surveys from one
participant to another or prevent access to surveys altogether.(222)
Efforts were made to overcome these difficulties through prior user-
testing of questionnaires.
 Variation in user-capability though again this was not likely to be an
issue here.(223)
 Respondents submitting multiple questionnaires.(221) Liaison with the
school IT facilitator indicated that there was no way of ensuring that
participants submit the completed questionnaire no more than once. It
was not possible to determine whether this did occur in this research
since all questionnaires were completely anonymous.
The questionnaire was developed to enable electronic delivery following close
liaison with the School E-learning support officer. Participants were asked to
rank each statement provided on a five point scale: Strongly Agree, Agree,
Undecided, Disagree and Strongly Disagree. The literature recommends using
no more than five points when adopting rating scales.(221) There has also
been some debate as to whether a “don’t know” category should be included
as a response option; some respondents may select this option without
thinking about other options but respondents may omit or guess questions if
this option is not available. McColl et al consequently recommend including
this.(221)
The questionnaire was then user-tested and sent to individuals who were not
likely to be part of the final cohort as follows: one academic with experience in
questionnaire development and use of Delphi, one academic also closely
involved in policy, one independent pharmacist prescriber and one pharmacist
prescriber also involved in medicines management. They were all sent the
following email:
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Dear all,
I am wondering whether it would be at all possible to help me out with user testing of
my questionnaire. This may be accessed using the link provided below. This is intended
to be a Delphi study where participants will be asked to indicate agreement or
disagreement with given statements which I have derived from previous focus group
discussions. I would be interested in knowing how long it takes to fill in and ease of
use. I have tried to select people who are involved in prescribing/teaching, involved in
strategy development or who have previously conducted Delphi studies.
All agreed to review the questionnaire. They reported taking 10-20 minutes to
complete and submit the questionnaire. A recurring comment was that the
participants felt that they should agree with all statements, increasing the
probability of acquiescence response bias. As a result of this comment, the
statements were reviewed and some statements rewritten to have more of a
negative meaning to them. [Appendix 5.1 - Questionnaire after user-testing,
(changes and comments are in blue)] However, on further discussion and
analysis, the original statements were retained, mainly since the revised ones
were not derived from the focus group discussions and consequently, did not
appear to be grounded in the data. Besides, McColl et al (221) conclude that
there is conflicting evidence as to what influence positively or negatively
worded questions have on response bias. They therefore recommend caution if
adding negatively phrased attitudinal items. Other recommended changes
were minor. These included changes to some statements and instructions and
giving the participants an option at the end to add on any statements if
necessary. The final questionnaire for round 1 is available at Appendix 5.2. The
following is an example of screen-shots from the final electronic questionnaire.
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5.3.3 Research Governance
The research proposal and the final questionnaire were reviewed by the School
of Pharmacy and Life Sciences, Robert Gordon University ethics committee in
July 2008. Following this, the proposal was submitted for review to the North
East of Scotland Research Ethics Committee in September 2008 with all
documentation submitted at Appendix 5.3. Approval was granted in October
2008, following a number of minor amendments (all correspondence and
reviewed documents at Appendix 5.4). The initial proposal indicated conducting
interviews with members of the Scottish Government aiming to determine
whether the consensus guidance produced by this research was in line with the
Scottish Government policy. However, as the research progressed, it was
evident that the research had moved beyond this, and therefore the interviews
were unlikely to add any further new information.
Since NHS staff were involved in completing the questionnaires, it was also
necessary to obtain Research and Development approval from all 14 NHS
health boards. Approvals were granted between December 2008 and January
2009 for 12 health boards, and these were included in this study. Approval for
the remaining two health boards was granted in March 2009 (the study was in
progress then) and June 2009 (the study was completed) and these were
therefore not included.
To protect the participants’ anonymity and to ensure that participants were
unaware of who else was invited to complete the questionnaire, the invitation
to participate was sent through the “Blind Carbon Copy” (bcc) facility in e-mail.
The same process was used in all further correspondence such as when
sending out the questionnaire web-link and reminders. All signed consent
forms were stored in a password protected laptop and no hard copies were
made. Throughout the process, respondent anonymity has been maintained
such that it was not possible to trace back questionnaire responses to any of
the respondents. All e-mail correspondence was done through the university e-
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mail account to ensure protection by the university firewall. E-mail addresses
of all respondents were destroyed upon completion of the research.
5.3.4 Process used to achieve consensus
Choice of expert panel
Selection of the expert panel forms an integral part of a sound methodology
involving Delphi.(215) There is agreement in the literature that the input of a
number of experts will enable more in-depth information to be provided than
that obtained from one individual.(208) However, there is a paucity of
guidance defining the criteria to be fulfilled by an “expert”, identification and
the likely number required. Fink et al provide some guidance on choosing an
expert panel as follows:
“Consensus participants should qualify for selection because they are
representative of their profession, have power to implement the findings, or
because they are not likely to be challenged as experts in their field.” (212)
There have been wide variations in panels reported in the literature with the
number of participants ranging from 4 to 3000.(211) It has been suggested
that the larger the sample, the greater the reliability of the research, but there
is no evidence that a larger sample will have any effect on reliability and
validity.(213) Hasson et al comment that participants who are knowledgeable
and interested in the topic are likely to increase content validity.(209) In their
discussion on “Consensus methods in prescribing research,” Campbell et al
recommend that an appropriate consensus method should include an expert
panel that reflects the stakeholders it is trying to represent and importantly
takes into account the research objectives of the study.(211) In view of this
recommendation by Campbell et al, key stakeholders likely to be involved in a
service redesign involving PP in secondary care were invited to form the final
expert panel. The choice was informed by evidence from the focus group
discussions (Chapter 3), the scoping exercise (Chapter 4) and discussion within
Chapter 5 – Development of Consensus Guidance 228
the research team. Both strategic and practising professionals formed part of
the final expert panel.
The key stakeholders in Scotland and potential participants as an expert panel
in this research were identified as follows:
a) Scottish Directors of Pharmacy were included since the background
scoping exercise indicated that it was likely they would be closely
involved in a service redesign from a strategic point of view.
b) Acute health board pharmacy directors [this post was not available for
all Scottish Health Boards] included as above. They were likely to be
more knowledgeable on secondary care issues, the area that the
research was focusing on.
c) Pharmacists who were authors of Scottish prescribing frameworks due to
their potential strategic role in local developments.
d) Secondary care practising pharmacists prescribing or on a prescribing
course – two pharmacists from each health board were included if
available and agreed to participate; pharmacists who had participated in
the initial focus group discussions were not included since their opinion
had already been considered to draw up this document.
e) Non-medical prescribing leads who were not pharmacists but direct
authors of frameworks and policies. These were included since it was
evident from the background scoping exercise that in most health
boards, the approach taken was to have a general non-medical
prescribing policy drawn up by pharmacy and nursing.
f) Chairmen of Area Drugs and Therapeutic Committees (ADTC). These
were included since non-medical prescribing policies are reviewed by
ADTC.
The following were excluded:
i) Pharmacists who were non-medical prescribing leads in their health
boards since all those identified were primary care rather than
secondary care practitioners which is the focus of this research.
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ii) Independent prescribers who had mentored pharmacists as
designated medical practitioners during their prescribing course. The
research team felt that the study was unlikely to be of direct
relevance to them and they were unlikely to be aware of the
practitioner’s perspective of the topic under investigation.
iii) Clinical pharmacy managers since following user-testing it became
apparent that it would be difficult to define and validate this role.
Consequently it was likely that the role would vary across health
boards.
Stakeholders in groups a, c and e above had already been identified in the
background scoping exercise and their e-mail addresses were available in the
public domain. Contact details for other stakeholders were identified using the
following procedure: an e-mail was sent out to all Directors of Pharmacy in
Scotland. If willing, they were asked to forward an invitation letter attached to
the e-mail to their respective health board chairmen ADTC, and pharmacists
who are prescribing or on a prescribing course. Those willing to be potentially
selected for participation to form part of a purposive sample (of strategic or
practicing professionals with involvement in pharmacist or non-medical
prescribing) made direct contact with the researcher. This ensured that contact
details were available only for those willing to participate. The recruitment
process is summarised as follows:
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Data collection and analysis
During February 2009, an e-mail was sent out to all individuals who had
indicated that they were willing to be contacted to take part in the Delphi study
(n=76). This e-mail included an invitation to participate, an information sheet
together with a consent form (Appendix 5.4). Participants consenting were
asked to return this form by e-mail.
In late February 2009, round 1 of the study was initiated when a web-link to
the questionnaire was sent out to all consenting (n=40). Participants were
encouraged to contact the research team if there were any technical difficulties
with accessing and completing the questionnaire. Should they prefer,
participants were given the option to ask for a paper copy of the questionnaire
Initial e-mail to all Directors of
Pharmacy in Scotland with invitation
letter
If willing
Forward invitation letter to potential
participants i.e.
a) Chairman ADTC
b) Pharmacists who are prescribing or
on prescribing course
If positive response obtained
Selected participants will be forwarded
electronically
a) Participant information leaflet
b) Consent form
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(in actual fact, none of the participants opted for this). To enhance response
rates, a reminder was sent out after seven days. Since the questionnaire was
completed anonymously, the reminder was sent to all individuals who were
sent out the initial e-mail. No literature was identified on enhancing response
rates to Delphi questionnaires, though a maximum of three rounds is
recommended since it is likely that response rates will start to fall due to
participant fatigue.(213) Participant follow up has been reported to produce an
increase in response rate to e-mail surveys though it is not clear how many
follow ups produce the optimal response rate.(223) No evidence on increasing
response rate specifically in Delphi questionnaires was identified in the
literature.
Following completion of round one, data was analysed for achievement of
consensus. Consensus was defined as 70% agreement (ranked strongly agree
or agree on Likert scale provided) with each statement. Since there was no
literature identified on the topic, a consensus value of 70% agreement was
thought to be a realistic target. Based on results of round one, a revised
questionnaire (see Appendix 5.5) was sent to the participants for ranking of six
statements – four statements were from the previous questionnaire and where
no consensus had been achieved, two statements were new and based on
comments made by the participants. Participants were also provided with the
group response for the original statements together with comments provided
for each. This was in line with the iterative process which is part of the Delphi
method.(211) The same process of dissemination of the questionnaire used in
round 1 was used in round 2 and this was completed in April 2009.
5.3.5 Characteristics of a good Delphi and application to this research
There has been much debate in the literature about the reliability and validity
of Delphi, with some recommendations that criteria for qualitative methods
may be more suited than those for quantitative methods.(209,211) There is
agreement that a sound methodology with a robust “decision trail” enhances
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the credibility, reliability and validity of Delphi research, with characteristics of
good Delphi methods identified.(213) This section will aim to describe these
and their application to this research.
 Selection of experts
A detailed description of this can be found at section 5.3.4 highlighting the
appropriateness of each participant.
 Consensus
There is no agreement in the literature as to what consensus is and Crisp et
al comment that this is “one of the most contentious components of the
method.” (208) To enhance validity and reliability, a definition of consensus
must be provided prior to starting the study; for example “statement is
supported by at least X% of participants for consensus to be achieved.”
(211,212) This will ensure that results are not open to an uninformed and
random judgement.(213) For the purpose of this research, consensus was
defined as at least 70% agreement with each statement and was
established at the protocol phase of the study.
 Feedback
When providing feedback as part of the iterative process, ratings of the
individual group members should be kept anonymous and democratic in
that ratings from all members of the group must carry equal weighting. It is
also recommended that where possible feedback should include both
quantitative statistics and qualitative comments if any have been
made.(211) Both these were provided anonymously and democratically as
part of round 2 (see Appendix 5.5). Campbell et al suggest that there may
be differences in results if providing “collective” (feedback from the entire
expert panel) or “selective” feedback (feedback from only the relevant
professional group).(211) There is not much evidence in the literature on
how this may affect selection bias of the same statement; in view of this,
collective feedback was provided in this research.
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 Response rates
Reminders and relevance of the topics to the panellists is likely to increase
response rates. However, nothing is known about how rates will bias results
in Delphi.(211) A response rate of 70% has been suggested for each round
to maintain the rigour of the method.(209)
 Specificity
As recommended by Fink et al every effort was made to ensure that
statements provided for ranking were clear and specific.(212)
 Iteration
The number of rounds that will be conducted should be specified
beforehand.(211) Two or three rounds are usually recommended, with
successive rounds helping to increase concurrent validity.(209) It was
originally planned to have a maximum of three rounds in this study;
however it was apparent that consensus was achieved after two rounds and
the study was consequently stopped.
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5.4 Results
5.4.1 Round 1
The number of participants consenting to participate and to whom a
questionnaire was forwarded was 40 (a total of 76 were invited to participate).
Thirty-five questionnaires were completed giving a response rate of 87.5%.
The participants indicated the following roles within their health boards, with
some participants having multiple roles.
Director of Pharmacy 4
Acute health board director 3
Chairman ADTC 4
Non-pharmacist author of non-medical prescribing policies 5
Pharmacist author of non-medical prescribing policies 10
Pharmacist prescriber 15
As previously indicated, consensus was set at 70% and therefore 25
participants were required to strongly agree or agree with a statement for
consensus to be reached with that statement. The number of statements
where consensus was reached was 27 out of 30 (level of agreement 70%-
100%) while the number of statements where there was disagreement was 3
out of 30 (level of agreement 17% - 66%). A detailed breakdown of the results
obtained together with any comments given for each statement is provided
below.
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A.Service Management
1. Succession Planning
A. It is important to undertake a systematic and objective assessment
of pharmaceutical needs in order to identify gaps in the current service
delivery and patient care.
Strongly agree Agree Undecided Disagree Strongly disagree
17 17 1 0 0
Consensus reached (97% of 35)
B. It is important to outline ways in which pharmacist prescribing may
improve patient care or encourage better utilisation of staff skills and
resources.
Strongly agree Agree Undecided Disagree Strongly disagree
16 19 0 0 0
Consensus reached (100%)
C. It is important to have a strategyxxii in place within the health board
that is based on available national guidance and that would establish
how pharmacist prescribing is to be implemented.
Strongly agree Agree Undecided Disagree Strongly disagree
16 17 2 0 0
Consensus reached (94%)
Comments
Use of the word strategy requires to be defined as appears to have been applied at a
lower level than would normally be the case. (Director of Pharmacy)
D. Ensure that any strategy in place may be applicable across different
practice settings and areas of care. This implies that the service is
generic and transferable.
Strongly agree Agree Undecided Disagree Strongly disagree
7 20 3 5 0
Consensus reached (77%)
xxii A detailed plan or scheme outlining the administrative and procedural structure
relating to pharmacist prescribing and that ensures that practice is compatible with any
relevant local or national standards or policies.
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Comments
The service is not generic and transferable – it is different in different clinical areas,
particularly paediatrics/neonates. (Pharmacist prescriber)
E. Consider the benefits and limitations of both pharmacist
supplementary and independent prescribing and determine which
would be best suited to deliver the service in different areas of care.
Strongly agree Agree Undecided Disagree Strongly disagree
11 19 2 3 0
Consensus reached (86%)
F. Involve pharmacists likely to be prescribing in discussions at the
planning phase to ensure that they have both sufficient background
information to prescribing prior to embarking on their course, and
sufficient knowledge as to where prescribing will be implemented in
their speciality.
Strongly agree Agree Undecided Disagree Strongly disagree
13 19 2 1 0
Consensus reached (91%)
Comment
Comprises two questions which have different answers. Pharmacists who line manage
potential prescribers need to be involved at the planning stage. These managers need
to ensure that all potential prescribers have an understanding of the plans. (Director of
Pharmacy)
G. Consider in which practice settings it may be more feasible to
introduce, implement and monitor pharmacist prescribing.
Strongly agree Agree Undecided Disagree Strongly disagree
15 19 1 0 0
Consensus reached (97%)
H. Consider procedures that would allow the smooth and safe
transition of patients from secondary to primary care if pharmacists
are an additional prescriber.
Strongly agree Agree Undecided Disagree Strongly disagree
13 19 2 1 0
Consensus reached (91%)
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Comment
Should not make any difference. [Non prescribing] pharmacist should be seeing these
patients anyway and should ensure smooth transition. In practice that non prescriber
becomes the prescriber so there is no change in this part of the care process.
(Pharmacist prescriber)
Other general comments provided for Section 1
The practicalities of service provision in different practice settings can be
pronounced. Hence clinical governance strategy must be tailored to particular
settings. (Pharmacist author of non-medical prescribing policy)
Must consider the governance aspects too of the prescriber potentially being the only
pharmacist. So who clinically checks their prescription? (Pharmacist author of non-
medical prescribing policy)
Essential to determine service need and strategy to address service need. Consider
redesign where pharmacist prescribing might replace other disciplines prescribing
practice in order to improve access to therapy, or improve quality of prescribing. Also
need to consider resource issues and make sure that the prescribing pharmacist is free
from other duties which might compete for the time available to prescribe. (Acute
health board director)
Specialist services in which prescribing is suitable in secondary care may not be a
viable option to transfer to primary care. (Pharmacist prescriber)
There are no questions which focus on identifying how many staff should be competent
to prescribe within a particular setting. This is a vital consideration for sustainability.
(Acute health board director)
2. Inter-professional working
A. Involve all key members of the multidisciplinary team who are
stakeholders when planning the strategy for pharmacist prescribing.
Strongly agree Agree Undecided Disagree Strongly disagree
19 15 1 0 0
Consensus reached (97%)
B. Determine how likely it is for other key members of the team to
accept pharmacists as prescribers.
Strongly agree Agree Undecided Disagree Strongly disagree
10 21 1 3 0
Consensus reached (89%)
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Comments
Agree, to smooth the implementation by identifying areas of concern of the
multidisciplinary team. However the standpoint must be thrust forward that this is
national policy and that it is going to happen no matter whether individuals agree or
not. Pharmacy has to take this forward with confidence. (Pharmacist prescriber)
As well as the prescribing team, we should consider if this will be acceptable for
patients- especially if clinical examination skills are required. (Non-pharmacist author
of non-medical prescribing policies)
C. Promote a good understanding of the pharmacist prescriber’s role
with other members of the multidisciplinary team.
Strongly agree Agree Undecided Disagree Strongly disagree
24 11 0 0 0
Consensus reached (100%)
D. Promote clearly defined roles relating to pharmacist prescribing
within the multidisciplinary team.
Strongly agree Agree Undecided Disagree Strongly disagree
20 13 1 1 0
Consensus reached (94%)
E. Promote clearly defined lines of communication relating to
pharmacist prescribing within the multidisciplinary team.
Strongly agree Agree Undecided Disagree Strongly disagree
17 17 1 0 0
Consensus reached (97%)
F. Encourage the development of non-medical prescribing
multidisciplinary teams.
Strongly agree Agree Undecided Disagree Strongly disagree
6 17 6 4 2
Consensus not reached (66% agree)
Comments
Suggest that question is wrongly worded – should say “Encourage participation of Non
Medical Prescribers within multidisciplinary teams” – would then strongly agree.
(Director of Pharmacy)
A multidisciplinary team is just that – multi disciplinary. There is no point creating a
separate non-medical prescribing multidisciplinary team because it should be routine,
not something outside the norm. (Pharmacist prescriber)
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Non-medical prescribing should be based around a central multidisciplinary team, each
member contributing. Extra teams would dilute, diffuse and potentially confuse lines of
communication and I consider them unnecessary. (Pharmacist prescriber)
Not sure that the question is clear. Would there not be medical prescribers involved in
the team too? (Pharmacist prescriber)
I agree with developing multidisciplinary teams of prescribers of all disciplines but I do
not agree that we should exclude medical prescribers from these teams. (Acute health
board director)
F would be dangerous as it appears to promote establishing a team to rival medical
prescribers. We must work with medics and develop consistent approaches and
standards. (Acute health board director)
I am not sure if question f reflects the quote. I think that pharmacist meant all
prescribers in multidisciplinary teams not just non medical prescribers. (Pharmacist
prescriber)
Felt that ALL prescribing should be integrated within one team for the appropriate area
and distinguishing between non medical and medical does not help. (Pharmacist author
of non-medical prescribing policy)
Other general comments provided for Section 2
This should be for local strategy, but not the multidisciplinary strategy for
implementation of pharmacy and non medical prescribing in general. (Non-pharmacist
author of non-medical prescribing policy)
As prescribing in this context is novel it is not helpful to put too rigid a framework on it
as this may stifle innovation. (Pharmacist prescriber)
Yes do all this but be prepared to be flexible in the light of experience. (Pharmacist
author of non-medical prescribing policy)
A to E seem self evident and I cannot understand why anyone would not agree
strongly. (Acute health board director)
This may come later but it is my impression that there is a significant capacity issue in
pharmacy for prescribing roles. That is why clinical nurse specialists in my hospital
have been able to apply the non-medical prescribing model much more effectively than
pharmacy. (Pharmacist prescriber)
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3. Quality Evaluation
A. Establish that systems are in place (and are defined, documented
and regularly reviewed) to promote patient safety and encourage
quality patient care when pharmacists are prescribing, which have
taken into account the “Clinical Governance Framework for Pharmacist
Prescribers and Organisations Commissioning or Participating in
Pharmacist Prescribing” and any other local governance structures or
strategies. (218)
Strongly agree Agree Undecided Disagree Strongly disagree
22 12 1 0 0
Consensus reached (97%)
B. Ensure that legal responsibilities and accountabilities are defined
and documented within the strategy and have taken into account the
“Professional Standards and Guidance for Pharmacist Prescribers”
which are part of the Pharmacist Code of Ethics.(219)
Consensus reached (91%)
Strongly agree Agree Undecided Disagree Strongly disagree
23 9 2 0 1
Comments
At my independent prescribing course I was quite alarmed by the (over) confidence
that some colleagues showed towards initiating prescribing in areas where they had no
competence eg respiratory pharmacist in GP practice considering prescribing
antidepressants! (Pharmacist prescriber)
Current methods for prescribing for in-patients in secondary care (non electronic)
mean that it is difficult to identify and quantify non medical prescribing input. This
should be given consideration, with recommendations until electronic prescribing
(HEPMA) is common place. (Non-pharmacist author of non-medical prescribing policy)
4. Practice Development
A. Consider any changes in current pharmacy service provision in
secondary care that may be needed to support the development of a
pharmacist prescribing service.
Strongly agree Agree Undecided Disagree Strongly disagree
14 20 0 0 1
Consensus reached (97%)
Comment
The initial evaluation must take into account the effectiveness of existing services as a
pharmacist prescribing service may have to be introduced on a cost neutral basis and
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may be in competition with these existing services. Obviously resource may be sourced
from the discipline to which the prescribing benefits. (Pharmacist prescriber)
B. Consider any additional resource/s that may be needed to ensure
provision and sustainability of a pharmacist prescribing service.
Strongly agree Agree Undecided Disagree Strongly disagree
19 15 1 0 0
Consensus reached (97%)
Comment
It may not be about additional resource but reconfiguration of existing resource.
(Director of Pharmacy, Chairman ADTC, Pharmacist author of non-medical prescribing
policy)
Review of skill mix within departments and on wards will be vital. (Pharmacist author
non-medical prescribing policy)
General comments for Section 4
Consider pharmacist prescribing only if warranted by a service – add value.
(Pharmacist author non-medical prescribing policy)
Pharmacist prescribing on wards should be as part of a multidisciplinary team of
prescribers doctors, nurses and pharmacists working within a care pathway any of
whom can assume the responsibility for prescribing for the patient at that point in the
pathway assuming they are competent to do so in that particular patients’
circumstances. (Acute health board director)
Half a service is worse than no service. With no service other healthcare professionals
make no assumptions of what might have been done. (Pharmacist prescriber)
Opportunities for pharmacist prescribing exist for out-patients and managing case
loads of patients in that setting. For example Pharmacist led pain clinics,
cardiovascular risk clinics, chemotherapy capecitabine clinics etc. (Acute health board
director)
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5. Outcome measures
A. The strategy should include ways of assessing outcomes to measure
any positive or negative impact of the role on direct patient care.
Strongly agree Agree Undecided Disagree Strongly disagree
17 17 0 1 0
Consensus reached (97%)
B. The strategy should include ways of assessing outcomes to measure
any positive or negative impact of the role on other healthcare
professionals.
Strongly agree Agree Undecided Disagree Strongly disagree
12 16 5 2 0
Consensus reached (80%)
Comments:
Outcome measures need to be broad ranging. (Acute health board director)
This is something we did – presenting practice audit results at a national conference
and during workshops. Not everyone needs to do it though – it just needs sufficient
data available to show it is of benefit and others can use this to help develop similar
services. (Pharmacist prescriber)
The implementation of the service should be evaluated with reference to the impact on
both the patient and the service. (Pharmacist prescriber)
It is every professional’s responsibility to assess the outcomes of their practice on their
patients. If the objective of the pharmacist prescribing service was to free other
disciplines time for example then this should be assessed but not routinely or on an
ongoing basis. (Acute health board director)
Possibility of deskilling other prescribers, such as junior medics, should be considered.
(Pharmacist prescriber)
Perhaps this work needs to be done before a strategy is put in place? A clear
improvement in service to patients is essential. (Pharmacist prescriber)
To work well as a team we don’t want to de-motivate other team members if they feel
threatened by new roles so will need careful handling, but prime consideration must be
to enhance patient care through improved access to required medicines –otherwise not
meeting the objective of original ‘Crown‘ report. (Pharmacist author non-medical
prescribing policy)
As per comments above. The most tangible impact may be in relation to patient
discharge scripts. (Non-pharmacist author non-medical prescribing policy)
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B. Role Development
1. Education
A. Provide support for pharmacists during training or pharmacists who
are planning to train to be prescribers.
Strongly agree Agree Undecided Disagree Strongly disagree
20 13 2 0 0
Consensus reached (94%)
Comments
As an independent prescriber, I have had many visits from other non-medical
prescribers to see the clinic I work at in practice. (I have had a visit from a podiatrist
not just pharmacists which helps with the multidisciplinary element to the clinic). I
think this should be an essential part of the "time in practice" element of the course. I
would be more than willing to mentor pharmacists with their learning. (Pharmacist
prescriber)
There are good existing models for support, developed by Nursing and Midwifery
colleagues for mentor and CPD support, currently used in relation to NMP. Within NHS
Fife this is open to Pharmacist and AHP colleagues. (Non-pharmacist author non-
medical prescribing policy)
B. Provide clearly defined pharmacist competencies to help
pharmacists achieve and maintain competency when prescribing
(“Maintaining Competency in Prescribing” produced by the National
Prescribing Centre may be a good resource). (220)
Strongly agree Agree Undecided Disagree Strongly disagree
15 17 3 0 0
Consensus reached (91%)
Comment
How do you write competencies for all the individual nuances of levels of practice &
expertise? Impossible. (Pharmacist prescriber)
C. Clearly define the level and type of experience required to prescribe
in different specialties.
Strongly agree Agree Undecided Disagree Strongly disagree
14 14 4 3 0
Consensus reached (80%)
Comment
QC - competence should be the measure rather than experience. (Director of
Pharmacy)
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D. Provide the necessary opportunities for education and training
following qualification as a prescriber.
Strongly agree Agree Undecided Disagree Strongly disagree
18 16 1 0 0
Consensus reached (97%)
Comment
Whilst the employer has some responsibility to provide support for an individual’s PDP
the individual prescriber is primarily responsible for their own CPD. (Pharmacist author
non-medical prescribing policy)
E. Ensure that pharmacists are able to demonstrate competence on an
on-going basis to prescribe in their area of practice.
Strongly agree Agree Undecided Disagree Strongly disagree
18 15 2 0 0
Consensus reached (94%)
Comment
While providing education and training after qualifying, there should be a level of
competence in management of conditions prior to undertaking the course, so that once
qualified they are competent to prescribe and manage their patients. (Non-pharmacist
author non-medical prescribing policy)
F. Ensure that the preparation for the role has taken into consideration
the pharmacists’ individual views and attitudes.
Strongly agree Agree Undecided Disagree Strongly disagree
11 14 9 1 0
Consensus reached (70%)
Comments
Only so far as to help filter the most appropriate individuals for the role and not to
influence the specification and nature of the role itself. (Pharmacist prescriber).
QF - require to be committed and competent. (Director of Pharmacy).
G. Provide the necessary mentoring scheme to pharmacists who are
prescribing.
Strongly agree Agree Undecided Disagree Strongly disagree
16 18 0 1 0
Consensus reached (97%)
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Comments
Lack of pharmacists currently prescribing may mean mentor has to be from another
profession. (Pharmacist prescriber)
Clinical supervision would be essential to support pharmacists particularly in the early
days of establishing this new role. (Pharmacist prescriber)
General comments
There is a bit of an "art" to prescribing which requires the prescriber to bring together
their knowledge and experience to make a professional prescribing judgement. I am
not convinced that we can define a set of competencies which can fully describe what
goes in to making that professional judgement. I don't think we have enough evidence
or experience of pharmacist prescribing to be able to define the level and type of
experiences required before authorising prescribing. The prescribing pharmacist needs
to make a judgment whether they are competent to undertake the prescribing decision
for their patient. In this kind of scenario a multidisciplinary peer group and a mentor is
essential. (Acute health board director)
May be difficult to be totally prescriptive here and do we do this for medical prescribers
so again need care in what we aim to achieve. (Pharmacist author of non-medical
prescribing policy)
2. Future orientation of service
A. Encourage all hospital pharmacists to prescribe in any specialty.
Strongly agree Agree Undecided Disagree Strongly disagree
2 4 14 12 3
Consensus not reached (17% agree; 43% disagree)
Comments
My indecision over ALL hospital pharmacists prescribing is due to (a) new entrants to
hospital pharmacy from other sectors and (b) newly qualified pharmacists who will
need mentoring before taking on this role. (Acute health board director, Pharmacist
prescriber, Pharmacist author non-medical prescribing policy)
QA. Would require to be implemented in a planned and phased basis. (Director of
Pharmacy)
QA. This is the final step in a process that pharmacists already initiate or participate in.
Inherent in becoming and maintaining prescriber status is considerable CPD. Becoming
a prescriber is a major pathway or opportunity in linking pharmacy even further with
the patient journey, becoming a more useful valued member of the multidisciplinary
team which improves the skill mix which in turn promotes appropriate use of staff
resource. (Pharmacist prescriber)
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QA. Pharmacist training should allow them to prescribe. Given that the value of a
professional in the NHS is valued by their knowledge skills and experience by and large
I think pharmacists at a senior level are adequately remunerated to prescribe. (Acute
health board director)
Pharmacist prescribing is not suitable for all areas of patient care. There are areas that
are ideal, e.g. intensive care and clinics. In other words specialist areas. (Pharmacist
prescriber)
I do not think it is something we should force upon pharmacists. Prescribers should
want to prescribe, but I feel it opens up many doors and enhances their role within the
multidisciplinary teams. It is part of my practice that I enjoy and get a great deal of
job satisfaction with. (Pharmacist prescriber)
Clinical pharmacy involves giving prescribing advice to prescribers (doctors). I
consider pharmacist prescribing to be only a small step further since already the
responsibility has been there but not 'signed for' directly. (Pharmacist prescriber)
In my view pharmacists should only prescribe when a suitable service model exists and
they have sufficient post registration training. A lot of our prescribing problems arise
because most junior doctors learn prescribing on the job. (Pharmacist prescriber,
Pharmacist author non-medical prescribing policy)
Prescribing is the future for all hospital pharmacist practitioners. There will be a period
pre and post registration where prescribing should be strictly supervised but following
a foundation training period all hospital pharmacists who have direct to patient
pharmaceutical care responsibilities should prescribe. (Acute health board director)
Prescribing should be limited to defined specialties with the appropriate pharmacists in
post as your previous questions have indicated. It is not appropriate for all hospital
pharmacists as a specialist knowledge within a specific area must be achieved before
prescribing can be undertaken. The pharmacist must also have the confidence of and
support from the multidisciplinary team they work with. (Pharmacist prescriber)
By saying all hosp pharmacists should prescribe this moves away from assessment of
need-it really does often depend on local circumstances .(Pharmacist author non-
medical prescribing policy)
B. Encourage the development of prescribing specialist roles.
Strongly agree Agree Undecided Disagree Strongly disagree
9 19 4 3 0
Consensus reached (80%)
C. Ensure that pharmacist prescribers are financially compensated in
line with their added responsibilities.
Strongly agree Agree Undecided Disagree Strongly disagree
9 12 10 4 0
Consensus not reached (60% agree; 11% disagree)
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Comments
It is not legal or ethical to pay someone to prescribe. Pharmacists should see it as part
of their expanded patient care role. (Pharmacist prescriber)
QC. Agenda for Change (AFC) should allow for this but in reality may actually not as
AFC tends to reward managerial aspects (of which prescribers have some) and not
clinical expertise aspects of job roles. In addition, the organisation should pay for the
cost of the extra indemnity insurance that is required by pharmacist prescribers.
(Pharmacist prescriber)
In terms of financial remuneration - absolutely agree as at this level you are a clinician
who happens to be a pharmacist rather than a pharmacist who prescribes. (Pharmacist
prescriber)
At least enough to compensate for the extra costs of registering as a prescriber and
the indemnity insurance. (Pharmacist prescriber)
I have stated undecided for question c as I think we may not yet be at this stage.
(Director of Pharmacy, Pharmacist prescriber, Chairman ADTC)
Generally true that AFC band should be based on an up-to-date job description
defining responsibilities. Nothing special here about prescribing. It covers all areas.
(Pharmacist author non-medical prescribing policy)
Other Non-Medical prescribers, in particular nurses, are not financially compensated for
this responsibility. Prescribing should be based on patient need not rewards. (Non-
pharmacist author non-medical prescribing policy)
Question C is a loaded question. Of course pharmacists should be appropriately
remunerated but it does not necessarily follow that taking on prescribing roles
increases the overall responsibility of the post or that if they are additional
responsibilities they are higher level responsibilities to existing roles. Potentially a
change in role could reduce grading weight. (Acute health board director)
Financial reward and banding should not be based on any single role component. This
should be debated in a wider arena as this has not been the case for NMAHP
colleagues. (Non-pharmacist author non-medical prescribing policy)
Once prescribing the responsibilities need to be written into the prescribers job
description and adequate weight given to this in AFC bandings. (Pharmacist author
non-medical prescribing policy)
As long as this doesn't attract onto course purely for financial reasons. Would need
parity across professions to avoid conflict of some receiving pay and others not.
(Pharmacist author non-medical prescribing policy)
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5.4.2 Round 2
The development of the questionnaire for round 2 of the Delphi has been
described previously in the method section. Twenty-nine questionnaires were
completed giving a response rate of 72.5%. The participants indicated the
following roles within their health boards, with some participants having
multiple roles.
Director of Pharmacy 3
Acute health board director 2
Chairman ADTC 2
Non-pharmacist author of non-medical prescribing policies 5
Pharmacist author of non-medical prescribing policies 9
Pharmacist prescriber 11
As previously indicated, consensus was set at 70% and therefore 20
participants were required to strongly agree or agree with a statement for
consensus to be reached with that statement. The number of statements
where consensus was reached was 3 out of 6 (level of agreement 76 - 90%)
while the number of statements where there was disagreement was 3 out of 6
(level of agreement 21 – 55%). A detailed breakdown of the results obtained
together with any comments given for each statement is provided below.
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1a. Encourage the development of non-medical prescribing
multidisciplinary teams.
Strongly agree Agree Undecided Disagree Strongly disagree
1 14 6 4 4
Consensus not reached (52% in agreement)
Comments
Question should read - encourage non medical prescribing within multiprofessional
teams (as opposed to multidisciplinary - discipline could be geriatrics, anaesthetics
etc). Because question requires to be reworded I have ticked undecided. (Director of
pharmacy)
I thought that the statement was concerning one MDT including NMP and medical
prescribers. Would not support a separate team of non-medical prescribers.
(Pharmacist prescriber, Non-pharmacy author non-medical prescribing policy)
Agree with some of the previous comments that the question is ambiguous and the
important ingredients are a multidisciplinary team and appropriate prescriber - either
medical or non-medical. (Pharmacist prescriber)
Would agree with the comment that non medical prescribers should be encouraged to
participate in existing multidisciplinary teams not to try and establish new teams.
(Pharmacist author non-medical prescribing policy)
I agree with the broad statement to encourage the development of non-medical
prescribing multidisciplinary teams, but only where there is a clinical need and only
where there is access to a shared medical record. All practitioners, involved in patient
care, do not need to have the ability to prescribe for their patient. (Non-pharmacist
author non-medical prescribing policy)
There is still some ambiguity to the question as the previous statements have shown,
however I take the question to mean; should non medical prescribing be developed
within multidisciplinary teams, as opposed to specific non medical MDTs being
developed that would work independently of the medical profession. As long as it is the
first of these two interpretations I agree, however if it is the second interpretation I
feel that the purpose of the team and it's responsibilities would have to undergo
careful consideration before being developed. (Non-pharmacist author non-medical
prescribing policy)
Although this should not be done in "competition" with medical prescribing
multidisciplinary teams. (Pharmacist prescriber)
I agree with comments that we should not be creating a barrier by excluding medical
prescribers. (Non-pharmacist author non-medical prescribing policy)
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1b. Statement developed from first round:
Encourage participation of pharmacist prescribers within
multidisciplinary prescribing teams.
Strongly agree Agree Undecided Disagree Strongly disagree
16 10 2 0 1
Consensus has been reached (90%)
Comments
We have to be careful to ensure the role of the Pharmacist remains distinct and does
not creep into a role where we take over work from other disciplines because of
convenience. We must look to where we can add value. (Pharmacist non-medical
prescribing policy)
I agree, but feel where I am based that we already have multidisciplinary prescribing
teams and CPD, but do feel that everyone has a role within the team, not just
pharmacists and therefore all prescribers should be encouraged to participate. (Non-
pharmacist non-medical prescribing policy)
2. Encourage all hospital pharmacists to prescribe in any specialty.
Strongly agree Agree Undecided Disagree Strongly disagree
1 5 6 15 2
Consensus not reached (21% agree)
Comments
With the current number of posts and graduates in Scotland there are a finite number
of services where pharmacists can provide a sustainable stand alone service. It is more
likely prescribing roles will only be limited to certain specialties. We must look for
sustainable developments and cherry pick where we can make a difference.
(Pharmacist author non-medical prescribing policy)
There are areas of hospital pharmacy where pharmacists may be working and
prescribing may not be an essential part of his/her job. Similarly there may be some
specialties where prescribing may not be suited to non-medical practitioners.
(Pharmacist prescriber)
Agree with statements regarding newly qualified pharmacists, therefore needs to be
time given for pharmacists to gain sufficient experience and confidence before
prescribing. NMP's should be limited to prescribing within their area of expertise or
retraining applied when changing specialty. (Pharmacist author non-medical
prescribing policy)
I disagree, all hospital pharmacists do not need to prescribe in any specialty,
prescribing must be based only where there is a clinical need. All pharmacists, involved
in patient care, do not need to have the ability to prescribe for their patient. (Non-
pharmacist author non-medical prescribing policy)
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I think this could be the case but way in the future. (Pharmacist prescriber)
Pharmacy is made up of a lot of specialties e.g aseptic, QA etc. Every bit as valid as
clinical and prescribing services. Horses for courses. (Pharmacist author non-medical
prescribing policy)
I have to continue to strongly disagree with this statement as the inclusion of 'any
specialty' does not take account of each individual prescribers area of competence and
confidence and would lead to undue pressures on pharmacists to prescribe within
specialities that they may not be comfortable with. (Non-pharmacist author non-
medical prescribing policy)
I agree with above statements that workforce planning and post requirements should
be considered pre accessing and attaining prescribing qualification, it may not be
necessary to have a qualification and there is no point in taking on this role if it is not
going to be utilised. (Non-pharmacist author non-medical prescribing policy)
3. Ensure that pharmacist prescribers are financially compensated in
line with their added responsibilities.
Strongly agree Agree Undecided Disagree Strongly disagree
2 14 2 10 0
Consensus not reached (55% agree)
Comments
There is an assumption here that carrying out a prescribing role increases
responsibility but this may not necessarily always be the case. The post has to be
considered as a whole. (Pharmacist author non-medical prescribing policy)
AFC banding should reflect this additional responsibility, but should be assigned to
posts if appropriate for improving patient care, and not to enhance the pharmacist's
banding. (Pharmacist prescriber)
Probably agree with some of statements above that we shouldn't be making it cost
anyone to take on the prescribing role as it will be beneficial to service. Therefore the
costs of additional indemnity and registration should be met by the service. This
doesn't necessarily mean an increase in pay but job descriptions should be amended to
take into account this responsibility and assessed by AFC panels for regrading if
appropriate. (Pharmacist author non-medical prescribing policy)
In so far as costs for registering and indemnity insurance. (Pharmacist prescriber)
Again I agree that the cost of added insurance and registering should be covered.
(Pharmacist prescriber)
Generally true that AFC band should be based on an up-to-date job description
defining responsibilities. Nothing special here about prescribing. It covers all areas.
(Pharmacist author non-medical prescribing policy)
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The current reality with regards to remuneration is that pay is decided under Afc
conditions, under these rules prescribing is a skill which will only effect a change in
banding if there are other changes to a role which increase the responsibilities of that
individual. It is not a clear cut question, and has been the subject of much debate at
NMP conferences since independent/supplementary prescribing began. (Non-
pharmacist author non-medical prescribing policy)
It is a shame this question was not reworded as it is ambiguous. This is actually a no-
brainer. Of course pharmacists should be paid appropriately for what they do but you
cannot assume that prescribing responsibilities should be remunerated more than
others. I have interpreted this as agreeing with the statement but it could equally be
undecided or disagree. The question is flawed because it presumes that prescribing
responsibilities are both additional and of higher banding weight than other
responsibilities. (Acute health board director)
Agenda for Change should allow an increased remuneration for prescribers over non-
prescribers. (Pharmacist prescriber)
Other Non-Medical Prescribers are not financially compensated for this responsibility.
Prescribing should be based on patient need not rewards. Pay should be based on up
to date job descriptions. (Pharmacist author non-medical prescribing policy)
I agree that all prescribers should be fairly remunerated for role. (Non-pharmacist
author non-medical prescribing policy)
4a. Ensure that the preparation for the role has taken into
consideration the pharmacist’s individual views and attitudes.
Strongly agree Agree Undecided Disagree Strongly disagree
3 19 6 1 0
Consensus reached (76% agree)
Comments
On reflection, the pharmacist's individual views and attitudes should influence whether
(s)he is suited to taking on the role and to then undertake the required preparation.
(Pharmacist prescriber)
Since the development of NMP training one of the barriers to developing effective NMP
roles has been inappropriate selection of candidates. Individuals’ views and attitudes
and motivation are central to the development of such roles and services. (Non-
pharmacist author non-medical prescribing policy)
Agree with first comment but generally unsure precisely what the question means.
(Acute health board director)
Should be about competencies and when NMP fully established will be linked to a post
and therefore determined and aligned to job specifications. (Pharmacist author non-
medical prescribing policy)
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4b. Statement developed from first round:
Ensure that appropriate pharmacists are selected for the prescribing
role by taking into consideration their individual views and attitudes
towards pharmacist prescribing.
Strongly agree Agree Undecided Disagree Strongly disagree
7 19 2 0 1
Consensus reached (90% agree)
Comments
It would seem unlikely that someone would be forced to take on a prescribing role.
(Pharmacist author non-medical prescribing policy)
I would have preferred this statement to reflect the pharmacist making the decision
about whether to apply for a post or develop his/her practice rather than being
'selected'. (Pharmacist prescriber)
Early implementer pharmacists must be interested and motivated for the role to work.
(Pharmacist author non-medical prescribing policy, Pharmacist prescriber)
This is a better question. However, in the future we may expect all pharmacists to
prescribe and so it will not be a question of selecting pharmacists for roles but simply
ensuring staff are appropriately prepared for roles. Their views and attitudes will be
largely irrelevant to this. (Acute health board director)
I agree if cognisance is given to needs of the service rather than desire of the
pharmacist. (Non-pharmacist author non-medical prescribing policy)
Should be about post requirements, skills and knowledge. (Pharmacist author non-
medical prescribing policy)
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5.5 Discussion
5.5.1 Key findings
This phase of the research set out to develop consensus guidance to facilitate
service redesign to involve PP in secondary care. This involved using and
confirming evidence obtained from the focus group discussions described in
Chapter 3. A Delphi approach was used to validate the evidence from the focus
groups by seeking the opinion of an expert panel, made up of strategic and
practising professionals likely to be involved in a service redesign involving PP
in secondary care.
Two rounds of Delphi were conducted with a response rate of 87.5% in round
one and 72.5% in round two. In round one, agreement was reached with 27
statements derived from the focus group discussions, providing triangulation
and validation of the focus group evidence. Agreement of over 90% was
reached with 20 of these statements (consensus was set at 70%). In round
two, six statements were included for ranking as follows:
 Four were statements as in round one; three where no agreement had
been reached (17% - 66% agreement in round one), and one statement
where a consensus of 70% was obtained. These statements were
provided for re-ranking to further validate the result obtained in round
one. Following re-ranking, no agreement was again reached with three
statements, and a 76% agreement with the fourth.
 Two were new statements derived from comments in round one.
Agreement was reached with both of these statements in round 2.
The statements where agreement was reached were included in the final
guidance aimed to facilitate a service redesign involving PP in secondary care
and are found in Section 5.4.
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5.5.2 Strengths and Limitations
This research has numerous strengths. To the author’s knowledge, this is the
first study to address a pharmacy strategic development involving PP using a
consensus development method. Though developments involving PP and other
areas may have used this approach, these have not been published and could
not be identified by the author. A search in the pharmacy database IPA using
the key words ‘Delphi’ and ‘pharmacist prescribing’ undertaken in June 2010
did not provide any hits; consequently no information could be identified on
how strategic developments involving PP in the UK have been undertaken. A
second search was conducted in June 2010 using the key words ‘Delphi’ and
‘pharmacy’ and no useful hits about processes used in strategic developments
were obtained. (Some other applications of the Delphi method in other areas of
pharmacy were identified and are described in Section 5.5.3.) Similarly, no
information on the process of strategic development or areas of service
redesign in pharmacy in Scotland was provided on NHS Scotland or the
Scottish Government website. Since nurse supplementary and independent
prescribing were introduced at the same time as PP, a search was conducted in
June 2010 using the database CINAHL using the terms ‘Delphi’ and ‘nursing
prescribing’ but again no hits were obtained.
It is clear from the results obtained through rounds one and two of the Delphi
that there was a high level of agreement with the evidence from the focus
group results. The objectives of the study to use and validate the information
obtained through the focus groups by seeking the opinion of an expert panel
were therefore met. The high response rate [87.5% in round 1 and 72.5% in
round 2] was above the 70% recommended by Hasson to maintain the rigour
of the method and to produce meaningful results (209) and was a further
strength of the research. This enabled compiling of the guidance to facilitate a
service redesign involving PP in secondary care. The usefulness and
applicability of these guidelines in practice would need to be evaluated through
further research.
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The composition of the expert panel was carefully considered to ensure that
the opinions of strategic and practising professionals likely to be involved in PP
were included. The author was satisfied that the participants provided a mix of
professionals with suitable expert knowledge in the subject area. This allowed
the input of strategic professionals as well as non-pharmacists with experience
in non-medical prescribing, who were not involved in the focus group
discussions.
The research focuses only on secondary care in Scotland and the guidance
provided is unlikely to be generalisable to other healthcare settings and other
geographical areas. The author believes that this may also be a strength since
issues affecting PP in secondary care are likely to be different from those in
primary care. The guidelines are consequently likely to be more detailed and
exhaustive than if all healthcare settings were considered. Likewise, the
guidance is only applicable to Scotland; again this may also be a strength since
the devolution of the healthcare system may have resulted in the healthcare
system in the different UK countries evolving in a different way. The guidance
may therefore be more complete than if guidelines considering the needs of all
the UK were drawn up.
There are limitations inherent with using a Delphi method, such as use of an
expert panel, and measures taken to maintain the credibility of the research
have been described in detail at Section 5.3.5. The questionnaire had 30
statements to ensure that all the evidence from the focus groups was included.
This exceeded the recommended 25 items; through user-testing it was
confirmed to be easy and quick to complete and studies in the literature in
other areas of pharmacy practice have successfully used more than 25
items.(224-6) The high level of agreement with the statements may indicate
an element of acquiescence response bias and a potential lack of specificity of
the statements provided. Measures taken to minimise this have already been
discussed in Section 5.3.2. The author is of the opinion that the statements
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reflect as closely as possible the evidence obtained from the focus group
research.
5.5.3 Comparison with the literature
As described above, this is the first study that uses Delphi relating to the
pharmacy prescribing area of practice. The literature reports a number of
studies, some of which explore and describe implementation of PP in different
healthcare settings including secondary care. A lack of implementation of PP
following a pharmacist qualifying as a prescriber and a lack of organizational
recognition are reported in secondary care.(130,197) Lack of succession
planning to ensure continuity of service,(130) and issues around funding,(131)
were also reported. These issues need to be resolved if pharmacist prescribers
are to reach their full potential, making better use of their skills and benefits
gained by the patients in better services. This was highlighted in the Crown
Report which recommended the introduction of non-medical prescribing.(76)
The author believes that this possibly identifies an area where further guidance
to facilitate implementation of PP is required in secondary care and these
guidelines may contribute to this area of prescribing literature.
Some applications of the Delphi method or approach in other areas of
pharmacy practice were identified in the literature. Within the UK, this has
been used to: develop criteria against which the quality of medicines use
review referral documentation can be accessed (224) and to establish a
dispensing error definition within a community pharmacy setting.(227)
Specifically within Scotland, a Delphi approach has been used to develop
competencies associated with training needs of public health for community
pharmacists,(226) and to generate a model of pharmaceutical care for the
patient with type 2 Diabetes Mellitus in primary care.(225) Unlike this
research, none of the studies described involved a service delivered in
secondary care. Outwith the UK, studies described were mainly from the US
and involved: developing components required for training of community
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pharmacists (228) and determining challenges facing pharmacy executives.
(229,230) A further study focused on developing a list of clinically significant
drug-drug interactions with oral anticancer and non anticancer drugs.(231)
Most of the studies report using a Delphi approach where questionnaire
statements in round 1 were derived from the literature (224,226-7,231-2) or
through previous research.(225) Similarly, a Delphi approach was applied in
this research where questionnaire statements in round 1 were derived from
previous focus group research and grouped into categories as described in the
literature. As in this study, more recent research has also used electronic
delivery considering this to be ideal for ease and speed of
response.(224,226,229-231) Reported response rates vary and range from
18% to 83% with most studies reporting a drop in response rate when
comparing round 1 to subsequent rounds. Comparatively, response rates in
this study were high with 87.5% in round 1 and 72.5% in round 2.
5.5.4 Discussion of findings
Overall, there was a high level of agreement with statements derived from
focus groups (27 out of 30). Therefore this validated and confirmed
information which was derived from the focus group discussions. This
agreement was of particular significance since the panel included healthcare
professionals with a more strategic role (e.g. Directors of Pharmacy, Chairmen
ADTC) as opposed to focus group participants who were solely ward-based
practising pharmacists. There was a high response rate with the literature
reporting that relevance and salience of a topic to participants as being one of
the most important reasons for a high response rate to survey questionnaires
[though there is no specific evidence about response rates in a
Delphi].(221,223,233) This engagement of the participants shows an interest
and possibly indicates a need for the guidance.
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In round one, there were more statements about service management (20 out
of 30) compared to role development derived from the focus group
discussions. The author believes that there may be a number of reasons for
this. It may reflect the composition of the focus group discussion participants
all of whom were ward-based practising pharmacists. Consequently, in their
view, service management may have a priority over role development. In fact,
most statements derived from the discussions were about succession planning
involving implementation and ensuring continuity of a PP service. This may
reflect the frustration on the part of the focus group participants that there is a
lack of implementation of PP in secondary care with a consequent lack of
utilisation of the pharmacist prescriber’s skills. This lack of implementation has
also been reported elsewhere in the literature.(130) The lack of
implementation may have led to having fewer statements in other categories
such as quality evaluation, outcome measures and practice development.
Despite the different composition of the expert panel which included a strategic
element together with non-pharmacist professionals, there was a high level of
agreement with these statements (19 out of 20) with 90% or more agreeing
with 15 of these statements. Only one statement was rejected in the service
management section. This may reflect a concern on the part of the expert
panel to ensure sustainability of a PP service following its implementation. The
author believes that the guidelines may facilitate a service redesign involving
PP by allowing consideration of areas such as succession planning even before
the pharmacist has embarked on a training course. This may minimise the
frustration expressed by focus group participants who felt that there was no
such planning and they were being trained as prescribers just to build up the
numbers. The guidelines may also prompt the consideration of other important
areas of implementation such as ensuring appropriate structures are in place
to allow safe practice, the support needed by pharmacist prescribers once they
are in practice and the integration of pharmacist prescribers with other
professionals within the multidisciplinary team.
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Having more statements in the service management rather than the role
development category may also reflect the fact that the focus group
participants were not as involved in the forward planning of the role as were
the expert panel. The level of agreement with statements in the role
development was less than that in the service management. There was
agreement with eight out of ten statements (agreement over 90% with five of
these statements) and two statements were rejected. The author believes that
this may reflect a role that is still under development with a high response rate
showing an interest in the future development of this role. It is believed that
the guidelines will stimulate discussion on the orientation of the specialist
pharmacist prescriber role in secondary care to allow maximal potential.
Interestingly, criteria that have been associated with role development in other
areas of the nursing literature (217) including research activity, leadership
qualities and consultancy, have not been considered in this research, neither
by the focus group participants, nor by the expert panel, again reflecting the
infancy of the pharmacist prescriber’s role in secondary care.
The expert panel rejected the statement “Encourage the development of non-
medical prescribing teams.” All comments in round one were made by
pharmacists in both practising and strategic roles and reflect a desire to have
one integrated multidisciplinary team that would promote inter-professional
working and incorporate both medical and non-medical prescribers. This
statement was also rejected in round two with comments again emphasizing a
need and desire to work within a single team made up of medical or non-
medical prescribers as appropriate. A modified statement in round two
developed from round one encourages “participation of PP within
multidisciplinary teams;” as expected, agreement was reached confirming the
need for non-medical prescribers not to work in isolation but to be integrated
with other healthcare professionals. Others have also reported that
pharmacists believe PP may result in better integration with the healthcare
team.(131) Interestingly, the importance of good communication and
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promotion of a team approach required for integration of non-medical
prescribers has also been highlighted by the medical profession.(129)
The statement “Encourage all hospital pharmacists to prescribe in any
speciality” was rejected in rounds one and two. Comments indicated a
polarized opinion among participants; some felt that all pharmacists should
prescribe: “prescribing is the future for all hospital pharmacist practitioners”
(Acute health board director). Others perceived this to be a more specialist role
– “prescribing should be limited to defined specialties with the appropriate
pharmacists in post“ (Pharmacist prescriber). Other participants commented
that prescribing within any specialty might lead to pharmacists prescribing
outwith their competence and comfort zone. Concern was also raised about
newly qualified pharmacist and pharmacists new to the job who would need
additional mentoring to take on such a role. Agreement was reached with the
statement “Encourage the development of prescribing specialist roles” and the
panel consequently indicated that this may be the more feasible direction and
future orientation of the pharmacist prescriber’s role in secondary care. This
may be an area that will develop or change as the pharmacist prescriber’s role
develops and becomes more established in secondary care.
The panel rejected the statement “Ensure that pharmacist prescribers are
financially compensated in line with their added responsibilities” in both rounds
one and two. A range of comments was provided with some healthcare
professionals showing strong agreement while others expressing concern that
PP cannot be assumed to include added responsibilities. Overall, these
comments seemed to indicate that a prescribing role and the responsibilities
this may bring with it should be reflected in the agenda for change banding
associated with a specific post. It is evident that this is still an area of much
debate and again reflects a role that is still being developed. Such economic
aspects of non-medical prescribing have also been reported in the nursing
literature where “nurses reported colleagues being dissuaded from prescribing
due to meagre salary increases relative to the extra responsibility.” (197)
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5.5.5 Further research
Further research is required to test the guidance for usefulness and to
determine whether it will help in the planning and implementation of PP. This
may take the form of an initial pilot study where both pharmacists in strategic
posts and practising pharmacists are asked to evaluate each statement within
their healthcare settings and ease-of-use of guidelines. Follow up in-depth
interviews may then be conducted with these professionals to gain insight into
whether the guidance would help in the planning and implementation stages of
PP and any recommended changes.
As the role develops, the guideline may need to be reviewed and updated such
that other criteria in the literature associated with role development may need
to be incorporated (previously discussed). Should PP be more widely
implemented in secondary care, focus groups with practising pharmacist
prescribers may help further inform the process of guideline review and
update. This guidance has been developed specifically within the Scottish
healthcare system – further research may indicate whether it is also applicable
within other healthcare systems. It has also focused on secondary care; it may
be worth exploring whether the process of development used to produce these
guidelines may inform other areas of pharmacy practice such as primary care.
Again, focus groups with the relevant pharmacists may help provide the
evidence to inform and guide modifications required.
5.5.6 Conclusion
Consensus guidelines have been developed to facilitate a service redesign
involving PP in secondary care. Evidence obtained from focus group discussions
was used to draw up these guidelines which were validated by seeking the
opinion of an expert panel and using a Delphi approach. There was a high level
of agreement with the statements derived from the focus groups. Statements
where consensus was achieved were included in the final guidance.
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Chapter 6
General Discussion
6.1 Introduction
This chapter summarises the way the phases of research evolved and key
findings in relation to their stated aims and objectives. Aspects of validity and
reliability and potential applications of the research for future policy and
practice are then described. The chapter concludes with ideas for future
direction in this pivotal area of pharmacy practice.
6.2 Evolution of the research programme
A reflective approach was employed throughout this research, promoting
consideration of research findings and implications for practice at each phase.
In addition, such an approach allowed the consideration of any emerging
policies or modes of practice. This iterative process enhances the robust nature
of the research.
The original research aim (in 2005) was “To explore the structures, processes
and outcomes involved in pharmacist prescribing of antimicrobials in secondary
care.” This was considered a timely area of research, since legislation for
pharmacist SP had been introduced in 2003, and hospital pharmacists
embraced the opportunity to extend their practice.(86,111) The increasing role
of the pharmacist in ensuring optimal antimicrobial use was also highlighted in
various Scottish and UK documents, (33-4,44-5) and specialist antimicrobial
pharmacists were of the opinion that a further expansion of the role was both
likely and desirable given the introduction of pharmacist SP.(47,48) To inform
the evolution of the research aim, a general literature review was conducted,
presented in Chapters 1 and 2 and in three distinct sections. In the first
section, strategies aimed at optimising antimicrobial use, driven by a concern
over increasing antimicrobial resistance were reviewed, with a focus on EU and
UK strategies. Within these strategies, the concept of an antimicrobial team
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with pharmacy involvement emerged and was developed.(13,14,27) The role
of the pharmacist within these teams evolved from a “policing” role, controlling
prescribing and checking adherence to guidelines, to an “advisory” role,
providing support and advising on prudent antimicrobial use within the AMDT.
Specific recommendations were made to develop roles for specialist
antimicrobial pharmacists, particularly within hospitals (33) [or specialist
infectious diseases pharmacists in EU literature (24)]. This approach has been
endorsed by the Scottish Government.(44-5) A summary of the development
of this pharmacist role within the UK is in Table 2.
In parallel with the development of the antimicrobial pharmacist’s role, the
recognised need to promote appropriate use of the skills of non-medical
professionals and to increase accessibility of the medicines to patients, led to a
change in UK legislation allowing PP. At the start of this PhD, legislation
allowed for pharmacist SP, but policy evolved to allow pharmacist IP.(97) The
practice of PP has been viewed by many as a natural extension to the role of
the hospital pharmacist, potentially providing many opportunities for the
pharmacist to optimise antimicrobial prescribing.(47,48,96) The next section of
the literature review, consequently, focused mainly on development of PP
within the UK and described and analysed the implementation and outcomes of
PP within the UK. Despite the fact that PP was described as being implemented
in different practice settings, including hospitals, a review of primary research
revealed limited focus on clinical, economic and humanistic outcomes of PP,
with no descriptions or primary research on PP of antimicrobials.
To explore further evidence based clinical roles for the pharmacist in
optimisation of antimicrobial use as part of an AMDT in hospitals, and
published outcomes of such interventions, a systematic review was conducted
and is presented as the third section of the literature review in Chapter 2. A
number of descriptive accounts and nine evaluative trials were identified. As
discussed in section 2.4.2, the small-scale, single-site nature of the trials and
the study quality (with only two being RCTs) made it difficult to draw any
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definite conclusions about outcomes following interventions of an AMDT (note
that despite descriptions of AMDT in the UK, none of the trials originated in the
UK). A role for the hospital pharmacist was identified within the dispensary, on
the wards, in the case of clinical pharmacists, and as a specialist infectious
diseases pharmacist. None of the roles described involved optimising
antimicrobial use through PP. These literature reviews have resulted in the
publication of two peer-reviewed papers.(112,195)
These limitations and gaps identified within the literature led to evolution of
the overall aim of this PhD as follows: To explore pharmacist prescribing in
hospitals in Scotland, with a focus on antimicrobials. The development of this
aim is presented at figure 7.
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Identified need to increase use of skills
of non-medical professionals and
increase accessibility of medicines to
patients
Crown Report recommends a review of
prescribing to consider non-medical
prescribing
SP legislation to allow pharmacist SP
Some descriptions and limited primary
research on PP identified
No descriptions or primary research on
PP of antimicrobials
Increased concern about resistance to
antimicrobials
Strategic (EU, UK and Scottish)
documents aimed at optimising
antimicrobial use with evolving role for
pharmacist
Potential for expansion of pharmacist
role to include PP of antimicrobials
To explore evidence based roles for
pharmacist as part of AMDT
Limited evidence for role with none
reported involving PP and no primary
research based in UK
Overall research aim: To explore pharmacist prescribing in hospitals in
Scotland with a focus on antimicrobials
Figure 7: A parallel and linked development of overall research aim
Gap
Gap
Literature
review on PP
Systematic
review
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The research was conducted in three phases, and their evolution and
development in response to results from each phase are described here. In
view of the above, the aim of Phase 1 was:
“To explore pharmacists’ views and perceptions of pharmacist
prescribing in secondary care with a focus on antimicrobials.”
A qualitative methodology in the form of focus groups was used to provide
in-depth, rich narratives. Analysis of the data generated through these
focus group discussions highlighted a general lack of implementation of PP
in secondary care, and a lack of NHS organisational support for pharmacists
to take on this extended role. Indeed, pharmacy hierarchical management
was perceived as a major barrier hindering PP implementation. As discussed
in detail in Section 3.4.3, key findings of barriers to implementation were in
accord with other published studies. Notably, studies based exclusively in
Scotland, reported higher numbers of pharmacists training and practising as
SP in a primary care setting.(131) At the time of completion of focus group
data analysis and interpretation, updated prescribing legislation permitted
pharmacists to train and practise IP.(96) The combination of these factors
strongly influenced the evolution and development of the next phase of the
research. The lack of PP of antimicrobials and indeed any PP within
secondary care facilitated formalising Phase 2 of the research which had the
following aim:
“To conduct a scoping exercise to determine the extent of
implementation of PP in secondary care in Scotland.”
This phase informed later research activities. Different methods and
approaches were used in this scoping exercise and are discussed in detail in
Chapter 4.
It was apparent from the scoping exercise that there had been little
evolution of PP implementation within the Scottish health boards studied
(see Table 20 in Chapter 4), with only one pharmacist identified as
prescribing antimicrobials (Section 4.1). Strategic policy information
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obtained from the Scottish Government at this time indicated priority for
developments of PP within primary care with no framework for
implementation of PP in secondary care.(207) Likewise, few Scottish health
boards reported having a framework in place to facilitate implementation of
PP in any setting. It is difficult to draw conclusions in an area of practice
that is so fluid and dynamic, and it is not possible to determine to what
extent the lack of frameworks (both on a national and local level) have
influenced the lack of implementation of PP. It was evident, however, that
there is a need to bridge the gap between training of pharmacists as
prescribers and implementation of PP in secondary care.
To enable the research to be of national importance, thus contributing to
practice and providing solutions to complex challenges, the final phase of
the research took a broader approach focusing on the general
implementation of PP in Scottish secondary care. The aim of Phase 3 of the
research was:
“To develop consensus guidance to facilitate service redesign to
involve pharmacist prescribing in secondary care.”
Draft guidance statements were based on evidence gathered from the focus
group discussions and the scoping exercise and consensus was achieved
using the Delphi method. A detailed description of the study design is
presented at Section 5.3. The development of the final questionnaire was a
very lengthy process involving numerous drafts, again involving reflection,
discussions with the supervisory team and with key local and national
experts together with identification of key documents adapted for use in this
research.(217) Drafts illustrating the development of the questionnaire are
available at Appendix 5.1 together with comments to illustrate the
“development process” and consequently the evolution of this tool. The
findings of the study are applicable to all PP within secondary care,
irrespective of patient group, and drug therapeutic classes, and are likely to
impact and also facilitate, PP of antimicrobials in secondary care. Factors
influencing evolution of the research are summarised in Figure 8.
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Figure 8: Factors contributing to evolution of the research
To explore the structures, processes,
and outcomes involved in PP of
antimicrobials in secondary care
Evolved to
To explore pharmacists’ views and
perceptions of PP in secondary care
with a focus on antimicrobials
Literature review
Peers – supervisory team
& UKCPA interest groups
Reflection
To conduct a scoping exercise to
determine the extent of
implementation of PP in secondary
care in Scotland
Analysis of focus groups
Further evolution of
policy
Published literature on
implementation of PP in
Scotland Change in focus to
general PP
To develop consensus guidance to
facilitate service redesign to involve
PP in secondary care
Initial broad research theme of PP of
antimicrobials
Background scoping
exercise indicates
need to bridge gap
between training and
implementation of PP
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6.3 Review of key findings
As part of this PhD project, data were generated and collected:
 To explore pharmacists’ views and perceptions of pharmacists’
prescribing in secondary care, with a focus on antimicrobials.
 To conduct a scoping exercise to determine the extent of
implementation of PP in secondary care in Scotland
 To develop consensus guidance to facilitate service redesign to
involve PP in secondary care.
A critique of available methodologies and a justification of each choice are
presented at Chapters 3, 4 and 5.
Research in Phase 1, was conducted with both pharmacist prescribers and
pharmacist non-prescribers, and aimed to explore their views and
perceptions of PP in secondary care, with a focus on antimicrobials. The
perceived lack of management support to take on a prescribing role, the
lack of planning to implement PP and the inability to sustain new services
such as prescribing, were among the major barriers to the implementation
of PP in secondary care. This was also true for pharmacist antimicrobial
prescribing, where there was no specific drive or incentive to encourage PP,
unless as part of a cost-cutting exercise. The CMP, as a requirement of SP,
was especially difficult to implement in acute situations, such as prescribing
of antimicrobials, likely to be characteristic of a hospital setting. The lack of
skills to diagnose was perceived as the main barrier to pharmacists IP.
Participating pharmacists believed that the patient’s clinical condition and
ward types were major determinants in the successful implementation of
PP, with this likely to be more feasible if prescribing for a chronic condition
and in an outpatient clinic setting. Numerous examples specific to
antimicrobials were provided by the participants to support this (see Table
18). Areas where pharmacists were already providing considerable input
and advice (Ex TDM advice relating to antimicrobials) and where guidelines
and protocols were available (e.g. surgical prophylaxis), were other settings
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where PP was perceived as likely to be a success. This research is the first
published evidence that focused specifically on antimicrobials and on
secondary care in Scotland.(234)
The next phase of the research set out to conduct a scoping exercise to
determine the extent of implementation of PP in secondary care in Scotland,
utilizing different sources of information, as discussed in Chapter 4. Follow
up of focus group participants showed that despite a change in legislation
allowing IP, and a desire for the participants to train as independent rather
than supplementary prescribers, there was little evolution in implementation
of PP in hospitals, within the sampled health boards. Information obtained
from the Scottish Government reinforced the fact that the focus of the
Scottish Government, at least during the first phases of PP, was mainly
primary care, with no framework available for implementation of PP in
secondary care. Likewise, few of the Scottish health boards reported having
a framework in place to facilitate implementation of PP, including secondary
care; however having a framework in place seemed to be linked with a
larger number of actively prescribing pharmacists. [Table 20]
Results from Phase 2 led to the third phase of the research, which aimed to
contribute to practice by bridging the gap between policy and practice and
facilitating implementation of PP in hospitals. This was conducted by
developing consensus guidance to facilitate service redesign involving PP in
secondary care. The guidance was based on evidence obtained from the
focus group discussions in Phase 1, with two rounds of a Delphi approach
used to validate the evidence, by seeking the opinion of an expert panel. A
detailed description of the process used is presented in Section 5.3. The
expert panel comprised both strategic (including non-pharmacists involved
in non-medical prescribing) and practicing professionals likely to be involved
in a service redesign involving PP, and consequently differed from the
participants in Phase 1, who were practicing pharmacists (both prescribers
and non-prescribers). There was a high response rate (87.5% in round one,
72.5% in round two) and a high level of agreement with statements derived
from the focus groups in round one, (27 out of 30) which is of particular
significance since the expert panel included healthcare professionals with a
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strategic role. Implications of these guidelines and indeed of all the phases
of the research for policy and practice are discussed in section 6.5 below.
6.4 Discussion of method
6.4.1 Clarifying author bias
The author is an academic pharmacist, with around 15 years of hospital
pharmacy experience mostly as a ward-based clinical pharmacist. Her
interest in antimicrobials and the potential for pharmacist involvement in
this area was generated during a period of practice in surgery where
numerous opportunities and a potential for pharmacist involvement to
optimise antimicrobial use through prescribing were noted. She therefore
came into the research with positive views of the potential opportunities to
optimise antimicrobial use, especially through PP. Likewise, members of the
supervisory team were involved in ongoing research relating to PP and as
educators of nurse and pharmacist prescribers. To minimise such inherent
biases, a systematic approach allowing “auditing” by a peer was adopted as
described in section 6.4.2 below. Regular meetings with the supervisory
team were also conducted to discuss emerging findings and interpretation of
the results. As an additional check, the author also had more formal
opportunities to answer questions about different phases of the research at
the student symposia organized by the school and during various
conferences when the research was presented as a poster or oral
communication (See Output at Introduction). Though the research was
conducted within the NHS health boards in Scotland, there was no input or
influence by the NHS on study design, data collection and interpretation of
findings or dissemination of results.
Throughout the research, measures were incorporated in the different study
designs to minimise other inherent biases and are described at length in
Sections 3.2.4 and Section 5.3.
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6.4.2 Focus group discussions
Discussion of the appropriateness of the qualitative methodology is given in
section 3.2.2. In particular, the iterative nature of this approach was
considered relevant to inform further phases.
There has been much debate as to how reliability and validity may be
achieved in qualitative research, with some researchers arguing that the
same principles of quantitative research are to be applied and others
debating that different criteria should be considered in qualitative research.
Murphy et al, in a systematic review of the literature, concluded that when
assessing qualitative research, no checklists or rigid constraints may be
applied; rather judgments need to be made as to the application of the
criteria within the specific context.(182) A detailed analysis of different
theories proposed is beyond the scope of this project; Bryman (181) and
Murphy (182) offer a comprehensive description.
Criteria to establish quality of qualitative research have been proposed by
Lincoln and Guba (181,182) and have been grouped as “trustworthiness.”
The four criteria are described below with specific relevance to this
research.
 Credibility – (may be matched with internal validity) ensures that the
research is carried out according to good practice and involves
submitting research findings to the participants to make sure that the
“world” has been understood in the appropriate way. This may involve
presenting the researcher’s analysis to the research subjects for
feedback on validity of conclusions. There are however a number of
disadvantages inherent in this approach in that feedback may become a
source of generation of new data rather than a test for credibility. This
issue has been discussed in depth by Murphy et al.(182) In view of the
above, respondent validation was not adopted in this project.
Confirmation of results through triangulation is another method for
ensuring credibility which has been adopted in this PhD project and is
described in Section 6.3.3.
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 Transferability – (may be matched with external validity) involves
providing the reader with a “rich” description to aid understanding and
visualizing the context, allowing the reader to decide whether the
conclusions may be transferred to another area. This has been provided
at each stage of this PhD research and has included a detailed
description of locations where focus groups have been conducted. To
further aid contextualizing, extracts from the focus group discussions are
included throughout the text. This study is limited in geographical
location to Scotland. The author believes that results, especially those
relating to barriers, may be different to the rest of the UK, particularly
since the literature indicates that the devolution of the healthcare
system may have resulted in countries having different priorities for
implementation of PP (see section 3.4.3). Literature from Northern
Ireland in particular, emphasizes the success of implementation of PP in
hospitals and consequently barriers highlighted in this PhD research may
not be relevant.(130) However, the different methods used, the different
timescales and the rapid pace of development in this area of practice
imply that any conclusions need to be considered with caution. The
practice of ward-based clinical pharmacy is well established throughout
the UK, and consequently, it is likely that both current and potential
clinical activities involving PP highlighted in this research are applicable
throughout the UK and may aid to inform expansion of PP in secondary
care as described in Section 6.5 below.
 Dependability - this involves taking an “auditing” approach with detailed
notes kept at every stage including: development of research aim or
question, selection of participants, “ad verbatim” transcripts and the
process by which findings are derived from data. To ensure this
verification, another researcher must be able to come to the same
conclusion using the raw data available. Each stage is then “audited” by
a peer. Such a systematic approach is also recommended by
Krueger.(189) To ensure this systematic approach, a very detailed step-
by-step breakdown has been built into and provided as part of the study
design of this PhD research (Section 3.2.4), including the method used
for the analytical process. This enables other researchers and readers to
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view the logical construction of conclusions. Transcripts of all focus
group discussions were independently analysed by a member of the
supervisory team. A descriptive account of the thematic analysis was
produced independently, and then compared to that of the author to
check for any discrepancies. None were found. The first group was
analysed by 2 separate researchers to add an extra validity check.
 Confirmability – this ensures that personal values and biases of the
research team have not adversely affected research conduct. Again this
“double check” was adopted through data analysis as described above.
6.4.3 Scoping Exercise
As discussed in Section 6.2, Phase 2 was conducted to inform further
phases of the research. Having been conducted exclusively in Scotland with
a focus on Scottish health boards and the Scottish Government, devolution
of the UK health system implies that information obtained from this stage of
the research is only applicable to Scotland.
6.4.4 Delphi study
A consensus method was considered appropriate for Phase 3 of the research
since it involved an area of pharmacy practice of little evidence. This phase
was providing triangulation as a quality assessment step as discussed in
Section 5.3.
There has been much debate on credibility, reliability and validity of
consensus methods, with recommendations that a rigorous method and
having a clear “decision trail” may overcome these issues. A discussion of
this in the context of Phase 3 of this research has been provided in Section
5.3.5.
Since the research focuses only on secondary care in Scotland and the
guidance provided is based on evidence generated in Scotland (through
Phases 1 and 2), it therefore needs further consideration to be transferable
to other healthcare settings and other geographical areas.
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6.5 Implications for policy and practice
6.5.1 Potential for a pharmacist prescribing role to optimise antimicrobial
use
More recently, further evidence (in addition to that reported in Chapter 2)
has been published, supporting the role of the hospital pharmacist in
optimising antimicrobial use. All such published trials and descriptions are
single-site and none from the UK. The main drivers described are the need
to minimise expenditure and to reduce bacterial resistance within hospitals.
Interventions focus on post-prescribing evaluation combined with clinical
pathways (235-237), or clinical pathways combined with restrictive policies
(See Section 2.3.2.).(238) Specific interventions made by the pharmacists,
as part of the AMDT, or by ward-based clinical pharmacists include
recommendations for IV-to-oral switch when appropriate (235,239),
streamlining in response to culture and sensitivity results (238,240), dose
adjustment in organ dysfunction (235,238), and ensuring appropriate
choice of antimicrobial based on patient’s allergy status.(238) Although
none involves pharmacists prescribing or altering antimicrobial treatment,
the interventions reported are similar to the activities participants in Phase
1 of this research noted as feasible (Table 17).
As more emphasis is placed on implementing antimicrobial stewardship
programmes in Scottish hospitals, policy makers may look to introduce PP
as a novel way of optimising antimicrobial use.(45) Newer methods of
identifying multi-drug resistant strains of bacteria, using polymerase chain
reaction, make it possible to obtain rapid results (241,242) and PP may
consequently enable more timely and effective therapy.
Pharmacists in Phase 1 of this research recommended a model for
pharmacist IP which may offer a safe and effective option for potentially
expanding and integrating PP of antimicrobials in Scottish hospitals. This
would help overcome perceived barriers to both SP and IP raised during
focus group discussion. The model outlined would involve a doctor making a
diagnosis and initiating treatment, and a pharmacist independent prescriber
adjusting and monitoring treatment without the need for a CMP and is
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described in section 3.4.3 and elsewhere in the literature.(129,130) This
model of prescribing has potential to translate to other therapeutic classes
and patient groups, as identified by pharmacists in Phase 1 of the research.
These include areas where pharmacists were already providing considerable
advice, such as adjustment of doses in organ dysfunction, and in response
to drug levels, clinical areas where protocols and guidelines are available
and areas of care where there is a shortage of medical doctors. Indeed,
many of the discussions were not limited to antimicrobial prescribing, but
drew on examples from other therapeutic classes, such as warfarin,
antihypertensive treatment and management of anaemia associated with
renal disease.
6.5.2 A consensus-based analysis guide and action planning tool to facilitate
implementation of pharmacist prescribing in Scottish hospitals
Evidence generated from this PhD research indicates that few pharmacists
trained as prescribers were actually practising and few Scottish health
boards reported having a strategy for implementation of NMP including PP.
There is a need to urgently support the implementation of PP into secondary
care practice in Scottish hospitals and is evident from all the information
obtained from stakeholders involved in Phases 1 and 2 of this research.
To facilitate implementation of PP in Scottish hospitals, the final consensus
guidance developed through Phase 3 of this research, has been developed
as a self-assessment toolkit to encourage use (see below). Self-assessment
toolkits have been previously used in addressing healthcare related
issues.(243) The overall objectives of this toolkit are: (a) to provide an
analytical strategy and an initial starting point to reflect on potential areas
of implementation and role development of PP in different areas of care
within an institution and (b) to inform debate on the managerial
requirements and future orientation of health board developments in PP.
The more experience gained through pharmacists utilizing their prescribing
skills, the more these guidelines may be further developed and refined. This
is especially so in the case of the role specific criteria presented in Section
B.
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Pharmacist Prescribing in Scottish Hospitals
A Self-Assessment Analysis Guide and Action Planning Tool to Facilitate
Implementation
As more pharmacists qualify as prescribers, there is a greater need to find ways in which pharmacist prescribing may be
implemented and supported in secondary care, while adding value to patient care.
These guidelines provide an analytical strategy and an initial starting point to reflect on potential areas of implementation and role
development of pharmacist prescribing in different areas of care within an institution.
They may inform debate on the managerial requirements and future orientation of health board developments in pharmacist
prescribing.
The more experience gained through pharmacists utilizing their prescribing skills, the more these guidelines may be further
developed and refined.
The toolkit is divided into two sections:
A) Service Management – this aims to encourage the efficient provision of the service
B) Role Specific - this section aims to provide detail of the educational and training support which needs to be provided to promote
role expansion, the work expected to be undertaken by a pharmacist prescriber, and the expected future orientation of the service
Date performed………………………………………………………………..
Date for next review……………………………………………………….
Responsibility for assessment…………………………………………
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A. Service Management
1. Succession planning: This means that there are managerial processes in place within a health board to ensure that the
role is not reliant on one person alone and that a system of staff development, supervision and support is in operation to
enable others to take on the role.(217) Statements within this section aim to assist successful planning, strategy
development for pharmacist prescribing and implementation of pharmacist prescribing making best use of the resource
available. They aim to highlight the importance of the planning phase of the service redesign consequently making it possible
to identify areas where pharmacists may improve the quality of patient care by utilising their prescribing skills following
qualification.
Considered Not
Considered
Action
Plan
By whom
By when
1.1 It is important to undertake a systematic and
objective assessment of pharmaceutical needs in
order to identify gaps in the current service
delivery and patient care.
1.2 It is important to outline ways in which
pharmacist prescribing may improve patient care
or encourage better utilisation of staff skills and
resources.
1.3 It is important to have a strategyxxiii in place
within the health board that is based on available
national guidance and that would establish how
pharmacist prescribing is to be implemented.
1.4 Ensure that any strategy in place may be
applicable across different practice settings and
areas of care. This implies that the service is
generic and transferable.
xxiii A detailed plan or scheme outlining the administrative and procedural structure relating to pharmacist prescribing and that
ensures that practice is compatible with any relevant local or national standards or policies.
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Considered Not
Considered
Action
Plan
By whom
By when
1.5 Consider the benefits and limitations of both
pharmacist supplementary and independent
prescribing and determine which would be best
suited to deliver the service in different areas of
care.
1.6 Involve pharmacists likely to be prescribing in
discussions at the planning phase to ensure that
they have both sufficient background information
to prescribing prior to embarking on their course,
and sufficient knowledge as to where prescribing
will be implemented in their speciality.
1.7 Consider in which practice settings it may be more
feasible to introduce, implement and monitor
pharmacist prescribing.
1.8 Consider procedures that would allow the smooth
and safe transition of patients from secondary to
primary care if pharmacists are an additional
prescriber.
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2 Inter-professional working: This means that the pharmacy role is part of a system of integrated professional working
which is inclusive in nature.(217) Statements within this section aim to act as a trigger to ensure that other members of the
multidisciplinary team likely to be stakeholders in the process, are involved at each stage of the service redesign. This is likely to
assist the acceptance and uptake of pharmacist prescribing both within the institution, and within a specific area of care. This
would also encourage the building of efficient multidisciplinary teams.
Considered Not
Considered
Action
Plan
By whom
By when
2.1 Involve all key members of the multidisciplinary
team who are stakeholders when planning the
strategy for pharmacist prescribing.
2.2 Determine how likely it is for other key members
of the team to accept pharmacists as prescribers.
2.3 Promote a good understanding of the pharmacist
prescriber’s role with other members of the
multidisciplinary team.
2.4 Promote clearly defined roles relating to
pharmacist prescribing within the
multidisciplinary team.
2.5 Promote clearly defined lines of communication
relating to pharmacist prescribing within the
multidisciplinary team.
2.6 Encourage participation of pharmacist prescribers
within multidisciplinary prescribing teams.
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3. Quality Evaluation: This refers to the issues including quality assurance and audit processes, risk management and
clinical governance which are used to evaluate the pharmacist prescribing service and ensure a safe and effective running of the
service.(217) Statements within this section aim to highlight the need to analyse the implementation of a pharmacist prescribing
service to ensure that its introduction does not compromise patient safety and quality of care. Any service redesign would need
to take into account guidance issued by the Royal Pharmaceutical Society of Great Britain relating to this matter.
Considered Not
Considered
Action
Plan
By whom
By when
3.1 Establish that systems are in place (and are
defined, documented and regularly reviewed)
to promote patient safety and encourage
quality patient care when pharmacists are
prescribing, which have taken into account the
“Clinical Governance Framework for Pharmacist
Prescribers and Organisations Commissioning
or Participating in Pharmacist Prescribing”
(218) and any other local governance
structures or strategies.
3.2 Ensure that legal responsibilities and
accountabilities are defined and documented
within the strategy and have taken into
account the “Professional Standards and
Guidance for Pharmacist Prescribers” which are
part of the Pharmacist Code of Ethics.(219)
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4. Practice Development: This refers to the overall change in practice within secondary care which may be expected to
accompany a service redesign which involves the establishment of pharmacist prescribing.(217) Statements within this
section aim to act as a trigger to consider how the development of the pharmacist prescribing role will fit into current
pharmacy service provision in secondary care. It may be necessary to analyse, review and change some current practices to
ensure that these will not jeopardise the sustainability of a pharmacist prescribing service.
Considered Not
Considered
Action
Plan
By whom
By when
4.1 Consider any changes in current pharmacy service
provision in secondary care that may be needed
to support the development of a pharmacist
prescribing service.
4.2 Consider any additional resource/s that may be
needed to ensure provision and sustainability of
a pharmacist prescribing service.
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5. Outcome measures: This refers to the evidence of both positive and negative consequences which are available to enable
the professional merit of the role to be assessed at two levels: direct patient care and effect on other health
professionals.(217) Statements within this section aim to act as a trigger to consider what outcomes may be indicative of the
consequences of pharmacist prescribing. Outcomes must be valid, reliable and easily measurable and need to relate to both
the clinical effects and the actual processes and procedures adapted. These may be of particular importance since there is
little evidence available describing the outcomes of pharmacist prescribing.
Considered Not
Considered
Action
Plan
By whom
By when
5.1 The strategy should include ways of assessing
outcomes to measure any positive or negative
impact of the role on direct patient care.
5.2 The strategy should include ways of assessing
outcomes to measure any positive or negative
impact of the role on other healthcare
professionals.
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B. Role Specific
1. Education: This refers to the individual continuing professional development and the opportunities for continuing education
provided for prescribing trainees and following qualification as a pharmacist prescriber.(217) Statements within this section
aim to highlight the importance of considering areas such as competencies and continuing professional development for
pharmacists who are prescribers. These may be of particular importance with the advent of independent prescribing, where a
pharmacist may prescribe any licensed medication (other than controlled drugs) for any undiagnosed condition. With
prescribing being a relatively newer task for pharmacists in secondary care, it may be necessary to provide support both for
prescribing trainees and prescribing pharmacists, to ensure they are comfortable within this expanded role.
Considered Not
Considered
Action
Plan
By whom
By when
1.1 Provide support for pharmacists during training or
pharmacists who are planning to train to be
prescribers.
1.2 Provide clearly defined pharmacist competencies to
help pharmacists achieve and maintain competency
when prescribing (“Maintaining Competency in
Prescribing” produced by the National Prescribing
Centre may be a good resource).(220)
1.3 Clearly define the level and type of experience
required to prescribe in different specialties.
1.4 Provide the necessary opportunities for education
and training following qualification as a prescriber.
1.5 Ensure that pharmacists are able to demonstrate
competency on an on-going basis to prescribe in
their area of practice.
1.6 Ensure that appropriate pharmacists are selected
for the prescribing role by taking into consideration
their individual views and attitudes towards
pharmacist prescribing.
1.7 Provide the necessary mentoring scheme to
pharmacists who are prescribing.
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2. Future orientation of service: This refers to the advisory or supportive role of the pharmacist prescriber towards other
healthcare professionals and patients. It also includes the level of practice that might be regularly expected from a specialist
pharmacist prescriber and may include expanding the boundaries of pharmacy practice, demonstrating independent clinical
decision making, carrying out systematic assessment and intervention and portraying a sophisticated use of clinical
knowledge.(217) Statements within this section aim to project the likely future development of the role of the pharmacist
prescriber, possibly moving from a “generalist” practitioner to a “specialist” practitioner.
Considered Not
Considered
Action
Plan
By whom
By when
2.1 Encourage the development of prescribing
specialist roles.
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6.6 Further research
The following section suggests some potential areas and the rationale for
further research. These are based on results and the limitations of this PhD
project.
1. Aim: To investigate drivers which facilitate implementation of PP within
hospitals in Scotland.
The scoping exercise in Phase 2 indicated that having a framework for NMP,
including PP, was potentially associated with more successful
implementation of PP. This proposed research would further inform policy
makers and managers on factors which assist the successful implementation
of PP by gaining insight into views and perceptions of stakeholders other
than those included in this study such as pharmacy and hospital managers,
medical staff and patients.
Potential method: Initial focus group discussions involving stakeholders
described above within a hospital where pharmacists are making use of
their prescribing skills and one where pharmacist prescribers are not and
aimed at exploring facilitators to implementation of PP in Scotland. This
would inform a questionnaire which may then be sent out to all
pharmacists-in-charge of hospital pharmacies in Scotland.
2. Aim: To evaluate the usefulness and applicability in secondary care
settings of the toolkit developed in this PhD research.
This would allow any changes to be made prior to recommending potential
use of the toolkit in all Scottish hospitals. The exercise may possibly be
extended outwith Scotland to explore its potential relevance to other UK
countries. This may be of particular relevance in view of recent evidence
published indicating that only half of the trusts in England responding to the
researchers had a strategy for developing IP.(244) Moreover, individuals
emerged as the key drivers to implement pharmacist IP rather than a
redesign of services. (This study could potentially be extended to evaluate
the usefulness and applicability of the toolkit outwith the UK; e.g. Australia
or Canada where PP is still in its infancy)
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Potential method: Pilot in a sample of health boards where pharmacists in
strategic posts and pharmacist practitioners will be asked to rank each
statement on a Likert scale for ease-of-use and applicability.
3. Aim: To develop a toolkit to facilitate implementation of PP in community
pharmacy and primary care settings in Scotland.
This would facilitate implementation of PP other than in secondary care.
Potential method: Focus groups with pharmacist prescribers and non-
prescribers working in community pharmacies and primary care settings to
explore their views and perceptions of barriers and facilitators to
implementation of PP within these settings. Using the same method adopted
in this PhD research, this may generate evidence to inform and guide
development of a toolkit specific to these settings.
4. Aim: To survey current prescribing-related activities of hospital
pharmacist prescribers within the UK.
This survey to all hospital pharmacist prescribers would enable a cross-
sectional analysis of activities that are being taken on as part of the hospital
pharmacist’s expanded role. This would be potentially useful to explore in
which therapeutic and clinical areas pharmacists have been most successful
in implementing PP. It may inform policy makers who are in the process of
planning a service redesign to incorporate PP.
Method: Questionnaire to all hospital pharmacists registered as prescribers.
5. Aim: To conduct in-depth case studies in locations where pharmacists are
prescribing antimicrobials.
This research would help to follow up anecdotal evidence through UKwide
discussion forums which indicate that some pharmacists may be prescribing
antimicrobials for specific indications such as prescribing surgical antibiotic
prophylaxis as part of pre-op clinics. This research would provide
information to policy makers who are exploring further roles for the
pharmacists, especially as part of the well established AMDT.
Method: In-depth case studies involving stakeholders likely to be involved in
PP of antimicrobials such as different grades of medical and nursing staff
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within the specialty, medical staff in microbiology, pharmacy management
and patients.
6.7 Conclusions
This PhD research has explored PP in hospitals in Scotland, with a focus on
antimicrobials. As part of the research, original data was generated using a
number of methods including focus group discussions and a Delphi
consensus method. An extensive literature review was also conducted to
inform the project. The data generated has added to the body of evidence
about the topic, as indicated by the three peer-reviewed papers focusing on
the literature review, one peer-reviewed paper discussing an aspect of
results in Phase 1 and a number of poster presentations and oral
communications presented at both national and international conferences.
Publication of results for Phase 3 of the research is planned in the next
academic year.
Phase 1 of the research indicated that few of the pharmacist supplementary
prescribers participating in the focus group discussions were using their
prescribing skills with numerous barriers for implementation of PP in
secondary care identified. Despite these barriers, pharmacists also identified
numerous areas where they perceived PP to be successful in a hospital
environment, mainly relating to antimicrobials, but with a potential to
transfer to other therapeutic classes also. Overall, there was a lack of
implementation of PP in the five health boards sampled, with an evident
lack of strategic planning to incorporate PP. This evidence indicates that the
pharmacists who were successfully prescribing were doing so out of their
own initiative to improve services to their patients, rather than as part of an
overall strategic plan. These results were supported by evidence generated
from the scoping exercise as part of Phase 2, and reinforced the fact that
there appears to be a gap between training of pharmacist prescribers and
the implementation of PP in hospitals in Scotland.
Based on the above evidence, the last phase of this research aimed to
bridge the gap between policy and practice, facilitating implementation of
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PP in hospitals. Consensus-based guidelines to facilitate a service redesign
involving PP in secondary care were developed based on evidence from the
focus group discussions. To encourage use, these were developed as a self-
assessment toolkit which could be used as an initial starting point to reflect
on areas of implementation of PP within a hospital, or to inform debate on
managerial requirements and future orientation of health board
developments in PP.
While the results and conclusions generated through this research need to
be interpreted with caution, the data generated through this research is an
original contribution to the evidence base around PP.
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